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A bstract
Synthetic routes to potent steroidal and non-steroidal sulphamate-based active 
site-directed inhibitors of the enzyme steroid sulphatase, a topical target in the 
treatment of postmenopausal women with hormone-dependent breast cancer, are 
described. Novel compounds were examined for oestrone sulphatase (El-STS) 
inhibition in intact MCF-7 breast cells and placental microsomes. The strategies 
adapted in order to develop steroid sulphatase inhibitors which, while active in vivo, 
are devoid of any oestrogenicity that would limit their use for breast cancer therapy 
(e.g. oestrone 3-O-sulphamate, EMATE) were broadly successful. Modifications to 
the A- and D-rings of EMATE, the design and synthesis of flavonoid sulphamates and 
the development of single ring, bicyclic non-fused ring, 2 fused/non-fused ring and 3 
ring sulphamate analogues are reported here.
2-Bromo and 2-iodo EMATE analogues were found to be about 100 and 4 
times more potent respectively as sulphatase inhibitors than EMATE in placental 
microsomes. Similar in vivo sulphatase inhibitory potencies of 2-EthylEMATE, 2- 
methoxyEMATE and 2-methoxyoestradiol 3-0-sulphamate to that of EMATE, but 
lack of any oestrogenicity, has identified these analogues as potential new lead 
compounds for development as potent steroid sulphatase inhibitors. These analogues 
were also found to be potent apoptosis inducers in MCF-7 breast cancer cells. A 
marked regression in tumour volume occurred when 2-methoxyEMATE was 
examined in intact rats with NMU-induced mammary tumours. Oestralactone 3-0- 
sulphamate was synthesised and found to be a potent steroid sulphatase inhibitor, and 
devoid of oestrogenic activity when tested at 2 mg/kg using an ovariectomised rat 
uterine weight gain assay. The starting materials for these analogues were synthesised 
by generally novel and efficient methods such that the preparation of their sulphamates 
could be carried on a large scale for further biological tests.
In general, although the single ring and bicyclic non-fused ring sulphamate 
analogues could inhibit sulphatase activity, they were considerably less potent than 
EMATE. Benzophenone 4,4'-0,Obis-sulphamate (BENZOMATE) a 2 non-fused 
ring sulphamate was a potent inhibitor, inhibiting in vivo steroid sulphatase activity by 
84% and 93% respectively at a single oral dose (1 mg/Kg and 10 mg/Kg) and is 
identified as a useful lead compound for further development. We also designed and 
synthesised a number of molecules that potentially possess both aromatase and steroid 
sulphatase inhibitory properties (flavonoid sulphamates). The isoflavane A',1-0 ,0-  
bis-sulphamate (equol bis-sulphamate) and flavone 6,4'-0,(9-bis-sulphamate were 
found to be the most potent inhibitors of all the flavonoid sulphamate analogues in 
vitro, inhibiting steroid sulphatase by about 99% at 0.1 pM in MCF-7 cells. The 
isoflavone 4',7-0,0-bis-sulphamate, the mono- and bis-sulphamate derivatives of 5,7- 
dihydroxyisoflavone were relatively potent inhibitors, inhibiting in vivo steroid 
sulphatase activity by 90%, 67% and 84% respectively at a single oral dose of 10 
mg/kg. Some of these flavonoid sulphamates were also found to be active against 
both enzymes (e.g. 5-hydroxy-7-methoxyflavone 4/-0-sulphamate, 5-hydroxyflavone 
4',7-0,0-bis-sulphamate and 5,7-dihydroxyflavanone 4'-0-sulphamate), thus 
demonstrating the novel concept of a dual inhibitor.
Several other inhibitors were found to be potent and the structure-activity 
relationships for different sulphamates were discussed. The availability of these 
steroid sulphatase inhibitors should enable the therapeutic value of this therapy to be 
examined in clinical trials in the near future.
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The nomenclature of organic compounds adopted in this thesis follows the rules of 
International Union of Pure and Applied Chemistry (IUPAC).
The references in the text are cited by means of superscript numbers which are run 
seriatim through the thesis. The system of reference listing follows the one employed 
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1 Introduction
1.1 Incidence of breast cancer
Breast cancer is the commonest cause of death in women aged between 40 and 
50 years in Western countries, affecting about one million women world-wide per 
year.1 In the United Kingdom, the disease is of high incidence and mortality. At one 
time there are about 110,000 women with breast cancer in the UK, with around 
25,000-29,000 new cases and 15,000-16,000 deaths reported annually.2 Overall, the 
disease affects 1 in 12 women in the UK, and with a standardised mortality rate of
28.4 per 100,000 females. It has been suggested that environmental rather than 
genetic factors constitute predominantly the international difference in breast cancer 
incidence rate.
The cause of breast cancer, like that of other cancers, is yet to be fully 
understood. Epidemiological studies demonstrate that breast cancer is a heterogeneous 
disease with all women randomly at risk of developing it at some stage of their lives.
The aetiology of breast cancer and the probability of developing the disease 
appears to be influenced by a number of risk factors. An early start of menarche (<12 
years) increases the risk of breast cancer, while an early menopause (<45 years) or an 
increase in parity decreases the risk.3'8 The disease is less common in women whose 
first pregnancy occurs before they reach the age 20;7 who are multiparous; in whom 
ovaries are removed before the age of 37; of the lower socio-economic groups; and of 
non-Caucasian race.9,10 Breast cancer is also less common in societies where breast­
feeding is widely practised.11 However, it is three to five times more common in
i l l
blood relatives of those who are affected by the disease. ’ A previous history of 
common cystic diseases of the breast, such as chronic mastitis, increases the risk of 
developing breast cancer by two to three fold, in particular with those who have been 
treated with androgens.14 Obesity is a further risk factor but this has the most 
significant effect in postmenopausal women.15,16 Other factors which might also 
increase the risk of developing the disease include a prolonged use of oral 
contraceptives, or hormone replacement therapy (HRT),17'19 a diet with a high
1
consumption of unsaturated fats and alcohol and an exposure to high energy
9nradiation. ' However, there are no epidemiological data yet available which would 
suggest that individual women can modify their risk in developing breast cancer by 
simply avoiding certain risk factors.
1.2 The role of oestrogens in the aetiology of breast cancer
Oestrogens are one of the two types of sex hormones secreted by the ovaries 
and they are required for the development of secondary sexual characteristics such as 
the growth and maintenance of the breast, vagina and uterus. Chemically oestrogens 
are distinct from other steroids by their aromatic A-ring with a hydroxyl group at C-3. 
There have been more than twenty different oestrogens identified biochemically but, 
oestrone (El), oestradiol (E2), and oestriol (E3) are the three main oestrogens of 
clinical interest. Of these oestrogens, oestradiol is the most biologically potent and 
abundant oestrogen released from the ovaries and is responsible for the onset of 
oestrus (heat) in animals as well as the control of the menstrual cycle in women. 
Oestradiol is readily oxidized in the body to oestrone which in turn can be converted 
in the liver to oestriol.24
The influence of ovarian hormones, especially oestrogens, on the development 
of breast cancer has long been recognised. Animal studies have repeatedly 
demonstrated that oestrogen administration can induce and promote mammary
n r  o / r
tumours in rodents. ’ Epidemiological observation that the risk of breast cancer is 
determined by several reproductive variables (such as pregnancy and age at menarche) 
asserts the involvement of oestrogens. Clinical studies have established that 
regression of some human breast cancers can be achieved by means of endocrine
97ablation therapy such as oophorectomy (ovariectomy); adrenalectomy and 
hypophysectomy;28 and administration of antioestrogens,29 or paradoxically, by
TOadministration of very high doses of oestrogens.
Although it is generally believed that oestrogens act as promoters rather than as 
carcinogens in the development of breast cancer, the underlying biological mechanism 
through which oestrogens exert their effects remains poorly understood. Various
2
theories have been put forward to explain the role of oestogens in the aetiology of 
breast cancer:
i) The 'oestriol ratio' hypothesis, first proposed by Lemon et al.31 and later modified 
by Cole and MacMahon,32 involves the relative concentrations of three endogenous 
oestrogens [E3]/[E1]+[E2]. According to this hypothesis a women is considered to be 
at high risk in developing breast cancer when the E3 level, since menarche, is lower 
than that of E1+E2 combined, i.e. a low E3 ratio.33*37
ii) The ‘oestrogen window’ hypothesis which was put forward by Korenman,38 who 
suggested that breast cancer is more easily induced by carcinogens when oestrogenic 
stimulation of the mammary gland is unopposed by progesterone which is believed to 
act as oestrogen-antagonist. This hypothesis is supported by the observation that 
multiparous women are at low risk.
iii) Another theory proposed by Siiteri et al?9 involves the role of sex hormone 
binding globulin (SHBG). SHBG which presents in human serum is capable of 
binding, with high affinity, to both androgens and oestrogens, and hence influences the 
availability of oestrogen to target cells. SHBG levels are correlated with the level of 
E2 in the serum.39 In addition, reduced SHBG levels have been reported to be 
associated with excess body weight39 (obesity) which is an established risk factor for 
breast cancer in postmenopausal women.
In spite of the various theories which have been put forward over the years in 
an attempt to explain the mechanism of action for oestrogens, it is worth noting that 
any explanation based solely on oestrogen exposure may be too simplistic and that a 
complex interaction may actually occur amongst oestrogens and other endogenous 
hormones, influencing the aetiology of breast cancer.
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1.3 The biosynthetic pathway for oestrogens

















Scheme 1. The Biosynthetic Pathway for Oestrogens. The enzymes involved are: (1) 
20,22-desmolase or cholesterol side chain cleavage enzyme (CSCC), (2) 17 a- 
hydroxylase, (3) 17,20-lyase, (4) aromatase, (5) 17/3-hydroxysteroid dehydrogenase, 
(6) oestrone sulphatase, (7) oestrone sulphotransferase and (8) 3/3-dehydrogenase or 
isomerase.
In premenopausal women, oestrogens are produced predominately in the 
ovaries. Oestrogens (mainly 17/3-oestradiol and oestrone) are synthesized in the 
granulosa cells of the ovarian follicles from androgens (testosterone and 
androstendione) by the enzyme aromatase under the influence of follicle-stimulating
4
hormone (FSH), during the first half of the follicular phase, and a combination of 
luteinising hormone (LH) and FSH during the second half of the menstrual cycle. The 
androgen precursors are produced in the adjacent thecal cells largely under the 
influence of LH.40 During pregnancy, the aromatisation reaction of androgen 
precursors to oestrogens (primarily oestriol) takes place predominantly in the 
placenta.41
After menopause, the production of oestrogens by the ovaries ceases and the 
adrenal gland becomes the major source of oestrogen precursors. While the adrenal 
does not secrete oestrogens directly, it releases androstenedione, and to a minor extent, 
testosterone under the adrenocorticotrophin hormone (ACTH): cortisol feedback 
control. The circulating androgens are then converted to oestrone extraglandularly by 
aromatase in non-ovarian tissues such as liver, muscle, fat, brain and hair follicles.42'45 
The enzyme 17/3-hydroxysteroid dehydrogenase then converts oestrone to oestradiol, 
the most biologically active oestrogen.
It has also been shown that oestrogens are produced in breast cancer tissue in 
situ from plasma precursors. The levels of oestrogens in breast tumour tissues are 10- 
fold higher than those in plasma46,47 and one possible explanation for this tissue : 
plasma gradient is a local production of oestrogens. Several workers have 
demonstrated the presence of intra-tumoural aromatisation activity.48,49 Meanwhile, 
local oestrogen synthesis by surrounding adipose tissue cells may also provide an 
additional supply of oestrogens to tumour cells.50 In addition to this, the formation of 
oestrone from its sulphate conjugate in breast cancer tissue in situ has been suggested 
to be quantitatively more important than production from androstenedione via 
aromatase.51 Oestrone can be conjugated into the biologically by inactive oestrone 
sulphate to form a slowly turning over storage pool with a potential back conversion to 
oestrone via the enzyme oestrone sulphatase (Scheme 1). Santen has detected a 
million-fold higher level of sulphatase activity than aromatase in breast tumours.52 
However, the sulphatase enzyme found in human breast tumours, while of high 
capacity, is of low affinity51 (see section 1.7).
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1.4 Oestrogen receptors
Since the early 1960s much evidence has accumulated to support the concept 
of the presence of oestrogen receptors within the target tissues. In order for oestrogens 
to regulate cell growth and function in humans, a specific protein called the human 
oestrogen receptor (hER) must be present. The hER gene has been cloned, 
sequenced and expressed.54,55 It was found to be composed of two non-overlapping 
functional domains : the first domain has a high affinity for oestrogen and the second 
has affinity for DNA. Upon binding of oestrogen to the first domain, conformational 
change is apparently triggered in the second domain, allowing it to productively 
interact with specific DNA nucleotides known as a transcriptional enhancer region. 
The result of this interaction is the greatly increased production of m-RNA from 
selected genes, one or more of which are probably essential for efficient tumour cell 
growth.54,55
Earlier studies have suggested that hER is present in cytoplasm although it has 
now been shown that the receptors are found predominantly in the nuclear 
compartment and that the cytosol receptors originally suggested are in fact preparation 
artefacts resulting from liberation of free receptors from the nucleus during 
homogenisation.56,57
A patient with high concentration of receptor protein (i.e. more than 10 fmol 
receptor protein /mg breast tissue) is designated as being oestrogen-receptor positive 
(ER+) whilst one with less than this value is regarded as oestrogen receptor negative 
(ER-).58 Overall, 70% of primary tumours are ER+; but while premenopausal women 
show 60% ER+ tumours, almost 80% postmenopausal women show ER+ tumours.59,60 
The majority of patients (50-60%) whose tumours are ER+ are expected to respond to 
many different types of endocrine therapy (see section 1.6.1). However, there is an 
addition of around 10% of ER- tumours are also expected to respond to such 
treatments.61 It is therefore clinically informative and useful to have the ER status of 
the mammary tumours defined prior to treatment so that the response of a patient to
fOendocrine therapy can be predicted more accurately in advance. ’
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1.5 Primary treatment of breast cancer
Removal of lump(s) in the breast(s) by surgery is often indicated as the first- 
line treatment for primary breast cancer. For small carcinomas (i.e < 2-3 cm in 
diameter), breast conserving surgical techniques such as i) lumpectomy: removal of 
the lump together with a limited margin of normal tissue (1 cm), without removing 
any of the overlying skin; and ii) quadrantectomy: removal of an entire quadrant of the 
breast harbouring the primary carcinoma with excision of the corresponding cutaneous 
area are widely used which aim to render the surgery more cosmetically acceptable 
and psychologically reassuring to the patients. For large carcinomas (i.e > 2-3 cm in 
diameter), the procedure of choice is generally mastectomy and total axially 
dissection, with preservation of the pectoral muscles. The traditional Halsted 
mastectomy, in which both major and minor pectoral muscles are removed in 
conjunction with axillary nodes, is performed today only in exceptional cases of 
extensive and regionally invasive tumours.
Post-operative radiotherapy (treatment by exposure to ionizing rays such as X- 
ray) is usually indicated after surgery especially when breast-conserving techniques are 
involved. The breast is irradiated to sterilise residual microscopic cancer cells so as to 
limit the incidence of local recurrences.64 This combined procedure of surgery and 
radiotherapy has been shown to be as effective as Halsted mastectomy (i.e. extended 
radical mastectomy) alone when performed on patients with small carcinoma.65 In 
some patients with high risk of local recurrence such as those with large tumours and 
multiple nodes involvement, irradiation of the thoracic wall is carried out after 
mastectomy. In the case of inoperable breast cancer when mastectomy is considered 
inadequate in controlling the disease and hence avoided, patients are treated with high 
doses of radiation over the breast and the regional nodes. Meanwhile, radiotherapy is 
occasionally used pre-operatively to reduce a large tumour mass to an operatable size 
so that the extensiveness of the mastectomy can be reduced.66 Furthermore, palliative 
irradiation for some metastatic locations such as bone, skin, lymph node or brain 
metastases has also been widely used. It was shown that adjuvant therapy given after 
surgery could help to prevent recurrence of the disease.
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The introduction of cytotoxic polychemotherapy to the management of primary 
breast cancer has been considered for reducing large tumours to an operable size so 
that conservational surgery can be carried out.67,68 However, this approach is yet to be 
widely adopted because it has many drawbacks especially in terms of high toxicity and 
side effects.
1.6 Treatment of advanced breast cancer
The prognosis of breast cancer is determined primarily by the hormone 
dependency of the tumours. Thus, whilst patients with hormone-dependent tumours 
may survive for many years postoperatively with little intervention, patients with 
hormone insensitive tumours in contrast have a much shorter disease-free interval and 
subsequent survival rate. However, the average survival of patients in both groups 
following a relapse is between 18 and 24 months.2
In advanced hormone-dependent breast cancer, metastases of the tumour from 
its primary site to lymph glands, peri-breast tissues, skin and bones would have 
already taken place. In more aggressive metastases, the lung, liver and brain are also 
being invaded. Patients with visceral metastasis have the poorest prognosis, with a 
much shorter disease-free interval. At present, the aim in the treatment of advanced 
breast cancer is not for a cure but for a palliative control.
1.6.1 Endocrine therapy
Endocrine therapy is based on the putative role of oestrogens in the 
initiation/promotion of breast cancer and derived from the finding of Beatson that 
oophorectomy produced a substantial response in patients with advanced disease.27 
Other endocrine manipulations such as adrenalectomy and pituitary ablation, also 
produced similar response but they are no longer employed because of high morbidity 
and mortality.
The contemporary first-line endocrine therapy for premenopausal patients with 
the ER+ advanced disease is either tamoxifen or ovarian ablation (surgical or
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chemical) and the average response rate is 60 per cent.2 For postmenopausal women, 
the first-line treatment is invariably tamoxifen. In patients who respond to these 
treatments, there is an average control of the disease for 15-20 months. However, 
eventually and inevitably, patients will progress (i.e. tolerance has developed to the 
therapeutic intervention) and second-line endocrine therapy is then initiated. There are 
usually up to 50 per cent of first-line treatment responders who will respond to the 
second-line regime. Unfortunately for non-responders of first-line treatment, only 
about 10 per cent will respond to a second-line hormone therapy.
In the past few years, the relatively new third-generation aromatase inhibitors 
(eg, anastrazole) have gradually replaced the progestins (eg, megestrol) as the drug of 
choice in the second-line treatment of postmenopausal patients. However, tamoxifen 
or ovarian ablation is still the option for treating premenopausal women at this stage.
When remission of the cancer occurs after the second-line treatment, up to 
10% of patients will respond to a third-line treatment if they have shown response to 
the previous two treatments. The treatment options at this stage are an aromatase 
inhibitor for premenopausal patients and either megestrol or an aromatase inhibitor for 
postmenopausal women.69 A fourth-line treatment using a high dose of androgen or 
oestrogen (additive hormone therapy) is only used when all the (other) endocrine 
options have failed.70
1.6.2 Endocrine ablation
Ovarian ablation either by surgery or irradiation has been an effective 
treatment in providing tumour regression in around one-third of premenopasual 
patients with recurrent breast cancer.71 The best response rate is observed in those 
patients with ER+ tumours. Among those non-responders to ovarian ablation, a 
further 10-20% of patients will show remission following adrenalectomy and/or 
hypophysectomy.72 Although many oncologists nowadays prefer to delay preforming 
ovarian ablation until the premenopausal patients have shown positive relapse because 
of the irreversible nature and unpleasant side-effects of the technique, a revival call for
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a prophylactic use of ovarian ablation after mastectomy in the management of early 
breast cancer in selected premenopausal patients has been raised.73,74
In postmenopausal women, ovarian ablation has rarely been effective71 since 
their ovaries have ceased to produce oestrogens. When endocrine ablative therapy is 
considered for these women, adrenalectomy and/or hypophysectomy is the treatment 
of choice particularly when the tumours are ER+. However, their role has been much 
diminished because of the advent of alternative endocrine therapies (e.g. anti- 
oestrogens and aromatase inhibitors, see later) and also studies carried out on the 
patients after ablative treatment have not demonstrated complete elimination of 
oestrogen production.75
1.6.3 Chemotherapy
For ER- patients and also ER+ patients who fail to respond to endocrine 
therapy, cytotoxic chemotherapy is their other treatment whose regimen for individual 
patient aims to maximize the killing of tumour cells but minimize the intolerable side 
effects associated with the treatment.
In ER- patients where cytotoxic chemotherapy is the first-line treatment, 
responses are in the range 40-60% with a relapse time of 6-10 months. However, as 
with endocrine treatment, subsequent chemotherapy after failure of first-line treatment 
carries a much lower response rate.
The cytotoxic regimens used for metastatic disease are much the same as those 
employed for adjuvant therapy.69,70 The use of a single cytotoxic agent in the 
treatment of metastatic breast cancer is found to be less effective than the combination 
regimen (polychemotherapy) 76,77 No single combination of cytotoxic agents has been 
shown to be the most effective (i.e. maximum response rate with minimum toxic 
effects) and the commonly employed combinations include: (i) CMF
(cyclophosphamide, methotrexate and 5-fluorouracil), (ii) CAF (cyclophosphamide 
/doxorubicin (adriamycin) and 5-fluorouracil) and (iii) MMM (mitozantrone, 
methotrexate and mitomycin C) which are given in several courses spaced over a
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period of 6 months (eg, every 3-4 weeks).78 Long-term maintenance therapy is no 
longer recommended since the effectiveness of such extended treatment is similar to 
that achieved after a shorter 6 month’s treatment.78 In resistant patients 
polychemotherapy may be followed by a course of vinblastine/methotrexate, paclitaxel 
or vinorelbine and this in turn may be followed by a further course of either 5- 
fluorouracil/folinic acid or vinblastine/mitomycin.69 Inevitably, patients treated with 
these cytotoxic agents will subsequently develop tolerance (probably as a result of an 
induction of a P I70 membrane glycoprotein which is a “drug extruder”) and the 
disease progresses.
1.6.4 Antioestrogens
Antioestrogens were initially developed for use as potential antifertility agents. 
However, it was upon the discovery of the presence of ER in breast tumours and the 
establishment of a causal relationship between the percentage of oestradiol and tumour 
viability, when the known pharmacological property of anti-oestrogens in blocking the 
binding of oestrogens to ER was fully evaluated for the treatment of hormone- 
dependent breast cancer. For the past 25 years antioestrogens have been used as the 
first-line treatment for hormone-dependent breast cancer.
The mechanism of action for antioestrogens is attributed to their ability in 
inhibiting competitively the high affinity binding of oestradiol to specific ER and so 
attenuating the biological effects of the oestrogens as a consequence.79,80 Recent 
evidence also suggests that antioestrogens, including tamoxifen, may act by (i) 
increasing the secretion of inhibitory growth factor (TGF f$) by ER+ cells which, in 
turn, may inhibit growth of adjacent cells,81 or (ii) modifying the biological response
through the enhancement of natural killer cell activity in patients with early breast
82cancer.
Tamoxifen (Fig.l), a non-steroidal compound and derivative of 
triphenylethylene is the most widely used antioestrogen to date. However, the drug 
is described as a partial agonist.84 Its main indication is for the first-line endocrine 
treatment of women requiring hormonal therapy. In one study, the overall objective
11
response rate to treatment with tamoxifen was found to be around 34% whilst disease 
stabilization was achieved in a further 19% of patients with the mean or median
or
duration of response varying between 2 and > 24 months. The response rate seems 
to increase with the age of the patients with elderly patients showing a significantly 
higher rate of response.86 Meanwhile, about 46% of patients with ER+ tumours will 
respond to tamoxifen whereas only around 12% of patients with ER- tumours are
or
responders. However, most patients, irrespective of their ER status, will be treated 
with tamoxifen at some stage of their treatment programme because of the very low 
toxicity profile of the drug. When the use of tamoxifen alone is compared with other 
forms of endocrine therapy such as ovarian ablation, adrenalectomy and oestrogens in 
the treatment of advanced breast cancer, the objective response rates have been found 
to be comparable but tamoxifen is better tolerated. It has also been shown, in 
general, that the use of tamoxifen in combination with other therapies such as 
endocrine therapy or cytotoxic chemotherapy has offered no improvement in the
Q /'
response rates than the use of tamoxifen alone. Recently, it has also been shown that 
a prophylactic use of tamoxifen in patients with a high risk of breast cancer decreases 
such risk by about 50%.
N(CH3 )2
"(CH2)9SO(CH2)3CF2CF3
Tamoxifen ICI 182 780
Figure 1. Structures of tamoxifen and ICI 182 780.
Other antioestrogens have also been used in the treatment of metastatic breast 
cancer and they include trioxifene,87 toremifene (Chlorotamoxifen) 88 and droloxifene
OQ
(3-hydroxytamoxifen) although the efficacy and safety data of these agents are
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limited. Meanwhile a new class of antioestrogen90 has been developed, the steroidal 
compounds ICI 164384, ICI 182780 (Fig.l) and RU 54876 which are more 
efficient91,92 than tamoxifen as antioestrogens and have shown little or no agonist 
activity.84,93 These steroidal agents may be useful as a first-line therapy in advanced 
disease or as a second-line therapy in advanced disease where tamoxifen has 
previously been used but failed.94 Other new non-steroidal antioestrogens (eg, 
idoxifene and raloxifene) are currently in clinical trials. While these agents are not 
pure antagonists, they appear to have less agonistic activity than tamoxifen.93
1.6.5 Aromatase inhibitors
Aromatase is the enzyme responsible for converting androgens to oestrogens.95 
In premenopausal women, the ovaries are the main site of oestrogen synthesis whose 
regulation is under a feedback control by the pituitary/hypothalamic axis. In 
postmenopausal women, the aromatisation of androgens into oestrogens takes place 
extraglandularly in peripheral tissues such as the adipose, muscles, liver and skin. 
Aromatase is an enzyme complex consisting of a cytochrome P450 haemoprotein and 
a ubiquitous electron-donating flavoprotein, NADPH-cytochrome P450 reductase.96 
The C19 androgen substrates androstenedione and testosterone bind to the P450 
aromatase (P450 arom) which catalyses the aromatization of the androgen A-ring and 
loss of the C19 methyl group to yield oestrone and oestradiol respectively.97,98 The 
enzyme is present in the majority of breast tumours. Inhibition of the enzyme blocks 
the synthesis of oestrogen in postmenopasual women.
Aminoglutethimide (AG, Fig.2) was the first aromatase inhibitor used 
clinically for the treatment of hormone-dependent breast cancer.99 However, the drug 
lacks adequate selectivity for aromatase and inhibits several other P450 enzymes of 
the steroidogenic pathway, blocking production of various adrenal steroids and 
necessitating the coadministration of a glucocorticoid. AG also possesses other 




Figure 2. Structures of first generation (Aminoglutethimide, AG) and second 
generation aromatase inhibitors (Rogletimide and Fadrozole)
Over the past decade, the clinical role of AG in the treatment of hormone- 
dependent cancer has been diminished substantially by the advent of a new generation 
of potent and selective aromatase inhibitors.93,100 Depending upon the manner in 
which the molecule binds to the enzyme active site, aromatase inhibitors can be 
classified into two types.
OH
Formestane Plomestane Exemestane
Figure 3. Structures of type I aromatase inhibitors
Type I inhibitors are predominately steroidal and are derivatives of 
androstenedione which bind to the steroid recognition site on the enzyme and are then 
activated by the catalytic mechanism of the enzyme. The reactive product so formed 
then covalently binds to the neighbouring amino acids leading to an irreversible 
inhibition of the enzyme. 101 Formestane (4-hydroxyandrostenedione, Fig.3) 100 is the
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prime example of a type I inhibitor and was the first of this type to be used clinically. 
However, due to a high first-pass metabolism, the drug has a poor oral bioavailability 
and is therefore administered intramuscularly which reduces patient compliance.93
Type II aromatase inhibitors are predominately non-steroidal bases, largely 
imidazoles and triazoles, which compete reversibly with androstenedione for the 
enzyme. AG belongs to this type of inhibitor group. In these molecules, the basic 
nitrogen atom ligates with the iron atom at the centre of the haem moiety of the 
enzyme while the rest of the structure of the inhibitor aligns more or less closely with 
the substrate (steroid) binding domain. 102
The third generation aromatase inhibitors (anastrazole, lentrozole and 
vorozole, Fig. 4) have potency and high selectivity for the enzyme and are well 
tolerated.93 In the UK, anastrazole is used in preference to AG.
Vorozole Letrozole Anastrozole
Figure 4. Structures of anastrazole (1), lentrozole (2) and vorozole (3)
Clinical use of aromatase inhibitors has shown similar results to those achieved 
with surgical adrenolectomy or hypophysectomy, but without the morbidity and 
significant mortality (4-15%) associated with the ablative techniques. Aromatase 
inhibitors are ineffective for premenopausal women due to their inability to suppress 
ovarian induced aromatisation. 103,104
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1.7 Steroid sulphatase inhibitors : A new endocrine therapy
C = C H
,OH
Figure 5. Structure of danazol
Steroid sulphatases regulate many important physiological processes, including 
the formation of neurosteroids, some aspects of reproductive function and part of the 
immune response. Dehydroepiandrosterone sulphatase in macrophages regulates the 
progression of To helper cells to the Thl phenotype105’106 which secrete cytokines 
which may be involved in the development of some autoimmune diseases. 
Neurosteroids are concentrated within the central nervous system (CNS) and are 
known to produce effects mediated by CNS. 107' 109 Among the effects associated with 
neurosteroids is the enhancement of memory. 110*112 The mechanism for this 
enhancement is not well understood but neurosteroids such as pregnenolone sulphate 
(PS) and dehydroepiandrosterone sulphate (DHEA-S) are known to inhibit the actions 
mediated by the GABAa receptor and facilitate those mediated by NMDA 
receptors. 107,108 The unsulphated analogues, pregnenolone and
dehydroepiandrosterone, can also enhance memory. However, since the metabolism 
of pregnenolone and DHEA between the sulphated and unsulphated forms occurs bi- 
directionally within the CNS, it is uncertain whether the sulphated and unsulphated 
forms produce memory enhancing effects independently or via metabolism from one 
analogue to the other. However, their pivotal role in regulating oestrogen synthesis in 
endocrine-dependent tumours has been the greatest stimulus to the development of 
potent steroid sulphatase inhibitors. Carlstrom et a / . 113 made the initial observation 
that danazol (Fig. 5), an isoxazole derivative of 17a-ethinyltestosterone, possesses 
steroid sulphatase inhibitory properties when it was found that the ratio of 
dehydroepiandrosterone sulphate (DHEA-S) to unconjugated DHEA increased in 
women treated with the drug for endometriosis. Subsequent in vitro studies confirmed
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the ability of danazol to inhibit DHEA sulphatase activity in breast tissues. 114 Since 
this finding, several research groups have set out to synthesize and develop potent 
steroid sulphatase inhibitors.
1.7.1 Role of steroid sulphatase in oestrogen synthesis in breast cancer and
endometrial cancer
There is now substantial evidence to imply that the in situ formation of 
oestrogens in breast tumours, and also possibly in endometrial tumours, from 
oestrogen precursors is the major contribution to the high oestrogen concentrations 
found in these tissues. 115,116 Concentrations of oestradiol in tumours are higher than 
those of oestrone, and also the levels of both oestrogens in tumours are considerably 
higher those in plasma of postmenopausal women. 117,118 Although breast and 
endometrial cancer affect adult women of all ages, the highest incidence is in 
postmenopausal women, at a time when ovarian production of oestrogens has ceased. 
However, oestrogens continue to be produced in postmenopausal women 
extraglandularly and, while adipose tissue is a major site of peripheral oestrogen 
synthesis, all the enzymes which are required for oestrogen formation from androgen 












HO ^  
Dehydroepiandrosterone (DHA)Oestrone Sulphate (E1S)
Scheme 2. The origin of oestrogenic steroids in postmenopausal women: E l, oestrone; 
S, sulphate; ST, sulphotransferase; STS, sulphatase; 17/3-HSD, 17/Thydroxysteroid 
dehydrogenase; ER, oestrogen receptor.
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These enzymes include aromatase, which converts androstenedione to 
oestrone, and 17/3-hydroxysteroid dehydrogenase, which reduces oestrone to 
oestradiol.120,121 Much of the oestrone formed from the aromatization of 
androstenedione is converted to oestrone sulphate by oestrone sulphotransferase,122 
and the biologically inactive E1S can be hydrolysed back to oestrone by the action of 
oestrone sulphatase.
Plasma concentrations of oestrone sulphate are 10-20 times higher than those 
of the unconjugated oestrogens,123 and the half-life of oestrone sulphate in blood (10- 
12h) is considerably longer than that of unconjugated oestrogens (20min).124 
Furthermore, the sulphatase pathway is thought to be the major route for breast tumour 
oestrogen synthesis, with at least 10 times as much oestrone in tumours originating via 
this route than is formed from androstenedione.51
The possibility that oestrone sulphate may act as a reservoir for oestrone 
synthesis in postmenopausal women was raised when studies on women with breast 
cancer being treated with aromatase inhibitors revealed that while inhibitors such as 
aminoglutethimide or 4-hydroxyandrostenedione effectively abolished peripheral 
aromatase activity, plasma oestrone and oestradiol concentrations unexpectedly only 
decreased by 40-50 %.125,126 In addition plasma E1S concentrations remain relatively
1 07  1 7 0high during treatment with aromatase inhibitors, ’ and it was reasoned that the 
conversion of oestrone sulphate to oestrone was the likely source of the unconjugated 
oestrogens which were still detectable in the plasma of women receiving aromatase 
inhibitor therapy.129 The results from these clinical studies prompted the synthesis of 
the steroidal analogue, oestrone-3-O-methylthiophosphonate (El-MTP, Fig.7, 2), 
which was the first compound specifically developed as a potential sulphatase 
inhibitor.130
1.7.2 DHEA sulphatase regulates the synthesis of androstenediol (an
oestrogenic hormone)
In addition to the El-STS pathway, there is a growing awareness that another 
steroid, androstenediol, which has oestrogenic properties may be of even greater 
importance in the support of growth and development of hormone-dependent breast
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tumours. This hormone, although an androgen, can bind to the ER and can stimulate 
the growth of ER+ breast cancer cells.131,132 Androstenediol also stimulates the 
growth of dimethylbenzanthracene-induced mammary tumours in the rat, and is able 
to stimulate tumour growth in the presence of an aromatase inhibitor, showing that it 
does not have to undergo conversion to an oestrogen in order to be able to stimulate 
tumour growth.133
It has been shown that almost 90% of androstenediol is derived from 
dehydroepiandrosterone sulphate (DHEA-S),134 either via i) the hydrolysis of DHEA-S 
to DHEA by DHEA sulphatase (DHEA-STS), with subsequent metabolism of DHEA 
to androstenediol, or ii) the conversion of DHEA-S to androstenediol sulphate, with 
subsequent hydrolysis to androstenediol (Scheme 2, page 17). Although the affinity of 
androstenediol for the ER is somewhat lower than that of oestradiol, plasma 
androstenediol concentrations are 100-fold higher than those of oestradiol. A 
significant correlation was also found between plasma DHEA-S and androstenediol 
concentrations in postmenopausal women, adding further evidence for DHEA-S being 
the major source of plasma androstenediol.135 The oestrogenic stimulation of 
hormone-dependent breast cancer is therefore more significantly reduced by inhibiting 
not only El-STS but also DHEA-STS.
1.7.3 Are oestrone sulphatase and DHEA sulphatase the same or different
enzymes?
Steroid sulphatase is found in most body tissues, and on examination of its 
distribution in the rhesus monkey the enzyme was detected in every tissue examined 
except the salivary gland. Mammalian aryl sulphatase is classified into three types, A, 
B, and C. The microsomal aryl sulphatase C (steryl sulphate sulphohydrolase, EC 
3.1.6.2), which is responsible for the hydrolysis of 3/3-hydroxysteroids has now been 
purified137,138.
The issue of whether El-STS and DHEA-STS are the same enzyme has not 
been fully resolved.139 However, the protein expressed by a transient transfection of a 
placental steroid sulphatase gene into COS-1 cells was found to be able to hydrolyse 
both E1S and DHEA-S, providing evidence for only one enzyme being responsible for
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the hydrolysis of both alkyl and aryl steroid sulphates.140 Furthermore, it has been 
shown that oestrone-3-O-sulphamate (see later), a potent steroid sulphatase inhibitor 
inhibits the hydrolysis of both E1S and DHEA-S.140,141 These results have further 
demonstrated that it should be possible to block the synthesis of oestrone and regulate 
that of androstenediol using a steroid sulphatase inhibitor.
1.7.4 Endocrine drugs as potential steroid sulphatase inhibitors
As previously discussed, in addition to its other pharmacological properties, 
danazol was the first drug being shown to have the ability to inhibit steroid 
sulphatase113 (62% at 10 pM in MCF-7 cells).142 Since this observation, a number of 
steroidal and non-steroidal drugs which are currently used to treat endocrine disorders, 
have also been examined for their potential as steroid sulphatase inhibitors. It has 
been reported that antioestrogens could decrease the concentration of oestradiol in 
breast cancer cells.143 Tamoxifen, 4-hydroxytamoxifen and the 'pure' antioestrogen 
ICI 168384 were all found to inhibit sulphatase activity,144 but with relatively high Ki 
values (e.g. 1130 pM). However in vivo, these antioestrogens were shown to have 
either no effect or increased liver sulphatase activity.144,145 The plasma oestrogen 
concentrations have been measured in postmenopausal women receiving tamoxifen 
therapy and it was found that there were only relatively minor alterations, or no 
changes, in plasma oestrogen concentrations.146
Progestogens and their derivatives (e.g demegestone, chlormadinone acetate, 
medroxyprogesterone and promegestone), some of which are widely used for oral 
contraceptive and hormone replacement therapies, were examined for their ability to 
inhibit steroid sulphatase activity in vitro and in Ww?.140,142,143,147,148 This group of 
endocrine drugs were all found to be considerably weak inhibitors of steroid 
sulphatase.
It is unlikely that these relatively weak inhibitory activities of antioestrogens 
and progestogens against steroid sulphatase will be of any clinical significance in the 
treatment of hormone-dependent breast cancer. In order that a new form of endocrine
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therapy, via the inhibition of steroid sulphatase, can be developed, there is a need for 
more specific and potent steroid sulphatase inhibitors.
1.7.5 Development of steroidal sulphatase inhibitors
Recognition of the pivotal role that steroid sulphatases have in regulating the 
synthesis of biologically active steroids has led to the development of potent 
inhibitors. Initial studies have revealed that steroid sulphates could inhibit sulphatase 
activity, and that one compound, androstendiol-3-sulphate (Fig. 6 ) was shown to have 
an Ki of 2 pM . 144,149,150 However, a major problem with steroid sulphates, which act 
as competitive inhibitors, is that while they are active in vitro, in vivo the sulphate 
group is liable to be removed by hydrolysis and hence releasing the biologically active 
unconjugated steroids. As yet there is no evidence that steroid sulphate inhibitors such
• . • 144 149 150as androstendiol-3-sulphate are active in vivo. ' '
A series of oestrone-3-sulphonyl derivatives were synthesized by Li et al. 151 as 
steroid sulphatase inhibitors of which the sulphonyl chloride (Fig.7, 1) was found to be 
the best inhibitor of the series, inhibiting oestrone sulphatase activity in placental 
microsomes by 65% at 60 pM . 151 Although compound 1 could have inactivated the 
enzyme via sulphonylation, preliminary data have suggested that other derivatives in 
this series are only weak competitive inhibitors. 151,152
OH
Figure 6. Structure of androstendiol 3-sulphate
Cox et a / . 153 in an attempt to generate antisera that are reactive directly to E1S 
has also observed that the antibodies which recognise oestrone-3-0- 
methylthiophosphonate (El-MTP, Fig.7, 2) also recognise E1S. This observation has
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therefore suggested that El-MTP may act as a steroid sulphatase inhibitor since it 
mimics E1S structurally and that its MTP moiety could act as a sulphate surrogate. In 
addition, this compound was found to be resistant to metabolism in vivo, suggesting 
that it was not an alternative substrate for oestrone sulphatase.
El-MTP was found to be about 14 times more potent than danazol in its ability 
to inhibit oestrone sulphatase activity in intact MCF-7 cells, and had a Ki of 37.5 pM 
for the inhibition of sulphatase activity in microsomes prepared from breast tumour 
tissue. 130 Incubation of El-MTP with liver or placental tissues confirmed its 
resistance to metabolism, whereas at least 50% of oestrone sulphate, incubated in a 
similar manner, was converted to oestrone.
Preliminary studies were attempted to examine the in vivo efficacy of El-MTP. 
However, since this compound is a competitive inhibitor, 130 it is difficult to 
demonstrate inhibition in tissues obtained from animals treated with this compound. 
This is presumably due to the fact that upon dilution and homogenization the inhibitor 
concentration at the active site of the enzyme is reduced, making it difficult to 
demonstrate inhibition. However, some evidence was obtained to indicate that E l- 
MTP does inhibit El-STS activity in vivo. Plasma oestradiol concentrations were 
measured in samples obtained from treated (1 mg/kg per day for 7 days s.c.) and 
untreated animals. The plasma oestradiol concentration was about 50% lower in 
treated rats, suggesting that El-MTP is active in vivo.
O
R
Figure 7. Structures of oestrone-3-sulphonyl chloride 1, R = SO2CI and oestrone-3-0- 
methylthiophosphonate 2, R = 0PS(M e)0‘
With the encouraging results of El-MTP, many groups have further explored 
other E1S analogues possessing sulphate surrogates as steroid sulphatase inhibitors.
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These compounds include oestrone-3-O-phosphate (Fig.8 , l ) , 154' 156 oestrone-3- 
methylsulphonate (Fig.8 , 2), oestrone-3-methylene sulphonate (Fig.8 , 3)155, oestrone- 
3-0-//-phosphonate (Fig.8 , 4) and DHEA-3-O-phosphate (Fig. 9) . 154 Oestrone-3-0- 
phosphate is a relatively potent steroid sulphatase inhibitor with Ki values of 0.89 
|LtM154 and 0.3 pM 155 when measured at pH 7.0. Oestrone-3-0-//-phosphonate (Fig.8 , 
4) was found to inhibit El-STS activity in MCF-7 cells by 80% at 10 pM . 156
Replacement of the sulphate group in E1S with a methylene sulphonate group 
has rendered a Kj value of 3 some 100-fold higher than the Km of oestrone sulphate, 
indicating that the bridging oxygen atom present in oestrone sulphate is essential for 
high affinity binding. Oestrone-3-methylsulphonate (Fig.8 , 2) and
dehydroepiandrosterone-3-O-phosphate (Fig.9) were found to be weaker inhibitors 
than oestrone-3-(9-phosphate (Table 1). Other derivatives of steroid sulphate 













Figure 8. Structures of steroid sulphatase inhibitors
Figure 9. Structure of dehydroepiandrosterone-3-O-phosphate
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E 1 -3-0-methy lsulphonate 28
E 1 -3-O-ethy lsulphonate 27
E 1 -3-O-buty lsulphonate 17
E 1 -3-0-//-phosphonate 80
E 1 -3-0-(methylphosphonate) 41
E 1 -3-0-(ethylphosphonate) 53
E 1 -3-0-(phenylphosphonate) 42
E 1 -3-0-(phenylphosphoramidate) 32
E l, oestrone; E2, oestradiol
El-MTP and other compounds therefore provided some indication as to the 
type of steroid derivatives which might be useful as steroid sulphatase inhibitors. 
While most compounds tested had a potency similar to that of El-MTP in their ability 
to inhibit oestrone sulphatase activity in MCF-7 cells and they were reversible 
inhibitors, one compound, oestrone-3-O-sulphamate (EMATE, Fig. 10, 1), and its N- 
methylated derivatives (Fig. 10, 2 and 3), were found to be more potent than El-MTP.
R
R
Oestrone-3-O-sulphamate (EMATE) 0 S 0 2NH2 (1)
oestrone-3-0-(A-methyl)sulphamate 0 S 0 2NHMe (2)
oestrone-3-0-(A,A-dimethyl)sulphamate 0 S 0 2NMe2 (3)
Figure 10. Structures of EMATE and its A-methylated derivatives
EMATE is about 100-1000-fold more potent than its A-methylated 
derivatives. 141 In vitro, EMATE inhibits El-STS activity by > 99% at 0.1 jjM  in 
intact MCF-7 breast cancer cells (Table 2) and in a time-and concentration-dependent
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manner in a placental microsomes preparation, indicating that it acts as an irreversible 
inhibitor. 141157 In contrast, oestrone-3-0-(Af,./V-dimethyl) sulphamate and El-MTP 
were found to be reversible inhibitors. Subsequent studies have also shown that 
EMATE inhibits DHA-STS. 140,141 EMATE is also active in vivo, inhibiting rat liver 
El-STS and DHA-STS activities almost completely when given either orally or 
subcutaneously. 145
EMATE was also examined for its ability to reduce the growth of oestrone 
sulphate-stimulated nitrosomethylurea-induced mammary tumours in the rat. This 
model has been widely used to evaluate a number of endocrine therapies and Santner
|  c o
et al. have initially demonstrated that physiological concentrations of oestrone 
sulphate could stimulate the growth of these tumours in ovariectomized rat. After the 
administration of EMATE (1 mg/kg for 12 days s.c.) the rate of oestrone sulphate- 
stimulated growth was reduced, with tumour regression being detected by the end of 
the study period. Oestrone sulphatase activity in the tumours and livers of treated 
animals was almost completely suppressed. 145
Table 2. Inhibition of oestrone sulphatase activity in MCF-7 cells by various steroid 
sulphamates______________________________________________________________
Compound % Inhibition
10 JJM 1 fiM o.i m
E 1 -3-O-sulphamate 99 99 99
E2-3-0-sulphamate - - 97
DHEA-3-O-sulphamate 46 - 14
In order to study further the structure-activity relationships for the sulphamate 
group in EMATE, analogues of EMATE were synthesized and tested for inhibition of 
El-STS, in which the 3-O-atom is replaced by other heteroatoms (S and N) , 159 these 
including, oestrone-3-sulphamide (Fig. 11, 1), oestrone-3-S-sulphamate (Fig. 11, 2) and 
oestrone-3-S-(iV,A-dimethyl) sulphamate (Fig.l 1, 3). These compounds were found to 
be only weak non-time-dependent inhibitors.
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Figure 11. Structures of oestrone-3-sulphamide (1) R = -NHSO2NH2, oestrone-3-S- 
sulphamate(2) R = -SSO2NH2 and oestrone-3-,S-(A,A-dimethyr)sulphamate(3) R = -
SS02N(CH3) 2
Therefore, the bridging oxygen atom in the sulphamate group (H2NSO2O-) of 
EMATE is required for its high potency and nature of inhibition. 159 As shown above 
when the A-atom of the sulphamate group of EMATE is increasingly methylated, 
significant reduction in the inhibition of El-STS activity resulted.
Further modifications of the sulphamoyl group of EMATE was carried out and 
its A-atom was alkylated to give e.g. oestrone-3-0-A-(piperidino)sulphamate (Fig. 12, 
1) and oestrone-3-0-(A,A-dibenzyl)sulphamate (Fig. 12, 2); and acylated to give e.g. 
oestrone-3-0-(A-acetyl)sulphamate (Fig. 12, 3) . 160 In comparison with EMATE, both 
compounds (Fig. 12, 1 and 2) were weak El-STS inhibitors and none of them was 
found to be an irreversible inhibitor. The A-acetyl derivative of EMATE (Fig. 12, 3) 
was found to exhibited time- and concentration-dependent inhibition of El-STS in a 
similar manner to EMATE. 160 This compound was also found to be potent inhibitor 
(inhibited El-STS by 93% at lOpM in placental microsomes), but it is considerably 
less potent than EMATE.
R
R
Oestrone-3-0-A-(piperidino)sulphamate /  \
OS°2N^   (1)
Oestrone-3-0-(A,A-dibenzyl)sulphamate -0 S0 2 N(CH2Ph)2 (2)
Oestrone-3-0-(A-acetyl)sulphamate -OSO2NHCOCH3 (3)
Figure 12. Structures of A-alkylated and acylated analogues of EMATE.
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EMATE also was tested for the reversal of scopolamine induced amnesia.161 It 
was administered alone and in combination with neurosteroid dehydroepiandrosterone 
sulphate (DHEA-S) to rats. When administered without DHEA-S, as a single acute 
dose, EMATE had no effect. However, when EMATE was administered without 
DHEA-S over 10 consecutive days, a significant improvement in retention was 
observed, suggesting that steroid sulphatase inhibition can potentiate the memory 
enhancing properties of DHEA-S. In the same study it has also been suggested that an 
increase in the levels of endogenous sulphated neurosteroid via the inhibition of 
steroid sulphatase activity may enhance learning and/ or memory function. These 
results suggest that increasing concentrations of sulphated neurosteroids by sulphatase 
inhibitors can amplify centrally mediated cholinergic functions including memory.161
1 f i 9However, EMATE was also shown to be a potent oestrogen, being five 
times more oestrogenic than ethinyloestradiol when administered orally to rats. The 
exact reasons why EMATE is such a potent oestrogen remain to be elucidated 
although current evidence suggests that it is acting as a pro-drug of oestrone.162 
Therefore, due to the sensitivity of endocrine-dependent tumours of the breast and 
endometrium to oestrogens, EMATE is clearly unsuitable for use as a sulphatase 
inhibitor in such diseases. EMATE and its oestradiol analogue were found to have 
higher systemic, but reduced hepatic oestrogenic activity than their parent steroids. 
However, these sulphamates could be utilized in developing natural oestrogens for 
oral oestrogen therapy. Clinical phase I studies using EMATE analogues, the 
oestradiol analogue and other steroid analogues (e.g. oestriol, ethinyloestradiol) have 
been started. A confirmation of the animal experiments in women may also lead to 
drugs with fundamental benefits in oral contraception and hormone replacement 
therapy.163164
1.7.6. Development of non-steroidal sulphatase inhibitors
The first series of non-steroidal steroid sulphatase inhibitors developed were 
based upon 5-acetoxy-3-(4-acetoxyphenyl)-l-ethyl-3-methylindole which was 
originally designed as a new class of mammary tumour inhibitory compounds. 3- 
Methyl-l-pentafluorophenylmethyl-6-sulphooxy-2-(4-sulphooxyphenyl)-4-
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trifluoromethylindole (Fig. 13) was found to be the most potent inhibitor of this class 
(IC50 of 80 /jM  using calf uterus sulphatase preparation) . 165
Na+ '0 S 0 20
0 S 0 20  Na+
Figure 13. Structure of 3-methyl-l-pentafluorophenylmethyl-6-sulphooxy-2-(4- 
sulphooxyphenyl)-4-trifluoromethylindole, disodium salt
In an alternative approach, a series of sulphamate derivatives of 
tetrahydronaphthol (THN-sulphamates, Fig. 14) and diethylstilboestrol (DES- 
sulphamates, Fig. 15) were synthesised and tested for their ability to inhibit oestrone 
sulphatase (Table 3) . 156
4 5
R
5,6,7,8-Tetrahydronaphthalene 2 -0 -sulphamate (THN- (1) -SO2NH2
sulphamate)
THN-2-O-Af-methylsulphamate (2) - S 0 2NHMe
THN-2-O-AUV-dimethylsulphamate (3) -S0 2 NMe2
Figure 14. Structures of THN-sulphamates
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R
(1) -S 0 2NH2
(2) -S 0 2NMe2
Figure 15. Structures of DES-bis-sulphamates
Table 3. IC50 values for sulphamate derivatives of tetahydronaphthol (THN) and 
diethylstilboestrol (DES) as measured in MCF-7 breast cancer cells. Values for 
oestrone-3-0-sulphamate (EMATE) and oestrone-3-O-methylthiophosphonate (E l- 
MTP) are included for comparison.____________________________________________
Compound I C 50
THN-sulphamate (Fig. 14, 1) 1 p M
THN-V-methylsulphamate (Fig. 14, 2) 25 p M
THN-V,V-dimethylsulphamate (Fig. 14, 3) >50 p M
DES-/?f?-sulphamate (Fig. 15, 1) 10 nM
DES-bis-V,V-dimethylsulphamate (Fig. 15, 2) 10 p M
El-MTP (Fig.7, 2) 100 nM
EMATE (Fig. 10, 1) 65 pM
While the iV,A-dimethylsulphamate of THN (Fig. 14, 3) was inactive when 
tested at 10 p M ,  THN-sulphamate (Fig. 14, 1 )  was found to be the most potent, 
inhibiting El-STS activity in intact MCF-7 cells by 15-79% over the 0.1-10 p M  range. 
Pretreating MCF-7 breast cancer cells with THN-sulphamate, in the same manner used 
to investigate the nature of EMATE inhibition, revealed that oestrone sulphatase 
activity only recovered by 22% compared with the activity in untreated cells. This 
result suggests that THN-sulphamate may act as a weak irreversible inhibitor. The 
sulphamate derivatives of DES were considerably more potent inhibitors than the 
THN derivatives. DES-bis-sulphamate (Fig. 15, 1) inhibited activity by more than 
90% at all concentrations tested (0.1-10 p M ) .  The IC50 values for the sulphamate 






EMATE and El-MTP in Table 2. Like EMATE, DES-bis-sulphamate (Fig. 15, 1) 
appears to act as an irreversible inhibitor. 156
Ei E 2 E3 r 4
(1) H H -OSO2NH2 H
(2) H c h 3 -OSO2NH2 H
(3) c h 3 c h 3 -OSO2NH2 c h 3
(4) H c f 3 -OSO2NH2 H
(5) c h 3 c h 3 -OSO2NH2 H
Figure 16. Structures of coumarin sulphamate derivatives
The finding that phenolic compounds such as THN could be utilised as E l- 
STS inhibitors led to the development of a series of coumarin sulphamate derivatives 
(Fig. 16, 1-5).166,167 The analogues synthesised and tested in this series included 
coumarin-7-O-sulphamate (Fig. 16, 1), 4-methylcoumarin-7-0-sulphamate
(COUMATE) (Fig. 16, 2), 3,4,8-trimethylcoumarin-7-0-sulphamate (Fig. 16, 3), 4- 
(trifluoromethyl)coumarin-7-0-sulphamate (Fig. 16, 4) and 3,4-dimethylcoumarin-7- 
O-sulphamates (Fig. 16, 5). These coumarin sulphamates were tested for their ability 
to inhibit El-STS activity using intact MCF-7 breast cancer cells or placental 
microsomes. Coumarin sulphamates (Fig. 16, 1-4) inhibited oestrone sulphatase 
inhibitory activity in a dose-dependent manner, and the inhibition at 10 pM ranged 
from 72% for (Fig. 16, 4) to 93% for (Fig. 16, 2). The I C 50 for inhibition of El-STS by 
COUMATE, measured using intact MCF-7 cells was 380 nM . 166,167 At 10 pM, 
COUMATE reduced the original El-STS activity by 95% after preincubating the 
enzyme with the inhibitor for 20 min. Also, COUMATE inhibited placental 
microsomal DHA-STS activity by 94% at the same concentration. 166,167 COUMATE 
was also tested in vivo in rats and a daily dosing at 10 mg/kg/day for 7 days had
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resulted in 85% inhibition of liver El-STS activity. In ovariectomised rats, the 
administration of COUMATE not only did not stimulate uterine growth (i.e. non- 
oestrogenic) but also was able to inhibit the ElS stimulation of uterine growth. The 
analogue of COUMATE 3,4-dimethylcoumarin-7-0-sulphamate (Fig. 16, 5), was 
found to be 12-fold more potent than COUMATE (IC50 = 30 nM, cf. 380 nM for 
COUMATE, in intact MCF-7 cells).167 As with EMATE, COUMATE was found to 
inhibit El-STS activity in a time- and concentration-dependent manner indicating that 
coumarin sulphamates in general act by a similar mechanism of action to EMATE.
1.7.7 Proposed mechanism of steroid sulphatase inhibition
Purohit et a/.141,168 have postulated that the mechanism of aryl sulphate 
hydrolysis may be analogous to the proposed mechanism of sulphuryl transfer by aryl 
steroid sulphotransferase.169,170 As shown in Scheme 3, it is proposed that a possible 
mechanism may involve direct nucleophilic displacement of oestrone from the 
sulphate group of oestrone sulphate, either by water in a one-step mechanism, or by a 
two-step mechanism involving a sulphated enzyme intermediate, which is 
subsequently hydrolysed by water to regenerate active enzyme. It is possible that, in 
the inactivation of oestrone sulphatase by EMATE, either the essential amino acid 
residue which is normally sulphated during catalysis, or a neighbouring residue, 
becomes irreversibly sulphamoylated (Scheme 3B). Support for such a mechanism, 
possibly involving a sulphamoylated intermediate, is provided by the finding that 
replacement of the bridging O-atom in the sulphamate group of EMATE by other 
heteroatoms, i.e. as in the 3-sulphamide (Fig.8, 1) and the 3-S-sulphamate (Fig.8, 2), 
not only reduces the potency of EMATE as an inhibitor, but also abolishes its active 
site-directed mode of inhibition.159 Recently, the crystal structures of a lysosomal
171 179sulphatase and human arylsulphatase A have been elucidated and the active site 
of the enzyme has been identified, suggesting a new mechanism for sulphatase ester 
hydrolysis.171'173 The application of our sulphatase inhibitors (sulphamates) utilising 
this new mechanism will be discussed in chapter 6.
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Scheme 3. Proposed mechanisms of oestrone sulphate hydrolysis by steroid 
sulphatase and enzyme activation by EMATE. (A) A possible mechanism for the 
hydrolysis of oestrone sulphate involves direct nucleophilic displacement of oestrone 
from the sulphate group of oestrone sulphate (E1S). (B) It is proposed that the 
inactivation of oestrone sulphatase by EMATE involves either the essential amino acid 
residue which is normally sulphated during catalysis or a neighbouring residue 
becomes irreversibly sulphamolyted: either by direct nucleophilic attack at the sulphur 
atom of EMATE by the enzyme or by the formation of a reactive aminosulphene 
intermediate by proton abstraction at nitrogen and subsequent loss of oestrone, 
followed by rapid sulphamoylation of the enzyme.
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1.8 Aims of this work
Our broad research efforts aim to block the action or synthesis of hormones 
which support tumour growth. Due to the oestrogenic activity of EMATE, a clear 
need for a steroidal/non-steroidal inhibitor, being metabolically stable, more selective 
and devoid of oestrogenic activity was identified. This is of importance not only in the 
potential exploitation of such an inhibitor in endocrine therapy, but also in related 
newly emerging and exciting indications related to autoimmune disease and memory 
enhancement (Alzheimer’s), where sulphatase inhibition may also be of therapeutic 
benefit.
The project aimed broadly to design and synthesise a range of steroidal and 
non-steroidal inhibitors based upon non-oestrogenic templates wide. The challenge 
was to synthesise steroidal/non-steroidal compounds as potent as EMATE, but with no 
uterine growth stimulating properties, and in some cases possibly also possessing 
intrinsic aromatase inhibitory properties.
We therefore focused upon synthesising a number of molecules that might 
potentially possess both aromatase and steroid sulphatase inhibitory properties 
(flavonoid sulphamates), other non-steroidal compounds (e.g. one ring, two ring and 




Flavonoids (flavone, isoflavone and flavanone) are ubiquitous secondary plant 
metabolites and it is estimated that a normal human diet is likely to contain about 1 
g/day of these natural compounds.174,175 Flavonoids, either natural or synthetic, are
i nfiknown to exhibit various biological activities. In particular, there are many 
compounds exhibiting antitumour177 or related activities, such as antimitotic 
activity178, topoisomerase,179 protein kinase C,180 several protein-tyrosine kinase, or
l O I
cyclin-dependent kinase. Flavonoids have also been shown to possess anti­
inflammatory, anti-allergic, anti-viral, anti-mutagenic, and anti-carcinogenic 
activities.182'185 Furthermore, some of these compounds were found to have 
oestrogenic or antioestrogenic activities as well as aromatase inhibitory activitiy.186-188 
The vast majority of flavonoids have low toxicity to human and animals.
The low rate of incidence of breast cancer in the Far East, (rather than genetic 
difference is an important factor), has been related to a high dietary intake of soya 
products containing flavones and isoflavones.189 Genistein, a flavonoid derivative, is 
commonly found in soya products. This compound has been reported to bind to the 
oestrogen receptor, inhibit tyrosine protein kinase and to have anti-angiogenic activity 
and anti-proliferative activity. The low rates of incidence of breast cancer among 
Japanese and Chinese, in relation to their high intake of soya products, may be
1 8 6  1 8 8  r\explained due to inhibition of aromatase ' and/ 17p-hydroxysteroid
dehydrogenase189 as it has been shown that some flavonoids present in soya products 
inhibit these enzymes.
During the last 10-15 years considerable research has been carried out to 
develop potent aromatase inhibitors, some of which are currently undergoing clinical 
evaluation. However, in three recent reports of postmenopausal women with breast 
cancer who received aromatase inhibitor therapy, plasma E1S concentrations remained 
between 400-1000 pg/ml127,128,190 which is high. In order to block not only the 
synthesis of oestrone from androstenedione, but also from E1S and the formation of
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androstenediol from dehydroepiandrosterone sulphate (DHA-S), there may be 
considerable therapeutic advantage to be achieved by treating such women with a 
combination of aromatase and sulphatase or even with a dual sulphatase/aromatase 
inhibitor, if such a molecule could be developed.
We have now explored the concepts of using flavonoids and related molecules 
as templates to design non-steroidal sulphatase inhibitors and also the idea of 
inhibiting sulphatase and aromatase activities with a single inhibitor by synthesising a 
series of flavonoid (flavone I, isoflavone II, flavanone III and isoflavane) 
sulphamates (Fig. 17-20,1-26).
2.2 Synthesis
The sulphamoyl group has been widely utilized as an activity-modifying 
substituent in several different classes of drugs. For example, TV-substituted steroidal 
sulphamates have been synthesised,191'195 including sulphamates of oestradiol,194’196'198 
to block metabolic conjugation, but their ability to inhibit El-STS was not explored. 
In most of the earlier works of this group (e.g. EMATE), the sulphamoylation of 
phenolic compounds was carried out directly with crude residue/crystalline 
sulphamoyl chloride, prepared according the method of Appel and Berger.199 
However, the continual handling of sulphamoyl chloride in the solid state proved to be 
cumbersome since this reagent is extremely hygroscopic and decomposes readily even 
on storage at low temperature. Nevertheless, it was found subsequently that these 
drawbacks could largely be surmounted if the freshly prepared crude sulphamoyl 
chloride was stored instead as a solution in anhydrous and sulphur impurities-free 
toluene under nitrogen.159
Flavonoid sulphamates (Fig. 17-20, 1-26) were prepared in an analogous 
fashion to other sulphamates described previously,157 for example, sulphamoylation of 
4',7-dihydroxyisoflavone (Diadzein) gave isoflavone-4',7-0,0-bis-sulphamate (Fig. 18, 
22) (Scheme 4). Briefly, a solution of the appropriate flavone, isoflavone or flavanone 
in anhydrous DMF was treated with sodium hydride (1.2 and 2.5 equiv. for 
monohydroxy and dihydroxy flavonoids respectively) at 0°C, under N2 , then
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sulphamoyl chloride in toluene (3-5 equiv) was added and after the mixture had 
warmed to room temperature overnight, the reaction was quenched with ethyl acetate 
and ice/water. The crude product, after work up for each flavonoid sulphamate, was 
purified by flash chromatography and recrystallisation. All compounds were fully 
characterized by spectroscopic and combustion analysis. The yield of the sulphamates 
were generally improved significantly by using excess of sulphamoyl chloride (> 5 
eq.).
Ei E2 E3 r 4 E3 R'4 E's
(i) o s o 2n h 2 H H H H H H
(ii) OH H H H H H H
(iii) H o s o 2n h 2 H H H H H
(iv) H OH H H H H H
(V) o c h 3 H OH H H H H
(1) o s o 2n h 2 H OH H H H H
(2) o c h 3 o s o 2n h 2 OH H H H H
(3) o c h 3 H OH H H o s o 2n h 2 H
(4) o c h 3 o c h 3 OH H o s o 2n h 2 o c h 3 H
(5) o c h 3 o c h 3 o c h 3 H o s o 2n h 2 o c h 3 H
(6) H H H H o s o 2n h 2 o s o 2n h 2 H
(7) o s o 2n h 2 H OH H H o s o 2n h 2 H
(8) o s o 2n h 2 H OH o s o 2n h 2 H H H
(9) o s o 2n h 2 H OH o s o 2n h 2 H o c h 3 H
(10) o s o 2n h 2 H OH o s o 2n h 2 o c h 3 o c h 3 o c h 3
(11) OH H OH o s o 2n h 2 o c h 3 o c h 3 o c h 3
(12) o s o 2n h 2 H H o s o 2n h 2 o c h 3 o c h 3 o c h 3
(13) OH H H o s o 2n h 2 o c h 3 o c h 3 o c h 3
(14) OH o s o 2n h 2 OH H H H H
(15) H o s o 2n h 2 H H H o s o 2n h 2 H
(16) H H H H H o s o 2n h 2 H
(17) o s o 2c h 3 H H H H H H
Figure 17. Stmctures of 7-hydroxyflavone (ii), 6-hydroxyflavone (iv), 5-hydroxy-7- 
methoxyflavone (v), flavone sulphamates (1-16) and flavone-7-methane sulphonate (17).
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(19) OSO2NH2 OH OCH3
(20) OSO2NH2 OH 0 S 0 2NH2
(21) OH OH OSO2NH2
(22) OSO2NH2 H OSO2NH2
Figure 18. Structures of /3-naphthoflavone sulphamates (18) and isoflavone
sulphamates (19-22)
O H  O
Ei r 2 E3
(23) O H H o s o 2n h 2
(23a) OH H O H
(24) o s o 2n h 2 O S O 2N H 2 O C H 3
Figure 19. Structures of (±) flavanone sulphamates (23 and 24) and (±) 4',5,7-
trihydroxy flavanone (23a)
D i a d z e in
O H
(i)
h 2n s o 2o
o s o 2n h 2
Scheme 4. Synthesis of isoflavone-4',7-0,O-bis-sulphamate (22), Reagents: (i) 
NaH/DMF, C1S02NH2, 0°C-RT, 12 h.
Commercially unavailable (±) equol (Fig.20, 25) was prepared by catalytic 
hydrogenation of diadzein (Scheme 4) in diglyme/acetic acid mixture using Pd-C .200 
The Pd-C catalyst was first suspended in glacial acetic acid and shaken in an 
atmosphere of oxygen for 3 days. The hydrogenation was rapid and the conversion 
into (±) equol was complete within 30 minutes. However, the disadvantage of this 
method is that a large amount of catalyst is required; in attempts to use less catalyst, 
the hydrogenation was found to be very slow and give a mixture of products. Flavone- 
7-methane sulphonate (Fig. 17, 17), was prepared by reacting 7-hydroxyflavone with 




Figure 20. Structures of (±) 4',7-dihydroxy isoflavane (25) and (±) isoflavane-4',7-
0 ,0 -bis-sulphamate (26)
A hydroxyl group at the 5-position of the flavonoids proved to be impossible to 
sulphamoylate even by using an excess of NaH. This was confirmed by attempting to 
sulphamoylate 5-hydroxy-7-methoxy flavone (Fig. 17, v). The reaction failed and a 
plausible explanation is the formation of a complex between the sodium and the 
ketone group occurring at the 4-position of the flavonoid, followed by the formation of 
an intramolecular hydrogen bond when the reaction was quenched (Fig. 21), as shown 
by ‘H NMR, the proton of the 5-position hydroxyl group was recorded at about 11-12 
ppm (downfeild).
Figure 21. The formation of a complex and the hydrogen bond between the C-5-OH 
and the C-4-C=0 of 5-hydroxy-7-methoxyflavone (v)
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The stability of different sulphamates was variable and influenced by several 
factors, such as conjugation and environmental conditions (functional groups in the 
sulphamate compounds, position of the sulphamate group(s) and the pKa of the 
starting phenol). To establish a relationship between activity and stability, studies of 
stability were carried out for selected flavonoid sulphamates i, iii, 1, 19 and 23, i) 
under similar conditions to those used for the bioassay and also ii) in methanol, using 
HPLC analysis. A stability study of EMATE under the same conditions was made for 
comparision. Stability studies of all flavonoid sulphamates were also earned out 
qualitatively in different solvents, including methanol, acetone, tetrahydrofuran (THF) 
and ethanol using TLC analysis.
Only the monosulphamate (Fig. 19, 23) could be obtained from (Fig. 19, 23a) 
even by using 2.5 eq. of NaH; the bis-sulphamate was either not formed, or it degraded 
due to instability. The resolution of the enantiomers of 5,7,4'-trihydroxyflavanone 
(23a) to determine the potentially active isomer, after sulphamoylation, was attempted 
using (S)-(+)-0-acetylmandelic acid. The 4'-acetylmandelic acid derivative of 23a (I) 
was obtained and no separation of diastereoisomers resulted. Perhaps the chiral centre 






Inhibition of El-STS in MCF-7 breast cancer cells and in placental 
microsomes by flavone (1-18), isoflavone (19-22) and flavanone (22-24) sulphamates 
are shown in Table 4 and Table 5 respectively. The inhibition of aromatase in 
placental microsomes by most flavonoid sulphamates is also included. The inhibitory 
activity of (±) equol bis-sulphamate 26 is also included in Table 5.
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The results can be summarized as follows: most of these compounds 
significantly inhibit El-STS in MCF-7 cells and placental microsomes at a 
concentration of 10 pM. Compounds 15, 20, 22, 23 and 26 are the most active in this 
series, with inhibitory activity about 99% in MCF-7 cells at 10 pM. In general, it was 
found that the sulphamates of isoflavone and isoflavane i.e. 26 are more potent than 
flavone and flavanone sulphamates as steroid sulphatase inhibitors. It was also found 
that bis-sulphamates are more potent than the corresponding monosulphamate (e.g. 2 0  
and 21).
Table 4. Inhibition of El-STS and aromatase activity by flavone sulphamates (1-16), 
flavone-7-methane sulphonate (17) and p-naphthoflavone 4'-0-sulphamate (18), - = 
not determined, *= inactive (< 1 0 %), *  = solubility problem, v = results not yet 
known, negative sign of %inhibition = stimulation effect, (i-iv; unpublished data; 
Purohit A, Willemsen E, Woo LWL, Reed MJ and Potter BYL).___________________
% Inhibition 
Sulphatase 
MCF-7 cells Placenltal microsomes
Aromatase
0.1 pM 1 pM 10 pM 10 pM 50 pM 100 pM 10 pM
i * * * 28 56 75 8 6
ii - - - - - - 96
iii - 9910.6 98.911.3 90 - - *
iv - - - - - - 30
1 - * 20.611.2 21 - - 76
2 11±2.7 5113 7811.7 3 8 7 *
3 35±4 8813.1 9910.6 65 79 77 85
4 * 1816.1 2713.5 * * * 93
5 29±0.8 2311.8 1210.5 5 8 6 *
6 * 1318 2911.3 * * * *
7 * 7910.8 9810.4 62 94 94 89
8 * * 1211.5 * * * 13
8 * * * * * * *
1 0 * * * * * * 35
1 1 * * * * * * 34
1 2 * * * * * * 2 2
13 * * * * * * 32
14 18±0.8 4211.3 9510.3 2512.7 5811.9 7810.1 *
15 >99 >99 >99 >99 >99 >99 V
16 15±7.0 6511.2 9610.2 7710.4 8510.7 7712 V
17 * * * -1413.5 -3312.9 -3710.7 V
18 13±5.9 7711.2 9510.1 2510.7* ** *+ V
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The effect of a sulphamate group when attached to a non-aromatic ring (in this 
case ring C of the flavonoids) was also evaluated and the products were found to be 
inactive (e.g 11 and 13), indicating again, as we expect, that the phenyl ring structure 
is required for potent inhibition.
In general, the aromatase inhibitory activity of flavone sulphamates (e.g. 1, 3, 4 
and 7, Table 4), was found to be more marked than flavanone sulphamates (23 and 24, 
Table 5) and isoflavone sulphamates (19-22, Table 5), which were found to be 
inactive.
Table 5. Inhibition of El-STS and aromatase activity by isoflavone sulphamates (19- 
22), flavanone sulphamates (23 and 24) and isoflavane sulphamate (26). - = not 
determined, *= inactive (< 1 0 %).______________________________________________
% Inhibition
Sulphatase
MCF-7 cells Placental microsomes
Aromatase
0.1 pM lp M 10 pM lOpM 50pM lOOpM lOpM
19 * 11+3.0 37±1.7 51 *
2 0 28±1.7 90±0.6 99±1.4 93 98 99 *
2 1 23±2.2 83±2.7 99±0.7 75 8 8 93 *
2 2 87±2.5 >99 >99 99 99 >99 *
23 30±2.8 79±1.2 98+1.2 2 1 - - 85
24 2±1.3 8 ±0 . 6 9±1.2 * * * 63
26 98±0.8 >99 >99 92±0.2 91 ± 0 3 98±0.3 13
The parent phenolic compounds of these sulphamates were all found to be 
inactive for inhibition of El-STS. This indicated that the sulphamate group is the core 
motif of these molecules recession to exhibit sulphatase inhibitory activity. In 
contrast, the aromatase inhibitory activity for some of these phenol parent compounds 
were evaluated in placental microsomes (e.g. ii and iv). It was found that in these two 
examples introduction of sulphamoyl group (i and iii) slightly reduce the aromatase 
inhibitory activity compare to the phenol parent compounds (ii and iv). 7- 
Hydroxyflavone (ii) inhibited aromatase activity by 96% at 10 pM in placental 
microsomes, while flavone 7-O-sulphamate (i) inhibited aromatase activity by 8 6 % at 
the same concentration (Table 4). Other parent phenol compounds of these
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sulphamates were not evaluated for aromatase inhibitory activity as they are done by
1 CA I Qfiother groups. ' The inhibitory activity of their sulphamates were compared with 
their results present in literature. In general the introduction of the sulphamoyl group 
to these flavonoids was found to have no influence on the aromatase inhibitory 
activity.
The IC50 of (±) equol bis-sulphamate 26 has been calculated in both assays and 
found to be 3nM and 600nM in MCF-7 cells and placental microsomes respectively.
Table 6 . Inhibition of El-STS in vivo for isoflavone sulphamates (20-22) and EMATE 
as measured in rat liver, 24 hours after a single oral dose in propylene glycol.________
Dosage % Inhibition
EMATE 1 mg/Kg >99
5-Hydroxy isoflavone-4',7- 0 ,0  -bis-sulphamate (20) 10 mg/Kg 84
5,'7-Dihydroxyisoflavone-4'-0 -sulphamate (21) 10 mg/Kg 67
Isoflavone-4',7- 0 ,0  -bis-sulphamate (22) 10 mg/Kg 90
The inhibition of oestrone sulphatase in vivo for selective flavonoid 
sulphamates (20-22) as measured in rat liver, 24 hours after a single oral dose in 
propylene glycol is shown in Table 6 . These compounds were found to be active with 
maximum activity of 90% (at 10 mg/kg) for isoflavone-4',7-(9-,0-bis-sulphamate 22, 
compared with EMATE > 99% (at 1 mg/kg).
2.4 Discussion
We have already demonstrated that oestrone-3-O-sulphamate (EMATE) is a 
potent irreversible inhibitor of El-STS . 141,157,201 However, since EMATE is highly
I rr\
oestrogenic, there is a need to develop other classes of potential inhibitors.
Having identified the key chemical structural requirement for potent sulphatase 
inhibition167 (i.e. phenolic ring structure and -O-sulphamoyl group), we considered 
that the introduction of the sulphamoyl group into the flavonoid structure might 
significantly engender sulphatase inhibitory activity and, also might provide new leads
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for the design of a dual non-steroidal sulphatase/aromatase inhibitor, as several 
flavonoids have aromatase inhibitory activity. 186' 188
Initially, 7-hydroxyflavone ii (a known potent aromatase inhibitor, 187 which 
inhibits this enzyme by 96% in placental microsomes at 10 pM) and 6 -hydroxyflavone 
iv (inhibits aromatase by 30% in placental microsomes at 10 pM) were 
sulphamoylated to give flavone-7-O-sulphamate i and flavone-6 -O-sulphamate iii 
respectively. Flavone-7-O-sulphamate, (i) was found to inhibit aromatase in placental 
microsomes by 8 6 % at 10 /iM, but was found to be inactive against El-STS in MCF-7 
cells at 0.1-10 /nM but inhibited El-STS in placental microsomes by 28%-75% at 10- 
lOOpM, while flavone-6 -O-sulphamate iii, was found to be inactive against aromatase, 
but found to inhibit El-STS activity in MCF-7 cells by 99% at lpM  and 10 fiM 
(unpublished data, Purohit A, Willemsen E, Woo LWL, Reed MJ and Potter BVL). 
These results were encouraging and supported the approach of synthesising flavonoid 
sulphamates, which may lead to the eventual development of dual 
aromatase/sulphatase inhibitors. Therefore, a number of flavonoid sulphamates have 
been designed and synthesised here (1-26).
Biological evaluation of the novel synthetic entities revealed that most of these 
flavonoid sulphamates (1-26) show potent sulphatase inhibition at 10 pM in MCF-7 
breast cells and in placental microsomes and also some of them show quite potent 
aromatase inhibition at 10 pM in placental microsomes (Table 4 & Table 5). 
Compounds (19, 20, 21, 22 and 23) inhibited El-STS in MCF-7 cells in ranges of 23- 
87% at 0.1 jiM, 79-99% at 1 fiM  and > 99% at 10 pM. When assayed in placental 
microsomes, these compounds inhibited El-STS between 21 and 99% at 10 pM. One 
of the best inhibitors in this series, isoflavone^'J-O.O-bis-sulphamate (2 2 ), inhibited 
El-STS activity in MCF-7 cells by 87% and > 99% at 0.1 jiiM and at 1 jjM  
respectively; and almost completely inhibited activity in placental microsomes at 1 0  
pM but no aromatase inhibition activity was detected (Table 5).
In an in vivo study, the inhibition of El-STS activity was also evaluated for 
compounds 20-24 (potent flavonoid sulphamates in vitro) and found to be significant. 
Isoflavone-4',7-0,0-bis-sulphamate (22) is the most potent compound with 90%
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inhibition in rat liver 24 hours after a single oral dose (10 mg/kg) administered in 
propylene glycol (Table 6 ).
The high potency of 22 might be due to its similarity to the structure of 
EMATE as shown by a computer modelling study (Fig. 22). The ring structure of this 
compound presumably mimics the steroid rings (A, B and D) of EMATE, and might 
be has similar hydrophobicity of EMATE, which required for extra binding to the 
enzyme and thus exhibit potent El-STS activity. However, it might also be acting by 
the same mechanism of EMATE, but we do not know if either one or both sulphamate 
group(s) are involved in the sulphamoylation of the enzyme. The spacing between the 
two phenyl rings of isoflavone sulphamates such as 2 2  has a certain degree of 
similarity to that of the diphenylethylene-type oestrogen (diethylstilboestrol, DES) 
whose oestrogencity has been attributed to a structural mimicry of oestradiol. Since 
DES-bis-sulphamate has been shown to be a potent El-STS inhibitor (IC50 lOnM in 
intact MCF-7 breast cells) , 156 the high potency observed for 22 could be the result of a 
similar mimicry of the steroid nucleus of EMATE. Indeed, as a computer modelling 






Figure 22. A computer modelling of EMATE and isoflavone-4',7-O,0-bis-sulphamate
(22)
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DES-bis-sulphamate Isoflavone 4',7-0,0-bis-sulphamate (22)
The isoflavone sulphamates 19-22 and isoflavane bis-sulphamate 26 were 
found to be potent El-STS inhibitors, but disappointingly were found to be inactive or 
have only poor inhibitory activity against aromatase in placental microsomes at 10 /jM  
(Table 5), while the corresponding flavone sulphamates were found to be more potent 
aromatase inhibitors (e.g 7). The difference in aromatase inhibition by such 
sulphamates might be due to binding affinity to the active site of the enzyme and it is 
likely that flavone sulphamates are better in binding to the aromatase active site than 
isoflavone or isoflavane sulphamates. This observation was also found to be similar 
for the parent phenol compounds, isoflavones are weaker aromatase inhibitors than 
flavones. 188 It has been postulated that the C-4 carbonyl group of flavone such as ii 
coordinate with the haem moiety of aromatase in a similar manner to 
aminoglutethimide and hence exhibit inhibitory activity against the enzyme.188a For 
isoflavone compounds, it is possible that such carbonyl group and haem iron 
interaction is made ineffectual by the aromatic via steric hindrance B-ring at the C-3 
position. For isoflavane compounds such interaction does not occur due to absence of 
the C-4 carbonyl group. It was also found that flavone 6 -O-sulphamate (iii) is a 
significantly weaker inhibitor of aromatase than flavone 7-0-sulphamate (i). This 
finding indicates that the region around the C- 6  position in the active site of aromatase 
might be very restricted or ineffective via steric hindrance by the aromatic ring.
Many sulphamates were noticed to be unstable at high temperature, in various 
polar solvents and decomposed in DMF (reaction solvent). Therefore, by using a 
larger excess of sulphamoyl chloride (> 5 eq.) than previously used157 the yield 
improved significantly. However, to improve understanding of the relationship 
between the activity and stability of flavonoid sulphamates, stability studies were
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carried out using HPLC analysis for some selective flavonoid sulphamates under a 
similar conditions to those used for the biological assay and also as a solution in 
methanol. In addition, a qualitative analysis (TLC analysis) of the stability of these 
selected compounds in different solvents including methanol, acetone, tetrahydrofuran 
(THF) and ethanol were also carried out. The following general results were 
observed:
i) Most of the flavonoid sulphamates which have extended conjugation (double bond 
in ring C of flavonoid structure) were unstable and decomposed rapidly to their parent 
compounds in biological media and methanol as shown in Figure 23-25.
ii) The presence of functional groups such as a methoxy, hydroxy or ketone in the 
rings structure of the sulphamates increased the degradation of such compounds, 
especially when these groups near by the sulphamate(s) group.
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Figure 23. HPLC stability study of selected flavonoid sulphamates in phosphate 
buffer saline (PBS) with 0.25M sucrose containing 30% methanol at 37°C, EMATE 
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Figure 24. HPLC stability study of selected flavonoid sulphamates in PBS with 
0.25M sucrose containing 10% methanol at 37°C, EMATE was included for 
comparison. Points are mean for triplicate determination.
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Figure 25. HPLC stability study of selected flavonoid sulphamates in methanol at RT. 
Points are mean for triplicate determination
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iii) In acetone, the sulphamates were found to be weakly stable and decomposed 
slowly, but were unstable and decomposed rapidly in methanol (Fig. 25), ethanol and 
DMSO. Most of the sulphamates were moderately stable in THF. Therefore, it is 
advisable, where possible, to freshly dissolve the test compounds in THF and use such 
solution within hours for biological assay to avoid substantial degradation from taking 
place.
iv) Most of the bis-sulphamates were noticed to decompose to a mixture of their 
corresponding mono-sulphamate first and then to their corresponding starting phenols 
(e.g. 7 and 22, as observed by TLC analysis).
v) It was found that flavone-6 -O-sulphamate (iii) is more stable than flavone-7-O- 
sulphamate (i) as shown by the HPLC stability studies (Fig. 23-25). It is reasonable to 
expect that the pKa value of 6 -hydroxyflavone (iv) will be similar to that of a simple 
phenol (i.e. ca. 10) since the phenolate group is meta to the C-4 carbonyl group and 
hence is not conjugated. In contrast, it is expect that 7-hydroxyflavone (ii) whose 
hydroxy group is para to the C-4 carbonyl group has a pKa lower than iv, as a result of 
conjugation. The phenolate of ii is therefore more stable and has a better leaving 
group ability than that of iv, rendering an easier cleavage of the bridging S-O bond in 
the sulphamate of ii (i.e. unstable). It was also found that when the sulphamoyl group 
is present at the 4'-position of flavonoid sulphamates it is more stable than if it is at 7- 
position because it might be has relatively lower leaving group ability (or higher pKa). 
For example, 5,7-dihydroxyflavanone 4'-0-sulphamate 23 is more stable and has 
significant activity compared with the 7-0-sulphamates of flavonoids (Fig. 23-25).
We believe that the ketone group and the conjugation in ring C of flavonoids 
play a major role in reducing the stability (by affecting the pKas values and hence the 
leaving group(s) abilities), which negatively affects the inhibition of El-STS activity. 
In order to confirm this and to improve the stability of the potent isoflavone 
sulphamates (19-22), we have synthesised (±) 4',7-dihydroxyisoflavane [(±) equol] 25 
and sulphamoylated it to produce the isoflavane-4',7-0,0-bis-sulphamate 26. As we 
expected this compound was found to be more stable in polar solvents than 
isoflavone-4',7-0,O-bis-sulphamate 22 as shown by a TLC analysis study, and was
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also found to be a potent El-STS inhibitor as 22 in both the MCF-7 cells and placental 
microsomes systems (26 being one of the most potent inhibitor in this series, inhibited 
El-STS activity in MCF-7 cells > 99 % at 0.1 fiM, Table 5). Thus, we can conclude 
that the presence of the ketone group at the 4-position of ring C in the flavonoid 
structure as well as the conjugation are not required for potent El-STS inhibition 
activity.
It was noticed that the stable sulphamates exhibited significant El-STS 
inhibitory activity, while the unstable compounds, in the main, showed only moderate 
or no activity. These stability studies were used as a guide to design and synthesise a 
stable flavonoid sulphamates by introducing the sulphamoyl group at the most 
favourable position of flavonoids with respect to stability (i.e. 6 -postion of A-ring or 
4'-position of B-ring of flavonoids structure) for sulphatase and potentially aromatase 
inhibition. Therefore, a number of other flavonoid sulphamates were synthesised (e.g. 
3, 4, 7, 14, 15, 16 and 23). As expected most of these sulphamates were found to be 
potent against both enzymes.
Compounds 3, 4, 7 and 23 inhibited aromatase activity by 85%, 93%, 89% and 
85% at 10 pM in placental microsomes respectively (Table 4 & 5). These compounds 
also inhibited El-STS in MCF-7 cells by 99%, 27%, 98% and 98% at 10 pM 
respectively. The results of these compounds prove our novel concept, that it is 
possible to inhibit both enzymes (El-STS and aromatase) by a potential dual inhibitor. 
However, it is desirable to establish whether the inhibition of aromatase by these 
compounds is actually an inherent property of the molecule or is the result of an in 
vivo activation to the parent phenols, since some of them are known potent aromatase 
inhibitors186' 188 (e.g, 7-hydroxyflavone, 4',5,7-trihydroxyflavone). Therefore, flavone- 
3/,4'-O,0-bis-sulphamate 6, flavone-4'-0-sulphamate 16 and flavone-7- 
methanesulphonate 17 were synthesised and evalulated for their ability to inhibit E l- 
STS and aromatase activity. Compound 6  was found to be a weak El-STS inhibitor 
(inhibited El-STS, 29% at 10 pM in MCF-7 cells) and was inactive against aromatase 
at 10 pM in placental microsomes. This weak inhibition may be due to that, the 
second sulphamate group (at C-3') may have caused the other sulphamate group at C-
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4' to be shifted in the binding site from the usual position occupied by the sulphamate 
group of those active compounds which have an unhindered sulphamoyl group at C-4' 
(e.g. 3 and 7), and hence it could not be activated effectively for the sulphamoylation 
of the enzyme. This also may be the the same reason of poor inhibition when a 
substituent such as a methoxy(s) were introduced at the flavonoid sulphamates rings 
(e.g. 2, 4, 5, 9, 10 and 11). This results have therefore highlighted the limited 
tolerance of the enzyme to substituents. It is also possible that the methoxy(s) or the 
second sulphamate group may conceivably shield the sulphamate group in such a 
manner that the putative proton abstraction, the first vital step proposed for the 
mechanism of El-STS inhibition by EMATE, is prevented from occurring. 
Compound 16 was found to be a potent El-STS inhibitor (inhibited El-STS activity 
by 96% at 10|liM in MCF-7 cells), compound 17 was found to be inactive against E l- 
STS (Table 4). We expect that compounds 16 and 17 will be inactive against 
aromatase (results not yet known). If our expectation is right, this demonstrates that 
the inhibition of aromatase activity is a result of the flavonoid sulphamate and is not 
due to an in vivo activation to the parent phenol compounds. The /3-naphthoflavone 
compounds were found to be relatively weak or inactive aromatase inhibitors188 
because their structure does not fit in the active site of the enzyme. However for 
further confirmation of the concept, 4'-hydroxy-/Tnaphthoflavone has been 
sulphamoylated to give /3-naphthoflavone 4'-0-sulphamate 18, which was evaluated 
for oestrone sulphatase inhibitory activity. This compound was found to be a potent 
sulphatase inhibitor (inhibited El-STS activity by 95% in MCF-7 cells at lOpM) and 
it is expected to be a relatively potent aromatase inhibitor and slightly better than its 
parent starting material (results not yet known). If our speculation is right, compound 
18 and other flavonoid sulphamates are possibly dual inhibitors. But in the case of 
unstable flavonoid sulphamates (e.g. flavone 7-O-sulphamate) or after 
sulphamoylation of the enzyme which releases the parent phenol compounds (see 
Chapter 6 ) these sulphamates might be act as pro-drugs.
As we expected that the 7-hydroxy or sulphamoyl group at 7-position or 4 ' was 
required for potent aromatase inhibitory activity (e.g. i, ii, 4, 18 and 23) and the 
sulphamoyl group at the 4' or 6  position of the flavonoid structure is required for 
potent sulphatase inhibitory activity. Further modifications have also been carried out
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in this series which significantly improve both sulphatase and aromatase inhibitory 
activities, e.g. flavone-5,7-dihydroxy-6-(9-sulphamate 14 and flavone-4',6-0,0-bis- 
sulphamate 15. Compound 15 shows potent El-STS inhibitory activity (inhibited E l- 
STS activity by > 99% at 0.1 pM in both MCF-7 cells and placental microsomes 
(Table 4) and is expected to have a moderate aromatase activity (results not yet 
known), while 14 is expected to show potent inhibtory activities against both enzymes 
(inhibited El-STS activity in MCF-7 cells by 96% at 10pM). Flavone-4',6-0,0-bis- 
sulphamate 15 was found to be the most potent El-STS inhibitor in these series (Table 
4). The inhibitory activity of this compound was evaluted in placental microsomes at 
low concentrations (lOnM, InM, 0.1nM....etc.), the IC50 for this compound was 
calculated and found to be 9.4nM in placental microsomes (c.f. to EMATE, 4nM).
Overall, this study has revealed that flavonoid sulphamates are a new series of 
potential El-STS inhibitors which can significantly inhibit El-STS activity as well as 
aromatase activity. We have also provided preliminary evidence in support of the 
novel concept of a dual sulphatase/aromatase inhibitor based upon the flavonoid 
system. However, more work is required to explore this goal thoroughly, but some of 
the compounds reported here should prove to be useful new leads, either alone (e.g 3, 
7 or 16 or 24) or as a combination of a potent El-STS inhibitor (iii or 14 or 15 or 18 or 
20 or 21 or 22 or 26) and potent aromatase inhibition (e.g. i or ii or 4).
2.5 Conclusion
This study has clearly demonstrated that the sulphamoyl group is essential for 
El-STS inactivation, as most of these flavonoid sulphamates are potent and 
significantly inhibited El-STS activity in MCF-7 cells and placental microsomes at a 
concentration of 10 pM or lower. Our data also indicate that flavonoid sulphamates 
(3, 4, 7 and 23) are potent sulphatase inhibitors which also possess potential aromatase 
inhibitory activity. These compounds therefore represent key lead compounds for 
optimization of potential dual sulphatase/aromatase inhibitors.
Flavonoid sulphamates may therefore be effective therapeutic agents in the 
treatment of oestrogen-dependent breast cancer, but it is crucial to be fully cognizant
51
of inherent stability problems. These results will lead also to further studies to design 
and maximize the activity of metabolically stable potent dual sulphatase/aromatase 
inhibitors, and to make the compounds completely devoid of oestrogenic activity, as it 
is known that some flavonoids are oestrogenic at high dose.202
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3 Other non-steroidal sulphamates
3.1 Background
Considerable progress has been made in developing a number of potent 
nonsteroidal/steroidal sulphatase inhibitors; while these inhibitors possess greater 
potency (Chapters one and two), their ability to inhibit sulphatase activity was still 
relatively modest compared to oestrone 3-(9-sulphamate (EMATE). EMATE 
inhibited steroid sulphatase activity in a time-and concentration-dependent manner141 
and was active in vivo on oral administration, 145 but this inhibitor proved to be a 
potent oestrogen. 162 Since then several strategies were therefore adopted in order to 
develop a nonsteroidal/steroidal inhibitor which, while active in vivo, was devoid of 
any oestrogenicity that would limit its use for breast cancer therapy.
EMATE
In any form of endocrine therapy, it is often desirable to treat patients with 
nonsteroidal agents since the steroidal counterparts may themselves, or through their 
metabolites, exert unwanted endocrinological effects. Indeed, despite its high potency 
as an oestrone sulphatase (El-STS) inhibitor, the use of EMATE in treating hormone- 
dependent breast cancer is restricted since it was found to be five times more
I AOoestrogenic than ethinyloestradiol orally.
Various structurally diversified nonsteroidal El-STS inhibitors, such as 
sulphate derivatives of 2 -phenylindoles165 and (p-O-sulphamoyl)-V- 
alkanoyltyramines203,204 have been reported. Our first nonsteroidal El-STS inhibitors 
were tetrahydronaphthalene-2-O-sulphamate (THN-sulphamate, Fig. 14, 1) and its N-
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alkylated derivatives (Fig. 14, 2 and 3),157 which were found to be much weaker 
inhibitors than EMATE. It was reasoned that sulphamates of alternative two-ring 
systems such as monohydroxylated coumarins were also likely to act as El-STS 
inhibitors. After establishing that 4-methyl-7-sulphooxycoumarin was a substrate for 
El-STS, a series of coumarin sulphamates were synthesised and examined, of which 
4-methylcoumarin 7-O-sulphamate (COUMATE) was found to be the most effective 
inhibitor. 166
3-M ethyl-l-pentafluorophenylm ethyI-6 -sulphooxy- 
2-(4-sulphooxyphenyl)-4-trifluorom ethylindole
(CH2)2NHCO(CH2)nCH3 H2N S020
THN-sulphamate(p-O-sulphamoyl)-A-alkanoyltyramine, n = 5-13
4-Methy 1-7-sulphooxy coumarin COUMATE
To study the structure-activity relationships for coumarin sulphamates. Three 
analogues of COUMATE, such as 6-methoxycoumarin-7-0-sulphamate (Fig.26, 27),
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and mono- and bis-sulphamates of a catechol-like coumarin (28 and 29) have prepared 
and examined. In addition, we have also explored the potential of other two-ring 
sulphamates such as those of tetralones and indanones (Scheme 5, 30-35) as effective 
inhibitors of El-STS.
Our initial studies to develop a nonsteroidal sulphatase inhibitor also involved 
the sulphamoylation of diethylstilboestrol (DES), which has two non-fused aryl rings. 
The mono sulphamate and bis-sulphamate derivatives of DES were considerably more 
potent inhibitors than the 2-fused ring tetrahydronaphthol (THN) sulphamates. 156,166 
DES-bis-sulphamate had an IC50 of 10 nM as assessed in intact MCF-7 breast cancer 
cells. 156,205 Diethylstilboestrol is a known potent oestrogen and toxic compound 
which would restrict the use of its bis-sulphamoylated compound in treating hormone- 
dependent breast cancer. However, the finding that it was not necessary to have a 
fused ring system for sulphatase inhibition led to the synthesis of a series of 
sulphamate analogues with non-fused ring structure (e.g. benzophenone sulphamates; 
Fig.27, 36-39).
DES-bis-sulphamate
Having identified the active pharmacophore (sulphamate group attached to 
phenyl ring) required for potent El-STS inhibition activity, several single ring (64, 65 
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Figure 26. Structures of coumarin sulphamates
6 -Methoxycoumarin 7-0-sulphamate (Fig.26, 27) was prepared from its 
corresponding starting coumarin. When 6,7-dihydroxy-4-methylcoumarin was treated 
with 2 equiv. of sodium hydride followed by an excess of sulphamoyl chloride (5 
equiv.), a mixture of the catechol-like coumarin sulphamates, 28 and 29, was formed. 
The separation of the mono-sulphamate, 29 from the bis-sulphamate, 28, was achieved 
by preparative TLC. The NMR data of 29 did not show the position of its mono- 
sulphamate group but it is likely to be at the C-6 -position i.e. structure 29 and not the 
other position at C-7). This assignment was made partly on the basis of the stability 
studies of 4-methylcoumarin 7-0-sulphamate (COUMATE) and 4-methylcoumarin 6 - 
O-sulphamate (6 -COUMATE). It was found that 6 -COUMATE was much more 
stable than COUMATE (unpublished data, Woo LWL, Purohit A, Reed MJ and Potter 
BVL). For this reason, it is most likely that sulphamoylation has occurred at the 6 - 
position to give 29 as the major product because 6 -phenolate is a stronger nucleophile 
than 7-phenolate. Some of 29 must be sulphamoylated a second time to give 28 and 
some of bis-sulphamate 28 decomposed back to 29. The 7-phenolate has a lower pKa 
and has a better leaving group ability than 6 -phenolate, rendering an easier cleavage of 
the bridging S-O bond in the sulphamate of 28 (i.e. unstable) to give 29. Other two- 
ring sulphamates (Scheme 5, 30-37, indanone and tetralone sulphamates) were also 
synthesised from their parent phenols in a similar manner. Some of these starting 
phenols were obtained by demethylating their corresponding methyl ethers using 
aluminum chloride in toluene at reflux.
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Scheme 5. Synthesis of indanone sulphamates (31-33) and tetralone sulphamate (35): 
(i) AlCl3/toluene/reflux; (ii) NaH/DMF, H2N S0 2C1.
The non-fused ring benzophenone sulphamates (Fig.27, 36-39) were also 
synthesised in a similar manner. When 4',4-dihydroxybenzophenone was treated with 
3 equiv. of sodium hydride followed by an excess of sulphamoyl chloride (5 equiv.), 
benzophenone 4',4-O,0-bis-sulphamate 36 (BENZOMATE), was the major product 
obtained (43%). In the same reaction, another fraction of lower polarity was also 
afforded (7%). This fraction was isolated and subsequently identified as the 
azomethine 37 which is an adduct of 36 and dimethylformamide (DMF) the solvent 
used for the reaction. A retrosynthetic analysis suggests that 37 could have been 
formed when one of the A-protons of 36 was removed (presumably by the presence of 
excess sodium hydride) and the resulting anion of 36 attacked a molecule of DMF at 
the carbonyl carbon followed by dehydration of the product upon acidification during 
the aqueous workup. In another reaction, 4,4'-dihydroxybenzophenone was 
sulphamoylated after the treatment with only 1 equiv. of sodium hydride. This time, 
the mono-sulphamate (4'-hydroxybenzophenone-4-0-sulphamate 38) was the major 
product and its separation from the bis-sulphamate and the starting material, was 
achieved by preparative TLC. Like flavonoid sulphamates, it is possible that
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benzophenone sulphamates are also unstable. Hence, a stability study of 36 was 
carried out under conditions similar to those used for the bioassay (i.e. in phosphate 
buffer saline with 0.25M sucrose at 37°C) and the degradation was followed by UV 
spectroscopy.
0 S 0 2N=CHN(CH3)2
Figure 27. Structures of benzophenone sulphamates (36-39)
Having identified that 36 was a potent El-STS inhibitor (inhibited El-STS by 
98% at lOpM in both MCF-7 cells and placental microsomes, vide infra), to study its 
structure activity-relationships and to improve the inhibitory activity of this lead 
compound, we synthesised different modified analogues of 36 and examined them for 
El-STS inhibition in order. These analogues include benzophenone-4-O-sulphamate 
(Fig.27, 39), chalcone sulphamates (Fig.28, 40 and 41), dibenzofuran-2-O-sulphamate 
(Fig.28, 42), 4,4'-0,O-bis-sulphamoyldiphenylmethane (Scheme 6 , 44), 4'-hydroxy-4- 
O-sulphamoyl-diphenylmethane (Scheme 6 , 45), benzophenone 3',3-0,0-bis- 
sulphamate (Scheme 7, 48) and 3'-hydroxybenzophenone-3-0-sulphamate (Scheme 7, 
49).
o s o 2n h 2
h2n s o 2o
h 2n s o 2o o s o 2n h 2
o s o 2n h 2
Figure 28. Structures of chalcone 4-0-sulphamate (40), chalcone 4'-0-sulphamate 
(41) and dibenzofuran 2-0-sulphamate (42)
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(i)
HO OH OH ROHO OR
4,4'-Dihydroxybenzophenone
45 S02NH2 H
Scheme 6 . Synthesis of diphenylmethane sulphamates (44 and 45): (i) Pd- 
C/96%ethanol, 6  h; (ii) NaH/DMF, H2N S0 2C1.
The 4',4-dihydroxydiphenylmethane (Scheme 6 , 43) was prepared by a 
catalytic hydrogenation of 4',4-dihydroxybenzophenone using Pd-C (10%) at RT at 
balloon pressure in ethanol for 6  h (Scheme 6 ) . 206 Nitration of benzophenone with a 
mixture of nitric acid and sulphuric acid gave 3',3-dinitrobenzophenone (Scheme 7, 
46, 53%). Reduction of 46 with stannous chloride in HC1 followed by 
hydroxydeamination of the crude salt by sodium nitrite in sulphuric acid gave 3',3- 
dihydroxybenzophenone 47 (49% ) . 207 Sulphamoylation of 47 gave a mixture of bis- 
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Scheme 7. Synthesis of benzophenone-3',3-0,0-bis-sulphamate (48) and 3'- 
hydroxybenzophenone 3-O-sulphamate (49): (i) H2S0 4 /HNC>3, 75 °C, 30 min.; (ii) a) 
SnCl2/HCl, 70 °C, 6  h.; b) NaN02/H2S 0 4, 0°C-A; (iii) NaH/DMF, H2N S02C1.
Further modified benzophenone analogues were also synthesized, these include 
sulphonyldiphenyl-4',4-0,0-bis-sulphamate (Fig.29, 50), thiodiphenyl bis- and mono-
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sulphamate 51 and 52, the bis- and mono- sulphamate of 2,6-anthraquinone 53 and 54, 
(l,3-adamantanediyl)diphenyl bis- and mono-sulphamates (Fig.30, 55 and 56), 1- 
cyclohexyl-l,l-(4',4-(9,Obis-sulphamoylphenyl)methanol (Scheme 8 , 60), benzo[6 ] 
naphtho[2,3-J]-furan-6,l l-dione-3-O-sulphamate (Scheme 9, 62) and (Z)-4-O- 
sulphamoyltamoxifen (Fig.31, 63).
The sulphamoylation of 59 (the starting material for 60) has most likely taken 
place at the two phenyl rings (at 4 and 4') to give the bis-sulphamate (60); as a para 
di-substituted system was observed at a lower field than that for 59 in the NMR of 60. 
The tris-sulphamate of 59 was not formed even by using 9 equivalents of 2,6-d\-tert- 
butyl-4-methylpyridine (DBMP) as a base. It is possible that the sulphamoylation of 
the C-l-hydroxyl group did not take place readily as a result of the lack of stability of 
intermediate(s) or more probably steric hindrance conferred by the flanking bulky 
groups at this tertiary. The pKa value of pyridine is about 5.19 whereas the pKa of 
2,6-di-r-butyl pyridine is 3.58; it is expected that the pKa of DBMP is ca. 3.6 and 
hence is a weaker base than pyridine. The tertiary aliphatic alcohol will not be strong 
enough an acid (pKa ca. 16-18) to be deprotonated by pyridine or DBMP and hence no 
sulphamoylation at this position (the C-l of 59).
h 2n s o 2o o s o 2n h 2
o s o 2n h 2 h o o s o 2n h 2h 2n s o 2o
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Figure 29. Structures of sulphonyldiphenyl-4',4-0,0-bis-sulphamate (50), 
thiodiphenyl-4',4-<9,0-bis-sulphamate (51), 4'-hydroxythiodiphenyl-4-(9-sulphamate 
















Scheme 8 . Synthesis of 1-cyclohexyl-1,1-(4,4'-0,G-bis-sulphamoylphenyl)methanol 
(60), (i) tert-butyldimethylchlorosilane/THF, imidazole, 3 h; (ii) cyclohexyl 
magnesium chloride/ether, 12 h; (iii) TBAF/THF, RT, 10 min (iv) DBMP/DCM, 
H2N S0 2C1, 2 h.
The above sulphamates except (60, Scheme 8 ) were prepared from their 
corresponding starting phenolic compounds in the usual manner. For the preparation 
of 60, 4',4-dihydroxybenzophenone was first protected by two tert-butyldimethylsilyl 
(TBDMS) groups to give the disilylated 57, which was reacted with cyclohexyl 
magnesium chloride (a Grignard reagent) to give 58. The TBDMS groups of 58 were 
cleaved by tetrabutylammonium fluoride (TBAF) in THF to give the tri-hydroxylated 
59 which, as a solution in DCM, was finally sulphamoylated by reacting with
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sulphamoyl chloride using 2,6-di-rm-butyl-4-rnethylpyridine (DBMP) as the base to 
give 60 (Scheme 8 ).
Benzo[£]naphtho[2,3-d]-furan-6,l 1-dione-3-O-sulphamate (Scheme 9, 62) was 
prepared from the parent compound 61 which was prepared by reacting 2,3-dichloro- 
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Scheme 9. Synthesis of benzo[b] naphtho[2,3-J]-furan-6,l l-dione-3-O-sulphamate 
(62), (i) NaOEt/ethanol, 12 h.; (ii) NaH/DMF, H2N S0 2C1.
Finally, a mixture of Z and E isomers (70:30) of 4-hydroxytamoxifen was also 
sulphamoylated in a similar fashion to give a mixture of E and Z 4 -0 -  
sulphamoyltamoxifen respectively (Fig.31, 63a & 63b). The designations for these 
sulphamates are the reverse of those for their starting phenols because a sulphamoyl 
phenyl substituent has a higher priority than an aminoalkoxy phenyl substituent 
according to the Cahn-Ingold-Prelog convention. Due to the high polarity of these 
sulphamates, the purification was difficult and as a result poor *H NMR and CHN 
analyses were obtained. However, shortage of starting material meant that this work 
could not be concluded satisfactory. These results are therefore preliminary only.
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■N(CH3 )2 ■N(CH3)2■N(CH3)2
(Z) 4-Hydroxytamoxifen (E) 4-Hydroxytam oxifenTamoxifen
'N(CH3)2•N(CH3)2
h 2n s o 2o
(E)-isomer (63a) (Z)-isomer (63b)
Figure 31. Structures of tamoxifen, (Z) and (£)-4-hydroxytamoxifen and E (63a) and
Z (63b) -4-O-sulphamoyltamoxifen
Using the active pharmacophore that our studies had identified, Li and his 
colleagues have designed, synthesized and tested a series of (/?-0-sulphamoyl)-./V- 
alkanoyl tyramines as potential sulphatase inhibitors. 166 We have further extended the 
work of Li et al. 203 by synthesizing several single ring and bicyclic non-fused ring 
sulphamates. We initially synthesized 4-/i-heptyloxyphenyl-0-sulphamate (Fig.32, 
64), as a minimal structure possessing the pharmacophore for sulphatase inhibition 
and a hydrophobic side chain.
^ \ . 0 ( C H 2)6CH3 H3c o v ^ ^ ^ N H C O ( C H 2)4CH=CHCH(CH3)2
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H2NS02Cr h 2n s o 2<t
65
Figure 32. Structures of 4-zi-heptyloxyphenyl-O-sulphamate (64) and F-capsaicin
sulphamate (65)
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HO (CH2)2NH2 +  CH3(CH2)12COCl -------
(ii)
R (CH2)2NHCO(CH2)12CH3
Tyramine 66 R = CO(CH2)i2CH3
67 R = H
(iii) h2n s o 2o (CH2)2NHCO(CH2)CH3
68
Scheme 10. Synthesis of (p-O-sulphamoylj-A-tetradecanoyl tyramine (6 8 ), (i) 
Et3N/THF, 23°C, 48 h.; (ii) DMF/CH3OH, NaHC03, A 1 h.; (iii) NaH/DMF,
H2NSO2CI.
Subsequently, a range of sulphamates were prepared including E-capsaicin 
sulphamate (Fig.32, 65), (/?-Osulphamoyl)-./V-tetradecanoyl tyramine (Scheme 10, 6 8 ), 
(a compound previously synthesised by Li et al., but made some different 
observations) and the two bicyclic non-fused long chain sulphamates: (p-O- 
sulphamoyl)-/V-(4-«-hexyloxybenzoyl) tyramine (Scheme 11, 71) and the n- 
octyloxybenzyl congener (Scheme 12, 73), which were analogous to Li et al.’s. The 
preparations of compounds 67 (Scheme 10) and 70 (Scheme 11) were attempted by 
reacting tyramine with the corresponding acid chloride at room temperature in the
on 1presence of triethylamine as described by Li et al. for the synthesis of TV-tridecanoyl 
tyramine. However, in contrary to the finding of Li et al. which showed the phenolic 
amide (A-tridecanoyl tyramine) as the major product, our reactions gave the amido 
esters ( 6 6  and 69) at 73% and 80% respectively instead. Compounds 67 and 70 were 
then synthesized by hydrolysing the ester group of 6 6  and 69 respectively in refluxing 
aqueous methanol containing sodium bicarbonate. For the synthesis of compound 72, 
a modified approach was adopted in which tyramine was allowed to react with the 
corresponding acid anhydride at 0°C. As expected, 72 was isolated as the major 
product with a yield of 72% which confirms our reasoning that the nucleophilicity of 
the phenolic moiety of tyramine is reduced and hence the selectivity for the formation 
of the phenolic amide improved by conducting the reaction at a lower temperature.
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HO (CH2)2NH2 +  CH3(CH2)5< COC1
ORRO OR
69 R = COPhO(CH2)5CH3, R, = (CH2)5CH3 71 R = S 02NH2, R, = (CH2)5CH3
70 R = H, Rj = (CH2)5CH3
Scheme 11. Synthesis of (/?-0-sulphamoyl)-/V-(4-«-hexyloxybenzoyl) tyramine (71), 
(i) Et3N/THF, 23°C, 48 h.; (ii) DMF/ CH3OH, NaHC03, A 1 h.; (iii) NaH/DMF,
H2N S02C1.
ho (CH2)2NH2 +  CH3(CH2)7I COC1
ORRRO OR
72 R = H, R, = (CH2)7CH3 73 R = S02NH2, R, = (CH^CH,
Scheme 12. Synthesis of (/?-0-sulphamoyl)-A/-(4-«-octyloxybenzoyl) tyramine (73), (i) 
Et3N/THF, 0°C, 48 (ii) NaH/DMF, H2N S0 2C1.
3.3 Results and Discussion
In order to explore the structure-activity relationships of a number of 2-ring 
structures, and also to investigate the possibility of developing a non-oestrogenic 
inhibitor via this approach, a series of sulphamate derivatives of THN were 
synthesized and tested. 166 Sulphamate derivatives of THN were relatively weak 
inhibitors of oestrone sulphatase activity with THN-sulphamate having an ICsoof lpM 
when tested in MCF-7 cells.
The finding that phenolic compounds such as THN could be utilised as 
oestrone sulphatase inhibitors led to the development of a series of coumarin
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sulphamate derivatives. 156 It was reasoned that the two-ring fused structure of 
coumarin analogues should mimic the A- and B-rings of the oestrone steroid nucleus. 
As previously found for EMATE, 141 COUMATE also inhibited oestrone sulphatase 
activity in a time- and concentration-dependent manner166 and in ovariectomised rats 
COUMATE administration did not stimulate uterine growth but was able to inhibit the 
E1S stimulation of uterine growth.209 Therefore, three modified analogues of 
coumarin were synthesized 27-29 and evaluated for El-STS inhibition. 6 - 
Methoxycoumarin 7-Osulphamate 27 was found to inhibit El-STS activity in MCF-7 
cells by 34% and 72% at 0.1 pM and 10 pM respectively (Table 7) being less active 
than COUMATE (IC50, 380nM) and the mono- 29 and the bis-sulphamate 28 of 
catechol-like coumarin were found to inhibit El-STS in MCF-7 cells by < 10% and 
31% at 10 pM respectively. These results indicated that the presence of methyl ether 
or sulphamoyl groups at 6 -position of the coumarin ring structure reduced the activity 
significantly. Substitution of the aromatic ring of COUMATE with a methyl ether 
group (e.g. Fig.26, 27) or sulphamate group (e.g. Fig.26, 28) results in reduction of 
COUMATE inhibition. A similar reduction is observed when the location of the 
sulphamate group is modified (e.g. Fig.26, 29). Our results have therefore highlighted 
the limited tolerance of the enzyme to substituents at these positions. It is possible 
that the methoxy group in 27 and the second sulphamate group in 28 may have caused 
the sulphamate group at C-7 to be shifted in the binding site from the usual position 
occupied by the sulphamate group of EMATE/COUMATE, and hence it could not be 
activated effectively for the sulphamoylation of the enzyme. These substituents may 
also conceivably shield the sulphamate group in such a manner that the putative proton 
abstraction, the first vital step proposed for the mechanism of El-STS inhibition by 
EMATE, is prevented from occurring.
Relocation of the sulphamate group from the usual C-7 to the C- 6  position 
virtually abolishes the inhibitory activities of the coumarin sulphamate in both of the 
biological system (29 cf. COUMATE, Table 7 and 8 ). It is likely that on binding to 
the enzyme active site, the sulphamate group in 29, which is at the C- 6  position of the 
coumarin ring, as opposed to the C-7 position in COUMATE, is not in close proximity 
to the essential amino residues responsible for their subsequent activation. The poor 
inhibition shown by sulphamate 29 could also be a consequence of the relatively poor
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leaving group abilities of its respective starting coumarin (6,7-dihydroxy-4-methyl 
coumarin). It is reasonable to expect that the pKa of 6,7-dihydroxy-4-methyl 
coumarin will be similar to that of a simple catechol (ca. 9.4) since its hydroxyl group 






Some of the tetralone and indanone sulphamates show encouraging inhibition 
in intact MCF-7 breast cancer cells (Scheme 5, 33 and 35, Table 7); all of these 
sulphamates inhibited El-STS activity in placental microsomes to a lesser extent than 
COUMATE (Table 7). It is therefore interesting to note that the inhibitory activity of 
COUMATE cannot be reproduced by simply replacing the coumarin ring with other 
two fused-ring systems having one aromatic ring similar to that of 4-methyl-7-hydroxy 
coumarin. The relatively disappointing inhibitory activities observed for this series of 
tetralone and indanone sulphamates could well be the result of less effective binding 
of these compounds to the enzyme active site and /or less activation of the sulphamate 
group by the aromatic substitutent.
Table 7. Inhibition of oestrone sulphatase activity in intact MCF-7 breast cancer cells
by sulphamates 27-29, 31-33 and 35.
% Inhibition of El-STS activity in MCF-7 cells
Compound O.lpM lpM IOjiM
27 33.8±5.3 34.1±1.8 72.1±1.3
28 < 1 0 < 1 0 31.2±2.6
29 < 1 0 < 1 0 < 1 0
31 13.5±3 22.6±5.8 71.3±1
32 < 1 0 15.5±9.9 74.1±2.8
33 33±2 91±0.6 99±2
35 10.4±3 47.8±1.7 93.5±0.8
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Table 8 . Inhibition of oestrone sulphatase activity in placental microsomes by 
sulphamates 27-29, 31-33 and 35._____________________________________________
% Inhibition of El-STS activity in placental microsomes
Compound lOpM 50pM lOOpM
27 < 1 0 42.9±1.9 69.9±1.3
28 < 1 0 < 1 0 < 1 0
29 < 1 0 < 1 0 < 1 0
31 19.6±3.1 37.7±0.9 50.3±1.2
32 < 1 0 < 1 0 < 1 0
33 < 1 0 < 1 0 < 1 0
35 12.3±1.0 16.5±2.1 27.0±1.1
Table 9. Inhibition of oestrone sulphatase activity in intact MCF-7 breast cancer cells 
by sulphamates 36-42, 44, 45, 48 and 49._____________________________________
% Inhibition of El-STS activity in MCF-7 cells
Compound O.lpM lpM lOpM
36 71.41±6.85 95.64±2.07 98.6912.82
37 46.3±13.6 83.5±1.9 93.911.2
38 34.8±1.7 83.8±0.5 96.711.0
39 < 1 0 33.04110.68 87.8912.02
40 < 1 0 24.34111.89 83.8110.17
41 < 1 0 33.04110.68 87.8912.02
42 21.3±1.5 67.911.9 97.110.8
44 2 2 .2 ±0 . 1 50.0110.1 93.310.1
45 < 1 0 39.310.1 92.410.1
48 75.3±0.8 98.410.3 99.910.1
49 < 1 0 30.715.6 87.211.8
Having identified that benzophenone-4',4-bis-sulphamate (BENZOMATE, 
Fig.27, 36) is a potent inhibitor, inhibiting El-STS activity by 72%, 96% and 99% at 
0.1 pM, 1 pM and 10 pM respectively in MCF-7 cells, and by 98%, 99% and 99% at 
10 pM, 50 pM and 100 pM respectively in placental microsomes (Table 9 &10), 
BENZOMATE was tested in vivo in rats at 1 mg and 10 mg/kg/day. 84% and 93% 
inhibition of liver oestrone sulphatase activity was observed, 24 h after a single oral 




Table 10. Inhibition of oestrone sulphatase activity in placental microsomes by 
sulphamates 36-42, 44,45, 48, and 49. - = not determined_________________________
% Inhibition of El-STS activity in placental microsomes
Compound lOpM 25pM 50jaM lOOpM
36 98.17±0.05 - 99.0310.05 99.210.0
37 85.3±1.4 92.110.0 94.710.4 96.610.1
38 62.1±1.4 82.010.4 88.110.3 92.810.2
39 76.73±2.47 - 88.0410.82 92.2810.41
40 47.41 ±0.05 - 75.1111.37 82.7710.23
41 71.27±2.42 - 75.7912.06 80.5111.87
42 28.8±3.2 48.510.5 62.012.8 75.811.2
44 2 2 . 1 1 0 .6 29.410.1 38.714.9 53.110.1
45 11.712.3 17.312.7 22.811.4 34.311.0
48 51.113.7 73.611.9 84.111.9 -
49 18.811.3 30.713.4 43.712.6 58.310.1
Table 11. Inhibition of oestrone sulphatase activity in intact MCF-7 breast cancer cells
3y sulphamates 50-56 and 61-63.
% Inhibition of El-STS activity in MCF-7 cells
Compound O.IjliM lpM lOpM
50 < 1 0 50.613.3 87.412.7
51 67.211.1 96.611.4 99.710.1
52 26.614.3 83.911.2 97.710.4
53 93.112.1 98.611.0 99.110.1
54 99.310.6 94.511.6 90.110.8
55 16.114.0 32.712.3 90.110.7
56 < 1 0 16.311.5 64.111.1
60 < 1 0 27.410.8 75.112.8
62 46.614.5 93.910.8 98.610.3
63 < 1 0 19.815.1 75.712.0
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Stability studies of BENZOMATE have been carried out under the similar 
conditions of the bioassay (in phosphate buffer saline with 0.25M sucrose at 37°C) 










o 2 0 -
0 50 100 150 200 250 300 350 400 450 500
H i t e  (nin)
Figure 33. Stability studies of BENZOMATE in phosphate buffer saline with 0.25M 
sucrose at 37°C containing 1% and 10% methanol. Points are mean for triplicate 
determination.
In the light of the encouraging inhibitory activities of BENZOMATE, it is 
important to have a better understanding of its structure-activity relationships, since 
this inhibitor represents a good lead template for designing potentially more potent 
nonsteroidal El-STS inhibitors. Hence, we synthesized several analogues of 
BENZOMATE and its congeners, in which (i) the mono-and bis-sulphamates of 
benzophenone-like compounds were prepared (38, 39), (ii) the sulphamate groups 
were relocated (48), (iii) the carbonyl group was removed (44 and 45) or replaced by 
other group(s) (50-52), (iv) the molecule has been conformationally restricted (42, 53, 
54 and 62), (v) an extra ring (aliphatic or aromatic) has been added (55, 56, 60 and 63) 
and (vi) the distance between the two non-fused-rings was extended (40, 41).
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Upon examination of the abilities of these BENZOMATE analogues (37-42, 
44, 45, 48-56, 60, 62 and 63) to inhibit El-STS activity (Table 9-12), almost all of 
them were found to be less effective inhibitors of El-STS than BENZOMATE, with 
the exception of benzophenone,3',3-bis-sulphamate 48, which was found to inhibit the 
El-STS activity to a similar extent as BENZOMATE. This indicated that such 
relocation of the sulphamate group has not had much effect on activity. These results 
have also shown a general pattern that the analogues which poorly inhibit El-STS 
activity in intact MCF-7 breast cancer cells (Table 7, 9 and 11) also perform poorly 
when examined in placental microsomes (Table 8, 10 and 12). Interestingly, the bis- 
sulphamates of these types of compounds are always more potent than their 
corresponding mono-sulphamates. This further demonstrates that the sulphamate 
group is the key chemical structural requirement for potent sulphatase inhibition. It is 
also worth mentioning that the corresponding starting materials for all these 
sulphamate analogues had no inhibitory activity against sulphatase in either assay.
Table 12. Inhibition of oestrone sulphatase activity in placental microsomes by 
sulphamates 50-56, 60 and 63, negative sign of %inhibition = stimulation effect._____
% Inhibition of El-STS ac tivity in placenta microsomes
Compound lOpM 25pM 50pM lOOpM
50 65.0±1.8 85.5±0.6 92.3±0.3 95.4±0.2
51 65.3±0.9 79.4±0.9 87.4±0.9 91.9±0.4
52 33. l id  .7 49.5±0.1 64.7±0.9 76.8±0.4
53 91.3±0.7 95.7±0.5 97.2±0.3 97.7±0.1
54 86.1±0.5 91.2±0.2 94.4±0.5 95.6±0.1
55 31.4±1.6 41.9±2.3 62.5±7.5 69.0±4.8
56 <10 15.9±0.9 32.5±1.1 60.1±3.4
60 <10 20.0±1.6 33.4±2.2 44.7±0.4
63 -28.0±1.1 -37.7±1.8 -31.8±1.3 -36.2±1.8
The DMF adduct (37) and the mono- sulphamate of BENZOMATE (38), were 
potent El-STS inhibitors, but slightly less potent than BENZOMATE. Replacement 
of the carbonyl group of BENZOMATE by methylene (44) or the whole carbonyl 
group by divalent sulphur (51) or a sulphonyl group (50) or aliphatic rings (55) or 
substitution with a cyclohexyl ring (60) significantly reduces the inhibitory activity of 
the sulphamate. Since, the carbonyl group of BEZOMATE is clearly required for
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potent activity, this might be to do with extra binding to the enzyme active site or 
conjugation with the phenyl ring with activation of the sulphamate group. Substituting 
the carbonyl group with a bulky ring (adamantanediyl, 55, cyclohexyl 60) abolishes 
the inhibitory activities of the BENZOMATE. These results therefore highlight the 
presumed limited tolerance of the enzyme to these bulky rings. It is possible that these 
rings may cause the sulphamate groups at 4 and 4'-positions to be shifted in the 
binding site from the position occupied by the sulphamate groups of BENZOMATE, 
and hence the analogue might not be activated effectively for the sulphamoylation of 
the enzyme. These rings may also conceivably shield any sulphamate proton 
abstraction, and thus the first vital step proposed for the mechanism of El-STS 
inhibition by EMATE, 141’159 is prevented from occurring. These rings may of course 
simply be so large, that the molecule cannot fit into the enzyme active site.
3-Hydroxybenzo[&]naphtho[2,3-<7]-furan-6,l 1-dione (61) and the 
anthraquinone derivatives are intercalating cytostatic agents and have anti-tumour 
properties. However, we considered that introduction of the sulphamate group (the 
key chemical structural requirement for potent sulphatase inhibition) into the structure 
of these compounds, might significantly engender sulphatase inhibitory activity and, 
might provide new lead for sulphatase inhibitors. Additionally, anthraquinones could 
serve as conformationally restricted analogue of BENZOMATE, to explore details of 
the potential active binding mode. The corresponding sulphamates (53, 54 and 62) of 
these compounds have been prepared and examined in MCF-7 cells and placental 
microsomes for El-STS inhibition. These sulphamates were found to be potent 
sulphatase inhibitors (Table 11 and Table 12). Both mono- and bis-sulphamates of 
anthraquinone (53 and 54) were found to inhibit El-STS inhibitory activity to a 
similar extend of BENZOMATE in both biological systems. These compounds 53 
and 54 were found to inhibit El-STS activity by 90-93%, 95-99% and >99 at O.lpM, 
ljiM and lOpM in MCF-7 cells respectively (Table 11) and by 8 6 % and 91% at 10pM 
in placental microsomes respectively (Table 12). Therefore, It is reasoned that the 
conformationally restricted analogues of BENZOMATE (anthraquinones) did not 
change its El-STS inhibitory activity. It was observed that 3-0-sulphamoyl- 
benzo[£]naphtho[2,3-d]-furan-6,l 1-dione (62) also kills the MCF-7 cells, indicating 
that these derivatives might be toxic and have additional activities. The question
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arises whether their inhibition of El-STS sulphatase results from the sulphamoyl 
group alone or is due to their other properties. This remains to be elucidated precisely, 
but the following observation was noted: the corresponding starting material of 62 has 
no inhibitory activity against El-STS when examined in MCF-7 cells at lOpM 
(inhibited El-STS by 3%) while 62 inhibited El-STS by 99% at the same 
concentration. When the percentage growth inhibition of MCF-7 breast cancer cells 
by 61 was examined, it was found to be 12%, 20% and 56% at 0.1 pM, lpM  and 
lOpM respectively compared to 62 which inhibited the growth of these cells by 41% 
and 44% at lpM  and lOpM respectively and was inactive at 0.1 pM, indicating that 
both the phenol (61) and the corresponding sulphamate (62) have the same property of 
inhibition of the growth of MCF-7 breast cancer cells.
(Z)-4-Hydroxytamoxifen is a metabolite of tamoxifen, the very widely used 
antioestrogen. As mentioned previously, in some studies this metabolite inhibits E l- 
STS activity, but with a relatively high Ki value (1130 pM ) . 144 However, we assumed 
that introduction of the sulphamoyl group into this molecule might significantly 
increase its potency against oestrone sulphatase. Unfortunately, the 4-0- 
sulphamoyltamoxifen (Fig.31, 63) was found to be only a poor sulphatase inhibitor, 
inhibiting El-STS activity by <10%, 20% and 75% at 0.1 pM, lpM  and lOpM in 
MCF-7 respectively (Table 11). The poor inhibition of 4-hydroxytamoxifen is due to 
the low affinity to bind to the enzyme active site (i.e. high Ki value). It is reasonable 
to expect that its sulphamate also binds poorly. This may be explained the poor 
inhibition of 4-O-sulphamoyltamoxifen isomers.
Li et al have synthesised and tested a series of (p-<9-sulphamoyl)-Af-alkanoyl 
tyramine as potential sulphatase inhibitors. They reported, in a placental 
microsomal assay that an increase in potency was detected as the length of the 
alkanoyl chain increased from heptanoyl-[-CO(CH2)5CH3] which had an IC50 of 
14.3pM to tetradecanoyl-[CO(CH2)i2CH3] with an IC50 of 56nM. A hexadecanoyl 
derivative was also shown to inhibit El-STS activity in MDA-MB-231 cells by 82% at 
lpM  and the ElS-stimulated growth of MCF-7 cells in a dose-dependent manner. 204  
It was reasoned that the phenyl portion of such an inhibitor would mimic the A-ring of 
EMATE with the alkanoyl group providing hydrophobic bulk to mimic the B, C and D
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rings of EMATE or acting as a membrane insertion motif which may increase the 
affinity of the inhibitor for the membrane-bound steroid sulphatase enzyme.
Li and his colleagues also have obtained convincing evidence that inhibition of 
steroid sulphatase activity in rats has a role in counteracting scopolamine-induced 
amnesia. Both EMATE161 and one of the non-steroidal (p-Osulphamoyl)-Af-alkanoyl 
tyramine inhibitors210 were effective in reversing scopolamine-induced amnesia. This 
finding offers the prospect of developing new potential therapeutic strategies for the 
treatment of Alzheimer’s disease in humans.
We found that it was not necessary to have a fused ring system for sulphatase 
inhibition and we extended the work of Li et al. This led to the synthesis of a series of 
sulphamate analogues with a single ring or bicyclic non-fused ring structure (64, 65, 
6 8 , 71 and 73). In the placental microsome oestrone sulphatase assay, these 
compounds proved to be relatively weak inhibitors with IC50S ranging from 10|iM- 
40|iM (Table 13). A single lOmg/kg dose of Zs-capsaicin (65) did result in a modest 
degree of inhibition of El-STS activity in rat uterine (57%) and liver (22%) tissues. 
The sulphate derivative of E-capsaicin was prepared and found to be a substrate for 
El-STS (Unpublished results; Woo LWL, Purohit A, Reed MJ and Potter BVL). The 
(p-0-sulphamoyl)-A-(4-hexyloxybenzoyl) tyramine (71) and (p-0-sulphamoyl)-A-(4- 
octyloxybenzoyl) tyramine (73) were also tested in vivo. After a single oral lOmg/kg 
dose, no inhibition of rat liver El-STS activity was detected.
Under the experimental conditions employed in our placental microsome E l- 
STS assay the IC50 for (p-O-sulphamoyl)-A-tetradecanoyl tyramine (6 8 ) was 2pM not 
56 nM as previously reported by Li et al.210 (Table 13). Administration of a single 
lOmg/kg oral dose of this compound did not result in any inhibition of rat liver E l- 
STS activity. The exact reason why these compounds (6 8 , 71 and 73) are inactive in 
vivo remains to be elucidated, but it might be due to pharmacokinetic properties, as 
these compounds are especially hydrophobic.
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Table 13. IC50 Values for single ring and bicyclic non-fused ring sulphatase inhibitors, 
- = not determined.
IC50 Values (pM)
Compound Placental Microsomes MCF-7 cells
64 40 1
65 25 0.1




Attempts to design and synthesise nonsteroidal El-STS inhibitors, in the light 
of the potent oestrogenicity of EMATE, has led primarily to the development of 
BENZOMATE (36), a significant improvement over our first lead nonsteroidal 
candidates (THF sulphamates and COUMATE). BENZOMATE is an orally active 
and nonoestrogenic active site-directed steroid sulphatase inhibitor, albeit less potent 
than EMATE, but more potent than COUMATE. Several modifications were made to 
the structure of BENZOMATE. These structure-activity relationships studies 
conducted on BENZOMATE clearly show that its carbonyl group is pivotal for 
inhibition of El-STS and that conformational flexibility is not required. A structurally 
modified BENZOMATE with highly potent activity might subsequently be designed 
and developed for therapeutic use in the treatment of hormone-dependent breast 
cancer and this compound, with its bis-sulphamoyl moiety represents an important 
new class of inhibitor and lead compound for the future.
All of the studies reported here, by ourselves and others since the publication 
of our initial report,157 have demonstrated the absolute requirement for at least one 
phenol sulphamate ester for activity. It seems clear that this must be the active 
pharmacophore required for steroid sulphatase inhibition. Other groups, not 
necessarily a ring structure (64, 65, 6 8 , 71 and 73), provide the extra motifs required 
for, presumably, effective binding to the active site and/or activation of the 
sulphamoyl group. We therefore propose the pharmacophore illustrated in Figure 34 
as the definitive molecular motif required in a steroid sulphatase inhibitor. No 
compound has yet been synthesized, acting like EMATE, that does not possess this
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functionality which we believe will be a crucial factor in the design of further active 
site-directed inhibitors of steroid sulphatase.
Additional rings or 
functionalities to 
enhance binding
Figure 34. Proposed pharmacophore for EMATE-like steroid sulphatase inhibitor.
h 2n s o 2o / ^ 5^ >\
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4 Steroid sulphamate analogues (tricyclic sulphamates)
4.1 Background
We have now established that nonsteroidal coumarin sulphamates, such as 
COUMATE and its analogues, tetralone sulphamates and indanone sulphamates are
i fnsteroid sulphatase inhibitors. The structure activity relationships for these 
sulphamates have shown that the ring systems (A and B) in these sulphamates are 
pivotal for inhibitory activities. It is possible that the potency of these sulphamates 
observed might be attributed to their binding to the enzyme active site via hydrophobic 
interactions provided inter alia by the B-ring. Since these sulphamates are 
presumably A/B ring mimics of EMATE, it is reasoned that analogues with 
substituents of increased hydrophobicity may further interact with other steroid 
recognising amino acid residue in the enzyme active site and hence should be more 
potent steroid sulphatase inhibitors. Recently, a number of further modifications have 
been made to the basic coumarin sulphamate structure, including the preparation of 
several novel tricyclic coumarin-based sulphamates. Preliminary results from 
investigations with these compounds have shown that it will be feasible to develop a 
non-steroidal, non-oestrogenic sulphatase inhibitor that is equipotent to, or better than, 
EMATE (unpublished results, Woo LWL, Purohit A, Reed MJ and Potter BVL).
In our continuing quest for the design of efficient non-steroidal inhibitors of 
El-STS with potency similar to EMATE and also for exploring the potential of other 
three-ring sulphamates as effective inhibitors of El-STS, we synthesized and 
evaluated several fused 3-ring sulphamates.
4.2 Synthesis
The Robinson annelation reaction, since its introduction over sixty years 
ago, 211,212 and with its subsequent modifications, has been one of the most widely used 
synthetic tools in organic chemistry. As illustrated in Fig.35, the original procedure
213involved nucleophilic attack of a ketone or ketoester enolate, in a Michael addition, 
on a vinyl ketone to produce the intermediate “3'-oxobutyl” Michael adduct 75.
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Subsequent internal aldol-type ring closure (condensation) to keto alcohol I, followed 




Figure 35. The mechanism of Robinson annelation (e.g 76)
Robinson annelation reactions have been useful in building up the carbon 
frame-work of complex natural products such as steroids. Therefore, we have utilized 
this reaction for preparation of three A/B/C fused ring mimics of a steroid. Our 
starting materials for this reaction were tetralone derivatives.
The action of ethyl formate on 6-methoxy-l -tetralone in the presence of 
potassium terf-butoxide gave an almost quantitative yield of 2-(hydroxymethylene)-6- 
methoxy-1-tetralone 74 (Scheme 13). Treatment of 74 with methylvinyl ketone in the 
presence of triethylamine gave 2-(3-oxobutyl)-6-methoxy-1-tetralone 75 in excellent 
yield (93%). Cyclization of 75 as shown above (Robinson annelation mechanism, 
Fig.35) with potassium hydroxide gave l,9,10,10a-tetrahydro-7-methoxy-3(2//)- 








Scheme 13. Synthesis of 1,9,10,10a-tetrahydro-7-O-sulphamoyl-3(2//)- 
phenanthrenone (78), (i) H C02C2H5/(CH3)3C0'K+, toluene -78 to -5 °C, 1 h, (ii) 
H2C=CHCOCH3/(C2H5)3N, MeOH, 3 days, (iii) KOH, MeOH/H20 , A 8 h, (iv) 
AlCl3/toluene, A 1 h or BBr3/DCM, 0°C (30 min), RT (30 min), (v) NaH/DMF, 
C1S02NH2, 12 h.
To the best of my knowledge the demethylation of 76 has not been attempted 
before and hence this was carried out for the first time by two different methods 
(aluminum chloride in toluene at reflux, method A) and (boron tribromide in DCM at 
0°C-RT, method B). Method B was found to be better than method A, as 
demonstrated by the purity of the product (77) so obtained which gave the right CHN 
analysis and also higher the yield of method B (83%) compared to that of method A 
(64%, Scheme 13). The demethylation of 76 was attempted using aluminum chloride 
in toluene at room temperature for 5 h, the methyl ether of 76 could not be cleaved 
except when the reaction mixture was heated under reflux as mentioned above 
(method A). The stereochemistry of the Robinson annelation reaction could not be 
controlled and thus a mixture of two enantiomers of 76 (I and II) were obtained. 




Like 76, 78 also contains a mixture of enantiomers and therefore it is important 
to interpret its biological activity on the basis that only one of the enantiomers might 
be biologically active against oestrone sulphatase.
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Scheme 14. Synthesis of 1,9,10,10a-tetrahydro-6-methoxy-7-O-sulphamoyl-3(277)- 
phenanthrenone (85) and its analogues (84, 87) (i) HC02C2H5/(CH3)3C0' K+, toluene 
-78 to -5°C, 1 h, (ii) H2C=CHCOCH3/(C2H5)3N, MeOH, 3 days, (iii) KOH, 
MeOH/H20 , reflux 15 min, (iv) AlC^/toluene, 2.5 h, RT, (v) AlC^/toluene, A, reflux 
30 min, (vi) NaH/DMF, C1S02NH2, 12 h.
Using a similar approach the 6-methoxy derivative of 76 1,9,10,10a- 
tetrahydro-6,7-dimethoxy-3(2//)-phenanthrenone 81 was also prepared, starting from 
6,7-dimethoxy-l-tetralone (Scheme 14).214 In the preparation of 81 from 80 and 
potassium hydroxide in methanol/water, the cyclization reaction time was only 15 
min., while the cyclization reaction time of 76 analogue from 75 under the similar
80
conditions was about 8  h. However, the presence of the methyl ether at the e x ­
position of 75 (80) lowers the reaction time significantly. The reason for this time 
difference in the preparation of these two analogues is to be elucidated. The 
demethylation of 81 was carried out with AICI3 in toluene under two different 
conditions: i) at room temperature which gave a mixture of the two mono-hydroxyl 
derivatives, 1,9,10,10a-tetrahydro-6-hydroxy-7-methoxy-3(2//)-phenanthrenone 82 in 
56% and l,9,10,10a-tetrahydro-7-hydroxy-6-methoxy-3(2//)-phenanthrenone 83 in 
25%; and ii) at reflux temperature which gave the dihydroxy derivative of 81, 
1,9,10,10a-tetrahydro-6,7-dihydroxy-3(2//)-phenanthrenone 86 in 8 8 % yield. The 
structures of 82 and 83 were tentatively assigned on the basis of their yields. It was 
observed that the methoxy group at the C-7-position of these three rings compounds 
(e.g 76) required harder conditions to cleave than that at the C-6 -position as observed 
upon the demethylation of 76 by AICI3 in toluene, no cleavage was occur at room 
temperature except at reflux temperature. However, demethylation of 81 with AICI3 
in toluene was carried out at room temperature which gave a mixture of two 
compounds (82 and 83), the compound of higher yield (56%) was assigned as 82 as 
the 6 -methoxy group of 81 was cleaved. It is expected that the electron density of the 
oxygen atom of 6 -methoxy of 81 is higher (stronger nucleophile) and it is thus able to 
form a complex with AICI3 faster and better than that of the oxygen atom at the 7- 
position. Compounds 81-87 are all racemic as in compound 76 and thus only one of 
the two enantiomers of the sulphamate 84, 85 and 87 might be biologically active. 
The mono sulphamate of 86 only was obtained, the bis-sulphamate either did not form 
or formed and decomposed to the mono-sulphamate (87a) due to lack of stability. The 
NMR data of 87 could not permit assignment as to which mono-sulphamate was 
formed (87a or 87b). It is most likely that the structure is 87a, due to the following 
evidence: i) it was observed that in all sulphamates prepared so far, the sulphamate 
group(s) in the aryl ring deshield the adjacent proton(s) more downfield as shown by 
*H NMR data, however, comparing the chemical shifts of the protons at the C-5 and 
the C- 8  of 86 and 87. It was found that the chemical shifts of C-5-H of 86 and 87 
about 7.17 and 7.73 ppm respectively and for C-8 -H about 6.58 and 6.77 ppm 
respectively. The difference of the chemical shifts of C-5-H in these two compounds 
(-0.6 ppm) and C-8 -H (-0.2 ppm), suggested that the sulphamate group is adjacent to 
the C-5-H not to the C-8 -H. This indicates that the structure of the mono-sulphamate
81
is structure 87a not 87b; ii) It is expected that the pKa value of the hydroxyl group at 
the C-6 -position of 86 has a higher value than that at C-7-position since is not 
conjugated with the extended conjugation. However, the 6 -phenolate is expected to be 
a stronger nucleophile, 87a is expected to be formed first and, as the major product, it 
might be the bis-sulphamate of 86 also formed and then decomposed back to give 87a 
due to the lack of stability as the leaving group ability at this position is high due to 
low pKa value; and iii) the biological results also support the structure as 87a (the 
sulphamate group at the C-6 -position) not the other analogue 87b (the sulphamate 
group at the C-7-position). It was observed that the optimum position of sulphamate 
group to express potent El-STS inhibitory activity by these sulphamates was found to 
be the C-7-position (see later). It was found that 87a is a weak El-STS inhibitor 
(Table 14 and 15), suggesting that its sulphamate group at the disfavoured position (C- 
6).
Catalytic hydrogenation of 76 gave a mixture of two compounds, 
l,4,4a,9,10,10a-hexahydro-7-methoxy-3(2//)-phenathrenone 8 8  and 1,4,4a,9,10,10a- 
hexahydro-7-methoxy-3(27/)-phenathrenol 89 in 31% and 67% yields respectively 
(Scheme 15). Demethylation of these compounds (88, 89) was problematic. Several 
methods were carried out to demethylate these compounds including: i) AICI3 in 
toluene under different conditions (room or reflux temperature) which did not work, 
(ii) AlCls/Nal either in acetonitrile or acetonitrile/DCM mixture (1:1) (at room or 
reflux temperature) was also tried but failed. In the above two methods of 
demethylation of 88 and 89, the starting material even could not be recovered. 
Therefore, the demethylations of 88 and 89 were performed using boron tribromide in 
DCM at 0°C (Scheme 15), but this method gave the corresponding phenols (90 and 
91) in low yield, 25% and 40% respectively. It was then reasoned that such synthetic 
problem might be overcome by demethylating 76 to 77 prior to catalytic 
hydrogenation. As expected, the catalytic hydrogenation of 77 gave 90 and 91 
(Scheme 15) cleanly and in a better yield (63% and 30% respectively). The problem 




Scheme 15. Synthesis of l,4,4a,9,10,10a-hexahydro-7-O-sulphamoyl-3(2//)- 
phenathrenol 92 and l,4,4a,9,10,10a-hexahydro-7-O-sulphamoyl-3(2//)- 
phenathrenone 93 (i) H2/Pd-C (10%), EtOAC, 50 psi, 12 h, (ii) BBr3 /DCM, 0°C (30 
min), RT (30 min), (iii) NaH/DMF, C1S02NH2, 12 h.
The catalytic hydrogenation (76 to 8 8  and 77 to 91) gave a mixture of 
diastereoisomers and enantiomer pairs. For example, since 88 has two chiral centres 
(4a and 10a), there are four possible stereoisomers of the molecule present in the 
structure (cis-cis, trans-trans, B and D; cis-trans and trans-cis, A and C, Fig.36). 
Compound 89 has three chiral centres (3, 4a and 10a) and thus has a maximum of 8 
stereoisomers (Fig.37). The stereochemistry of 90, 91, 92 and 93 should be the same 
as what has been described for 8 8  and 89. For some compounds (8 8 , 89 and 90) 
different isomers could be seen in the lH NMR spectra. The aromatic proton at the 5- 
position splits into two doublets (8 8 ) or three doublets (89 and 90, integrating for one 
proton) in these compounds (Fig.38).
83
Figure 36. The possible stereoisomers of l,4,4a,9,10,10a-hexahydro-7-methoxy- 
3(2//)-phenathrenone (88). A-C, B-D are enantiomer pairs where as AB, AD, CB and
CD are di astereoi somers.
The sulphamoylation of the phenol derivatives of the 3 ring fused system 
compounds (Scheme 13-Scheme 15) was carried out by treating them with sulphamoyl 
chloride in DMF using NaH as a base. In the case of 6,7-dihydroxy derivative 86 the 
mono sulphamate only could be isolated as the major product (as previously 
mentioned, the structure most likely is 87a, the sulphamate at the 6-position) and in 
the case of 90, the mono-sulphamate (92) was isolated. In theory the sulphamoylation 
of 90 should take place at both hydroxyl groups (C-7-OH and C-3-OH) as 2.5 equiv. 
of NaH were used, but the mono-sulphamate of this compound only was isolated; it is 
possible that the bis-sulphamate was formed, but due to high polarity of this 
compound, bis-sulphamate could not be isolated. The sulphamate group of this 
compound is most likely to be at the C-7-position (92). The structure was confirmed 
by the 'H NMR data [as no proton for the C-7-OH at 6-9 ppm as in compound 90 (9.0 
ppm)] and also supported by the biological results (this compound was found a potent 
El-STS inhibitor in both biological systems; Table 14 and 15. In all sulphamates 
synthesised so far, one of the structure requirements for the potent El-STS inhibitory
activity, the sulphamate group(s) and the aryl ring; the sulphamate group(s) must be 












Figure 37. The 8  possible stereoisomers of l,4,4a,9,10,10a-hexahydro-7-methoxy- 




Figure 38. NMR spectra shows splitting pattern at the C-5 of the different isomers of
compounds 88, 89 and 90.
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Reduction of the carbonyl group of 76 with sodium borohydride in THF/IPA to 
give the corresponding alcohol II was carried out but failed (Scheme 16), and the 
product that was isolated was a phenanthrene derivative, most likely 94 as shown by 
NMR (not very pure) and mass spectroscopy data. We think that II was formed but it 
was extremely unstable and elimination of water took place to give 94, whose 




Scheme 16. Reduction of l,9,10,10a-tetrahydro-7-methoxy-3(2//)-phenanthrenone
(76), (i) NaBH/THF/IPA, 16 h.
4.3 Results
The ability of the 3-ring sulphamates (78, 84, 85, 87a, 92 and 93) to inhibit E l- 
STS activity was examined in intact MCF-7 breast cancer cells (Table 14). The ability 
of 87a, 92 and 93 to inhibit El-STS activity was also examined in placental 
microsomes (Table 15). Of the different 3-ring sulphamates tested, 1,9,10,10a- 
tetrahydro-7-0-sulphamoyl-3(2H)-phenanthrenone (78) was the most efficient 
inhibitor in this series but was found to be less active than EMATE, COUMATE and 
BENZOMATE. At a concentration of 10 pM, 78 inhibited El-STS activity in MCF-7 
cells almost completely (99.5%, Table 14). As discussed before, compound 78 
consists of two enantiomers and hence only one might be active. The fact that a 
racemic mixture of 78 was assayed could explain the lower activity of this sulphamate
86
compared with COUMATE and BENZOMATE. In general, most of these analogues 
show potent inhibition of El-STS activity in MCF-7 cells at 10 pM, ranging from 
75.81 % for 1,9,10,10a-tetrahydro-7-hydroxy-6-(9-sulphamoyl-3(2//)-phenanthrenone 
(87a), to 99.5% for l,9,10,10a-tetrahydro-7-0-sulphamoyl-3(2//)-phenanthrenone (78) 
(Table 14).
Table 14. % Inhibition of El-STS activity in MCF-7 intact breast cancer cells by 3- 
ring sulphamates, * = Inactive________________________________________________
Compound % Inhibition of El-STS activity in MCF-7 cells
0.1 pM lp M 10 pM
78 26.4±3.3 90.0±0.6 99.5±0.3
84 3.6±1.8 56.6±1.3 97.0±0.1
85 15.4±1.3 66.5±0.3 97.6±0.1
87a * 4.83±4.96 75.81±1.43
92 23.6±3.17 80.54±4.18 95.35±1.99
93 23.9±4.7 83.9±0.6 98.3±0.4
The inhibition of El-STS activity in placental microsomes was assessed for the 
three sulphamates 87a, 92 and 93 (Table 15). The inhibition by 87a in placental 
microsomes was about 16% at various concentrations (0.1-10 pM), while for 92 the 
inhibition ranged from 22% at 0.1 pM to 73% at 10 pM. At low concentrations (0.1- 
lpM) these analogues have either moderate or low El-STS inhibitory activity in both 
assays (MCF-7 cells and placental microsomes). 1,9,10,10a-tetrahydro-7-hydroxy-6- 
0-sulphamoyl-3(2//)-phenanthrenone (87a) was inactive at 0.1 pM in MCF-7 cells.
Table 15. % Inhibition of El-STS activity in placental microsomes for 3-ring structure 
sulphamates (87b, 92 and 93), - -  not determined._______________________________
Compound % Inhibition of El-STS activity in placental microsomes
0.1 pM lp M 10 pM
87a 16.47±1.49 10.31±7.43 15.97±2.38
92 21.66±1.31 31.85±0.02 73.22±0.28
93 - - 56.1 ±0.1
87
4.4 Discussion
Since the unexpected discovery that the potent steroid sulphatase inhibitor 
EMATE is also a highly active oestrogen, we have been exploring alternative 
phenolic-based nonsteroidal ring structures, whose sulphamates might exhibit steroid 
sulphatase inhibition but be devoid of oestrogenicity. 167 Our interest lies in coumarin, 
tetralone and indanone ring systems which show inhibitory properties after 
sulphamoylation. Structurally, these systems bear a resemblance to oestrogens 
because of an apparently crude mimicry of the steroid skeleton and therefore the 
molecules might mimic the A/B ring system of oestrogens. We then extended our 
reasoning that tricyclic sulphamates which crudely mimic the A/B/C ring of EMATE 
might exhibit steroid sulphatase inhibition but yet not be oestrogenic.
Therefore, several phenanthrene derivatives were prepared utilising the classic 
Robinson annelation reaction. Since some of these compounds were reported nearly 
32 years ago214 without full characterization, part of our aim was to increase their yield 
and also to report modem spectroscopic analysis.
Although active, and often rather potent, these 3-ring sulphamate analogues 
did not achieve inhibition of oestrone sulphatase (Table 14 and Table 15) at the same 
level as those of EMATE and other established non-steroidal sulphamates (Chapter 2 
and 3) in vitro. The relatively weak inhibition of El-STS exhibited by these analogues 
could be due to different reasons, for example poor stability, weak binding to the 
enzyme and conformational effects. Also, many of the compounds tested exist as a 
mixture of several different stereoisomers; it is therefore impossible to distinguish 
what the individual effects of these isomers might be. It was noticed that most of 
these sulphamates are fairly unstable in organic solvents (as observed by TLC, e.g 78 
and 85). From previous experience, this is perhaps due to the extended conjugation 
that present in these compounds which increases the ability of the 3-ring moiety to 
leave by stabilising the phenolate ion so formed upon cleavage of the sulphamate 
group. An introduction of a substituent (OCH3) at the C- 6  (85) of the 78 ring reduces 
the inhibitory activity of this sulphamate from 26% to 15% and from 90% to 67% at 
0.1 pM and 1 pM for 78 and 85 respectively (Table 14). It is therefore, thought that
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there is a limit of tolerance of the enzyme to substituent at this position. It is also 
possible that the methoxy group in 85 may have caused the sulphamate group at C-7 to 
be slightly shifted in the binding site from the usual position occupied by the 
sulphamate group of EMATE/78, and hence it could not be activated effectively for 
the sulphamoylation of the enzyme. The methoxy group may also conceivably shield 
the sulphamate group in such a manner that the putative proton abstraction, the first 
vital step proposed for the mechanism of El-STS inhibition by EMATE is occurred 
slowly or prevented from occurring. Changing the location of the sulphamate group 
from the 7-position of 85 to the 6 -position (84) also decreases the El-STS inhibitory 
activity from 15% to 4% and from 67% to 57% at 0.1 pM and 1 pM respectively. It is 
likely that on binding to the enzyme active site, the sulphamate group in 84, which is 
at the C- 6  position of this three ring sulphamate, as opposed to the C-7 position in 85, 
is not in close proximity to the essential amino acid residues responsible for their 
subsequent activation. The poor inhibition shown by the sulphamate 84 could also be 
a consequence of the relatively poor leaving group ability. In both 84 and 85 when the 
expected phenolate anion is formed as a result of loss of the sulphamoyl group, one 
canonical structure of the corresponding phenolate ion is disfavorable by the presence 
of the electron donating group (OCH3) in the or^o-position. However, this is equal to 
84 and 85. In 85 further stabilisation of the phenolate ion is possible with extended 
conjugation and this may lead therefore to a lower of the phenol pKa for 83 than 82 
and improvement the leaving group ability, leading to a more potent compound (85). 
In the other words it is reasonable to expect that the pKa of 84 is higher than 85 since 
its sulphamate at the C- 6  position is not conjugated to the extended conjugation 
(double bond at C-4). Comparison of the activity of these regioisomers 84 with 85, 
differing only in positioning of the sulphamate and the methoxy groups, demonstrates 
that the sulphamate group must be at the 7-position and not the 6 -position for 
optimum El-STS inhibition, although a real difference in activity only becomes 
apparent at 0.1 |xM. However, the activity difference may also stem from isomer 
effects.
Similarly, changing the methoxy group at the C-7 of 84 to a hydroxy group 
(87a), reduces the inhibitory activity significantly in both biological systems (Table 14 
and 15). 1,9,10,10a-Tetrahydro-7-hydroxy-6-Osulphamoyl-3(2/T)-phenanthrenone
89
(87a) was inactive at low concentration (0.1 pM), showed moderate activity at 10}iM 
(76%) in MCF-7 cells (Table 14) and showed low activity in placental microsomes at 
10|iM (16%, Table 15). It is possible that intermolecular hydrogen bonding between 
the C-7 hydroxy and the NH2 in the sulphamate group at the C-6 -position of 87a 
formed, which unable the sulphamate group to bind to the active site of the enzyme as 
this hydrogen bond might be shifted the sulphamate group from the usual position as 
previously discussed or lower the leaving group ability of sulphamoyl group and hence 
could not be effectively sulphamoylate the enzyme. Such a hydrogen bond will not 
form in 84. This may therefore account for the lower potency of this compound.
To study the structure-activity relationship for these 3-ring sulphamate 
analogues, specifically for 78 the best inhibitor in this series (Table 14), we have 
prepared and examined two analogues of 78 (92 and 93). In compound 93 the double 
bond was removed (as a result 4 isomers are present), while in compound 92 the 
carbonyl group at the 3-position as well as the double bond were reduced ( 8  
stereoisomers resulted). It was found that in both cases the inhibitory activity slightly 
decreased from 90% to 80% and 99.5% to 95% at lpM  and IOjliM respectively in 
MCF-7 cells (Table 14). They were slightly less potent than 78. However, rather than 
the stereochemistry (number of isomers present) an important factor was, when the 
olefinic double bond was saturated, the analogues so afforded (92 and 93) were found 
to be less effective inhibitors of El-STS than 78 (Table 14). This indicated that the 
double bond is required for potent El-STS inhibition activity, but the stereochemistry 
difference between these analogues should be considered as another factor which 
might be affecting the activity.
In general it was difficult to compare the inhibitory activity of these 3-ring 
sulphamates due to the difference in stereochemistries of the various isomers, since 
most of these sulphamate analogues are a mixture of stereoisomers. Hydrophobicity 
and stability are important factors for potent El-STS inhibition activity. The D-ring of 
EMATE was demonstrated to be an important factor for its activity and oestrogenicity 
(see Chapter 5); mimicry possibly due to hydrophobicity and extra binding to the 
enzyme active site. The lack of mimicry of the D-ring of EMATE in these 3-ring 
sulphamates might be one of the reasons why these compounds are not so potent as
90
El-STS inhibitors compared to EMATE. The stereochemistry of these analogues may 
be an additional factor for the difference in activity. In the case of 78, there are two 
enantiomers (racemate) present and we do not know which one is the active isomer as 
it is difficult to separate these isomers (both may in principle be active). If only one 
isomer is active, it is reasonable to expect that such enantiomer would be at least twice 
active as the racemic mixture of 78. With compounds 92 and 93, at least each 
compound has eight-four isomers respectively and the active isomer might be present 
only at 12.5-25%. This might be one of the reasons why these compounds are not so 
potent as El-STS inhibitors.
4.5 Summary
In conclusion, we have prepared a range of 3-ring sulphamate analogues and 
examined their abilities to inhibit oestrone sulphatase activity. Unfortunately, all these 
sulphamates showed modest inhibition of oestrone sulphatase relative to the most 
potent compounds known, but they are reasonable inhibitors at 10|iM in MCF-7 cells. 
This may be attributed to the following factors: the lack of stability, weak binding of 
the molecule to the active site of the enzyme, lack of the hydrophobicity (e.g. D-ring); 
and stereochemistry. The best inhibitor in this series was 1,9,10,1 Oa-tetrahydro-7-O- 
sulphamoyl-3(2//)-phenanthrenone (78). At lOfiM, it showed comparable inhibition 
to EMATE and other potent non-steroidal inhibitors. The inhibitory results of these 
sulphamates have also shown a general pattern that analogues which inhibit El-STS 
activity poorly in intact MCF-7 breast cancer cells (Table 14) also perform poorly 




A major impetus to the development of steroid sulphatase inhibitors has been 
the realization that in order to improve the therapeutic response to endocrine therapy 
for women with hormone-dependent breast cancer, not only the aromatase enzyme 
must be inhibited, but also the synthesis of oestrogenic steroids via other routes. The 
steroid sulphatase enzyme regulates the formation of oestrone from oestrone sulphate 
(E1S), a steroid conjugate present at high concentrations in tissues and blood of
191 141women with breast cancer. ’ This sulphatase also controls the formation of
dehydroepiandrosterone (DHA) from DHA-sulphate (DHA-S). DHA can 
subsequently be reduced to 5-androst-3p,17p-diol (Adiol), a steroid with oestrogenic 
properties that is capable of stimulating the growth of breast cancer cells in vitro132 
and inducing mammary tumours in vivo.133 In addition to the role that steroid 
sulphatase has in promoting tumour growth, there is now evidence that it is involved 
in regulating part of the immune response106,215 and cognitive function. 161,210
The first potent sulphatase inhibitor identified, oestrone-3-O-sulphamate 
(EMATE) 141,147 proved, unexpectedly, to be oestrogenic. 162 A number of strategies 
have therefore been adopted to design and synthesize non-oestrogenic inhibitors. 
Subsequent structure-activity studies have confirmed that the sulphamate group 
attached to an aryl ring is the active pharmacophore required for potent inhibition of 
steroid sulphatase activity. 167
The structure activity relationships for EMATE have not been extensively 
studied. Only the modification of the sulphamoyl group has been studied. It has been 
shown that the bridging oxygen atom between the steroid nucleus and the sulphamoyl 
group (H2NSO2O) is indispensable for inhibitory activity of EMATE. Hence, 
analogues of EMATE, where the bridging atom is either a sulphur or nitrogen atom, 
are weak non-time-dependent inhibitors. 159 A significant reduction in the inhibitory 
activity of EMATE results when the N  atom of the sulphamate group is methylated. 
Recently, Woo et al160 have further explored the effects of modifying the sulphamate
92
group of EMATE on inhibition of El-STS activity by acylating the N  atom and 
replacing its protons entirely with large alkyl groups. It was found that the N- 
acetylated derivative of EMATE inhibits El-STS activity irreversibly, but with lower 
potency than EMATE while the A-benzoylated derivative, 3-0-(piperidino)sulphamate 
and A,A-dibenzyl derivatives of EMATE are weakly reversible inhibitors.160
EMATE inhibited steroid sulphatase activity in a time- and concentration- 
dependent manner141 and was active in vivo on oral administration.145 This inhibitor 
proved to be a potent oestrogen, being five-times more active than the synthetic
| C.<\
oestrogen, ethinyloestradiol on oral administration to rats. The exact reason why 
EMATE is such a potent oestrogen remains to be elucidated, although current 
evidence suggests that it is acting as a prodrug of oestrone. Due to the sensitivity of 
endocrine-dependent tumours of the breast and endometrium to oestrogen, EMATE is 




A major concern related to the use of oestrone derivatives as steroid sulphatase 
inhibitors is that such compounds may be converted in vivo to oestrogenic metabolites. 
To examine the oestrogenic effects of two possible metabolites of oestrone-based 
sulphatase inhibitors, Selcer & Li216 investigated the effects of 3-aminooestrone and 3- 
thiooestrone on the growth of the rat uterus in ovariectomized animals. These 
compounds were found to be well tolerated in vivo at up to 100 pg/day. Neither 3- 
amino-nor 3-thio-oestrone had any effect on uterine weight when tested at 25 pg/day, 
indicating that they were not oestrogenic. These compounds did not block the ability 
of oestradiol to stimulate uterine growth and, therefore, are not antioestrogenic. 
However, the 3-amino-and 3-thio-oestrone derivatives, when tested in vitro, only
93
inhibited sulphatase activity by 10-15%. Thus, a different approach to non- 
oestrogenic potent steroid sulphatase inhibitors is required.
It has previously been shown that substitution of the aromatic ring at C-2 
and/or C-4 of the oestrogens by various groups or modifications to their D-ring greatly
0 1 7  0 1 Qreduces oestrogenicity compared with the parent compounds. ' We initially 
synthesized a number of A-ring modified analogues of EMATE, which include the 
2/4-nitro, 2/4-n-propyl, 2,4-di-w-propyl, 2/4-allyl and 2,4-diallyl derivatives. The 
allyl-substituted derivatives were found to be more potent El-STS inhibitors than the 
propyl analogues but were all considerably less potent than EMATE when examined 
in placental microsomes (Table 16). In contrast, the 2/4-nitro analogues were potent 
sulphatase inhibitors with 4-nitroEMATE being 5 times more active than EMATE. 
The 4-nitro, 4-rc-propyl and 4-allyl derivatives were also tested in vivo for their 
oestrogenicity and ability to inhibit sulphatase activity. While 4-nitro was potent 
inhibitor in vivo, it increased uterine growth in ovariectomized rats to a similar extent 
to that of E1S, but 50% lower than the stimulation resulting from administration of 
EMATE. 4-«-Propyl and 4-allyl EMATE had no stimulatory effect, but they were less 
potent, inhibiting sulphatase activity by 70% and 40% respectively (tested at 2 
mg/kg/day for 5 days).220
Table 16. I C 5 0  of steroid sulphatase activity in placental microsomes for A-ring 






4-«-propylEMATE > 1 0 0
2,4-di-rc-propylEMATE > 1 0 0
2-allylEMATE 2.5
4-allylEMATE 9.0
2,4-diallylEMATE > 1 0 0
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In an attempt to extend this approach, to understand structure activity 
relationships and to reduce the oestrogenicity of EMATE, whilst retaining the potent 
sulphatase inhibitory properties associated with this type of molecule, further 
modifications have been made to A- and D-rings of the steroid nucleus. 2- 




Scheme 17. Direct iodination of oestrone, (i) Q 1CI2 . H2O/I2/DCM, 24°C, 48 h or 
CuC12.2H20 /I2/DCM, reflux °C, 24 h or Cu(CH3C02)2.H20/l2/acetic acid, 55°C, 22 h.
A partial synthesis of 2-methoxy oestrogens was first reported by Fishman. 
Since then many synthetic procedures have been reported for the 2-methoxy222'225 and
000 00A4-methoxy oestrogens, ’ the most interesting of which involves a direct conversion 
of 2-halo (2-iodo/2-bromo) oestrogens into the corresponding methoxy derivatives in 
high yield.227 However, the direct iodination of oestrone (Scheme 17) with iodine- 
copper chloride or iodine-copper acetate as catalyst in either dichloromethane or acetic 
acid at room temperature or under reflux ' gave in our hands a mixture of 2- 
iodo/4-iodo oestrone which could not separated by flash chromatography or 
preparative TLC, since these regioisomers have similar R / values. From this 




In the literature,231’232 the 2-halo (2-Iodo/2-bromo) oestrogens have also been 
prepared by a selective A-ring halodethalliation of oestrogen-thallium (El) bis 
(trifluoroacetate) by treatment of the complex in dioxane solution with a copper salt to 
afford 2-substituted oestrogen acetates (97, 100, 110), which upon deacetylation gave 
2-halo oestrogen in excellent yield (72-85%, Scheme 18) as described by Ghaffari et 
al, 231 and Page et al.232 Oestrogen acetates (96, 109) were prepared by treatment of 
the respective starting oestrogen with acetic anhydride in pyridine under reflux. 2 - 
Iodo/2-bromo oestrogen acetates were not isolated by Page et al. Treatment of 2-iodo 
oestrone 1 0 1  or 2 -iodo oestradiol 1 1 1  with sodium methoxide in methanol-
9 9 7DMF/pyridine in the presence of copper chloride as described by Numazawa et al. 
unexpectedly gave the desired 2-methoxy oestrogens (103,112) in low yields (5%, cf. 
75-95%, Scheme 18). However, no starting material could be recovered.
Several modifications of the Numazawa et al?21 approach have therefore been 
attempted to obtain 2 -methoxy oestrogens in better yield, but unfortunately, without 
significant improvement. 2,4-Dibromooestrone 105 was prepared in a quantitative 
yield by reacting oestrone in ethanolic solution with Af-bromosuccinimide for 24 hours 
at room temperature (Scheme 18).233 The sulphamoylation of 2-bromo 98 and 2-iodo 
1 0 1  oestrone was performed by reacting the compounds with sulphamoyl chloride 
after treatment with sodium hydride in DMF as described previously. The sulphamate 
derivatives of 95 as well as 105 could not be obtained by treating them with 
sulphamoyl chloride using either NaH in DMF or di-terf-butyl-4-methylpyridine 
(DBMP) in dichloromethane (DCM) as bases. This might be due to lack of stability, 
since the presence of two flanking electron-withdrawing groups (iodine and bromine) 
lower the pKa(s) and thus increase the leaving ability of the parent phenolic steroids 
significantly. Perhaps these sulphamates were not even formed.
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h 2n s o 2o
Ej X = 0 = 0  
E2  X = CHOH
97 X = C=0, R = 
100 X = C=0, R = 
110 X = CHOH, R
H3COCO H3COCO
96 X = C=0  
109 X = CHOCOCH3
X = C=0, R = Br 
X = C=0, R = I 
X = CHOH, R =
103 X = C=0 
112 X = CHOH
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Scheme 18. Synthesis of 2-methoxyoestrone 3-0-sulphamate (104); i) 
(CH3C0)20/CH3C02H, pyridine A, 2h, (ii) a) TI(OCOCF3)3/TFA, 0°C, 24 h, b) CuX2, 
dioxane, A, (iii) K2C 0 3/Me0H, A, 3 h, (iv) NaOCH3, MeOH/CuCl2/pyridine, N2, A, 
30 min, v) NaH (1.2 eq.)/ DMF, C1S02NH2, N2, (vi) N- bromosuccinimide/EtOH, 24 
h.
There are other syntheses of 2-methoxy/4-methoxy oestrogen being reported in 
the literature.223'225,234 However, they were unsuitable either because they are too long 
or inefficient like the above method. Nonetheless, different approaches were adopted 
and modified in attempting to prepare 2-hydroxy/2-methoxy oestrogens. These 
include:
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i) Diazotization of oestrone derivatives
Nitration of oestrone with conc. nitric acid gave 4-nitrooestrone 113, 2-nitrooestrone 
114 and 2,4-dinitrooestrone 115 which could be separated by fractional 
recrystallization (Scheme 19).235 Benzylation of 4-nitrooestrone followed by 
reduction of nitro group by means of sodium hydrosulphite in alkali, provided 4- 
aminooestrone 3-benzyl ether 117.222 The conversion of 4-nitro/ 2-nitrooestrone or 4- 
aminooestrone 3-benzyl ether to the corresponding hydroxy oestrone derivatives with 
sodium nitrite in sulphuric acid failed. Possibly these compounds were formed in low 
yield as the reactions were carried out in small scales (100 mg) or not reacted. 4- 
Aminooestrone 118 was prepared in good yield (84%) by catalytic hydrogenation of 
113. The catalytic hydrogenation of 114 gave 2-aminooestrone which was unstable 
and decomposed quickly to several inseparatable products (as indicated by TLC). The 
reason for the instability of 2-amino oestrone remains unclear. Sulphamoylation of 
118 using one equivalent of sodium hydride gave 4-sulphamido-oestrone 3-0- 
sulphamate 119 as the major isolated product (57%), instead of 4-aminooestrone 3-0- 
sulphamate (Scheme 19). The sulphamate of 2,4-dinitrooestrone 115 could not be 
obtained using similar methods applied for 95 and 105, probably due to the bulkiness 
of the groups or lack of stability of the sulphamate caused by these electron 
withdrawing groups (NO2) as a result of increase the leaving ability of the sulphamoyl 
group.
ii) Direct hydroxylation of oestrone
Oxidation of arylthallium analogues is an efficient simple method for the preparation 
of phenols. Taylor et al.236 reported the use of thallium (ET) trifluoroacetate (TTFA) 
in TFA as an effective agent for the thallation of aromatic substrates to effect aromatic 
substitutions. We attempted to prepare 2-hydroxyoestrone acetate by oxidizing 
oestrone-thallium (HI) bis-(trifluoroacetate) with lead tetraacetate in the presence of 
triphenylphosphine, as described by Taylor et al. The reaction was unsuccessful and 
the starting material could not be recovered.
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Scheme 19. 2-and/or 4-Substituted derivatives of oestrone; i) HNO3/CH3CO2H, 10- 
75°C (ii) H2/Pd-C/THF, 12 h, (iii) NaH/DMF, BnBr, (iv) Na0H/Na2S20 4, acetone, A- 
RT, 12 h, (v) NaH (1.2 eq.)/ DMF, C1S02NH2, N2,
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iii) Dakin reaction of 2-acetyloestrone
237Xie et al. have reported the preparation of 2-hydroxyoestrone (catechol-like) in 
excellent yield (93%) by treating 2-acetyloestrone 123 with alkaline hydrogen 
peroxide (3%) at 12 °C for 5 hours. Since the method used by Xie et al. in preparing 
123 gave poor yield (57%), by-product and was difficult to perform, we carried out 
Friedel-Crafts acetylation of oestrone methyl ether 120 by a mixture of aluminum 
chloride and acetyl chloride in nitromethane to give 2 -acetyloestrone methyl ether 121 
in good yield (87%) followed by demethylation of 121 with HBr in acetic acid to 
afford 123 (Scheme 20) which was then subjected to oxidation under the same 
conditions described by Xie et al. However, oxidation of 123 did not proceed by the 









Scheme 20. Synthesis of 2-ethyloestrone 3-0-sulphamate (127); (i) A1C13/AcC1, 
CH3NO2, 5 h, (ii) HBr/AcOH, A 2h, (iii) H2/Pd-C (10%), THF/EtOH, 50 psi, 24h, (iv) 
AlCl3/NaI; DCM/CH3CN; A 5h, (v) NaH (1.2 eq.)/ DMF, C1S02NH2, N2, 12 h
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Catalytic hydrogenation of 121 in THF at room temperature and atmospheric 
pressure for 5 h gave 2-(r-hydroxyethyl)oestrone-3-methyl ether 122 (90%) instead of 
the desired 2-ethyloestrone 3-methyl ether 125. However, on repeating the 
hydrogenation in THF/ethanol (1:2) at 50 psi for 24 h gave a mixture of 125 (78%) 
and 122 (10%). 2-Ethyloestrone 126 (83%) was obtained successfully by 
demethylation of 125 with an aluminum chloride-sodium iodide-acetonitrile system 
under reflux. Sulphamoylation of 126 was performed by treating with sulphamoyl 
chloride in the presence of di-terf-butyl-4-methylpyridine (DBMP) in dichloromethane 
for 2 h to give 2-ethyloestrone 3-O-sulphamate 127 in good yield (77%, Scheme 20). 
The sulphamate derivative of 2-acetyl oestrone 123 could not be obtained by treating 
123 with sulphamoyl chloride using either NaH in DMF or DBMP in DCM as bases, it 
is possibly due to the same reason as described before for the sulphamoylation of 95, 
105 and 115.
iv) Baeyer-Villiger rearrangement
Baeyer-Villiger reaction of 2-acetyloestrone 3-methyl ether 121 or 2-acetyloestrone
0 0  A123 in a similar manner as described by Nambara et al. with m- 
chloroperoxybenzoic acid (MCPBA)-chloroform solution at room temperature gave a 
mixture of products which could not be separated by flash chromatography as they had 
nearly the same R/values. It might be that MCPBA also oxidized the 17-carbonyl 
group of 121 or 123. Avoidance of this unwanted oxidation by protecting the 17- 
carbonyl group as a ketal or by other protecting groups (e.g dithio or hemithio ketal) is 
not feasible since such moieties would be cleaved under acidic conditions such as that 
of a Baeyer-Villiger oxidation. Therefore, we attempted to reduce the 17-carbonyl 
group of 121 selectively to an alcohol without reducing the 2-acetyl carbonyl group. 
However, the reduction reaction of 121 with sodium borohydride in THF/IPA (1:1) 
mixture for 16 hours gave a mixture of two products; one was found to be 2-(l'- 
hydroxyethyl)oestradiol 3-methyl ether 124 (60%). The NMR data of 124 showed 
only the presence of one isomer, but the stereochemistry at C-2-CHOH could not be 
assigned and we do not know which diastereoisomer has been formed. The other 
compound (30%) could not be fully identified, perhaps it was some derivative of 124 
or the styrene derivative of 124 (Scheme 21) which is likely formed by losing a 
molecule of water from the C-2-(l'-hydroxyethyl) group. The mass spectroscopy
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(FAB+) of the second compound shows a peak at 313.1 with 100% intensity which 
corresponds to the molecular mass of the styrene derivative of 124 (312). It is possible 
that this peak (313.1) in the mass spectrum is the mass ion peak of this compound, but 
the mass spectrum of the first compound 124 isolated from the same reaction also 
shows a peak at 330.1 with 55% intensity as the mass ion peak as well as a peak at
313.1 with 100% intensity; results of loss one molecule of water; which makes 
assigning the second compound more difficult (the spectroscopic data for the 





Scheme 21. Reduction of 2-acetyloestrone methyl ether, (i) NaBH4/THF/IPA, 16 h.
All the above methods failed to allow preparation of 2-methoxy/4-methoxy 
oestrone/oestradiol in good yield. Cushman et a/.238,239 have prepared 2-alkyloxy 
oestradiol derivatives including 2-methoxyoestradiol in a multistep reaction with good 
yields. The method described by Cushman et al. was hence adopted to prepare 2- 
methoxyoestradiol. Oestradiol 108 was prepared by reduction of oestrone with 
sodium borohydride in a THF/IPA (1:1) mixture in almost quantitative yield (97%). 
The two hydroxyl groups of oestradiol were then protected as benzyl ethers (76% 
yield, cf. 60%) by deprotonation with sodium hydride in DMF followed by alkylation 
of the alkoxide anions with benzylbromide. Bromination of the resulting dibenzyl 
derivative 128 with bromine in acetic acid gave the 2-bromo derivative 129 in 83% 
yield (cf. 75%). The 2-formyl-3,17P-bis(benzyloxy)oestra-l,3,5(10)triene 131 was 
prepared by two methods: Method A, which involves halogen-lithium exchange on 
the 2-bromo compound 129 to afford the 2-lithio derivative, which was directly
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formylated with DMF to give 131 in 80% yield; Method B, in this method 131 was 
prepared in a similar manner to method A, from 2-iodooestradiol 3,17^3-bis-benzyl 
ether 130 in slightly better yield (89%). Method B gave a cleaner reaction which made 
131 easier to purify by flash chromatography as less side-products were formed. 130 
was prepared from 111 (which was prepared as described above) in a similar manner 
to 129, but tetrabutylammonium iodide was added and the reaction mixture was not 
refluxed as in the preparation of 129. Baeyer-Villiger oxidation of 131 with MCPBA 
in dichloromethane, followed by acid hydrolysis of the resulting formate, yielded the 
phenol 133 in excellent yield (70%, Scheme 22). MCPBA used for the reaction was 
purified by extraction with dichloromethane/brine to discard the impurities and dried 
(< 50°C) to remove water. The 2-hydroxy-3,17j3-dibenzyl oestradiol 133 was then 
alkylated with iodomethane/iodoethane/ or allyl bromide using anhydrous potassium 
carbonate in DMF to give 134,135,136 respectively (Scheme 22). Alkylation of 133 
with n-propyliodide to get the 2-n-propoxy derivatives gave a mixture of two 
compounds which were difficult to separate by flash chromatography. Thus the 2- 
propoxy derivative was obtained through alkylation of 133 with allylbromide and then 
hydrogenation of the double bond of the allyl group. The attempted preparation of the 
desired analogue 2-methoxyoestradiol 112 by hydrogenolysis of the two benzyl ether 
protecting groups of 134 with palladium (10% or black)/ palladium hydroxide on 
charcoal in ethanol/THF mixture as described by Cushman et al. gave four different 
products. As observed by TLC, these products have very similar R/values in a variety 
of mobile phases which made them difficult to separate. The hydrogenolysis was 
carried out in duplicates using different solvents and catalysts but all these attempts 
failed to give the desired compound 112. Perhaps the 17(3-benzyl ether group is 
sterically hindered by the angular methyl group and hence is not easy to be cleaved 
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132134 R  =  CH3
135 R  =  C2H5
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Scheme 22. Synthesis of 2-alkyloxy-3,17/Tdibenzyl oestradiol (134, 135 and 136); (i) 
a) NaH/DMF, 0°C (15 min); b) BnBr, A 25 min, 23°C 12 h. (ii) Br2, AcOH, THF, 0- 
23°C 1.5 h, (iii) a) NaH/DMF, 0°C (15 min); b) BnBr, «-Bu4N+I‘, 23°C 24 h. (iv) a) n- 
BuLi/THF, -78-0°C, 2h; b) DMF, -78-0°C, lh, (v) a) MCPBA/DCM, 23 °C, 15 h, b) 
Me0H/H2S 0 4, 1.5 h, (vi) K2C 0 3/Me0H/RI or RBr, A (2h), 23°C 24h, (vii) H2-Pd-C 
(10% or black)/EtOH, THF, 50 psi, 23 °C 24 h.
The deprotection of the two benzyl ethers of 134 was carried out by applying a 
novel method for the deprotection of the benzyl ether groups using an aluminum 
chloride-sodium iodide-acetonitrile system at room temperature (Scheme 23). This 
method was previously used to deprotect the methyl ether as described by Node et 
al.2A0 but was never utilized to deprotect the benzyl ether. A model of oestradiol 
3,17/3-dibenzyl ether was selected first, to study the application of this method and to 
select the proper conditions for cleaving the two benzyl ethers without deprotecting 
the methyl ether. Therefore, the experiment was carried out under two different 
temperatures and reaction periods, at 0°C and room temperature for 6 h and overnight 
respectively. It was found that at 0°C the 17/Tbenzyl ether group was easily cleaved,
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as the major product was the oestradiol 3-benzyl ether in 80% yield. However, when 
the reaction was carried out at room temperature the major product was oestradiol in 
91% yield. Therefore, using this method it was possible to cleave the sterically 
hindered benzyl ether and, as a result, the two benzyl ether groups of oestradiol were 
cleaved. Our initial concern in applying this method to 134 was the possibility of 
cleaving the 2-methyl ether at the same time. For this reason, 6-methoxytetralone, a 
compound containing a methyl ether was selected as a model analogue to 134 to study 
the effect of this method in cleaving aromatic methyl ethers under the above 
conditions. It was found that 6-hydroxytetralone was obtained when the reaction 
mixture was heated under reflux for 10 h and no demethylation was observed at room 
temperature for 48h. However, when the debenzylation of 134 was carried out at 
room temperature for 48 h., it was found that its 2-methyl ether was also partially 
cleaved and a mixture of the desired 2-methoxyoestradiol 112 (25%) and its catechol - 





Scheme 23. Debenzylation of 2-methoxyoestradiol-3,17/Tdibenzyl ether, (i) 
AlCl3/NaI; DCM/CH3CN; 23°C 24 h.
In comparison with other approaches attempted previously, the above method 
was use to prepared 2-methoxyoestradiol in a reasonable yield and is by far the 
optimum method for its preparation. The problem for the synthesis of 2- 
methoxyoestradiol was therefore partially solved, but to improve the yield, it is better 
to follow the same method with different protection groups rather than the sterically 
hindered benzyl ether which was difficult to cleave.
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Attempts to prepare 2-methyloestradiol by catalytic hydrogenation of 2- 
formyloestradiol dibenzyl ether 131 using Pd (10% or black) in anhydrous 
methanol/THF mixture at 50 psi for 48 h as described by Cushman et al.238 (Scheme 
22), gave only 2-(hydroxymethyl)oestradiol 17/3-benzyl ether 132 in 92% yield, thus 
supporting the concept that the 17/3-benzyl ether of 2-substituted oestradiol derivatives 
is difficult to cleave even after subjection to catalytic hydrogenation for an extended 
period. The sulphamoylation of this compound 132 was attempted by treating it with 
sulphamoyl chloride using various bases including NaH in DMF, anhydrous potassium 
carbonate in DMF or DBMP in DCM but the sulphamoylation gave too many 




Scheme 24. Sulphamoylation of catechol-like 137, (i) DBMP (9 eq.)/ DCM,
C1S02NH2, 23°C 2 h
Direct sulphamoylation of the catechol-like 137 with sulphamoyl chloride 
using DBMP as a base in dichloromethane for 2 h, gave predominantly 2,3-bis- 
sulphamate 138 (49%) and a small amount of the tris-sulphamate 139 (5%). As 
mentioned previously, it is expected that in the presence of a weak base such as 
DBMP (pKa ~ 3-4), the sulphamoylation reaction will take place predominantly at the 
C-2 and C-3-OH whose pKa values are ca. 10 (c.f. phenol) whereas that of C-17-OH 
is ca. 17-18 (c.f. R-OH) (Scheme 24). The purification of these sulphamates (138 and 
139) was carried out by flash chromatography, but it was difficult to obtain them in 
very pure forms and as a result the CHN analyses were out of the acceptable range.
For the preparation of mono sulphamate analogues of poly hydroxy 
compounds such as 2-methoxyoestradiol 112, silyl ether technology was a useful tool.
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This approach was adopted for the synthesis of the starting material with a selectively 
protected 17-hydroxy group (Scheme 25). Thus, the bis-terr-butyldimethylsilyl ether 
140 (TBDMS) of 112 was exposed for 10 minutes to 1 eq. of tetrabutylammonium 
fluoride (TBAF) in THF to give phenol 141 quantitatively, which was converted to 
sulphamate 142 using DBMP as a base in DCM for 30 minutes. The 17-silyl ether of 
142 was then cleaved by a mixture of acetic acid:water:THF (3:1:1) for 5 days at room 
temperature to give 2-methoxyoestradiol 3-0-sulphamate 143 (Scheme 25). 










Scheme 25. Synthesis of 2-methoxyoestradiol 3-O-sulphamate (143); (i) imidazole, 
TBDMSC1/DMF, 23°C, 24 h, (ii) TBAF (leq.)/THF, 10 min, (iii) DBMP (3 eq.)/ 
DCM, C1S02NH2, 23°C 2 h, (iv) AcOH:H20:THF, 3:1:1, 23°C, 5 days.
Oestradiol is metabolised by a hydroxylation at the 2 or 4 position, with 
subsequent methylation to less polar monomethyl ethers (2-methoxyoestradiol, 2- 
hydroxy-3-methoxyoestradiol or 4-methoxyoestradiol, 4-hydroxy-3- 
methoxyoestradiol) by catechol-O-methyltransferase (COMT).241 In the literature, 2- 
hydroxy-3-methoxyoestradiol 147 was prepared by selective methylation of catechol 
by diazomethane242 and the purification of the two mono and dimethylated products 
were achieved by HPLC. The difficulty of synthesising compounds such as 2-
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hydroxyoestradiol 3-methyl ether 147 makes it very costly (1 g costs ca. $24000) and 
limits pharmacological and biological studies of these compounds. Here, we prepare 
147 in a novel, efficient (60%) and short method (three steps from oestrone methyl 
ether) as follows:
First, oestradiol methyl ether 144 was prepared by reduction of oestrone methyl ether 
in almost quantitative yield (94%). Initially, the hydroxyl group at 17)3 position of 144 
was protected as the benzyl ether (65%), by deprotonation with sodium hydride in 
DMF followed by alkylation of the alkoxide anion with benzyl bromide to give 
oestrone 3-methyl ether 17/3-benzyl ether 145. Friedel-Crafts acetylation of 145 by a 
mixture of aluminum chloride and acetyl chloride in nitromethane gave 2,17)3- 
diacetyl-3-methyl ether oestradiol 146 in 71% yield (Method A, Scheme 26). 
Surprisingly, the 17/2- benzyl group of 145 during the acetylation reaction was cleaved 
and the acetylation also was took place at 17)3 to give the diacetyl derivative 146. 
Therefore, it was not required to protect the 17/3-hydroxyl group of 144 with benzyl 
ether and Friedel-Crafts acetylation of 144 directly gave 146 in 85 % yield (method B) 
which was also found to be better than method A. Baeyer-Villiger oxidation of 146 
with MCPBA in dichloromethane, followed by acid hydrolysis of the resulting acetate, 
gave the 2-hydroxy-3-methoxyoestradiol 147 in 60% yield (Scheme 26). Protection, 
selective deprotection and sulphamoylation of 147 to give 3-methoxyoestradiol-2-<9- 
sulphamate 151 was carried out in a similar fashion to the sulphamoylation of 143 as 
described above using silyl technology for protection (Scheme 26).
Friedel-Crafts acetylation of oestrone,oestradiol and oestradiol-3,17 p-bis- 
acetate 109 was carried out similarly to the manner described above to prepare the 
catechol and then 2-methoxyoestradiol, but in the case of acetylation of 
oestrone/oestradiol directly a mixture of products was obtained and they could not be 
fractionated by flash chromatography or preparative TLC, while in the case of 
acetylation of 3,17p-diacetyloestradiol 109, no reaction occurred and the starting 
material was recovered. The presence of the electron donating group (e.g. methyl 
ether) at the C-3 of the oestrone or oestradiol derivatives was found to be essential for 
the Friedel-Crafts acetylation to take place and give selectively the desired products 
(acetylation at the C-2 of steroid ring) in high yield. However, in the case of the
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presence of an acetate at the C-3 of oestrone, no reaction occurs and in the presence of 
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Scheme 26. Synthesis of 3-methoxyoestradiol 2-0-sulphamate (151); (i)
NaBH4/THF/IPA, 16 h, (ii) a) NaH/DMF, 0°C (15 min); b) BnBr, A 25 min- 23°C 12 
h, (iii) A1C13/AcC1, CH3N 0 2, 3 h, (iv) a) MCPBA/DCM, 23 °C, 15 h; b) 
Me0H/H2S 0 4, 1.5 h, (v) imidazole, TBDMSC1/DMF, 23 °C, 24 h, (vi) TBAF 
(leq.)/THF, 10 min, (vii) DBMP (3 eq.)/ DCM, C1S02NH2, 23 °C 2 h, (viii) 
AcOH:H20:THF, 3:1:1, 23 °C, 5 days.
The preparation of 2-hydroxy-3-methoxyoestradiol 147 via a novel efficient 
method as described above (Scheme 26), stimulated our interest to attempt the 
preparation of 2-methoxyoestradiol 112 using the same approach (Scheme 27). 
Hence, we prepared 112 starting from 2-acetyloestradiol 17(3-acetate 3-methyl ether 
145 as follows: First, 145 was demethylated in a similar manner of demethylation of
2-ethyloestrone 125 using aluminum chloride iodide-acetonitrile system at reflux 
temperature ( 8  h) to give 2-acetyloestradiol 17/3-acetate 152 in a good yield (8 6 %).
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The hydroxyl group at C-3 of 152 was protected as its benzyl ether by deprotonation 
with anhydrous K2C 0 3 in DMF, followed by alkylation of the alkoxide anion with 
benzyl bromide to give 153 (85%). Baeyer-Villiger oxidation of 153 with MCPBA in 
DCM, followed by acid hydrolysis of the resulting acetate yielded 2-hydroxyoestradiol
3-benzyl ether 154 in 50%. Alkylation of 154 with iodomethane using anhydrous 
K2CO3 in anhydrous DMF gave 2-methoxyoestradiol 3-benzyl ether 155 (95%). 
Hydrogenolysis of 3-benzyl ether group of 155 with 10% palladium on charcoal at 










Scheme 27. Synthesis of 2-methoxyoestradiol (112); (i) AlCb/Nal; DCM/CH3CN; A 
8 h, (ii) a) K2C 0 3/DMF; b) benzyl bromide, rc-Bu4N+I\ 23°C 48 h, (iii) a) 
MCPBA/DCM, 23 °C, 15 h; b) Me0H/H2S 0 4, refluxed 1.5 h, (iv)
K2C 0 3/Me0H/CH 3I, 23°C 48h, (v) H2-Pd-C (10%)/EtOH, THF, 23 °C 12 h.
The above novel method for preparation of 2-methoxyoestradiol was found to 
be the best method reported so far. The presence of the benzyl ether lowered the yield 
of the Baeyer-Villiger oxidation step (50%), compared to 60% for this oxidation when 
the methyl ether was present as described in the preparation of 2-hydroxyoestradiol 3- 
methyl ether 147. The reason for reduction of the yield has still to be elucidated. This 
approach was easy and could still potentially be improved. Now 2-methoxyoestradiol 
can be prepared in large scale at low cost.
110
Oestrone sulphate (Fig.39) 156 and 2-methoxyoestrone sulphate 157, were 
prepared by treating the parent compounds with sulphur trioxide-pyridine complex in 
pyridine under anhydrous conditions. Their sodium salts were prepared by treating the 
free acid of these compounds with sodium hydroxide in methanol.
In an attempt to establish a new easier method for preparing oestrone 3 - 0  
methylphosphonate 158 a new approach was applied. Deprotonation of the hydroxyl 
group of oestrone was carried out with sodium hydride in DMF instead of pyridine as 
previouly described.243 Upon addition of methylphosphonic dichloride and quenching 
the reaction oestrone 3-Omethylphosphonate 158 was formed, but a small amount of 
di-oestrone 3-Omethylphosphonate (dimer) was also present as indicated by mass 
spectroscopy (a peak at 601).
158157156
Figure 39. Structures of oestrone sulphate 156, 2-methoxyoestrone sulphate 157 and
oestrone 3-methylphosphonate 158
Dioestrone 3-methylphosphonate (dimer)
The purity of 156 and 157 was determined by HPLC using gradient elution of 
methanol/water (50-70%) as mobile phase (Fig.40). Figure 40 shows that oestrone
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(99%) and 2-methoxyoestrone obtained from Sigma are impure and oestrone sulphate 












Figure 40. HPLC studies comparing the purity of oestrone, oestrone sulphate (156), 2- 
methoxyoestrone and 2-methoxyoestrone sulphate (157).
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5.2.2 D-ring modifications
The oxidation of a steroid ring ketone to a lactone was first reported by 
Gardner and Godden244 using ammonium persulphate for oxidation of coprostan-3- 
one. The conversion of a 17-keto steroid to a 5-ring lactone was first reported by 
Westerfeld245 who oxidised oestrone with alkaline hydrogen peroxide (10%) for 3 
days. Subsequently, a few years later Jacobsen246 with a different approach oxidised 
oestrone with peracid in acetic acid to a lactone which was chemically similar to 
Westerfeld’s lactone but had different physiological properties. Several related 
lactones have been also prepared by the microbiological oxidation of steroids.247,248 
None of the above methods was appropriate for preparation the steroid lactones in 
satisfactory yield.
Our initial attempts to prepare oestralactone by oxidation of oestrone with 
peracids (trifluoroperacetic acid or m-chloroperbenzoic acid) were unsuccessful. The 
Baeyer-Villiger oxidation of oestrone by these peracids gave two products which 
unfortunately could not be fully identified. But according to the NMR data the 
oxidation had taken place at the A-ring of oestrone for one compound and somewhere 
else, but not also at the 17-keto group of oestrone for the second one. However, by an 
adaptation of Westerfeld method245 using 6% hydrogen peroxide and longer reaction 
time (5-7 days), we have significantly improved the yield of oestralactone 159 (84%, 
cf 20% for Westerfeld approach, Scheme 28). The purification of oestralactone at the 
beginning was difficult due to its extreme insolubility, but by increasing the reaction 
time from five to seven days, the starting material (oestrone) was totally converted to 
oestralactone and there was no need for further purification by flash chromatography 
at the end of this long reaction time. The oestralactone could not be recrystallized 
from the usual organic solvents because of its extreme insolubility, and high melting 
point (>350°C), but the purity determined by TLC, and later by CHN and mass 
spectroscopy gave satisfactory results.
Of the two possible structure of oestralactone (A and B), Westerfeld assumed 
its structure to be structure A not B. This assumption was made on the basis that the 
steroidal lactone obtained by this method could be opened by treatment with methanol
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in the presence o f HC1 or H2S 0 4 to give a hydroxy methyl ester derivative. W esterfeld  
argued that the lactone B would resist such acid-catalysed transesterification since its 
acyl group is more sterically hindered than that o f A  in the presence o f a tertiary a -  
carbon. Our N M R  analysis is the first to provide modern spectroscopic data for this 
com pound and also supports this assignment o f W esterfeld that the structure o f  
oestralactone is A. N o peak was observed at about 4.1 ppm in the *H NM R, which  




W esterfeld formulated the reaction as involving the cleavage o f D-ring, either 
between carbon atoms 16 and 17 or, more probably, 13 and 17, fo llow ed  by the 
addition o f the elem ents o f hydrogen peroxide to g ive an intermediate dihydroxy acid, 
which lactonized on acidification o f the reaction mixture to form oestralactone 159, as 





Scheme 28. Synthesis o f  oestralactone (159) and oestralactone 3-O-sulphamate (160) 
(i) 6% H20 2/N a 0 H , 7 days, (ii) HC1, (iii) NaH (1.2 eq .)/ DM F, C 1S02N H 2
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According to W esterfeld’s assumption, the reaction mechanism  could be as follow s:
OOH
Oestralactone
The proposed mechanism  by W esterfeld involves a hydroxide ion attack at a tertiary 
carbon which is likely to be wrong. The mechanism involved in this reaction is likely  
to resem ble that o f either Baeyer-Villiger oxidation or Dakin reaction or 
rearrangement o f  hydrogen peroxide since these reactions have nearly similar 
m echanism s which could be as follow s:
E, Oestralactone A
OOH
The hydrogen peroxide ion ( OOH) attack the C-17 carbonyl group, loss o f  the 
leaving group ( OH), and migration o f the C-13 to the resulting electron-deficient 
oxygen atom. The migration must have occurred between the C-13 and the C -17 to 
give oestralactone A, because if  the migration occurs between the C -16 and the C -17  








The C-13 migrated to give oestralactone A not C-16 to give oestralactone B, 
because being a tertiary alkyl group, C-13 is better able to stabilise the positive charge 
on the recipient O-atom. The order of migration according to Baeyer-Villiger 
oxidation is tertiary alkyl > secondary alkyl, aryl > primary alkyl > methyl. Since, C- 
16 is a secondary alkyl, the migration occurred between C-13 and C-17 not C-16 and 
C-17. Wendler et al.2A9 and Murray et al.250 have made other observation which 
supported this migratory preference of C-13 over C-16 to give oestralactone A. They 
oxidized 3/Tacetoxyandrostan-17-one, as a model, with peracetic acid and they argued 
that C-13 migration to C-17 (electron deficient) proceeds with the least movement of 
atoms in space and through a transition state wherein the expanded D-ring possesses a 
chair form. The migration of the secondary alkyl C-16, on the other hand, would pass 
through a higher energy transition state, wherein the D-ring would possess a boat 
form. Oestralactone sulphamate 160 was prepared by reacting oestralactone in DMF 
with sulphamoyl chloride after treatment with sodium hydride.
Another D-ring modified derivative of oestrone, oestrone oxime 161 was 
prepared in excellent yield (96%) by an adaptation of the method described by Bernard 
and Hayes,251 in which hydroxylamine hydrochloride was used instead of 
hydroxylamine acetate. Briefly, refluxing a mixture of oestrone, sodium hydroxide 
and hydroxylamine hydrochloride in ethanol (Scheme 29) gave oestrone oxime, which 
was converted to the corresponding sulphamate using the standard method.167 Of the 
two possible geometrical isomers for oestrone oximes, Nagata et al.252 and other 
groups253 have argued for the anti-isomer, since they believed this form would be 
more stable than the ^yn-form and that the transition state leading to the anti-oxime 
may have an energy lower than that in the case of the syw-isomer. However, this
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argument has never been proved unequivocally. TLC analysis of 161 showed a single 
spot despite running the plates in different mobile phases, indicating the presence of 
one isomer. The lH NMR spectrum was also consistent with the presence of one 
isomer. In an attempt to confirm which isomer was obtained from this reaction, we 
attempted NOE experiments on 161, but the results were inconclusive, perhaps 
because of the exchangeable hydroxyl group of the oxime. In order to prove 
unambiguously the structure of 161 we undertook an X-ray crystallographic study on 
the compound, which clearly has demonstrated the presence of only one geometrical 
isomer (i.e. the anti-isomer, E).
Our study is the first to provide modern spectroscopic data and an X-ray crystal 
structure for oestrone oxime. The CHN analysis for oestrone oxime was out of the 
acceptable range, but by considering a methanol content (from the crystallization 
solvent), which is involved in hydrogen bonding to the molecule as shown by the X- 
ray structure, then the CHN values become correct. The sulphamoylation reaction 
(Scheme 29) was performed by reacting the oestrone oxime with sulphamoyl chloride 
in DMF after treatment with sodium hydride (2.5 eq.) gave the mono sulphamate at C- 
3 (162, 25%), and not the bis-sulphamate. The bis-sulphamate might be formed but 
due to high polarity of this compound (or instability) it could not be isolated.
h2n so 2oOestrone ——
Scheme 29. Synthesis of Zs-oestrone oxime (161), oestrone oxime 3-0-sulphamate 
(162) (i) NaOH/ EtOH, NH2OH. HC1, 2h, reflux, (ii) NaH (2.5 eq.)/ DMF, C1S02NH2
A Beckmann rearrangement of 161 with thionyl chloride at 40-49°C gave the 





Scheme 30. Synthesis of oestralactam (163) and oestralactam 3-O-sulphamate (164), 
(i) SOCl2 /40-49 °C, (ii) NaH (1.2 eq.)/ DMF, C1S02NH2
Bernard and Hayes proved the structure of oestralactam 163 by opening the 
lactam ring to form a primary carboxylic acid, not a tertiary carboxylic acid, which 
could be the case if the other isomer was formed. This primary carboxylic acid 
formed was readily esterified with methanol in the presence of an acid catalyst. Our 
X-ray crystallographic data demonstrated the structure of the oestrone oxime as the E- 
isomer which is expected to give 163 as the most likely of the two possible structures. 
This consistent with the migration of the anti group in the transition state of the 
Beckmann rearrangement. Our study also is the first to provide modem spectroscopic 
data for this compound and supports the structure of oestralactam 163. No peak was 
observed at about 3.2 ppm in the 'H NMR spectrum which indicates that the C-16- 
CH2 is next to the carbonyl group (-CH2CO-NH-R, 163, CH2 is about 2.2 ppm) not to 
an NH (-CH2NH-CO-R). It was also observed in the ‘H NMR spectrum, that the NH 
is a broad singlet (i.e next to the carbonyl group, 163) not a triplet (i.e if it is next to 
the C-16-CH2).
5.2.3 X-ray crystallography
A crystal of Zs-oestrone oxime 161 was obtained using a slow recrystallization 
from aqueous methanol (90%), and was used for data collection. The asymmetric unit 
was seen to consist of 2 molecules with the same chirality, hydrogen bonded to each 
other via their oxime functionalities and one molecule of methanol (Fig. 41). The 
hydrogen attached to 02A  is also involved in hydrogen bonding to the solvent oxygen 
(methanol). The geometric parameters for both molecules are similar within 2
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estimated standard deviations. While the absolute stereochemistry of the steroid 
skeleton is not in any doubt, the structure as solved was not able to prove this. All 
four rings and the key features of the steroid are clearly visible. Figure 41 shows only 
one geometrical isomer [anti-isomer (£)]. All C-C bond lengths were in the range 
1.351-1.556A and all the C-O bond lenghts between 1.377-1.404A, with bond angles 
ranging from 99.6-128.21°. All C-N bond lenghths were in the range 1.277-1.28A and 
all N-O bond lenghts between 1.425-1.433A. An examination of the supramolecular 
array of 161 revealed that the lattice is dominated by polymeric strands along b due to 
extended hydrogen bonding. In addition to the interactions within the asymmetric 
unit, H2 also interacts with Ol of the molecule generated via the x, 1+y, z symmetry 
transformation. Also, the proximity of 05  as presented to OlA by the x, -1+y, z 
operation seems indicative of a further interaction between the methanolic proton (not 
located) and this latter oxygen. The hydrogen-bonding interaction in £-estrone-oxime 
161, viewed along the a axis, are shown in Figure 42. For full details, see Appendix 2.
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Figure 41. ORTEX plot of asymmetric unit in the X-ray crystal structure of F-estrone- 
oxime 161, Thermal Ellipsoids are shown at 30% probability level.
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Figure 42. Hydrogen-bonding interaction in Zs-estrone-oxime 161, viewed along the a 




The ability of the A-ring modified EMATE derivatives (compounds 99, 102, 
104,119,127,138,139,143,150,151 and 156) to inhibit oestrone sulphatase activity 
was examined in MCF-7 breast cancer cells and in placental microsomes (Table 17 & 
Table 18). Most of these analogues tested were found to be potent inhibitors in both 
biological systems. The 2-bromo- and 2-iodo derivatives of EMATE were the most 
efficient inhibitors and were more potent inhibitors than EMATE. The IC50S for 
inhibition of El-STS activity by 2-bromoEMATE (99) and 2-iodoEMATE (102) were 
calculated from the results obtained using placental microsomes and found to be 
250pM (cf. to EMATE, 25nM in the same assay) and 0.9nM (c.f. to EMATE; 4nM in 
the same assay); 99 being about 100 and four times more potent than EMATE 
respectively. The other analogues (104,119,127,138,139 and 143) were also found 
to be potent inhibitors in both biological systems (Table 17 and 18). The 2-methoxy 
derivative of EMATE (104) was an efficient inhibitor and was as potent an inhibitor as 
EMATE. At a concentration of 0.1 pM, 2-methoxyEMATE inhibited microsomal 
sulphatase activity by > 99% and its IC50 for inhibition of El-STS activity was found 
to be 30nM in placental microsomes (Table 18). The IC50 of 4-sulphamido EMATE 
(119) was also found to be 7nM (c.f. to EMATE; 65pM) in MCF-7 cells.
To determine the effects of steroid sulphamates on cell morphology and their 
ability to induce apoptosis in MCF-7 cells (see later, page 134), the growth inhibition 
of MCF-7 cells by some selective analogues (104, 127, 143 and 156) was also 
examined (Table 19).
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Table 17. Inhibition of El-STS activity in intact MCF-7 breast cells by A-ring 
modified EMATE analogues, *= inactive; - = not determined______________________
% Inhibition and IC50 of ElI-STS activity in MCF-7 Cells
Compound O.lpM I jliM 10pM i c 50
2-BromoEMATE (99) >99 >99 >99 -
2-IodoEMATE (102) >99 >99 >99 -
2-MethoxyEMATE (104) >99 >99 >99 -
4-SulphamidoEMATE (119) 91.4±0.81 99.6±1.22 >99 7nM
2-EthylEMATE (127) 70.2±0.8 96.7±0.4 99.7±0.4 -
Catechol-like tris-sulphamate (138) 97±1.2 97±0.8 99±1.0 -
Catechol-like bis-sulphamate (139) 97±0.5 97.1±1.0 98±1.3 -
2-Methoxyoestradiol 3-0-sulphamate (143) >99 >99 >99 -
3-Methoxyoestradiol 2-0-sulphamate 17p- 
TBDMS (150)
* * * -
3-Methoxyoestradiol 2-0- sulphamate (151) < 10 16.3±2.5 68.5±2.3 -
2-Methoxyoestrone sulphate (156) * * * -
Table 18. Inhibition of El-STS activity in placental microsomes by A-ring modified 
EMATE analogues, negative sign of %inhibition = stimulation effect, - = not 
determined.
% Inhibition of El-STS activity in plcental microsomes
Compound O.lpM lpM 10pM IC50
(MM)
2-BromoEMATE (99) 96.8 >99 >99 0.25x10'5
2-IodoEMATE (102) 90 97.3 99 0.0009
2-MethoxyEMATE (104) >99 >99 >99 0.03
4-SulphamidoEMATE (119) 22.5 54.7 88.8 -
2-EthylEMATE (127) 11 34 80 2.4 jiM
Catechol tri-sulphamate (138) 44.4 87 98 0.14
Catechol bis-sulphamate (139) 42.3 86 98 0.13
2-Methoxyoestradiol 3-O-sulphamate (143) >99 >99 >99 -
3-Methoxyoestradiol 2-0-sulphamate 17(3- 
TBDMS (150)
- - -39.5 -
3-Methoxyoestradiol 2-0- sulphamate (151) - - -11.0 -
2-Methoxyoestrone sulphate (156) - - - -
Table 19. Growth inhibition of intact MCF-7 breast cancer cells by 2-methoxy-, 2- 
ethylEMATE, 2-methoxyoestradiol 3-O-sulphamate and 2-methoxyoestrone sulphate, 
*= inactive, * = same as 104 (results not yet available).___________________________
% Gowth inhibition of MCF-7 cells
Compound O.lpM lpM lOpM
2-MethoxyEMATE (104) 2.4±2.12 2.75±3.78 57.07+0.46
2-EthylEMATE (127) 0.25±0.1 21.16±0.3 22.42+0.1
2-Methoxyoestradiol 3-0-sulphamate (143) * * *
2-Methoxyoestrone sulphate (156) * * *
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5.3.2 Nature of inhibition
It was previously shown that EMATE acts as an irreversible, active site- 
directed inhibitor. The ability of 2-methoxyEMATE to act in such a manner was 
therefore also examined. For this, intact cells were pre-treated with inhibitor for 2 h at 
37 °C and subsequently washed five times with phosphate buffer saline (PBS) and 
then assayed for remaining sulphatase activity. The 2-methoxyEMATE was found to 
act as an irreversible inhibitor with no recovery of activity being observed at 1 pM and 
10 pM.
5.3.3 In Vivo studies
Having identified a number of A-ring modified EMATE derivatives which 
retained a range of sulphatase inhibitory properties, the 2-methoxy and 2-ethyl 
derivatives were selected for in vivo testing. In animals receiving vehicle only, liver 
sulphatase activity was found to be 352+11 nmol/h/mg protein. EMATE, and its 2- 
methoxy and 2-ethyl derivatives (tested at 2 mg/kg/day for 5 days) all inhibited rat 
liver sulphatase activity by 95% or more. E1S which was administered to animals as a 
positive control for the oestrogenicity bioassay had no inhibitory effect on in vivo 
sulphatase activity. Both E1S and EMATE stimulated uterine growth in the 
ovariectomized animals by 169 and 414%, respectively, compared with the animal 
receiving vehicle only. In contrast, the 2-methoxy and 2-ethyl derivatives were devoid 
of any oestrogenicity.
The multiple oral dose-response of 2-methoxyEMATE 104 was examined in 
vivo for 5 days (Table 20). It was found that 104 is a potent El-STS inhibitor even at 
low concentration; it inhibits liver El-STS activity by 78% at 0.1 mg/kg oral dose 
(Table 20).
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Table 20. Inhibition of rat liver El-STS activity in vivo by 2-methoxyEMATE at three 
different doses.




Fotsis et al.25A found that when 2-methoxyoestradiol was administered (100 
mg/kg, p.o.) to mice orally with induced mammary tumours every other day for 12 
days, the growth of tumours arising from subcutaneously injected Meth A sarcoma and 
B16 melanoma was reduced by 57% and 83% respectively. Klauber et al.255 also 
found that when 2-methoxyoestradiol was administered (75mg/kg/day for 1 month) to 
mice orally, the growth of a MDA-MB-435 human breast carcinoma cells (ER-) 
induced tumours in mice was suppressed by 60%. Fotsis et al. assumed that the 
tumour-suppressing effect of 2-methoxyoestradiol was due to inhibition of tumour 
induced angiogenesis (formation of new blood vessels) rather than direct inhibition of 
the proliferation of tumour cells. Therefore, 2-methoxyEMATE was also examined in 
intact rats with NMU-induced mammary tumours. It was found for two out of three 
animals receiving 2-methoxyEMATE (20mg/kg/d, p.o.) a marked regression in tumour 
volume occurred (Vdn/Vdo % represents the tumours volumes on day 6 or 11 
compared with their original volumes at the start of the experiment, Fig.43). The 
tumour volume in the third animal may have also started to regress as the others, but 
the study was not continued due to a limited supply of 2-methoxyEMATE. In the 
same study as shown in Figure 43, for the three control animals receiving propylene 
glycol, their tumour volumes were either increased or showed no change. In another 
experiment, two intact rats with NMU-induced mammary tumours were treated with 
2-methoxyoestrone (only two animals were used because of the high cost and poor 
availability of this compound) at the same dose as 2-methoxyEMATE for 11 days. In 
contrast to 2-methoxyEMATE, the tumour volumes were in these rats only determined 
before (vol 0) and at the end of treatment with 2-methoxyoestrone (vol 11). It was 
found that the Vdl 1 /Vdo% for one rat was 75 where as the other one was 100. This 
indicates that 2-methoxyoestrone rendered a modest regression (25%) for one tumour 
but no change for the other tumour. It is then reasoned that if 2-methoxyEMATE was 
acting as a prodrug for the formation of 2-methoxyoestrone in vivo then we should
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have seen a regression of the tumours in animals treated with 2-methoxyoestrone. In 
contrast to the results obtained with 2-methoxyoestrone, no complete regression of a 
tumour was detected (only 25%). This indicates that 2-methoxyEMATE is not simply 
acting as a pro-drug for the formation of 2-methoxyoestrone. Obviously we need to do 
more studies and, if possible, measure 2-methoxyEMATE/2-methoxyoestrone 
concentration in plasma to confirm this hypothesis.
2-Methoxyoestradiol 3-0-sulphamate 143 was also prepared and evaluated for 
its El-STS inhibitory activity and found to have a similar potency as 2- 
methoxyEMATE both in vitro and in vivo and was also found to be devoid of any 
oestrogenicity. When the sulphamoyl and methoxy groups of this compound were 
interchanged to give its congener 3-methoxyoestradiol 2-0-sulphamate 151, a 
significant reduction in potency was observed for 151. It was expected that the 
carbonyl group and the hydroxyl group at the C-17 of oestrogens are required for high 
binding affinity to oestrogen receptors and it was also observed that these groups in 
the sulphamate analogues are required for this binding affinity and potent El-STS 
activity (see later). Therefore, in order to elucidate the effects on El-STS inhibitory 
activity by altering these groups, 3-methoxyoestradiol 2-Osulphamate 17p-TBDMS 
(150) was synthesised and examined for its ability to inhibit El-STS activity in MCF- 
7 breast cells. It was found to be inactive at 10pM. It is reasoned that the presence of 
the tetra-butyl-di-methylsilyl group at C-17 of 151 abolished the El-STS inhibitory 
activity (69%, Table 17). Therefore, It is possibly that 150 has less binding affinity to 
the enzyme active site than that of 151. Obviously we need to do more studies to 
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Figure 43. Effects of vehicle, 2-methoxyoestrone 3-Osulphamate or 2- 
methoxyoestrone on NMU-induced tumour growth in intact rats.
5.3.4 D-ring modifications
The ability of the D-ring modified EMATE derivatives [oestralactone 
sulphamate (LAMATE, 160), oestrone oxime sulphamate (OMATE, 162) and 
oestralactam sulphamate (164)] to inhibit oestrone sulphatase (El-STS) activity was 
examined in MCF-7 breast cancer cells and in placental microsomes (Table 21 and 
Table 22). Compounds (160), (162) and (164) were found to be potent inhibitors of 
oestrone sulphatase with potencies similar to that of EMATE (> 99% at 0.1 fiM, Table 
21) in MCF-7 cells. In vivo by the oral route, these sulphamates also inhibited rat liver 
oestrone sulphatase activity to a similar extent to that of EMATE (95%, Table 23). 
However, in contrast to EMATE, they have less stimulatory effects on uterine growth 
in the ovariectomized rats except for OMATE 162 which is about two-fold more 
oestrogenic than EMATE. One analogue, (160) was found to be devoid of 
oestrogencity and has thus been selected for an in vivo tumour study in rats.
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Table 21. Inhibition of El-STS activity in MCF-7 cells by D-ring modified 
sulphamates (160,162 and 164)____________________________________________
Compound 160 162 164
lOfiM 99.9±0.2 99.8±0.1 99.9±0.3
lpM 98.4±0.8 99.9±0.2 99.6±0.3
O.lpM 97.9±1.3 98.7±0.4 98.9±0.2
O.OIjjM 97.0±0.6 94.2±0.6 89.9±0.1
InM 78.6±2.3 73.0±0.3 45.1 ±0.9
O.lnM 23.5±3.7 70.6±1.2 2 2 .1± 1.1
Table 22. Inhibition of El-STS activity in placental microsomes by D-ring modified
sulphamates (160,1<>2 and 164)





The IC50 for oestrone oxime sulphamate (162) in placental microsomes was calculated 
to be about 0.1 jliM.
Table 23. Inhibition of liver El-STS activity in vivo by EMATE, oestralactone 
sulphamate 160, oestrone oxime sulphamate 162 and oestralactam sulphamate 164. 
Dosage: (2mg/kg/day, 5 days)__________________ ______________________________





Table 24. Inhibition of liver El-STS activity in vivo by oestralactone sulphamate 160 
at three different doses.





The dose-response of inhibition of liver El-STS activity in vivo by 
oestralactone sulphamate (LAMATE, 160) at three different doses was also examined 
(Table 24). In addition, the recovery of liver El-STS activity from treatment was 
determined for eight days after a single oral dose of LAM ATE (lOmg/kg, Table 25).
Table 25. The recovery from and % inhibition of rat El-STS activity by LAM ATE
160 after a single oral cose (10 mg/kg)





Steroidal A- and D-ring modified analogues
5.4.1 A-ring modifications
Steroid sulphatases regulate a number of important physiological and 
pathological functions in the body. There is currently considerable interest in 
developing a sulphatase inhibitor that will be safe to use in human studies.
Based on previous observations that modifications to the A- and D-ring of the 
oestrone steroid nucleus could greatly reduce oestrogenicity,217'220 a number of A- and 
D-ring modified oestrogen-based sulphamate analogues were synthesized and tested in 
attempt to identify an inhibitor which retains the potent sulphatase inhibitory 
properties of EMATE, is orally active but devoids of any oestrogenicity. The A-ring 
modified compounds include the 2-bromo, 2-iodo, 2-methoxy, 2-ethyl, 4-sulphamido 
derivatives of EMATE. Analogues of oestradiol sulphamates were also prepared. 
These include the bis and tris-sulphamate of the catechol-like, 2-methoxyoestradiol 3- 
O-sulphamate and 3-methoxyoestradiol-2-0-sulphamate. An examination of the 
ability of these EMATE analogues to inhibit oestrone sulphatase (El-STS) activity in 
placental microsomes revealed that the 2-bromo derivative was the most efficient
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inhibitor (IC50 = 250pM, cf. to EM ATE, 25nM in the same assay) being 100 times 
more active than EMATE. In contrast, 2-iodo, 2-methoxy and 2-ethyl analogues were 
also found to be efficient inhibitors with 2-iodo being 4 times more potent than 
EMATE (IC50 0.0009|liM, c.f. to EMATE; 0.004jiM, in placental microsomes). The 
2-ethyl analogue was found to be a reasonably potent inhibitor, it inhibits El-STS 
activity in MCF-7 cells by 70% at O.lpM and >99% at l|iM  and 10pM (Table 17). 
The 2-methoxyEMATE was found to be potent inhibitor as 2-bromo and 2-iodo 
derivatives of EMATE in MCF-7 cells (inhibited El-STS activity by >99% at 0.1 JiM), 
but relatively weaker in placental microsomes at low concentrations (IC50 = 30nM). 
The 4-sulphamidoEMATE derivative (IC50, 7nM in MCF-7 cells) was found to be a 
potent El-STS inhibitor but to a less extent than 2-methoxyEMATE.
In vivo testing of selected A-ring modified analogues revealed that the 2- 
methoxy- and 2-ethylEMATE derivatives inhibited rat liver oestrone sulphatase 
activity to a similar extent to that of EMATE (95%). When tested for oestrogenicity 
in ovariectomized rat uteri, the 2-methoxy and 2-ethylEMATE analogues were devoid 
of oestrogenic properties.
To investigate whether changes to the A-ring have altered the nature of 
inhibition, 2-methoxyEMATE, was examined as an example for its ability to 
irreversibly inhibit sulphatase activity. As previously found for EMATE, 2- 
methoxyEMATE acted as irreversible sulphatase inhibitor.
In a study which employed the Allen-Doisy vaginal smear bioassy, Patton and 
Dmochowski217 some years ago reported a number of modifications to the oestrogen 
steroid nucleus which reduces its oestrogenicity. Replacement of the hydrogen at C-2 
by a propyl or allyl group greatly reduced the oestrogenicity of these compounds. 
Substitution with an alkyl group at the C-4 position resulted in compounds which were 
even less oestrogenic than their corresponding C-2 isomers. However, similar studies 
have revealed that while 4-nitro-oestradiol was 200 times less active than oestradiol, 
the 2-nitro derivative was considerably less oestrogenic than the C-4-nitro isomer. 
Patton and Dmochowski concluded from their study that the decrease in oestrogenicity 
which resulted from substitution with alkyl groups at the C-2 and/or C-4 position was
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probably due to the bulkiness of the groups. No doubt this also applies to the ability 
of our EMATE derivatives to act as sulphatase inhibitors. They also postulated that 
steric interaction between the alkyl group at C-4 and a 6-hydrogen atom may distort 
the conformation of the molecule. Such a mechanism could potentially impede the 
ability of the C-4-sulphamidoEMATE derivative to gain entry into the active site of 
the sulphatase enzyme. In addition, it was noted that the rotation of the alkyl groups at 
C-4 would be restricted whilst their rotation at C-2 would be relatively unrestricted. 
They postulated that this could account for the differences in the oestrogenicity of the 
C-2 and the C-4 alkyl oestrogens. Again, such a mechanism may also account for the 
differences in sulphatase-inhibitory potency between the C-2 (e.g. 2-ethyl or 2- 
methoxy) and C-4 (e.g. 4-sulphamido) substituted EMATE derivatives. The marked 
difference in the oestrogenicity of 4-nitro and 2-nitro-oestradiol was thought to result 
from the deleterious effect of intramolecular hydrogen bonding of the 2-nitro group 
with the C-3 hydroxyl group. Due to the steric interaction with the C-6-hydrogen 
atoms, such bonding does not occur with the 4-nitro group, making the 4-nitro 
compound a considerably more potent oestrogen than its corresponding C-2 isomer. It 
is possible that intramolecular hydrogen bonding of the catechol sulphamates also 
occurs. This may therefore account for the lower potency of the catechol sulphamates 
(c.f. to EMATE). The catechol sulphamates were found to be potent inhibitors but 
less potent than the 2-methoxyEMATE and this might be due to formation of the 
hydrogen bond in the catechol sulphamates and such a hydrogen bond will not form in 
the 2-methoxyEMATE. In general, an introduction of a substitutent at the C-2 (99, 
102, 104, 127, 138, 139 and 143) or the C-4 (119) position of the EMATE ring 
slightly reduces the inhibitory activity of the sulphamate (e.g. 2-methoxyEMATE has 
IC50 = 30nM, cf. to EMATE; IC50 = 4nM in placental microsomes and 119 has IC5o= 7 
nM in MCF-7 cells, c.f. to EMATE; IC50 65pM), except for 2-bromo and 2-iodo 
derivatives of EMATE which were found to be highly significant potent El-STS 
inhibitors. Our results have therefore highlighted that there is limited tolerance of the 
enzyme to substituents at these positions. It is also possible that the group methoxy in 
104, the sulphamido in 119, the ethyl in 127 and the second sulphamate group in 139 
may have caused the sulphamate group at C-3 to be slightly shifted in the binding site 
from the usual position occupied by the sulphamate group of EMATE, and hence it 
could not be activated effectively for the sulphamoylation of the enzyme. These
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substituents may also conceivably shield the sulphamate group in such a manner that 
the putative proton abstraction, the first vital step proposed for the mechanism of E l- 
STS inhibition by EMATE, is occurred slowly or is prevented from occurring. The 
apparent significant potency against El-STS activity of 2-bromo and 2-iodo 
derivatives of EMATE remains to be confirmed. How could such activity be 
explained ? Perhaps this could be done by employing leaving group ability, o-
9^ 6Bromophenol and o-iodophenol have pKa values 8.42 and 8.46 respectively. It is 
expected therefore that 2-bromooestrone and 2-iodooestrone have approximately 
similar pKa values 8.42 and 8.46 respectively. 4-Nitrooestrone has a pKa value ca. 
7.22 (cf. to o-nitrophenol value). 4-NitroEMATE was found to be 8 times more 
potent than EMATE,220 but a stability study demonstrate this compound is much less 
stable than EMATE (unpublished data, Woo LWL, Purohit A, Reed MJ and Potter 
BVL). The pKa value of 2-bromooestrone is possibly the optimum value for a leaving 
group from a sulphamate ester as well as allowing high stability (stability study not yet 
done). Clearly, leaving group pKa is not the only factor since there is a great 
difference between the bromo and iodo compounds, although the pKas of the halo- 
phenols are similar. These derivatives are not expected to possess any oestrogenicity 
(the oestrogenicity and the inhibition of liver El-STS activity studies in vivo are in 
progress). These preliminary evaluations have shown that 2-bromo and 2-iodo 
EMATE derivatives have activity significantly higher than EMATE, perhaps upto 
100-fold greater for 2-bromoEMATE. These somewhat surprising, but exciting. If 
this is the case perhaps we should also prepare more derivatives of this type (e.g. 2- 
chloro and 2-fluoro EMATE analogues) which possibly could have similar potencies 
or better, since their pKa values are in close range to the 2-bromo and 2-iodo 
derivatives. The pKa values of o-chlorophenol and o-fluorophenol 8.48 and 8.81 
respectively.256 2-FluoroEMATE might also has advantage over 2-bromoEMATE as 
it will metabolically more stable towards hydroxylation at the 2-position.
In vivo, the potency of 2-methoxy and/or 2-ethyl EMATE was found to be 
similar to that of EMATE, but the lack of any oestrogenicity has identified this 
analogue as a potential new lead compound for development as a potent steroid 
sulphatase inhibitor.
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As we know, the high cost of the starting material (2-methoxyoestrone) for 2- 
methoxyEMATE was a serious disadvantage. Therefore, we attempted to synthesise 
2-methoxyoestrone in an efficient, cheap and simple fashion so that the preparation of 
2-methoxyEMATE could be carried on a large scale for further biological tests. This 
had led to the synthesis of 2-methoxyoestradiol 3-0-sulphamate, the sulphamates of 2- 
hydroxyoestradiol and 3-methoxyoestradiol 2-Osulphamate in an novel and efficient 
manner. The ability of these derivatives to inhibit oestrone sulphatase activity was 
examined using MCF-7 cells and placental microsomes. 3-Methoxyoestradiol 2-0-  
sulphamate was found to be a weak El-STS inhibitor and inhibited El-STS activity by 
67% at 10 jjM  in MCF-7 cells. However, such relocation of the sulphamate group 
from the usual C-3 to the C-2 position virtually abolishes inhibitory activities of the 2- 
methoxyoestradiol 3-O-sulphamate in both of the biological systems (Table 17 and 
18). It is likely that on binding to the enzyme active site, the sulphamate group in 3- 
methoxyoestradiol 2-O-sulphamate (I), which is at the C-2 position of the A-ring, as 
opposed to the C-3 position in 2-methoxyEMATE/ 2-methoxyoestradiol 3-O- 
sulphamate, is not in close proximity to the essential amino acid residues responsible 
for their subsequent activation.
OH
151OHI
The poor inhibition shown by this sulphamate 151 could also be a consequence 
of the relatively poor leaving group abilities of its starting material 147. It is 
reasonable to expect that the pKa of starting material of 151 will be similar to that of a 
simple phenol (ca. 10) or higher since its hydroxy group at C-2 is not near the 
sterically hindered C -6  of the steroid ring or due to the presence of electron donating 
group (O CH 3) at the C-3.
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2-MethoxyEMATE was selected for animal tumour studies. Preliminary 
results have shown a highly significant regression in the NMU-induced tumour model 
in intact rats. This indicates that this compound is effective aginst real tumours. With 
this inhibitory activity profile and lack of oestrogenicity, 2-methoxyEMATE should be 
a good STS inhibitor to be put forward for consideration in clinical trials, once we 
understand more about its mode of action.
2-Methoxyoestradiol is a naturally occurring mammalian metabolite formed by 
hepatic hydroxylation of oestradiol (by NADPH-dependent cytochrome P450 enzyme) 
followed by O-methylation149,257 (by catechol-0-methyltransferase,241 COMT). 2- 
Methoxyoestradiol, has a very low affinity for the oestrogen receptor. This might 
explain why 2-methoxyEMATE and other 2-substituted analogues are devoid of any 
oestrogenicity. General interest in 2-methoxyoestradiol has been stimulated by its 
cytotoxicity in cancer cell cultures, which is associated with the inhibition of mitosis, 
uneven chromosome distribution, and increase in the number of abnormal 
metaphases.258,259 Recently it has been discovered that 2-methoxyoestradiol binds to 
the colchicine binding site of tubulin, resulting in either inhibition of tubulin 
polymerization or formation of a polymer with altered stability, properties and 
morphology, depending on the reaction conditions.260 These observations suggest that 
2-methoxyoestradiol could be functioning as a natural regulator of mammalian 
microtubule assembly and function. In addition to these antitubulin and antimitotic 
properties of 2-methoxyoestradiol, recent in vitro results have shown that it also 
inhibits angiogenesis (the creation of new blood vessels), which is required for the 
growth of solid tumours.254,255,261'263 When investigated in vivo by oral administration 
in mice, 2-methoxyoestradiol was found to be a potent inhibitor of the 
neovascularization of solid tumours and their growth. These in vivo antitumour 
effects were accompanied by no apparent signs of toxicity. In order to study the 
effects of 2-methoxyEMATE (104), 2-ethylEMATE (127) and 2-methoxyoestradiol 3- 
O-sulphamate* (143) on cell morphology and their ability to induce apoptosis in 
MCF-7 (oestrogen receptor positive), MDA-MB-231* (oestrogen receptor negative)
j|t
breast cancer cells and also fibroblasts derived from normal and malignant breast 
tumours (* = results not shown), these compounds were initially examined in the 
MCF-7 cells systems and were found to be potent apoptosis inducers, resulting in cells
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damage. The growth inhibition data by these analogues are shown in Table 19. 2- 
Methoxyoestrone was also shown to have induced apoptosis in MCF-7 cells, but its 
activity was weaker than 2-methoxyEMATE (0.1 pM) and also a higher dose (10|iM) 
was required to be effective (results not shown). However, when a sulphamate group 
is present on the C-3 position of 2-methoxyoestrone, the potency of apoptosis 
induction increased significantly; the reason for this remains to be elucidated. 2- 
EthylEMATE also shares a similar property to 2-methoxyEMATE albeit less potent 
(Table 19); this may be because the 2-ethyl group is a good steric mimic of the 2- 
methoxy group. In addition, it is possible that the 2-ethyl group will not be 
metabolically as labile as the 2-methoxy group to the enzymatic activity of 
demethylase and so 2-ethylEMATE could be a better new lead for further studies.
In view of these exciting results, we decided to synthesise and investigate other 
analogues, therefore we synthesised the 2-methoxy sulphate sodium salt to examine if 
it is active in any of these assays. As the sulphamate appeared more active than 2- 
methoxyoestrone we examined whether the sulphate derivative is active or not. 
Preliminary results for 2-methoxyoestrone sulphate shown that it appears to be 
inactive, although we need to test it at higher concentration, when more becomes 
available. It is reasoned that the potent growth inhibition of MCF-7 cells is due to the 
presence of the sulphamate group in such compounds.
Our introduction of the sulphamoyl group increased the potency of the 2- 
methoxyoestrogens significantly as anticancer agents, making these sulphamate 
compound lead potent anticancer agents. An array of new A- ring modified analogues 
of EMATE has been synthesised in an effort to overcome the oestrogenicity of 
EMATE and to improve on the El-STS inhibitory activity. These objectives have 
resulted in 2-methoxy, 2-ethyl EMATE or 2-methoxyoestradiol sulphamate, which are 
potent steroid inhibitors in vitro and in vivo and are devoid of any oestrogenicity. 
Besides, they are potent El-STS inhibitors they have potent antitubulin and also 
anti tumour activities.
In conclusion, a new class of El-STS inhibitors, which were also found to be 
potent tubulin polymerization inhibitors, has been synthesised with 2-
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methoxyEMATE, 2-ethylEMATE and 2-methoxyoestradiol 3-O-sulphamate as the 
leading compounds. These sulphamates are more potent as El-STS inhibitors, 
cytotoxic agents in cancer cell cultures and as tubulin polymerization inhibitors than 
the natural metabolites (2-methoxyoestrone, 2-methoxyoestradiol) itself, and these 
analogues are being investigated in vitro as anticancer agents. Further work will 
concentrate on the synthesis of these analogues in efficient ways to realise their 
therapeutic potential as anticancer agents.
5.4.2 D-ring modifications
Dorfman and K ind219 previously examined the effect of removal of the oxygen 
function at C-17 of the D-ring of the oestrone nucleus on oestrogenicity. Using a 
mouse uterotrophic assay the relative potency of oestra-l,3,5(10)-trien-3-ol was only 
11% as active as oestrone by the subcutaneous route. A number of D-ring modified 
sulphamate analogues of EMATE were synthesised and tested for their ability to 
inhibit El-STS activity in vitro and in vivo. D-ring modified compounds include 
oestralactone-3-O-sulphamate (LAMATE), oestrone oxime 3-O-sulphamate 
(OMATE) and oestralactam 3-O-sulphamate. Initially, as an example, Purohit et al. 
synthesised 17-deoxyoestrone-3-0-sulphamate (NOMATE). This compound inhibited 
El-STS activity in MCF-7 cells by 97% at 0.01 pM, similar to the inhibition achieved 
with EMATE.205
EMATENOMATE
In vivo, in ovariectomised rats NOMATE when given at 0.1 mg/kg or 1.0 
mg/kg per day p.o. for 5 days almost completely inhibited (98%) liver oestrone 
sulphatase activity. Whereas the parent compound, 17-deoxyoestrone at 1 mg/kg, had
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no significant inhibitory effect on oestrone sulphatase activity although, it did increase 
uterine growth in the ovariectomised rat by 235% compared with control animals. 
However, NOMATE at 0.1 mg/kg, a dose that almost completely inhibited El-STS 
activity, had no effect on uterine growth. This shows that at 0.1 mg/kg NOMATE is 
devoid of oestrogenic activity. At a 10-fold higher dose, however, NOMATE did 
stimulate uterine growth (80% vs controls) but to a significantly lower degree (p<0.05) 
than that caused by 17-deoxyoestrone.205 The encouraging inhibitory activity and 
lower oestrogenicity of NOMATE, makes this inhibitor a good lead template (of the 
D-ring modified analogues) for the design of non-oestrogenic and more potent 
steroidal El-STS inhibitors. Hence, we have synthesized other analogues of D-ring 
modified EMATE, in which the C-17 carbonyl is converted to an oxime, and the five- 
membered ring to a six-membered ring lactone and lactam.
In our continuing search to overcome the oestrogenicity of EMATE, the most 
potent irreversible inhibitor of El-STS, we synthesized oestrone oxime, oestralactone 
and oestralactam sulphamates. As described above, the D-ring is one of the factors 
responsible for oestrogenic activity of EMATE. E-oestrone oxime (161) had a weak 
oestrogenic activity (ca 40-fold less than oestrone)264,265 but was found to possess no 
anti-oestrogenic activity in rats.264 Its relative affinity, determined using a calf cytosol 
preparation, was about 50% lower than the value of oestrone. While oestrone 
oxime was considerably less potent than oestrone in an oestrogenic bioassay, it was
Of\f\only 2.5-times less active as a postcoital anti-fertility agent, suggesting some 
separation of its uterotrophic and anti-fertility effects. Oestralactone (159) was found 
to be about 14 times less oestrogenic than oestrone.245 We anticipated that, by 
introducing a sulphamoyl group to 159 and 161 as one of the structural requirements 
for El-STS inhibitory activity to gives oetralactone 3-O-sulphamate (LAMATE, 160) 
and oximo-3-O-sulphamoyl-l,3,5(10)-estratriene (oestrone oxime 3-O-sulphamate, 
OMATE, 162), might also possess a lower oestrogenicity but retain inhibitory potency 
against steroid sulphatase.
Compounds LAMATE (160), OMATE (162) and oestralactam sulphamate 
(164) were tested in MCF-7 cells and placental microsomes preparations and were 
found to be potent inhibitors of oestrone sulphatase with potencies similar to that of
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EMATE (> 99% at 0.1 |iM, Table 21 & Table 22). In vivo by the oral route, these 
sulphamates also inhibited rat liver oestrone sulphatase activity to a similar extent to 
that of EMATE (99%, Fig.44) . 145 However, in contrast to EMATE, they have less 
stimulatory effects on uterine growth in the ovariectomized rats except for oestrone 
oxime 3-O-sulphamate (OMATE) which is about two-fold more oestrogenic than 
EMATE (Fig.45). One analogue, (LAMATE, 160) was found to be devoid of 
oestrogencity upon screening by ovariectomized rat uterine-weight gain assay and has 
thus been selected for an in vivo tumour study in rats. The IC50 for inhibition of E l- 
STS by OMATE in placental microsomes was found to be 80nM, which compares 
with a value of 93nM for EMATE. 141
OMATE 162 was also tested for its oestrogenicity using an ovariectomised rat 
uterine weight gain assay. In ovariectomized rats receiving vehicle only, the average 
uterine weight (expressed as uterine weight/total weight x 1 0 0 ) was found to be
0.036±0.001 (mean ± SD). For animals receiving EMATE, there was a significant 
increase in uterine weight (0 . 1 1  ± 0 .0 2 , p<0 .0 1 ) and also for those administered with 
OMATE (0.15 ± 0.01, p<0.001). The difference in uterine weight between animals 
receiving EMATE or OMATE was also significant (p<0.05). Surprisingly, therefore, 
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Figure 44. In vivo inhibition of rat liver El-STS activity by EMATE, LAMATE 
(160), OMATE (162) and oestralactam 3-O-sulphamate (164). The ovarictomized rats 
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Figure 45. In vivo oestrogenicity study of EMATE, LAMATE (160), OMATE (162) 
and oestralactam 3-O-sulphamate (164). The ovarictomized rats were dosed at 2 
mg/kg, o.d.x 5days.
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The reason why this OMATE is more oestrogenic than EMATE remains to be 
elucidated. As previously noted, studies carried out by Peters and colleagues264 
reported that oestrone oxime was about 40-times less oestrogenic than oestrone on oral 
administration. However, orally administered oestrogens are generally only poorly 
absorbed from the gastro-intestinal tract and it was only with the development of the 
synthetic oestrogen, ethinyloestradiol, that a potent orally active oestrogen became 
available. It has recently been shown that the addition of a sulphamoyl group to 
oestrone renders the product (EMATE) 5-times more oestrogenic than 
ethinyloestradiol on oral administration.162 Thus, the addition of a sulphamoyl group 
greatly increases the oestrogenicity of oestrone and a further enhancement of activity 
by oral administration has now also been achieved by the introduction of an oxime 
function at the C-17 position of EMATE. It is likely, but remains to be confirmed, 
that the enhanced oral activity of EMATE, as compared with that of oestrone, results 
from its passage through the liver without undergoing metabolism. Once transit 
through the liver has been achieved and oestrone is released from the pro-drug, it will 
be subjected to the normal pathways of oestrogen metabolism and inactivation, i.e. 
hydroxylation and conjugation. In vivo, there is evidence that after the oral 
administration of EMATE, oestradiol rather than oestrone is the major circulating 
oestrogen released. Oestradiol can be oxidised to the less potent oestrogen, 
oestrone, by oestradiol 17p-hydroxysteroid dehydrogenase, Type II (E2DH II), which 
is widely distributed in body tissues.267 It is possible that the introduction of the 
oxime function hinders metabolic inactivation by E2DH n, thus making OMATE 
more oestrogenic in vivo than EMATE. If the oxime function of OMATE does indeed 
render it more resistant to metabolic inactivation than EMATE, and thus more 
oestrogenic, it may have some advantage over EMATE for use in hormone 
replacement or oral contraceptive therapies, but it would be unsuitable for the use in 
endocrine-dependent tumours of the breast and endometrium. However, the D-ring of 
the steroid nucleus structure and sulphamoyl group plays an vital role in the 
oestrogenicity in such compound (e.g. OMATE).
The identification of a potent non-oestrogenic steroid sulphatase inhibitor such 
as (LAMATE, 160) should be of considerable value in evaluating the potential of a
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steroid sulphatase inhibitor in the treatment of endocrine-dependent cancers. This 
compound was selected for animal tumour study.
In conclusion, a number of A- and D-ring modified derivatives of EMATE 
have been synthesized and tested in vitro and in vivo in an attempt to identify a potent 
steroid sulphatase inhibitor which devoids of any oestrogenicity properties. 2- 
MethoxyEMATE, 2-ethylEMATE, 2-methoxyoestradiol 3-O-sulphamate and 
LAMATE were potent inhibitors in vitro and in vivo and had no oestrogenic effects on 
uterine growth in the ovariectomized rat. In view of the antiproliferative and anti- 
angiogenic properties associated with 2-methoxyoestradiol, the sulphamoylated 
derivative of this steroid and others two (2-methoxy and 2-ethylEMATE) have 
considerable therapeutic potential.
5.5 Summary
It is now generally acknowledged that in order to improve the response rate to 
endocrine therapy using enzyme inhibitors in women with breast cancer it will be 
necessary to achieve complete oestrogen deprivation. While potent, specific 
aromatase inhibitors are now available, the clinical response has been somewhat 
disappointing.268,269 During the last few years, since the identification of the active 
pharmacophore required for potent sulphatase inhibition, considerable progress has 
been made in the development of steroidal and non-steroidal inhibitors and several 
potent candidates have now been identified and are currently undergoing pre-clinical 
testing. The availability of these steroid sulphatase inhibitors should enable the 
therapeutic value of this therapy to be examined in a clinical trial in the near future.
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6 Proposed mechanisms of sulphate cleavage by sulphatase and
steroid sulphatase inhibition by EMATE and related synthetic
sulphamates
6.1 Background
The sulphatase family of enzymes catalyze the hydrolysis of sulphuric acid 
esters from a wide variety of substrates including glycosaminoglycans, glycolipids and 
steroids. Eleven different mammalian sulphatases have been identified; eight in 
lysosomes and three associated with microsomal membranes.171173 Deficiencies of 
specific lysosomal sulphatases that are involved in the degradation of glycosamino-
270glycans lead to rare inherited clinical disorders termed mucocopolysaccharidoses.
In these disorders all sulphatases are inactive because an essential post-translational 
modification of a specific active-site cysteine residue to oxo-alanine does not occur 
(Scheme 31). In all the different sulphatases which have been resolved so far, 
including steroid sulphatase, the active site amino acid residues are conserved.171' 173
Scheme 31. The post-translational modification of the essential active-site cysteine 
residue in Af-acetylgalactosamine-4-sulphatase, a human lysosomal sulphatase
(adapted from Bond et a/.).171
Cysteine 91
gem-diol sulphate ester (I) Oxo-alanine
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6.2 Mechanisms of sulphate cleavages by sulphatase
In order to understand the catalytic mechanism of sulphatases, Bond et al171 
have determined the crystal structure of Af-acetylgalactosamine-4-sulphatase (4-S). It 
was found that the structure of 4-S is a monomer with two domains, the larger of 
which belongs to the a/p class of proteins and contains the active site. Bond et a l 
proposed that the cysteine residue (Cys91), as the sulphate derivative of the aldehyde 
species (oxo-alanine, Scheme 31), is readily located by the presence of a mutagenesis 
cluster of the conserved residues (Asp53, Asp54, Cys91, Pro93, Ser94, Arg95, 
Lysl45, His 147, His242, Asp300, and Lys318, Fig.46). Two site-directed changes 
(Cys91 to Ser and Cys91 to Thr) were performed by Bond et al. which were shown to 
destroy the enzyme activity, emphasizing the identity of Cys91 as the essential 
cysteine residue. The sulphate is bound to an a metal ion, which Bond et al. have 
identified as calcium. Bond et al. have also interpreted the electron density around the 
sulphate as resulting from a covalently linked gem-diol sulphate ester (I, Scheme 31). 
The sulphate ester observed in the crystals could, in principle, be formed simply by 
addition of sulphate to the aldehyde resulting from modification of Cys91. It has been 
proposed by von Figura270 that this cysteine residue in sulphatase undergoes a 
conversion to oxo-alanine and that the free aldehyde function is stabilized either as an 
enol or is linked to an amino or hydroxyl group of the polypeptide forming a SchifFs 
base or a hemi-acetal respectively. The presence of the aldehyde group in the residue 
was demonstrated by reduction of the enzyme with sodium borohydride under 
conditions specific for aldehyde reduction, and identification of a resultant serine 
residue in the sequence in place of the encoded cysteine.270 In addition, the structure 
of a vanadate-inhibited form of the 4-S enzyme has also been solved, which shows 
that vanadate has replaced sulphate in the active site (Cys91) and the vanadate is 
covalently linked to protein.171 This now provides a model for the active site of 
steroid sulphatase.
Bond et al. proposed that the hydrolysis of substrate ester by 4-S involves the 
following sequence. The presumed covalently linked sulphate (I, Scheme 31), which 
was assumed to be the resting form of the enzyme, may either be released by 
hydrolysis involving a nucleophilic attack, possibly by water, or it may be only
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relatively weakly bound to the enzyme and could be in equilibrium with the free 
aldehyde form. The substrate, glycosaminoglycan sulphate in the case for 4-S, then 
binds to the enzyme and its sulphate group forms a covalent ester bond to residue 91. 
A nucleophile such as water, another residue of the protein or a hydroxyl group of the 
substrate attacks the sulphur atom, making a 5-coordinate intermediate stabilized by 
the metal ion (calcium). This intermediate then collapses, breaking the bond between 
the sulphur and the glycosidic oxygen, releasing the glycosaminoglycan and leaving 
the sulphate bound to residue 91, as depicted in Scheme 31. The above described 
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Figure 46 : Sketch view of the catalytic site of iV-acetylgalactosamine-4-sulphatase 
showing hydrogen-bonded interactions (dashed lines) that stabilize the sulphate ester. 
The seven coordinate metal ion is on the left. A salt-bridge interaction between 
Lysl45 and the O (carboxyl) atom of Asp53, which is not coordinated to the metal 
ion, and a number of charges and double bonds are omitted from the figure for clarity 
(adapted from Bond et a l  1997).
Recently, Recksiek et a lll?l have elucidated the catalytic mechanism of sulphate 
ester hydrolysis by two other members of the human aryl sulphatase family: aryl 
sulphatase A (ASA) and aryl sulphatase B (ASB). Both enzymes share a unique post-
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translational modification of a conserved cysteine residue (Cys69 for ASA and Cys91 
for ASB) that is essential for sulphate ester cleavage which involves the oxidation of 
residue at Cp yielding L-Ca-formylglycine (oxo-alanine) in which an aldehyde group 
replaces the thiomethylene group of the side chain of cysteine. This modification 
occurs in the endoplasmic reticulum and is directed by a short linear sequence 
surrounding the cysteine to be modified. From the crystal structure of ASA and ASB, 
it has been shown that the formylglycine residue is located in a positively charged 
substrate binding pocket, in which a metal ion is coordinated (Mg2+). The electron 
density at the formylglycine side chain in crystals of ASA was interpreted as an 
aldehyde hydrate (I) and in crystals of ASB as a sulphate adduct of the aldehyde (II). 
Two different catalytic mechanisms for ASB and ASA have therefore been proposed.
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For ASB, the reaction sequence is thought to be initiated by the formation of a 
sulphate ester by addition of the substrate to the oxogroup of formylglycine (or oxo- 
alanine). The substrate alcohol is then supposed to be released with the help of a 
nucleophile such as water, leaving the sulphate bounded to the enzyme (Scheme 32). 
This proposed catalytic mechanism of ASB by Recksiek et a l173 is similar to the 
mechanism of N- acetyl gal actosamine-4-sulphatase as proposed by Bond et al.111 
However, for ASA Recksiek et al. proposed that the reaction cycle starts with the 
formation of an aldehyde hydrate, which was observed in the crystal structure. One of 
the geminal hydroxyl groups cleaves the sulphate ester by nucleophilic substitution of 
the substrate alcohol (transesterification) leading to the same covalent intermediate as 
the resting form observed for ASB (cf. Scheme 32). The second, non-esterified 
hydroxyl group of the covalent intermediate is proposed to induce an elimination of 
sulphate resulting in the regeneration of the aldehyde (Scheme 33).
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Sulphate ester (resting form)
Scheme 32. Proposed reaction of ester cleavage for aryl sulphatase B (ASB)
In order to discriminate between the two mechanisms proposed for sulphatase 
ester cleavage by ASA and ASB, Recksiek et al have constructed mutant proteins of 
ASA in which the active site formylglycine, derived from cysteine, is replaced by a 
serine. This substitution leads to a sulphatase protein that can no longer be modified 
to the formylglycine containing form. It was found that both serine mutants of ASA 
and ASB make one catalytic half-cycle, thereby cleaving the sulphate ester of the 
substrate to form a sulphoserine-containing derivative (III). This observation strongly 
suggested that wild-type sulphatases initiate sulphate ester cleavage by a 
transesterification step as described in Scheme 33. If formation of the sulphated 
intermediate would be initiated by addition of the sulphate ester to the oxogroup as 
proposed for ASB in Scheme 32, substitution of the formylglycine by serine should 
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Recksiek et a l  then further demonstrated that the sulphoserine-containing 
enzyme intermediate was stable at pH 5 and was slowly hydrolysed at alkaline pH. 
These characteristics are analogous to that of alkaline phosphatase whose 
phosphoserine intermediate is also stable at pH 5, but is hydrolysed at alkaline pH 
with no desulphation at acidic pH. The reason for the trapping of such sulphoserine 
intermediate and the failure of the serine mutants to release the sulphate and thereby 
completing the catylytic cycle is ascribed to the absence of a second, non-esterified 
hydroxyl group at the Cp atom of the sulphated residue. This hydroxyl group, which 
presents in wild type sulphatases because of the hydration of the formylglycine 
residue, polarises the Cp-O bond of the sulphate ester intermediate which leads to the 
elimination of sulphate by cleavage of this bond. The elimination regenerates 




Cysteine Oxo-alanine (formylglycine) Aldehyde hydrate
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Aldehyde hydrate Oxo-alanine (formylglycine) Sulphate ester (resting form)
Scheme 33. Proposed reaction of ester cleavage for aryl sulphatase A (ASA)
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6.3 Proposed mechanisms of steroid sulphatase inhibition by EMATE and 
related synthetic sulphamates
Although EMATE has not been shown to be active against other sulphatase 
enzymes apart from steroid sulphatase, based on the above insight into the active of 4- 
S, ASA and ASB proposed mechanisms for sulphate hydrolysis by these enzymes 
(Scheme 31-33) and given that the essential residues for sulphatase activity are 
conserved within the sulphatase family, several mechanisms for the inhibition of 
steroid sulphatase activity by EMATE (or other related sulphamates) could be 
proposed (Scheme 34, 35 and 37). The mechanisms proposed here thus replace the 
more schematic ones that have generally been proposed before.141
i) Involvement o f the oxo-alanine residue
Since it has been proposed by Bond et a l ni that the resting sulphated 
derivative of oxo-alanine could be in equilibrium with its free form, potential attack by 










Scheme 34. Proposed mechanism of EMATE-induced inhibition of steroid sulphatase. 
All the above boxed structures represent potential dead-end enzyme inhibition
complexes.
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O S 0 2N H -C H -N M e
0 S 0 2N=CHN(CH3)2
Scheme 35. Synthesis of sulphamate 36 and azomethine sulphamate 37 from 4,4'- 
dihydroxybenzophenone and the proposed mechanism for the formation of 37: (i) 
NaH/DMF, H2NS02C1.
The first step is a nucleophilic attack on the oxo-alanine by the amino group of 
the sulphamate group to give 1 (Scheme 34) which could be either hydrolysed by 
water to give oestrone and the sulphamoylated enzyme (2, Scheme 34) or eliminate 
water first to give the azomethine form (3, Scheme 34) which on hydrolysis could give 
oestrone and the imino sulphamoylated enzyme (4, Scheme 34), 4 could also be 
formed from 2. The formation of the azomethine benzophenone derivative (Scheme 
35) as described previously in the sulphamoylation reaction of 4,4'- 
dihydroxybenzophenone is possible supporting evidence of this mechanism in a non- 
enzymatic reaction. The sulphamoylation of 4,4'-benzophenone gave benzophenone 
4,4'-0,0-bis-sulphamate 36 (43%) and the azomethine-containing compound 37 
which is an adduct of 36 (7%) with DMF. A retrosynthetic analysis as mentioned 
previously suggests that 37 could have been formed when one of the A-protons of 36 
was removed (presumably by the presence of excess sodium hydride) and the resulting
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anion of 36 attacked a molecule of DMF at the carbonyl carbon followed by 
dehydration of the product upon acidification during the aqueous workup (Scheme 
35). Alternatively, since DMF is not a strong electrophile, the actual species attacked 
may be the corresponding iminium-O-sulphamate 37a. In our usual small-scale 
synthesis of EMATE, such an adduct of EMATE and DMF, which is less 
chromophoric than 37, was not easily detected on TLC. However, we did isolate a 
fraction in our subsequent large-scale syntheses of EMATE whose 'H NMR spectrum 
suggested the presence of the adduct (unpublished data).
ii) Involvement o f the aldehyde hydrate (gem-diol residue)
Another mechanism could be possible (Scheme 36); a nucleophilic attack by 
the aldehyde hydrate on the sulphamate group could give the sulphamoylated enzyme 
1 (Scheme 36) which presumably is the dead-end product. This would be directly 
analogous to the mechanism proposed for aryl sulphatase A. The product I is 
presumably unable to proceed further, i.e. the sulphamate can not be expelled by the 
other hydroxyl group of the gem diol.
H2N— S— OR
EMATE
HO.. /O H  
CH






Scheme 36. Proposed mechanism of EMATE induced inhibition. Boxed product is
the suggested dead-end product.
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Hence, EMATE or other irreversible sulphamates could be acting by the two 
different proposed mechanisms as shown above (Scheme 34 & Scheme 36).
iii) Random specific or non-specific sulphamoylation by an aminosulphene 
mechanism
It is also possible that irreversibly inhibiting sulphamate esters, including 
EMATE, could inhibit steroid sulphatase in a more random manner by a specific or 
non-specific sulphamoylation of amino acid residues in the active site. Because of the 
curvature of the inactivation plots modification of two residues was suspected (the 
analysis of pH dependence of enzyme activity and of enzyme inactivation by EMATE 
provides evidence that two ionizable groups with pKa values of 7.2 and 9.8 are 
involved).141 Evidence in favour of inactivation of histidine has been reported 
(Purohit et al)141 and tyrosine was also suspected, since the pH dependence of the 
inactivation process correlated with a residue of pKa 9.8. However, we now know 
that the conserved active site residues do not include tyrosine, and so some other 
residue of similar pKa must be found. The most likely residues with the similar pKa 
is lysine (e.g. Lys318 and Lysl45), which has a pKa value of -10 in proteins 
compared to tyrosine -10-12.271
wwyw*
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N H ---------- ► + Oestrone
Aminosulphene Non-specific sulphamoylated enzyme
Oestrone + """S— NHj
Non-specific sulphamoylated enzyme
R =
T an amino acid residue = within the active site 
H of sulphatase
Scheme 37. Non-specific sulphamoylation of sulphatases by EMATE. Boxed 
structure represent potential dead-end enzyme.
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Such random specific or non-specific inactivation of steroid sulphatase by 
EMATE is expected to involve the sulphamoylation of one of the conserved amino 
acid residues, either by i) a direct nucleophilic attack at the sulphur atom of EMATE 
by an amino acid residue (Scheme 37) or ii) by the formation of a reactive 
aminosulphene intermediate from the amino of EMATE via El/cB process, possibly 
initiated by an enzyme catalysed proton abstraction from the amine of the sulphamate 
group and most likely stimulated by H-bonding to the bridging O-atom (Scheme 37). 
Both mechanisms will rapidly lead to a sulphamoylated enzyme intermediate which, 
we propose, could be a dead-end product.
We thus suspect that irreversible active site modification could be on both 
Lys318 or 145 and His242 or 147. It is instructive to speculate what these 
modification could be. For lysine we would therefore expect the sulphamide product
i.e.:
Lys'
and for histidine the similar sulphamide-type product i.e.:
NHS—NH2
His
In the known chemistry of sulphatase it is well known that sulphamides are very 
inactive species. They are therefore excellent candidates for a dead-end product of 
enzyme inactivation. Indeed, it is also entirely possible that the gem-diol sulphamate 
(I) proposed in Scheme 36 might be a intermediate that could further react with a 
neighbouring histidine or a lysine residue to generate a final sulphamide species.
All the above proposed mechanisms of sulphamates including EMATE remain 
to be elucidated and many questions remain to be answered before any of these 
mechanisms can be confirmed. Nonetheless, we now have good models for
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understanding how these inhibition of sulphatase by sulphamate esters may work and 
there are real models that can be tested by experiment in the future.
6.4 Summary
Based on the proposed mechanisms of sulphatase by Bond et al171 
Recksiek et al173 we provide a model for the active site of steroid sulphatase, 
propose that the inhibition of steroid sulphatase by EMATE may involve one 
combination of the following mechanisms:
(i) A nucleophilic attack on the oxo-alanine by the sulphamate amino group to give 1 
(Scheme 34) which could be either hydrolysed by water to give oestrone and the 
sulphamoylated enzyme or eliminate water to give an azomethine species (2, Scheme 
34) which on hydrolysis gives oestrone and the corresponding sulphamoylated 
enzyme.
(ii) A nucleophilic attack by one of the hydroxy groups of the aldehyde hydrate on the 
sulphamate group of EMATE (and other related sulphamates) could give the 
sulphamoylated enzyme 1 (Scheme 36) which presumably is a dead-end product (or 
may be react further as discussed with Lys or His residues). However, such a 
sulphamoylated “dead-end product” resembles closely the sulphated aldehyde hydrate 
intermediate as proposed for the sulphate cleavage by ASA (Scheme 33) and it is 
difficult to envisage how the S-O-C bonds in the former are more resistant to cleavage 
than those in the later. In addition, if this proposed mechanism is valid, why is it that 
the potency of EMATE decreases significantly by 100-1000 fold when the sulphamate 
group is increasingly methylated141 and also why is the activity reduced significantly 
when the bridging oxygen in EMATE is replaced by other hetero atoms (e.g. N, S), 
since neither the amino group nor the bridging atom of the sulphamate is involved in 
the inactivation process.
(iii) The sulphamoylation of one of the conserved amino acid residues, either by: a) a 
direct nucleophilic attack at the sulphur atom of EMATE by an amino acid or, b) by 





mechanism would explain why the A-methylated and A,A-dimethylated EMATE 
analogues are 100 and 1000 fold less potent than EMATE respectively.141 In the case 
of the A-methylated analogue of EMATE the putative proton abstraction step is still 
possible to form methylaminosulphene (C>2S=NMe), which being, less reactive than an 
aminosulphene, might sulphamoylate the enzyme more slowly. In the case of N,N- 
dimethylated analogue this abstraction step is prevented from occurring. This might 
explain the low activity of these A-alkylated analogues. It was found that when the 
protons of the sulphamate in EMATE are completely alkylated with other moieties 
(such as dibenzyl and piperidyl), not only the activity of these analogues were reduced 
significantly but also the nature of inhibition changed (reversible inhibition)160 
suggesting that these analogues could possibly act by a different mechanism and that 
the A-protons of EMATE are essential for the formation a reactive aminosulphene and 
potent irreversible inhibition. It is also found that when one proton of the amino group 
of the sulphamate group of EMATE is replaced by an acetyl group (I), this compound 
found to be potent irreversible inhibitor (inhibited El-STS activity by 93% at lOpM in 
placental microsomes, considerable less potent than EMATE).160 It is possible that 
the proton abstraction step is still possible to form an aminosulphene derivative (II).
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However, it is important to recognise that EMATE might act by more than one 
mechanism. It is possible that EMATE acts by one of the above proposed mechanism 
alone or a combination of the three mechanisms. Since the post-translational modified 
Cys91 might exit in the oxo-alanine or the aldehyde hydrate form, the percentage of 
each form in the active site is difficult to determine, but we expected that the aldehyde 
hydrate is the major form. The likelihood of EMATE inhibiting steroid sulphatase via 
random specific or non-specific sulphamoylation should not be underestimated. These 
three proposed mechanisms remain to be elucidated and it is important also to 





All reagents and solvents employed were of general purpose or analytical grade 
unless otherwise stated, and purchased from either Aldrich or Sigma Chemicals or 
Lancaster Synthesis.
Silica gel refers to silica gel, Merck, grade 60. Product(s) and starting material 
were detected either viewing under UV light or treating with a methanolic solution of 
phosphomolybic acid followed by heating. NMR spectra were determined using 
acetone-d6 , CDCI3 or DMSO-d6 as solvent and TMS as internal standard, unless 
otherwise stated. The JH NMR and 13C NMR spectra were recorded on a Jeol GX 
270 at 270 MHz and on a Jeol EX 400 at 400 MHz NMR spectrometer. The 
following abbreviations are used to describe resonances in JH NMR and 13C NMR 
spectra: s, singlet; d, doublet; br, broad; t, triplet; q, quartet; m, multiplet and 
combination such as dd, doublet of doublets. IR spectra were determined as KBr 
discs, using a Perkin-Elmer 782 Infra-Red Spectrophotometer. Melting points were 
determined on a Reichert-Jung Kofler Block and are uncorrected. Mass spectra were 
recorded on VG 7070 and VG Autospec instruments at the Mass Spectrometry Service 
at the University of Bath. FAB-mass spectra were carried out using m-nitrobenzyl 
alcohol (m-NBA) as the matrix. HPLC stability studies were determined using LDC 
Constametric 3000 HPLC Pump and Spectrometer 3000 variable wave length detector. 
CHN analysis was determined using gas chromatography at the Microanalysis Service 
at the University of Bath.
All reagents and solvents used were stored away from moisture and light and 
dried before use. Low temperature experiments were conducted using a well insulated 
external bath containing either ice/water with NaCl for 0°C or carbon dioxide pellets 
with acetone or using cold plate. Experiments requiring anhydrous conditions were 
guarded by mean of a drying tube containing self-indicating silica. Evaporation of 
solvents was carried out with a rotary evaporator at reduced pressure (water pump) and 
on stated occasions, followed by the use of a high vacuum pump. Samples were dried 
in drying tube under high vacuum and low temperature.
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7.1.2 Biological assay o f sulphamates
All assays were performed at the Department of Endocrinology and Metabolic 
Medicine, Imperial College School of Medicine, St. Mary’s Hospital, London by and 
in collaboration with Dr. A. Purohit and Professor Michael Reed.
/ .  Sulphatase Inhibitor: Sulphatase inhibition was assessed using placental 
microsomes (100,000 g) preparations or in intact MCF-7 breast cancer cells as 
described previously.141,157 Placental microsomes were incubated with 3H-E1S, 
adjusted to 20 (iM with unlabelled substrate, in the absence or presence of the 
inhibitor.
2. Aromatase Inhibitor: Placental microsomes were also used to assess the aromatase 
inhibitory properties of flavonoid sulphamates using a tritiated water release assay.145 
Placental microsomes (200 |il) were incubated with [1 P~3H\ androstenedione, 60 pM 
and l|iM  and lpM NADPH in the absence or presence of inhibitor.
7.1.3 Stability studies o f synthetic sulphamates 
Method A  (by HPLC)
An 1-2 mg sample of sulphamate was dissolved in 1 ml of HPLC grade methanol and 
lOOpl of this methanolic solution was then diluted with 900pl of phosphate buffer 
saline (PBS, freshly prepared by dissolving one tablet of phosphate buffer saline in 
100 ml distilled water) pre-incubated at 37°C. The resulting mixture, being kept in a 
water-bath at 37°C throughout the experiment, immediately analysed (t = 0 min) and 
then at 5, 10, 20, 30, 60 and 120 min after the first injection (the injection interval may 
be varied, depending upon the rate of degradation of sulphamate). Mobile phase used 
was 90%, 70%, 30% and 10% (methanol/water). But in recent studies low 
concentration of methanol was used in the mobile phase (10%) to minimise the 
possibility of degradation of sulphamates by methanol. The flow rate was 1 ml/min. 
To select the optimum wavelength of absorptions by different sulphamates, the UV 
spectrum of each test compound between 200-350 nm was determined. The tanax 
selected for EMATE-type compounds was 270 nm. As the concentration of the 
sample is not known accurately, sensitivity on the integrator or recorder was adjusted 
by trial and error.
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Method B (by UV fo r  benzophenone 4,4'-OfO-bis-sulphamate)
An 1-2 mg of sulphamate was dissolved in 1 ml of HPLC grade methanol. Of this 
methanolic solution, 10|il and lOOjxl were diluted with 990jal and 900|il of phosphate 
buffer saline (PBS, prepared as in method A) pre-incubated at 37°C respectively. To 
select the optimum wavelength of absorptions, the UV spectrum of the test compound 
was obtained and it was found that the benzophenone 4,4'-0,<9-bis-sulphamate (36) 
absorbed strongly between 330-400nm. The mixtures, being kept in a water-bath at 
37°C throughout the experiment and the measurement of the absorptions (results from 
sulphamate degrdation) were made at intervals from 0 - 8  h for both concentrations. 
Blanks were prepared containing 1% or 10% methanolic solution in PBS without the 
sample. The decomposition percentage vs. time was plotted. As the amount of the 
sample is not known accurately, sensitivity on the integrator or recorder is adjusted by 
trial and error.
7.1,4 Preparation ofsulphamoyl chloride
Sulphamoyl chloride was prepared by the reaction of chlorosulphonyl isocyanate with 
formic acid according to the method of Appel and Berger. 199 To anhydrous sulphur- 
free toluene (150 ml) chlorosulphonyl isocyanate (25 g., 177 mmol) was added at 0°C 
under an atmosphere of N2 . After stirring, formic acid (6.0 ml, 156 mmol) was added 
dropwise at 0 °C under N2 . The resulting white light emulsion was kept stirring 
overnight and the toluene removed by using a water vacuum pump to give a light 
yellow crude of sulphamoyl chloride (16.24 g, 79%). A standard solution (ca 0.70 M) 
of sulphamoyl chloride was then prepared by dissolving the crude crystalline product 
in anhydrous sulphur-impurities-free toluene and stored in the refrigerator under N2 . 
No titration was attempted on this sulphamoyl chloride solution whose molarity was 
estimated according to the weight of the original crude sulphamoyl chloride obtained 
after workup. Toluene used for preparing sulphamoyl chloride solution was purified 
according to the method described.272 Cold toluene (1-3 litres) was placed in a 
separating funnel and washed with cold conc. H2SO4 (100 ml/litres, 3-4 times), once 
with water, once with aqueous 5% NaOH and again with water until neutral, dried 
with anhydrous MgSCU followed by sodium metal overnight and then fractionally 
distilled under N2 from the sodium metal and stored in dark under N2 .
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Anhydrous formic acid used for preparing sulphamoyl chloride was purified according
979the method described. Formic acid (98%) was stirred overnight with boric 
anhydride and then distilled under N2 , stored in dark under N2 .
7.1.5 General method fo r  sulphamoylation
Starting with the parent compound, the sulphamate derivatives were prepared 
essentially as previously described,157 unless stated otherwise, In this regard, a 
solution of the appropriate parent compound in anhydrous DMF was treated with 
sodium hydride [60% dispersion; 1.2 and 2.5 equiv. for monohydroxyl and dihydroxyl 
compounds respectively, unless stated otherwise] at 0°C under an atmosphere of N2 . 
After evolution of hydrogen had ceased, sulphamoyl chloride in toluene [excess, ca. 5- 
6 eq.] was added and the reaction mixture was poured into brine after warming to 
room temperature overnight and ethyl acetate was added. The organic fraction was 
washed exhaustively with brine, dried (MgS0 4 ), filtered and evaporated under reduced 
pressure. The crude product obtained was purified by flash chromatography or 
preparative TLC followed by recrystallisation to give the corresponding sulphamate. 
All the compounds were characterised by spectroscopic and combustion analysis.
7.1.6 X-ray crystallography
The X-ray crystallographic study of oestrone oxime 161 was carried out by Dr Mary 
Mahon in the Dept, of Chemistry, University of Bath. Full details are given in 
Appendix 2.
7.2 Synthesis o f  sulphamates
7.2.1. Synthesis offlavonoid sulphamates 
5-Hydroxyflavone 7-O-sulphamate (1)
Upon sulphamoylation, 5,7-dihydroxyflavone (1.0 g, 3.933 mmol) gave crude product 
(1.13g) which was fractionated by flash chromatography (chloroform/acetone, 8:1). 
The yellow residue that was obtained (324 mg, 24%) was further purified by 
recrystallisation from ethyl acetate/hexane (1:1) to give 1 as yellow crystals (213 mg, 
16%); mp 195-200 °C (dec.); TLC (chloroform/acetone, 12:1, 8:1 and 4:1): R/s 0.21, 
0.25 and 0.44 respectively; vmax (KBr) 3360 (NH2), 1650 (C=0), 1380 (-SO2-) cm.'1;
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8h (270 MHz, acetone-c^) 6.75, 6.98 and 7.17 (3H, three s, C-3-H, C-6-H and C-8-H), 
7.63 (2H, br s, exchanged with D20 ,-0 S 0 2NH2), 7.65 (3H, m, C-3'-H, C-4'-H and C- 
5'-H), 8.15 (2H, d, / =  7.7 Hz, C-2'-Hjind C-6'-H) and 13.0 (1H, br s, exchanged with 
D20 , C-5-OH); MS m/z (FAB+) 334.1 [100, (M+H)+], 255.0 [25, (M+2H-S02NH2)+]; 
MS m/z (FAB-) 484.1 [14, (M+NBA)'], 332.1 [100, (M-H)"], 253.1 [50, (M- 
S 0 2NH2)+]; A cc. MS (FAB+) 334.0392, Ci5Hi2N 06S requires 334.0385. Found C, 
54.0; H, 3.39; N, 4.21; Ci5H nN 06S requires C, 54.03; H, 3.33; N, 4.20%.
5-Hydroxy-7-methoxy flavone-6-O-sulphamate (2)
Upon sulphamoylation, 5,6-dihydroxy-7-methoxyflavone (500 mg, 1.760 mmol) gave 
a crude product (680 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The yellow residue that was obtained (463 mg, 72%) was 
further purified by recrystallization from acetone/hexane (1:2) to give 2 as yellow 
crystals (347 mg, 54%); mp 209-212°C; TLC (chloroform/acetone, 8:1, 4:1 and 2:1): 
Rfi 0.13, 0.33 and 0.65 respectively; vmax (KBr) 3380 (NH2), 3200 (OH), 1720 (C=0 
), 1380 (-SO2-), c m 1; Sh (270 MHz, DMSO-d6) 3.95 (3H, s, OCHj), 7.06 (1H, s, C-3- 
H or C-8-H), 7.11 (1H, s, C-8-H or C-3-H), 7.6 (3H, m, C-3'-H, C-4'-H and C-5'-H), 
7.84 (2H, s, exchanged withD20 , -OSO2NH2), 8.13 (2H, d, J = 7.0 Hz, C-2'-H and C- 
6'-H) and 13.06 (1H, s, C-5-OH); MS m/z (FAB+) 364.0 [100, (M+H)+], 284.1 [40, 
(M+H-S02NH2)+]; A cc. MS (FAB+) 364.0511 Ci6H 14N0 7 S requires 364.0491. 
Found C, 52.5; H, 3.68; N, 3.66; Ci6Hi3N 07S requires C, 52.89; H, 3.61; N, 3.85%.
5-Hydroxy-7-methoxyflavone-4 '-O-sulphamate (3)
Upon sulphamoylation, 4',5-dihydroxy-7-methoxyflavone (75 mg, 263.8 pmol) gave a 
crude product (112 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The yellow residue that was obtained (77 mg, 80%) was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 3 as yellow 
crystals (55 mg, 57%); mp 189-192°C; TLC (chloroform/ acetone, 8:1 and 4:1): Rys 
0.16 and 0.26 respectively; vmax (KBr) 3500 (NH2), 3300 (OH), 1660 (C=0), 1380 
(S02) cm'1; 5h (270 MHz, acetone-de) 3.94 (1H, s, C-7 -OCH3), 6.36 (1H, d, J  = 2.5 
Hz, C-6-H or C-8-H), 6.73 (1H, d, J  = 2.2 Hz, C-8-H or C-6-H), 6.84 (1H, s, C-3-H) 
7.35 (2H, br s, exchanged with D20 , -S02NH2), 7.54 (2H, d, J = 8.8 Hz, C-3'-H and
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C-5'-H or C-2'-H and C-6 '-H), 8.18 (2H, d, J  = 8 . 8  Hz, C-2'-H and C-6 '-H or C-3'-H 
and C-5'-H) and 12.81 (1H, s, C-5-OH); MS m/z (FAB+) 364.0 [100, (M+H)+], 285.1 
[15, (M-S02NH2)+]; MS m/z (FAB-) 361.9 [95, (M-H) ], 283.0 [100,(M-S02NH2)']; 
Acc. MS (FAB+) 364.0500 Ci6H14N 07S requires 364.0491.
5-Hydroxy 4',6,7-Trimethoxyflavone -3'-0-sulphamate (4)
Upon sulphamoylation, 3/,5-dihydroxy-4',6,7-trimethoxyflavone (75 mg, 217.8 jimol) 
gave a crude product (103 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow residue that was obtained (58 mg, 65%) was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 4 as yellow 
crystals (32 mg, 36%); mp 197-199°C; TLC (chloroform/acetone, 4:1 and 2:1): R/s 
0.175 and 0.44 respectively; vmax (KBr) 3360 (NH2), 3260 (OH), 1620 (C=0), 1370 
(S0 2) cm'1; 8 h [270 MHz, DMSO-de/ CDC13, (ca 1:5)] 3.88 (3H, s, OCH3), 3.95-3.986 
(6 H, 2 x s, 2 x OCH3), 6 . 6 6  (1H, s, C-3-H or C-8 -H), 6.71 (1H, s, C-8 -H or C-3-H), 
7.16 (1H, d, J  = 8 . 8  Hz, C-5'-H or C-6 -H), 7.63 (2H, s, exchanged with D20,- 
0 S0 2NH2), 7.86 (1H, d, J  = 8 . 8  Hz, C-5'-H or C-6 '-H), 7.97 (1H, d, J = 2.2 Hz, C-2'- 
H) and 12.74 (1H, s, C-5-OH); MS m/z (FAB+) 424.1 [100, (M+H)+], 344.1 [10, 
(M+H-S02NH2)+]; MS m/z (FAB-) 422.1 [100, (M-H)'], 344.1 [20, (M+H-S02NH2)']; 
Acc. MS m/z (FAB+) 424.0714 Ci8H18N 09S requires 424.0702. Found C, 51.1; H, 
3.38; N, 4.33; Ci8Hi7N 09S requires C, 51.06; H, 3.31; N, 4.05%.
4',5,6,7-Tetramethoxyflavone -3'-0-sulphamate (5)
Upon sulphamoylation, 3'-hydroxy-4/,5,6,7-tetramethoxyflavone (75 mg, 210 jxmol) 
gave a crude product (96 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow residue that was obtained (59 mg, 6 6 %) was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 5 as yellow 
crystals (35 mg, 39%); mp 138-141°C; TLC (chloroform/acetone, 8:1, 4:1 and 2:1): 
R/S 0.10, 0.27 and 0.59 respectively; vmax (KBr) 3420 (NH2), 1640 (C=0), 1380 
(S02) cm'1; 6h (270 MHz, acetone-d6) 3.93 (12H, m, 4x OCH3), 6.55 (1H, s, C-3-H or 
C-8 -H) 7.13 (1H, s, C-3-H or C-8 -H), 7.23 (2H, br s, exchanged with D20 , - 
0 S0 2NH2) 7.24 (1H, d,J=  8.4 Hz, C-5'-H) and 7.93 (2H, m, C-2'-H and C-6 '-H); MS 
m/z (FAB+) 437.9 [100, (M+H)+], 359.0 [10, (M+H-SQ2NH)+]; MS m/z (FAB-) 436.0
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[100, (M-H)+], 357.0 [10, (M-H-S02NH2)*]; Acc. MS (FAB+) 438.0866 Ci9H2oN09S 
requires 438.0859.
Flavone-3',4'-0,0-bis-sulphamate (6)
Upopn sulphamoylation, 3',4'-dihydroxyflavone (450 mg, 1.717 mmol) gave a crude 
product (763 mg) which was fractionated by flash chromatography (ethyl 
acetate/acetone/hexane, 2:1:1). The residue that was obtained (376 mg, 53%) was 
further purified by recrystallization from acetone/hexane ( 1 :2 ) to give 6  as white 
crystals (173 mg, 25%); mp 170-172°C; TLC (ethyl acetate/acetone, 2:1 and ethyl 
acetate/acetone/hexane, 2:1:1): R/s 0.7 and 0.51 respectively; vmax (KBr) 3240 (NH2), 
1630 (C=0), 1390 (S02) cm 1; 8 h [270 MHz, DMSO-cy CDC13 (ca 1:3)] 6.91 (1H, s, 
C-3-H), 7.47-7.8 (5H, m, Ar-H), 7.97 (4H, br s, exchanged with D20 , C-3 '-0 S0 2NH2 
and C-4 '-OS0 2NH2), and 8.15 (2H, d, J = 7.7 Hz, Ar-H); MS m/z (FAB+) 413.1 [100, 
(M+H)+], 334.1 [20, (M+2H-S02NH2)+], 254.1 [20, (M+H-2 x S 0 2NH2)+]; MS m/z 
(FAB-) 411.0 [100, (M-H)'], 332.1 [35, (M-S02NH2)'], 253.1 [40, (M+H-2 x 
S 0 2NH2)']; A c c . MS 413.0120 Ci5Hi3N20 8S2 requires 413.0113.
5-Hydroxyflavone-47-0,0-bis-sulphamate (7)
Upon sulphamoylation, 4',5,7-trihydroxyflavone (72 mg, 258.4 pmol) gave a crude 
product (117 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 2:1). The yellow residue that was obtained (70 mg, 63%) was 
further purified by recrystallization from acetone/chloroform (1:2) to give 7 as yellow 
crystals (45 mg, 32%); mp > 198°C (dec.); TLC (chloroform/acetone, 4:1 and 2:1): R/S 
0.083 and 0.385 respectively; vmax (KBr) 3380 (NH2), 3260 (OH), 1650 (C=0), 1390 
(S02) cm’1; 6 h  (270 MHz, DMSO-cU) 6.76 (1H, s, C-3-H), 7.23 (2 H, d, J  = 2.4 Hz, C-
6 -H and C-8 -H), 7.5 (2H, d, J  = 8.4 Hz, Ar-H of B-ring), 8.27 (2H, d, J = 9 .1 Hz, Ar- 
H of B-ring), 8.38 (4H, br s, exchanged with D20 , C^-OSO^NH? and CT-OSOoNH?) 
and 12.87 (1H, s, C-5-OH); MS m/z (FAB+) 428.7 [80, (M+H)+], 349.8 [25, (M+2H- 
S 0 2NH2)+], 270.9 [25, (M+2H-2x S 0 2NH2)+]; MS m/z (FAB-) 426.7 [80, (M-H)’],
347.8 [80, (M-S02NH2)-], 268.9 [50, (M+H-2xS02NH2)']; Acc. MS (FAB+) 429.0057 
Ci5Hi3N20 9S2 requires 429.0062.
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5-Hydroxyflavone-3,7-0,0-bis-sulphamate (8)
Upon sulphamoylation, 3,5,7-trihydroxyflavone (75 mg, 269.2 pmol) gave a crude 
product (0.123 g) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow residue was obtained (58 mg, 54%) was further 
purified by recrystallization from ethyl acetate/hexane ( 1 :2 ) to give 8  as yellow 
crystals (31 mg, 28%); mp 171-173°C; TLC (chloroform/acetone, 4:1 and 2:1): R/S 
0.26 and 0.54 respectively; vmax (KBr) 3360 (NH2), 3260 (OH), 1660 (C=0), 1390 
(S02) c m 1; 8 h  (270 MHz, acetone-d«) 6.81 (1H, d, 7 = 2.2 Hz, C-6 -H or C-8 -H), 7.21 
(1H, d, / =  2.2 Hz, C-8 -H or C-6 -H), 7.31 (2H, br s, exchanged with D20 , OSO9NH7), 
7.54 (2H, br s, exchanged with DzO, -OSC^NHz), 7.64 (3H, m, Ar-H of B-ring), 8.14 
(2H, m, Ar-H of B-ring) and 12.29 (1H, s, C-5-OH); MS m/z (FAB+) 428.9 [100, 
(M+H)+], 348.9 [50, (M+H-S02NH2)+], 270.0 [25, (M+2H-2xS02NH2)+]; MS m/z 
(FAB-) 426.9 [85, (M-H)'], 347.9 [100, (M-S02NH2)'], 269.0 [80, (M+H-2xS02NH2)' 
]. Acc. MS: m/z 429.0086 CisHi3N20 9 S2 requires 429.0063. Found C, 42.11; H, 
3.06; N, 6.13; Ci5Hi2N20 9S2 requires C, 42.06; H, 2.82; N, 6.54%.
5-Hydroxy-4'-methoxyflavone-3,7-0,0-bis-sulphamate (9)
Upon sulphamoylation, 3,5,7-trihydroxy-4'-trimethoxyflavone (75 mg, 250 |Limol) 
gave a crude product (0.116 g) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow residue (54 mg, 47%) was further purified by 
recrystallization from acetone/hexane (1:2) to give 9 as yellow crystals (29 mg, 26%); 
mp > 192°C (dec.); TLC (chloroform/acetone, 4:1 and 2:1): R/S 0.19 and 0.55 
respectively; vmax (KBr) 3420 (NH2), 1620 (C=0), 1360 (S02) c m 1; 8 h (270 MHz, 
acetone-ck) 3.94 (3H, s, OCHs), 6.80 (1H, s, Ar-H), 7.14 (3H, m, Ar-H of B-ring), 
7.39 (2H, br s, exchanged with D20 , 0 S 0 2NH2), 7.50 (2H, s, exchanged with D20 , - 
0 S0 2NH2), 8.2 (2H, d, 7= 6 .7  Hz, Ar-H of B-ring) and 12.43 (1H, br s, C-5-OH); MS 
m/z (FAB+) 459.1 [100, (M+H)+], 379.1 [55, (M+H-S02NH2)+], 300.1 [15, (M+2H- 
2xS0 2NH2)']; MS m/z (FAB-) 456.2 [20,(M-2H)‘], 378.1 [100, (M-S02NH2) ], 299.1 
[70, (M+H-H-2xS02NH2)']; A c c . MS 459.0174 C16Hi5N2Oi0S2 requires 459.0168. 
Found C, 41.98; H, 3.06; N, 6.11; Ci6Hi4N 2Oi0S2 requires C, 41.92; H, 3.08; N, 
6. 11%.
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5-Hydroxy-3 ',4',5'-Trimethoxyflavone-3,7-0,0-bis-sulphamate (10) and 5,7- 
dihydroxy-3',4',5'-trimethoxyflavone-3-O-sulphamate (11)
Upon sulphamoylation, S.SJ-trihydroxy-S'^'^'-trimethoxyflavone (200 mg, 558.4 
jimol) gave a crude product (231 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow residue that was obtained (108 mg, 39%) was 
further purified by recrystallization from acetone/hexane ( 1 :2 ) to give 1 0  as yellow 
crystals (69 mg, 25%); mp 124-126 °C; TLC (chloroform/acetone, 4:1 and 2:1): R/S 
0.19 and 0.53 respectively; vmax (KBr) 3360 (NH2), 3260 (OH), 1660 (C=0), 1430 
(S 02) c m 1; 8 h [270 MHz, DMSO-d*,/ CDC13, (ca 1:3)] 3.91 (3H, s, OCH3), 3.95 (6 H, 
s, 2xOCH3), 6.83 (1H, d, / =  1.8 Hz, Ar-H of A-ring), 7.12 (1H, d, J=  2.2 Hz, Ar-H of 
A-ring), 7.39 (2H, s, C-2'-H and C-6 '-H), 7.72 (2H, s, exchanged with D20 , 
0 S0 2NH2), 8.06 (2H, s, exchanged with D20 , 0 S0 2NH2) and 12.2 (1H, s, C-5-OH); 
MS m/z (FAB+) 519.1 [100, (M+H)+], 439.1 [60, (M+H-S02NH2)+], 360.1 [10, 
(M+2H-2xS02NH2)"]; MS m/z (FAB-) 517.1 [85,(M-H)'], 438.1 [100, (M-S02NH2)'],
359.1 [80, (M+H-2xS02NH2)']; Acc. MS 519.0387 Ci8H 19N2Oi2S2 requires 519.0379.
The less polar fraction gave a yellow residue (53 mg, 22%) which was further purified 
by recrystallization from ethyl acetate/hexane (1 :2 ) to give 1 1  as yellow crystals (26 
mg, 11%); mp 189-192°C; TLC (chloroform/acetone, 8:1, 4:1 and 2:1): R/s 0.10, 0.32 
and 0.62 respectively; vmax (KBr) 3500 (NH2), 1660 (C=0), 1390 (S02) cm'1; 8 h 
[270 MHz, DMSO-de/ CDC13, 1:1) 3.84 (3H, s, OCIh \  3.91 (6 H, s, 2 x 0 0 ^ ) ,  6.27 
(1H, s, Ar-H), 6.51 (1H, s, Ar-H), 7.33 (2H, s, C-2'-H and C-6 '-H), 7.84 (2H, br s, 
exchanged with D20 , -OSOzNH^, 10.8 (1H, s, C-7-OH) and 12.43 (1H, s, C-5-OH); 
MS m/z (FAB+) 440.1 [100, (M+H)+], 360.1 [80, (M+H-S02NH2)+]; MS m/z (FAB-)
438.1 [100, (M-H)'], 359.1 [80, (M-S02NH2)']; Acc. MS 440.0633 Ci8Hi8NOi0S 
requires 440.0651.
3',4',5'-Trimethoxyflavone-3,7-0,0-bis-sulphamate (12) and 7-hydroxy-3 ',4\5'- 
trimethoxyflavone-3-O-sulphamate (13)
Upon sulphamoylation, SJ-dihydroxy-S'^'^'-trimethoxyflavone (200 mg, 563.4 
pmol) gave a crude product (285 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow residue that obtained (212 mg, 75%) was 
further purified by recrystallization from acetone/hexane ( 1 :2 ) to give 1 2  as light
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yellow crystals (123 mg, 44%); mp 182-184 °C; TLC (chloroform/acetone, 4:1 and 
2:1): R/s 0.14 and 0.21 respectively; vmax (KBr) 3480 (NH2), 1610 (C=0), 1420 
(SO2) cm'1; 8 h  (270 MHz, acetone-d6) 3.85 (3H, s, OCH3), 3.94 (6 H, s, 2 xOCH3), 7.48 
(3H, m, C-6 -H, C-2/-H and C-6 '-H), 7.69 (4H, br s, exchanged with D20 , 2x- 
0 S0 2NH2), 7.79 (1H, s, C-8 -H) and 8.27 (1H, d, / =  8.3 Hz, C-5-H); MS m/z (FAB+)
502.9 [100, (M+H)+], 423.0 [60, (M+H-S02NH2)+], 344.1[10, (M+2H-2xS02NH2)+]; 
MS m/z (FAB-) 501.0 [100, (M-H)’], 422.0 [80, (M-S02NH2) ], 343.0 [75, (M+H- 
2xS02NH2) ]; A c c . MS 503.0444 Ci8Hi9N20 n S 2 requires 503.0430.
The less polar fraction gave 13 as light yellow residue (12  mg); m.p 159-162  °C; TLC 
(chloroform/acetone, 4:1 and 2:1): R/s 0.23 and 0 .5 0  respectively; vmax (KBr) 3 5 0 0  
(NH2), 3 2 5 0  (OH), 1620 (C=0 ), 1420 (S02) cm'1; MS m/z (FAB+) 4 2 4 .0  [100 , 
(M+H)+], 3 4 4 .0  [70, (M+H-S02NH2)+]; MS m/z (FAB-) 4 2 2 .0  [100 , (M-H)'], 3 4 3 .0  
[70, (M-S02NH2)']; A cc MS m/z (FAB+) 4 2 4 .0 7 0 2  CigH igNO sS requires 424 .0 7 0 3 .
5,7,-Dihydroxyflavone 6-O-sulphamate (14)
Upon sulphamolyation, 5,6,7-trihydroxyflavone (400 mg, 1.480 mmol) gave a crude 
product (495 mg) which was fractionated by flash chromatography 
(chloroform/acetone gradient). The yellow residue was obtained (350 mg) was further 
purified by recrystallization from acetone/hexane (1:2) to give 14 as yellow crystals 
(273 mg, 53%); mp 196-198 °C; TLC (chloroform/acetone, 8:1,4:1 and 2:1): R/s 0.15, 
0.26 and 0.34 respectively; vmax (KBr) 3500-2500 (NH2 and OH), 1670 (C=0), 1380 
(S02) cm'1; 8 h (400 MHz, DMSO-dg) 6.69 (1H, s, C-3-H), 7.04 (1H, s, C-8 -H), 7.63 
(3H, m, C-3'-H, C-4'-H and C-5'-H), 7.76 (2H, br s, exchanged with D20 , -SC^NHz)
10.03 (1H, br s, C-7-OH) and 13.3 (1H, br s, C-5-OH); MS m/z (FAB+) 349.9 [100, 
(M)+], 269.9 [50, (M-S02NH2)+]; MS m/z (FAB-) 501 [10, (M-H-NBA) ], 348.[100, 
(M-H) ], 269.0 [50, (M-S02NH2) ]; Acc. MS (FAB+) 350.03219 Ci5Hi2N 07S requires 
350.03344. Found C, 51.9; H, 3.21; N, 3.86; Ci5Hn N0 7S requires C, 51.58; H, 3.17; 
N, 4.01%.
Flavone-4'-6-0,0-bissulphamate (15)
Upon sulphamoylation, 4'-6-dihydroxyflavone (500 mg, 1.967 mmol) gave a crude 
product (730 mg) which was fractionated by flash chromatography
164
(chloroform/acetone gradient). The yellow residue that was obtained (510 mg) was 
further purified by recrystallization from acetone/hexane (1:2) gave 15 as a yellow 
crystals (365 mg, 45%); mp > 162°C (dec); TLC (chloroform/acetone, 8:1): R / 0.2; 
vmax (KBr) 3300 (-NH2), 1630 (C=0), 1370 (-S02N-) cm’1; 6h (400 MHz, DMSO-d6)
7.12 (1H, s, C-3-H), 7.5 (2H, dd, JC-t-h, c -3" -h =  8 . 8  Hz, C-3'-H and C-5'-H), 7.72 (1H, 
dd, 7 C-5-h, C-7-H = 2.7 Hz and 7 C-8-h, c -7-h = 9.2 Hz, C-7-H), 7.93 (2H, m, C-5-H and C-8 - 
H), 8.18 (4H, 2 br s, exchanged with D20 , 2 x-S0 2NH2), and 8.25 (2H, d, J  = 8.5 Hz, 
C-2'-H and C-6 '-H); MS m/z (FAB+) 412.9 [100, (M+H)+], 329.9 [25, (M-H- 
S 0 2NH2)], 305.9 (20), 305.9 (15), 287.9 (20), 271.9 (25), 257.0 (20), 243.0 (30); MS 
m/z (FAB-) 410.9 [100, (M-H)’], 331.9 [85, (M-H-S02NH2)], 292.0 (25), 276.0 (25),
258.0 (30), 215.0 (30); Acc. mass (FAB+) 413.0104 requires Ci5Hi3N20 8S2 413.0113. 
Found C, 43.17; H, 2.85; N, 6.53 requires Ci5Hi2N20 8S2 C, 43.69; H, 2.93; N, 6.79%.
Flavone 4'-0-sulphamate (16)
Upon sulphamolyation, 4'-hydroxyflavone (500 mg, 2.09 mmol) gave a crude product 
(640 mg) which was fractionated by flash chromatography (chloroform/acetone 
gradient). The pale white residue was obtained (593 mg) was further purified by 
recrystallization from acetone/hexane (1:2) to give 16 as white crystals (445 mg, 
67%); mp 218-220 °C; TLC (chloroform/acetone, 8:1): Rf  0.2; vmax (KBr) 3360 
(NH2), 1620 (C=0), 1390 (S02) cm'1; 5h (270 MHz, DMSO-d*) 7.1 (1H, s, C-3-H),
7.5 (3H, m, C-8 -H, C-3'-H and C-5'-H), 7.83 (2H, m, C-6 -H and C-7-H), 8.08 (1H, 
dd, 7 C-7-h, c-5-H = 2 .1  Hz and 7 C-6-h, c-s-h  = 7.7 Hz, C-5-H) and 8.25 (4H, m, 2H 
exchanged with D20 , -S0 2NH2 and C-2'-H and C-6 '-H); MS m/z (FAB+) 317.9 [100, 
(M)+], 238.9 [15, (M+H-S02NH2)+], 173.0 (10); MS m/z (FAB-) 470.0 [25, (M-NBA)' 
], 316.0 [100, (M-H)'], 237.0 [55, (M-S02NH2)']; Acc. MS (FAB+) 318.0445 
Ci5Hi2N 0 5S requires 318.0436. Found C, 56.9; H, 3.4; N, 4.23; C15H11NO5S requires 
C, 56.78; H, 3.49; N, 4.41%.
Flavone-7-methane sulphonate (17)
To a stirred solution of 7-hydroxyflavone (lOOmg, 42 pmmol) in anhydrous pyridine 
(3 ml) at 0 °C under N2, methane sulphonyl chloride (0.2 ml, 2.584 mmol) was added 
dropwise Subseqeuently, the reaction mixture was allowed to warm to room 
temperature and stirred was continued overnight. The reaction mixture was then
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poured into an ice-water (20 ml) and extracted with ethyl acetate (5x 20 ml). The 
combined organic extracts were dried over anhydrous MgSC>4 , filtered and the solvent 
was removed under reduced pressure. Final traces of pyridine were removed by 
repeating co-evaporation with toulene. The crude product was precipitated by 
methanol to give a yellow solid ( 1 1 0  mg), which recrystallized from methanol to give 
compound 17 as pale yellow crystals (90 mg, 6 8 %); mp 169-170°C (lit. 160°C)273; 
TLC (chloroform/acetone, 8:1): R/0.61; vmax (KBr) 1630 (C=0) cm'1; 8 h  (400 MHz, 
CDC13) 3.26 (3H, s, OSO2CH3), 6.85 (1 H, s, C-3-H), 7.33 (1H, dd, 7 C-8-h, c-6-h = 2.4 
Hz and 7 C-5-h, c-6-h =  8 . 8  Hz, C-6 -H), 7.55 (3H, m, C-3'-H, C-4'-H and C-5'-H), 7.6 
(1H, d, «/ic-6-H , C -8-H  = 2.1 Hz, C-8 -H), 7.95 (2H, dd, Jc.3' - h ,  c -2'-h =  7.8 Hz and 7 C-4'-h, c -2'- 
h  = 2.8 Hz, C-2'-H and C-6 '-H) and 8.3 (1H, d, 7 C-6-h, c -5-h = 8 . 8  Hz, C-5-H); MS m/z 
(FAB+) 317.1 [90, (M+H)+], 281.1 (15), 147 (50), 72.9 (100); Acc. MS (FAB+) 
317.0514 C 16H12O5S requires 317.0484.
p-Naphthoflavone-4'-O-sulphamate (18)
Upon sulphamoylation, 4'-hydroxy /?-naphthoflavone (200 mg, 693.7 fimol) gave a 
crude product ( 2 2 0  mg) which was fractionated by flash chromatography 
(chloroform/acetone gradient). The pale white residue that was obtained (186 mg) was 
further purified by recrystallization from acetone/hexane ( 1 :2 ) to give 18 as white 
crystals (150 mg, 59%); mp 245-247 °C; TLC (chloroform/acetone, 8:1): R / 0.25; 
vmax (KBr) 3300 (NH2), 1630 (C=0), 1380 (S02) cm'1; 8 h  (270 MHz, DMSO-de) 
7.26 (1 H, s, C-3-H), 7.5 (2 H, d ,J  = 8 . 8  Hz, C-3'-H and C-5'-H), 7.7 (1 H, t, 7 = 7.5 Hz, 
C-7-H or C-8 -H) 7.81 (1H, t, J  = 7.3 Hz, C-7-H or C-8 -H), 7.92 (1H, d ,J=  8.9 Hz, C- 
10-H or C-ll-H), 8.12 (1H, d, J  = 7.9 Hz, C -ll-H  or C-10-H), 8.23 (2H, br s, 
exchanged with D20 , -SO2NH2), 8.3 (2H, d, J  = 8 . 6  Hz, C-2'-H and C-6 '-H), 8.4 (1H, 
d, J  = 9.2 Hz, C-9-H) and 9.96 (1H, d, J  = 8 . 6  Hz, C-9-H); MS m/z (FAB+) 367.9 
[100, (M)4], 349.0 (30), 330.0 (70), 319.0 (25), 305.0 (40) 287.0 [55, (M-S02NH2)+],
272.0 (70), 257.1 (80), 243.0 (75); MS m/z (FAB-) 366.0 [100, (M-H)-], 349.0 (55),
328.0 (50), 317.0 (45), 292.1 (45), 276.0 (75), 258.0 (70), 243.0 (25); Acc. MS m/z 
368.0584 Ci9H 14N 0 5S requires 368.0592. Found C, 61.9; H, 3.45; N, 3.63; 
C 19H 13NO5S requires C, 62.12; H, 3.57; N, 3.81%.
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5-Hydroxy-4'-methoxyisoflavone 7-0-sulphamate (19)
Upon sulphamoylation, 5,7-dihydroxy-4'-methoxyisoflavone (800 mg, 2.817 mmol) 
gave crude product (650 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The yellow residue that was obtained (266 mg, 26%) was 
further purified by recrystallization from ethyl acetate/hexane (1:1) to give 19 as 
yellow crystals (211 mg); mp 184-188 °C; TLC (chloroform/acetone, 8:1 and 4:1): Rf  
0.22 and 0.59 respectively; vmax (KBr) 3300 (NH2), 1660 (C=0), 1400 (S02) cm'1; 
8 h (270 MHz, acetone-de) 3.86 (3H, s, OCH,), 6.75 (1H, d, J  = 2.2 Hz, C-6 -H or C-8 - 
H), 7.04 (3H, m, C-6 -H or C-8 -H, and Ar-H of B-ring), 7.49 (2H, br s, exchanged with 
D20 , OSO2NH2), 7.58 (2H, d, J  = 7.0 Hz, Ar-H of B-ring), 8.41 (1H, s, C-2-H), 13.05 
(1H, br s, C-5-OH); MS m/z (FAB+) 364.0 [100, (M+H)+], 284.1 [12, (M+H- 
S 0 2NH2)+]; MS m/z (FAB-) 515.1 [12, (M-H+NBA)'], 362.1 [100, (M-H)'], 283.1 
[70, (M-S02NH2)']; A cc . MS (FAB+) 364.0494 C 16H 14NO7S requires 364.0491. 
Found: C, 52.8; H, 3.65; N, 3.81; Ci6Hi3N 07S requires C, 52.89; H, 3.61; N, 3.85%.
5-Hydroxyisoflavone-4\7-OyO-bis-sulphamate (20) and 5,7-dihydroxyisoflavone- 4 -
O-sulphamate (21)
Upon sulphamoylation, 4',5,7-trihydroxyisoflavone (500 mg, 1.85 mmol) gave a crude 
product (650 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The light yellow residue that was obtained (329 mg, 42%) 
was further purified by recrystallization from ethylacetate/hexane ( 1 :2 ) to give 2 0  as 
beige crystals (197 mg, 25%); mp > 198 °C (dec.); TLC (chloroform/acetone, 4:1 and 
2:1): R/s 0.14 and 0.24 respectively; vmax (KBr) 3460 (NH2), 1650 (C=0), 1400 
(S02) cm'1; 8 h (270 MHz, acetone-de) 6.78 (1H, d, J  =2.2 Hz, C-6 -H or C-8 -H), 7.03 
(1 H, d, J  = 2.2 Hz, C-8 -H or C-6 -H), 7.4 (4H, br s, exchanged with D20 , 
2 x0 S0 2NH2), 7.43 (2H, d, /  = 8.4 Hz, Ar-H of B-ring), 7.72 (2H, d, J  = 8.4 Hz, Ar-H 
of B-ring), 8.51 (1H, s, C-2-H) and 12.93 (1H, s, C-5-OH); MS m/z (FAB+) 428.9 
[100, (M+H)+], 350.0 [20, (M+2H-S02NH2)+], 272.1 (30); MS m/z (FAB-) 426.9 
[100, (M-H)'], 347.9 [95, (M-S02NH2)'], 269.0 [30, (M+H-2xS02NH2)']; Acc. MS 
m/z (FAB+) 429.0083 Ci5Hi3N20 9S2 requires 429.0063. Found C, 42.0; H, 2.91; N, 
6.45; Ci5Hi2N20 9S2 requires C, 42.06; H, 2.82; N, 6.54%.
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The less polar fraction gave 21 as light yellow residue (112 mg, 17%) which was 
further purified by recrystallization from ethyl acetate/hexane (1:3) to give 21 as pale 
white crystals ( 6 8  mg, 10%); mp 189-192 °C; TLC (chloroform/acetone, 4:1 and 2:1) 
R/s 0.23 and 0.33 respectively; vmax (KBr) 3500-3300 (NH2), 3200 (OH), 1680 
(C=0), 1610, 1400 (SO2) cm 1; 8h (270 MHz, acetone-ds) 6.32 (1H, d, J=  2.2Hz, C-6 - 
H or C-8 -H), 6.46 (1H, d, .7 = 2 . 2  Hz, C-8 -H or C-6 -H), 7.32 (2H, br s, exchanged with 
D20 ,- SO2NH2), 7.42 (2H, d, J  = 8.4 Hz, Ar-H of B-ring), 7.69 (2H, d, J  = 8.4 Hz, Ar­
i l  of B-ring) 8.31 (1H, s, C-2-H), 9.53 (1H, s, C-7-OH) and 12.9 (1H, s, C-5-OH); MS 
m/z (FAB+) 350.0 [100, (M+H)*], 271.1 [15, (M+2H-S02NH2)+]; MS m/z (FAB-)
347.9 [100, (M-H)'], 269.0 [20, (M-S02NH2)']; Acc. MS (FAB+) 350.0347 
C 15H 12NO7S requires 350.0335. Found C, 51.0; H, 3.16; N, 3.90; C15H 11NO7 S 
requires C, 51.58; H, 3.17; N, 4.01%.
Iso flavone-47-0,O-bis-sulphamate (22)
Upon sulphamoylation, 4',7-dihydroxyisoflavone (450 mg, 1.717 mmol) gave a crude 
product (769 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The pale white residue (553 mg, 70%) was further purified 
by recrystallization from acetone/hexane (1:2) to give 22 as white crystals (327 mg, 
41%); mp > 195 °C (dec.); TLC (chloroform/acetone, 4:1 and 2:1): R/s 0.21 and 0.40 
respectively; vmax (KBr) 3400 (NH2), 1640 (C=0), 1360 (S02) cm'1; 8 h (270 MHz, 
DMSO-de) 7.37 (2H, d, J  = 8 . 8  Hz, Ar-H of B-ring), 7.42 (1H, dd, 7 C-8-h, c-6-h = 2.2 
Hz, / c - 5-h, C-6-H = 8 . 8  Hz, C-6 -H), 7.7 (2H, d, J  = 8 . 8  Hz, Ar-H of B-ring), 8.09 (2H, br 
s, exchanged with D20 , 0 S0 2NH2), 8.24 (1 H, d, J = 8 . 8  Hz, C-5-H), 8.36 (2H, br s, 
exchanged with D20 , OSC^NH^ and 8.63 (lH,s, C-2-H); MS m/z (FAB+) 412.9 [100, 
(M+H)+], 334.0 [25, (M+2H-S02NH2)+], 255.1 (20); MS m/z (FAB-) 410.9 [100, (M- 
H)'], 332.0 [70, (M-S02NH2) ], 253.0 [30, (M+H-2xS02NH2)']; Acc. MS m/z (FAB+) 
413.0119 Ci5Hi3N20 8S2 requires 413.0113. Found C, 44.0; H, 2.94; N, 6.62; 
Ci5Hi2N20 8S2 requires C, 43.69; H, 2.93; N, 6.79%.
(±) 5,7-Dihydroxyflavanone 4'-0-sulphamate (23)
Upon sulphamoylation, 4',5,7-trihydroxyflavanone (1.0 g, 3.675 mmol) gave crude 
product (965 mg) which was fractionated by flash chromatography 
(chloroform/acetone gradient). The pale yellow oil obtained (345 mg, 27%), solidified
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on standing, was subsequently further purified by recrystallisation from ethyl 
acetate/hexane (1:1) gave 23 as white crystals (259 mg, 20%); mp 211-213 °C; TLC 
(chloroform/acetone, 4:1) R/0.21; vmax (KBr) 3420 (NH2), 3260 (OH), 1640 (C=0), 
1380 (S0 2N) cm 1; 5h (400 MHz, acetone-de) 2.84 (1H, dd, Ab = 17.4 Hz and 7ax,eq =
3.1 Hz, C -3-H b), 3.19 (1H, dd, JBA= 16.9 Hz and /„ ,» =  12.8 Hz, C-3-HA), 5.62 (1H, 
dd, /ax.eq = 3.1 Hz and J^  = 12.8 Hz, C-2-H), 5.9 (1H, d, /  = 2.0 Hz, C-6 -fLor C-8 - 
H), 6.01 (1H, d, J = 2.0 Hz, C-6 -H or C-8 -H), 7.20 (2H, br s, exchanged with D20 , - 
0 S0 2NH2), 7.40 (2H, d, J = 8.7 Hz, Ar-H of B-ring), 7.66 (2H, d, J  = 8.7 Hz, Ar-H of 
B-ring), 9.65 (1H, br s, C-7-OH) and 12.15 (1H, s, C-5-OH); MS m/z (FAB+) 352.0 
[100, (M+H)+], 272.1 [14, (M+H-S02NH2)+]; MS m/z (FAB-) 504.1 [20, (M+NBA)'],
350.1 [100, (M-H)’], 271.1 [45, (M-S02NH2)’]; Acc. MS (FAB+) 352.0496 
C 15H 14NO7S requires 352.0491. Found C, 51.1; H, 3.68; N, 3.98; C 15H 13NO7S 
requires C, 51.28; H, 3.73; N, 3.99%.
(±) 5-Hydroxy 4 -methoxyflavanone-3', 7-0, O-bis-sulphamate (24)
Upon sulphamoylation, 4'-methoxy-3',5,7-trihydroxyflavanone (1.0 g, 3.308 mmol) 
'gave a crude product (1.672 g) which was fractionated by flash chromatography 
(chloroform/acetone, 2:1). The yellow residue that was obtained (715 mg, 47%) was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 24 as 
yellow crystals (513 mg); mp 186-188 °C; TLC (chloroform/acetone, 4:1 and 2:1): Rf  
0.13 and 0.35 respectively; vmax (KBr) 3380 (NH2), 3280 (OH), 1640 (C=0), 1390 
(S02) cm'1; 8 h  (270 MHz, acetone-d6) 2.92 (1H, m, C-3-Ha), 3.36 (1H, m, C-3-Hb), 
3.91 (3H, s, OCHj), 5.68 (1H, dd, 7ax,ax = 12.8 Hz, and = 3.2 Hz, C-2-H), 6.47 
(2H, d, 7c-6-h , c-8-H = 2.8 Hz, C-6 -H and C-8 -H), 7.07 (2H, br s, exchanged with D20 , - 
0 S0 2NH2), 7.24 (1H, d, 7 C-5'-h, c-6'-h = 8.4 Hz, C-5'-H), 7.50 (2H, br s, exchanged with 
D20 , -OS0 2NH2), 7.55 ( 1 H, dd, JC-5'_h. c-6'-h = 8.4 Hz, Jc.r-n. c-6'-h = 2.2 Hz, C-6 '-H), 
7.75 (1H, d, Jc.2'-H, c-6"-H = 2.2 Hz, C-2'-H) and 12.02 (1H, s, C-5-OH); MS m/z 
(FAB+) 460.9 [100, (M+H)+], 381.9 [20, (M+2H-S02NH2)+], 303.0 (25); MS m/z 
(FAB-) 458.9 [100, (M-H)’], 379.9 [20, (M-S02NH2)’], 301.0 [20, (M+H-2xS02NH2)’ 
]; Acc. MS (FAB+) 461.0337 Ci6Hi7N2OioS2 requires 416.0325.
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(±) 4'y7-Dihydroxy isoflavane (Equol) (25)
A suspension of Pd-C (10%, 2.2 g) was stirred under air in glacial acetic acid (15 ml) 
for three days before adding to a solution of 4',7-dihydroxyisoflavone (500 mg, 1.906 
mmol) in diglyme (60 ml). After 30 min.of catalytic hydrogenation at balloon 
pressure, the reaction mixture was filtered and the residue was washed with diglyme 
and hot acetic acid. The combined filtrates were evaporated and the crude obtained 
was dissolved in ethyl acetate, washed with 5% aqueous sodium bicarbonate (100 ml), 
water, dried (MgSCU), filtred and evaporeted to give a pale white crude (385 mg) 
which was recrystallized from aqueous ethanol (90%) to give 25 as white crystals (361 
mg, 81%); mp 156-158 °C (lit. 158 °C);200 TLC (chloroform/acetone, 8:1 and 4:1): R/s 
0.53 and 0.36 respectively; vmax (KBr) 3380-2720 cm'1; 8 h  (400 MHz, acetone-d6, 
cosy) 2.89 (2H, m, C-4 -H2), 3.1 (1H, m, C-3-H), 3.94 (1H, t, J = 10.4 Hz, C-2-Ha), 
4.18 (1H, m, C-2-He), 6.29 (1H, d, Jc.6 -h, c-8-h = 2.4 Hz, C-8-H), 6.37 (1H, dd, Jc.7-h, 
C-6-H = 8.2 Hz, JC-8-H , c-6-H = 2.4 Hz, C-6-H), 6.82 (2H, dd, Jc-2'-h, c -3'-h=  8.6 Hz, Jc-s', c- 
3'-H = 2.7 Hz,C-3'-H and C-5'-H or C-2'-H and C-6'-H), 6.89 (1H, d, 7 C-6-h, c -5-h = 8.2 
Hz, C-5-H), 7.16 (2H, dd, 7 C-5'-h. c -2'-h = 8.2 Hz, 7 C-6'-h. c -2'-h = 2.7 Hz, C-2'-H and C- 
6'-H or C-3'-H and C-5'-H), 8.15 (1H, br s, C-7-OH or C-4'-OH) and 828 (1H, br s, C- 
4'-OH or C-7-OH); 6C (400 MHz, acetone-d6, cosy) 32.64 (t, C-4), 38.77 (d, C-3), 
71.56 (t, C-2), 103.64 (d, C-8), 108.83 (d, C-6), 114.04 (s), 116.28 (d, C-3' and C-5'), 
129.24 (d, C-2' and C-6'), 133.39 (s, C-l'), 155.96 (s), 157.19 (d, C-7 or C-4') and 
157.55 (d, C-4' or C-7); MS m/z (FAB+) 242.1 [100, (M)+], 213.1 (5), 185.1 (5), 177.1 
(10), 167.1 (25), 152.1 (30), 135.0 (40), 123.0 (45), 105.0 (35), 95.0 (30), 78.9 (30),
68.9 (35), 56.9 (55); MS m/z (FAB-) 393.2 [55, (M-H+NBA)'], 241.2 [100, (M-H)-],
227.1 (10), 215.1 (15), 198.1 (30), 181.1 (20), 162.1 (10), 139.1 (40), 124.1 (20),
106.0 (25), 92.0 (25) and 62.0 (10); Acc. MS (FAB+) 243.1001 C 15H 15O3 requires 
243.1021. Found C, 74.3; H, 5.77; C15H14O3 requires C, 74.36; H, 5.82%.
(+) Isoflavane-4',7-0,O-bis-sulphamate (26)
Upon sulphamoylation, 25 (150 mg, 619.8 jimol) gave crude product (254 mg) which 
was fractionated by flash chromatography (chloroform/acetone gradient). The brown 
residue that was obtained (96 mg, 38%) was further purified by recrystallisation from 
acetone/hexane (1:2) to give 26 as light brown crystals (61 mg, 24%); mp > 120 °C
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(dec.); TLC (chloroform/acetone, 4:1 and 2:1): R/s 0.22 and 0.34 respectively; vmax 
(KBr) 3160 (NH2), 1380 (S02) cm'1; 8 h  (400 MHz, acetone-ds) 3.1 (2H, m, C-4-Jfc),
3.13 (1H, m, C-3-H), 4.12 (1H, t, J  = 10.4 Hz, C-2-Ha), 4.35 (1H, dd, J, = 3.1 Hz and 
J2= 10.7 Hz C-2 -Heq), 6.78 (1H, d, 7C-6-h, c -8 - h  = 2.4 Hz, C-8 -H), 6.84 (1H, dd, J C - 7 - h , c -
6-h = 8.4 Hz, Jc-8-h, C-6-H = 2.4 Hz, C-6 -H), 7.13 (4H, br s, exchanged with D2O, 
2 XOSO2NH2), 7.18 (1H, d, /c-6-H ,c-5-H = 8 . 2  Hz, C-5-H), 7.32 (2H, m, Ar-H of B-ring), 
7.44 (2H, m, Ar-H of B-ring); MS m/z (FAB+) 400.0 [100, (M)+], 321.1 [40, (M+H- 
S 0 2NH2)+], 243.2 (25); MS m/z (FAB-) 553.0 [15, (M+NBA)'], 399.0 [100, (M-H)'],
96.0 (10), 77.9 (20); Acc. MS (FAB+) 400.0405 C 15H 16N2O7S2 requires 400.0399. 
Found: C, 44.6; H, 4.0; N, 6.54; C15H16N2O7S2 requires C, 44.99; H, 4.03; N, 7.0%.
7.2.2 Synthesis o f other non-steroidal sulphamates
6-Methoxycoumarin-7-O-sulphamate (27)
Upon sulphamoylation, 7-hydroxy-6-methoxycoumarin (70 mg, 364.3 pmol) gave a 
yellow residue (109 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The pale yellow residue that was obtained (78 mg) was 
further purified by recrystallization from acetone/hexane (1:2) to give 27 as beige 
crystals (59 mg, 63%); mp 174-176 °C; TLC (chloroform/acetone, 4:1 and 2:1): R/s 
0.23 and 0.31 respectively; vmax (KBr) 3340-3200 (NH2), 1710 (C=0), 1390 (S02) 
c m 1; §h (270 MHz, acetone-d«) 3.92 (3H, s, OCH3), 6.43 (1H, d, J  = 9.7 Hz, C-3-H), 
7.31 (2H, br s, exchanged with D20 , OS02NH2), 7.36 (1H, s, C-8 -H), 7.44 (1H, s, C-
5-H) and 7.98 (1H, d, J  = 9.7 Hz, C-4-H); MS m/z (FAB+) 271.9 [100, (M+H)+],
191.9 [20, (M-S02NH)+]; MS m/z (FAB-) 269.8 [100, (M-H)'], 255.8 (5), 190.9 
[40,(M-SO2NH2)']; Ac MS (FAB+) 272.0225 Ci0HioN06S requires 272.0229. Found 
C, 44.5; H, 3.36; N, 5.07; C 10H,NO6S requires C, 44.28; H, 3.34; N, 5.16%.
4-Methylcoumarin-6,7-0,O-bis-sulphamate (28) and 4-methyl-7-hydroxycoumarin-
6-O-sulphamate (29)
Upon sulphamoylation, 4-methyl-6,7-dihydroxycoumarin (500 mg, 2.550 mmol) gave 
a yellow crude product. A 120 mg sample of the crude material (330 mg) was 
fractionated by fractionating on preparative TLC (ethyl acetate/acetone/hexane, 2:1:1). 
The band at Rf  0.74 gave a beige residue (36 mg) which was further purified by
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recrystallization from ethyl acetate/hexane (1:2) to give 28 as white crystals (24 mg, 
7%); mp 169-172 °C; vmax (KBr) 3420-3220 (NH2), 1670 (C=0), 1400 (S 02) cm 1; 
8 h  (400 MHz, DMSO-ds) 2.44 (3H, s, C-4-CH,), 6.5 (1H, s, C-3-H); 7.55 (1H, s, C-8 - 
H), 7.81 (1H, s, C-5-H), 8.21 (2H, s, exchanged withD20 , 0SO 2NH2),and 8.4 (2H, s, 
exchanged with D20 , 0 S 0 2NH2); MS m/z (FAB+) 350.9 [100, (M+H)+], 272.0 [30, 
(M+H-S02NH)+]; MS m/z (FAB-) 348.9 [100, (M-H)'], 269.9 [40, M -S0 2NH2)']
191.0 [30, M-H-2xS02NH)']; Acc. MS (FAB+) 350.9960 CioHuN20 8S2 requires 
350.9957. Found C, 34.6; H, 2.91; N, 7.69; Ci0H 1()N2O8S2 requires C, 34.29; H, 2.88; 
N, 8.0%.
The band at R/ 0.62 gave a white residue (73 mg) which was further purified by 
recrystallization from acetone/hexane (1:2) to give 29 as white crystals (60 mg, 24%); 
mp 203-205 °C; vmax (KBr) 3400-3280 (NH2 and OH), 1670 (0=0), 1390 (S02) cm’ 
'; 8 h (400 MHz, DMSO-ds) 2.37 (3H, s, C-4-CHj), 6.22 (1H, s, C-3-H), 6.89 (1H, s, 
C-8 -H), 7.6 (1H, s, C-5-H), -8.0 (2H, br s, exchanged with D20 , OSO9NH7) and -  11 
(1H, very br s, OH); MS m/z (FAB+) 272.1 [100, (M+H)+], 255.2 (60), 193.2 [35, 
(M+H-S02NH)+]; MS m/z (FAB-) 270.0 [100, (M-H)*], 191.1 (30, M -S02NH2)*]; Acc. 
MS m/z (FAB+) 272.0233 Ci0Hi0NO6S requires 272.0229. Found C, 43.8; H, 3.37; N, 
5.11; Ci0H9NO6S requires C, 44.28; H, 3.34; N, 5.16%.
5-Hydroxy-l-indanone (30)
To a suspension of aluminium chloride (2.09 g, 15.21 mmol) in anhydrous toluene 
(60ml) 5-methoxy-l-indanone (1.0 g, 6.166 mmol) was added. The brown/green 
mixture that formed was refluxed, under N2 for 30 minutes, cooled and cautiously 
quenched with water. The resulting mixture was then extracted into ethyl acetate (150 
ml). The organic portion that separated was washed with water, dried (MgSC>4), 
filtered and evaporated to give an orange brown residue (903 mg) which was 
recrystallized from acetone/hexane (1:5) to yield 30 as yellow/brown crystals (787 mg, 
5.312 mmol, 8 6 %); mp 182-185 °C (lit. 183°C);274 TLC (ethyl acetate/hexane, 1:1 and 
2:1) R/s 0.26 and 0.54 respectively; vmax (KBr) 3360 (OH), 1670 (C=0), 1590 cm"1; 
8 h (270 MHz, acetone-cL) 2.55 (2H, m, C-3 -H2) 3.04 (2H, t, J  -  6.0 Hz, C-2 -H2), 6.89 
(2H, m, C-4-H and C-6-H), 7.53 (1H, d, /  = 8.1 Hz, C-7-H), 9.37 (1H, br s, exchanged 
with D20 , C-5-OH); MS m/z (FAB+) 149.1 [100, (M+H)+]; MS m/z (FAB-) 147.1
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[100, (M-H)']; Acc. MS (FAB+) 149.0588 C9H90 2 requires 149.0603. Found C, 72.40 
; H, 5.46; C9H80 2 requires C, 72.96; H, 5.44%.
l-Indanone-5-O-sulphamate (31)
Upon sulphamoylation, 5-hydroxy-1-Indanone (250 mg, 1.687 mmol) gave a crude 
product (397 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The yellow brownish residue that was obtained (162 mg) 
was further purified by recrystallization from acetone/hexane (1:2) to give 31 as beige 
crystals (121 mg, 31%); mp 174-176 °C; TLC (chloroform/ acetone, 4:1 and 2:1): R/s 
0.25 and 0.56 respectively, vmax (KBr) 3300-3200 (NH2), 1660 (C=0), 1400 (S02) 
c m 1; 8h (270 MHz, acetone-ds) 2.68 (2H, t, J ~ 6.0 Hz, C-3 -H2), 3.19 (2H, t, J ~ 5.9 
Hz, C-2 -H2), 7.36 (3H, m, 2H exchanged with D20 , OS02NH2, and C-6-H), 7.51 (1H, 
s, C-4-H) and 7.71 (1H, d, 7 = 8 .4  Hz, C-7-H); MS m/z (FAB+) 228.1 [100, (M+H)+],
148.1 [10, (M-S02NH2)+]; MS m/z (FAB-) 226.1 [100, (M-H) ], 147.1 [20, (M- 
S 0 2NH2)']; A c c . MS (FAB+) 228.0327 C9H 10NO4 S requires 228.0331. Found C, 47.8; 
H, 4.04; N, 6.12; C9H9NO4 S requires C, 47.57; H, 3.99; N, 6.16%.
1-Indanone 4-O-sulphamate (32)
Upon sulphamoylation, 4-hydroxy-1-Indanone (500 mg, 3.375 mmole) gave a crude 
product (560 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The brown residue that was obtained (159 mg) was further 
purified by recrystallization from ethyl acetate/hexane (1:3) to give 32 as 
brown/yellow crystals (80 mg, 11%); mp 193-196 °C; TLC (choroform/acetone, 8:1, 
4:1 and 2:1): R/s 0.11, 0.32 and 0.37 respectively: vmax (KBr) 3420-3200 (NH2), 
1620 (C=0), 1400 (S02) cm'1; 5H (270 MHz, acetone-de) 2.67 (2H, m, C-3 -H2), 3.25 
(2H, t, /  ~ 5.9 Hz, C-2-Ifc), 7.39 (2H, br s, exchanged with D20 , 0 S 0 2NH2), 7.52
(1H, t, J  = 7.7 Hz, C-6 -H), 7.64 (2H, m, C-5-H and C-7-H); MS m/z (FAB+) 228.1 
[100, (M+H)+]; MS m/z (FAB-) 380.0 [20,(M+NBA)“], 226.0 [100, (M-H)“]; Acc. MS 
(FAB+) 228.0312 C9HioN04S requires 228.0331.
l-Indanone-6-O-sulphamate (33)
Upon sulphamoylation, 6 -hydroxy-1-indanone (545 mg, 3.683 mmol) gave a crude 
product (763 mg) which was fractionated by flash chromatography
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(chloroform/acetone, 4:1). The yellow residue that was obtained (521 mg) was further 
purified by recrystallization from acetone/hexane (1:2) to give 33 as yellow crystals 
(315 mg, 37%); mp 155-157 °C; TLC (chloroform/ acetone, 4:1 and 2:1): R/s 0.32 and 
0.45 respectively; vmax (KBr) 3320-3220 (NH2), 1690 (C=0), 1400 (S02) cm '1; 8 h 
(270 MHz, acetone-d«) 2.71 (2H, m, C-3-fch), 3.19 (2H, t, J ~ 5.9 Hz, C-2-Hz), 7.26 
(2H, br s, exchanged with D2O, OSO2NH2), 7.57 (2H, m, C-5-H and C-7-H) and 7.67 
(1H, d, J  = 9.2 Hz, C-4-H); MS m/z (FAB+) 381.0 [20, (M+H+NBA)*] 228.0 [100, 
(M+H)+], 148.0 [15, (M+H-S02NH2)+]; MS m/z (FAB-) 379.9 [25, (M+NBA)'] 225.9 
[100, (M-H)'], 146.9 [8 , (M-S02NH2)']; Acc. MS (FAB+) 228.0336 C9H10NO4 S 
required 228.0335. Found C, 47.7; H, 3.99; N, 6.12; C9H9NO4 S requires C, 47.57; H, 
3.99; N, 6.16%.
7-Hydroxy-l-tetralone (34)
7-Methoxy-l-tetralone (4.0 g, 22.7 mmol) was added at room temperature to a 
suspension of aluminum chloride (7.65 g, 57.37 mmol) in anhydrous toluene (100ml). 
The brown/green reaction mixture was heated under reflux for 30 minutes, cooled and 
cautiously quenched with water. The resulting mixture was extracted with ethyl 
acetate (200 ml). The organic portion that separated was washed with water, dried 
(MgSC>4), filtered and evaporated to give an orange brown residue (3.71 g) which was 
recrystallized from acetone/hexane (1:5) to give 34 as white crystals (3.49 g, 21.52 
mmol, 95%); mp 165-167 °C (lit. 165-166°C);275 TLC (ethyl acetate/hexane, 1:1 and 
2:1): R/s 0.58 and 0.69 respectively; vmax (KBr) 3500-3200 (OH), 1630 (C=0), 1590 
cm'1; 8 h (270 MHz, acetone-d6) 2.07 (2H, m, C-3 -H2), 2.55 (2H, t, J  ~ 6.5 Hz, C-4- 
H2), 2.87 (2H, t , J =  5.9 Hz, C-2 -H2), 7.02 (1H, dd, 7 C-8-h, c-6-h = 2.9 Hz and J C-s-h, c-6- 
h =  8.2 Hz , C-6 -H), 7.17 (1H, d, 7 C-6-h ,c -5-h = 8.1 Hz, C-5-H), 7.39 (1H, d, 7 C-5-h-c-8-h  
= 2.6 Hz, C-8 -H) and 8.55 (1H, br s, exchanged with D2O, OH); MS m/z (FAB+)
163.1 [100, (M+H/J; MS m/z (FAB-) 161.1 [100,(M-H)']. Found C, 73.9; H, 6.15; 
C10H 10O2 requires C, 74.06; H, 6.21%.
l-Tetralone-7-O-sulphamate (35)
Upon sulphamoylation, 7-hydroxy-l-tetralone (1.0 g, 6.164 mmol) gave a crude 
product (1.51 g) which was fractionated by flash chromatography 
(chloroform/acetone, 4:1). The beige residue that was obtained (764 mg) was further
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purified by recrystallization from acetone/hexane (1:1) to give 35 as beige crystals 
(433 mg, 29%); mp 150-152 °C, TLC (chloroform/acetone, 4:1 and 2:1): R/s 0.6 and 
0.63 respectively; vmax (KBr) 3500-3200 (NH2), 1670 (C=0), 1390 (S02) cm'1; 8 h 
(270 MHz, acetone-d6) 2.16 (2H, m, C-3-lk), 2.63 (2H, t, /  ~ 6.5 Hz, C-4 -H2), 3.02 
(2H, t, J -  6.0, C-2-HA 7.21 (2H, br s, exchanged with D20 , 0 S 0 2NH2), 7.45 (2H, m, 
„C-5-H and C-6 -H) and 7.84 (1H, d, J  ~ 1 Hz, C-8 -H); MS m/z (FAB+) 242.2 [100, 
(M+H)+]; MS m/z (FAB-) 240.1 [100,(M-H)']. Found C, 49.9; H, 4.60; N, 5.85; 
C 10H 11NO4S requires C, 49.78; H, 4.60; N, 5.81%.
Benzophenone-4,4'-0,O-bis-sulphamate (36) and azomethine derivative (37)
Upon sulphamoylation, 4,4'-dihydroxybenzophenone (1.0 g, 4.668 mmol) gave a 
crude product (1.63 g) which was fractionated by flash chromatography 
(chloroform/acetone gradient). The band at Rf  0.46 (chloroform/acetone, 2:1) that 
collected gave a creamy residue (1.17 g) which was further purified by 
recrystallization from acetone/chloroform (1:2) to give 36 as white crystals (730 mg, 
43%); mp 182-184 °C; vmax (KBr) 3340 (NH2), 1660 (C=0), 1370 (S02) c m 1; 8 h 
(270 MHz, acetone-d6) 7.36 (4H, br s, exchanged with D20 , 2 XOSO7NH7), 7.51 (4H, 
d, J  = 8 . 8  Hz, C-3-H, C-3'-H, C-5-H and C-5'-H) and 7.9 (4H, d, J  = 8.4 Hz, C-2-H, 
C-2'-H, C-6 -H and C-6 '-H); MS m/z (FAB+) 372.9 [100, (M+H)+], 293.0 [30, (M+H- 
S 0 2NH2)+], 213.1 [ 10,(M+H-2xSO2NH2)+]; MS m/z (FAB-) 370.9 [100, (M-H)'],
291.9 [82, (M-S02NH2)-], 213.0 [20, (M+H-2xS02NH2)']; Acc. MS (FAB+) 373.0177 
Ci3Hi3N20 7S2 requires 373.0164. Found C, 41.9; H, 3.24; N, 7.50; Ci3H12N20 7S2 
requires C, 41.93; H, 3.25; N, 7.52%.
The band at R/0.57 (chloroform/acetone, 2:1) that collected gave a beige residue (183 
mg) which was further purified by recrystallization from acetone/hexane ( 1 :2 ) to give 
37 as white crystals (130 mg, 7%); mp 158-160 °C; vmax (KBr) 3340-3240 (NH2), 
1650 (C=0), 1370 (S02) cm 1; 6 H (270 MHz, acetone-c^) 3.09 (3H, s, -N-CHg), 3.3 
(3H, s, -N-CIfc), 7.36 (2H, br s, exchanged with D20 , OSO/NHz), 7.48 (2H, d, J  =
8.79 Hz, C-3-H and C-5-H or C-3'-H and C-5'-H), 7.52 (2H, d, /  = 8 . 8  Hz, C-3-H and 
C-5-H or C-3'-H and C-5'-H) 7.82 (2H, d, 7= 8 . 8  Hz, C-2-H and C-6 -H or C-2'-H and 
C-6 '-H), 7.84 (2H, d, J=  8 . 8  Hz, C-2-H and C-6 -H or C-2'-H and C-6 '-H,) and 8.14 
(1H, s, S 0 2N=CH-); MS m/z (FAB+) 427.9 [100, (M+H)+], 349.0 [20, (M+H-
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S 0 2NH)+], 294.1 [1 0 , (M+2H-S02N=CH-N(Me)2)+]; MS m/z (FAB-) 425.9 [1 0 0 , (M- 
H)'], 347.0 [40, (M-S02NH2) ], 293.0 [10, (M+H-S 0 2N=CH-N(Me)2)']; Acc. MS 
(FAB+) 428.0582 Ci6Hi8N3 0 7S2 requires 428.0586.
4 -Hydroxybenzophenone-4- O-sulphamate (38)
Upon sulphamoylation using 1 eq. of NaH, 4,4'-dihydroxybenzophenone (300 mg, 
1.400 mmol) gave a crude product (420 mg) of which 100 mg was fractionated on 
preparative TLC (chloroform/acetone gradient). The white residue that was isolated 
(46 mg) was further purified by recrystallization from ethyl acetate/hexane (1:2) to 
give 38 as white crystals (32 mg, 32%); mp > 152 °C (dec.); TLC 
(chloroform/acetone, 4:1 and 2:1): R/s 0.27 and 0.41 respectively; vmax (KBr) 3500- 
3000 (NH2 and OH), 1630 (C=0), 1590, 1380 (S02) c m 1, 8 h (270 MHz, acetone-d6)
7.0 (2H, d, J  = 8 . 8  Hz, C-3'-H, and C-5'-H), 7.3 (2H, br s, exchanged with D20 , 
0 S0 2NH2), 7.48 (2H, d, J  = 8.4 Hz, C-3-H, and C-5-H), 7.77 (2H, d, J = 8.4 Hz, C-2- 
H and C-2'-H or C-6 -H and C-6 '-H), 7.8 (2H, d, /  = 8.42 Hz, C-2-H and C-2'-H or C-
6 -H and C-6 '-H) and 8.1 (1H, br s, exchanged with D20 , C-4'-OH); MS m/z (FAB+)
447.1 [10, (M+H+NBA)+], 294.0 [100, (M+H)+], 215.1 [10, (M+H-S02NH)+]; MS 
m/z (FAB-) 446.1 [20, (M+NBA)'], 292.1 [100, (M-H)'], 213.1 [30, (M-S02NH2)']. 
Found C, 53.1; H, 3.9; N, 4.55; Ci3H nN 05S requires C, 53.24; H, 3.78; N, 4.78%.
Benzophenone-4-O-sulphamate (39)
Upon sulphamoylation, 4-hydroxybenzophenone (1.0 g, 5.045 mmol) gave a crude 
product (1.45 g) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The creamy residue that was isolated (716 mg) was further 
purified by recrystallization from ethyl acetate/hexane (1:2) to give 39 as white 
crystals (495 mg, 35%); mp 134-136 °C; TLC (chloroform/acetone, 4:1 and 8:1): R/s 
0.68 and 0.35 respectively; vmax (KBr) 3360 (NH2), 1390 (S02) cm'1; 5h (270 MHz 
acetone-de) 7.35 (2H, br s, exchanged with D20 , SCbNH?), 7.5 (2H, d, J  = 8 . 8  Hz, C- 
3-H and C-5-H), 7.55-7.75 (3H, m, C-3'-H, C-4'-H and C-5'-H), 7.84 (2H, m, C-2'-H 
and C-6 '-H), 7.88 (2H, d, J  = 8 . 8  Hz, C-2-H and C-6 -H); MS m/z (FAB+) 278.0 [100, 
(M+H)+], 198.0 [10, (M+H-S02NH2)+]; MS m/z (FAB-) 430.0 [15, (M+NBA)"], 276.0 
[100, (M-H)-], 197.0 [25, (M-SQ2NH2)“]; Acc. MS m/z (FAB+) 278.0503
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Ci3Hi2N 04S 278.0487 requires. Found C, 56.1; H, 4.01; N, 5.12; C 13H 11NO4S 
requires C, 56.31; H, 4.0; N, 5.05%.
Chalcone-4-O-sulphamate (40)
Upon sulphamoylation, 4-hydroxychalcone (1.0 g, 4.46 mmol) gave a crude product 
(1.44g) which was fractionated by flash chromatography (chloroform/acetone, 8:1). 
The creamy residue that was obtained (719 mg) was further purified by 
recrystallization from ethyl acetate/hexane (1:2) to give 40 as white crystals (464 mg, 
34%); mp 136-138 °C; TLC (choroform/acetone, 8:1, 4:1 and 2:1): R/s 0.24, 0.48 and 
0.66 respectively; vmax (KBr) 3500-3220 (NH2), 1670 (C=0), 1390 (S02) cm"1; 5h 
(270 MHz, acetone-d6) 7.27 (2H, s, exchanged with D2O, OSO2NH2), 7.42 (2H, d, /  =
8.79 Hz, C-3-H and C-5-H), 7.62 (2H, m, C-3'-H, C-4'-H and C-5'-H), 7.85 (2H, d, J  
= 14.7 Hz, CH=CH), 7.95 (5H, d, J  = 6.2 Hz, C-2-H and C-6 -H) and 8.18 (2H, d, /  =
7.7 Hz, C-2'-H and C-6 '-H); MS m/z (FAB+) 304.0 [100, (M+H)+], 224.1 [10, (M+H-
S 0 2NH2)+]; MS m/z (FAB-) 302.0 [100, (M-H)-], 223.0 [40, (M-S02NH2)*]; Acc. MS 
(FAB+) 304.0646 C 15H 14NO4S requires 304.0644. Found C, 59.1; H, 4.29; N, 4.64 
C15H 13NO4S requires C, 59.40; H, 4.32; N, 4.62 %.
Chalcone-4'-0-sulphamate (41)
Upon sulphamoylation, 4'-hydroxychalcone (1.0 g, 4.46 mmol) gave a crude product 
(1.5 g) which was fractionated by flash chromatography (chloroform/acetone, 8:1). 
The creamy residue that was obtained (723 m) was further purified by recrystallization 
from ethyl acetate/hexane (1:2) to give 41 as white crystals (425 mg, 31%); mp 187- 
189 °C; TLC (chloroform/acetone, 8:1, 4:1 and 2:1): R/s 0.17, 0.26 and 0.62 
respectively; vmax (KBr) 3340 (NH2), 1660 (C=0), 1390 (SO2) cm*1; 5h (270 MHz, 
acetone-d6) 7.34 (2H, s, exchanged with D2O, OSO2NH2), 7.49 (5H, m, C-3', 5', 3, 4 
and C-5-H), 7.88 (4H, m, CH=CH and C-2-H, C-6 -H), 8.25 (2H, d, J  = 8 . 8  Hz, C-2'-H 
and C-6 '-H); MS m/z (FAB+) 304.0 [100, (M+H)+], 225.1 [10, (M+2H-S02NH2)+];
MS m/z (FAB-) 302.0 [100, (M-H)"], 223.1 [35, (M-S02NH2)-]; Acc. MS (FAB+) 
304.0654 C15H14NO4S requires 304.0644. Found C, 59.1; H, 4.29; N, 4.65; 
C15H 13NO4S requires C, 59.40; H, 4.32; N, 4.62%.
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Dibenzofuran-2-O-sulpharnate (42)
Upon sulphamoylation, 2-hydroxydibenzofuran (1.0 g, 5.429 mmol) gave a crude 
product (1.31 g) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The beige residue that was obtained (561 mg) was further 
purified by recrystallization from ethyl acetate/hexane (1:2) to give 42 as white 
crystals (319 mg, 23%); mp > 120 °C (dec.); TLC (chloroform/acetone, 8:1, 4:1 and 
2:1): R/s 0.31, 0.55 and 0.70 respectively; vmax (KBr) 3400 (NH2), 1600 (C=0), 1370 
(S 02) cm'1; 8 h (270 MHz, acetone-cL) 7.18 (2H, br s, exchanged with D20 , SO7NH7), 
7.46 (2H, m, C-4-H and C-5-H), 7.56 (1H, t, J  = 7.7 Hz, C-7-H), 7.7 (2H, t, /  = 7.3 
Hz, C-3-H_and C-6 -H), 8.07 ( 1H, d, J= 2.2 Hz, C-l-H) and 8.16 ( 1H, d, J= 7.7 Hz 
,C-8 -H); MS m/z (FAB+) 417.0 [13, (M+H+NBA)*], 263.1 [100, (M)+], 183.1 [60, (
M -S0 2NH2)+]; MS m/z (FAB-) 416.0 [15, (M+NBA)"], 262.0 [100, (M-H)-]. Found 
C, 54.6 ; H, 3.46; N, 5.22; Ci2H9N 04S requires C, 54.75; H, 3.42; N, 5.32%.
4,4 '-Dihydroxydiphenylmethane (43)
To a solution of 4,4'-dihydroxybenzophenone (1.0 g, 4.668 mmol) in ethanol (25 ml) 
Pd-C (10%, 200 mg) was added and the resulting suspension was subjected to 
hydrogenation at balloon pressure at room temperature for 6  h. Upon removal of the 
supported catalyst was removed by filtration, the filtrate was evaporated to give a 
white residue ( 1 . 0 2  g) which was recrystallized from ethyl acetate/hexane ( 1 :2 ) to give 
43 as white crystals (854 mg, 91%); mp 158-160 °C (lit. 161-162 °C) ; 206 TLC 
(chloroform/acetone, 8:1 and 4:1): R/s 0.28 and 0.63 respectively; vmax (KBr) 3500- 
3000 (OH), 1600 c m 1; 8 h (270 MHz, acetone-d6) 3.8 (2H, s, -CH2-), 6.75 (4H, m, C-
3-H, C-3'-H, C-5-H, C-5'-H), 7.03 (4H, m, C-2-H, C-2'-H, C-6 -H, C-6 '-H) and 8.1 
(2H, br s, exchanged with D20 , C-4-OH and C-4'-OH); MS m/z (FAB+) 200.1 [100, 
(M)+]; Acc. MS (FAB+) 200.0842 C13H 12O2 requires 200.0915.
4,4'-0,0-Bis-sulphamoyldiphenylmethane (44) and 4-Osulphamoyl-4'- 
hydroxydiphenylmehane (45)
Upon sulphamoylation, 43 (825 mg, 4.120 mmol) gave a beige crude product (1.3 g) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
fraction that collected with an R/0.43 (chloroform/acetone, 4:1) gave a white residue
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upon evaporation (471 mg) which was further purified by recrystallization from 
acetone/chloroform (1:2) to give 44 as white crystals (389 mg, 26%); mp 175-177 °C; 
vmax (KBr) 3500-3000 (NH2), 1390 (SO2) cm'1; 8 h (270 MHz, acetone-d6) 4.03 (2H, 
s, -CH2-), 7.10 (4H, br s, exchanged with D2O, 2xOSO?NHA 7.25 (4H, d, J=  8 . 8  Hz, 
C-2-H, C-2'-H, C-6 -H and C-6 '-H) and 7.34 (4H, d, J= 8 . 8  Hz, C-3-H, C-3'-H, C-5-H 
and C-5'-H); MS m/z (FAB+) 512.0 [40, (M+H+NBA)*], 358.0 [90, (M)+], 279.0 [50, 
(M+H-S02NH2)+]; MS m/z (FAB-) 511.1 [40, (M+NBA)+], 357.1 [100, (M-H)+],
278.0 [30, (M-S02NH2)+]. Found C, 43.5; H, 3.89; N, 7.64; CnHuOeNzSz requires C, 
43.57; H, 3.94; N,.7.82%.
The fraction that collected with an R/0.52 (CHsCl/acetone, 4:1) gave a beige residue 
(150 mg) which was recrystallized from acetone/hexane (1:2) to give 45 as white 
crystals (120 mg, 10%); mp 128-130°C; TLC (chloroform/acetone, 8:1): R/  0.27; 
vmax (KBr) 3500-3300 (NH2), 3240 (OH) 1390 (S02) cm'1; 8 H (270 MHz, acetone-d**) 
3.90 (2H, s, -CH2-), 6.77 (2H, d, 7C-2'-h, c-3'-h, 7C-6'-h, c-5'-h= 8 . 8  Hz, C-3'-H and C-5'- 
H), 7.07 (4H, d, 7c-2-h, c-3-h = 8 .1  Hz, 2H exchanged with D2O, Ar and C-4- 
OSO2NH2), 7.21 (2H, d, 7= 8 . 8  Hz, Ar), 7.28 (2H, d, J=  8 . 8  Hz, Ar) and 8.18 (1H, br 
s, exchanged with D20 , C-4'-OH); MS m/z (FAB+) 279.0 [100, (M)+], 200.1 [30, 
(M+H-S02NH2)+]; MS m/z (FAB-) 432.2 [40, (M+NBA)'], 278.1 [100, (M-H)']; Acc. 
MS (FAB+) 279.0584 C 13H13O4NS requires 279.0643. Found C, 56.0; H, 5.16; N, 
4.74; C 13H13O4NS requires C, 55.90; H, 4.69; N,.5.01%.
3,3 '-Dinitrobenzophenone (46)
To a stirred mixture of benzophenone (10 g, 54.88 mmol) in conc. sulphuric acid (55 
ml) at room temerature was added a mixture of conc. nitric acid ( 6  ml) and conc. 
sulphuric acid (14 ml). The reaction mixture was then slowly heated to 75 °C, and 
maintained at this temperature for 30 min. After cooling to room temperature, the 
reaction mixture was poured over crushed ice. The gummy mass that formed hardened 
on keeping and after being grinded into powder was washed with water until washing 
were neutral, air-dried and recrystallised from butanone (73 ml). The solid that formed 
after overnight was washed first with butanone and then with ethanol to give crude 46 
as a yellow solid (7.9 g, 53%); an analysis a sample was recrystallized from methanol 
to give 46 as pale yellow crystals; mp 144-146°C (lit. 148-149 °C) ; 207 TLC
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(chloroform/acetone, 8:1): Rf  0.8; vmax (KBr) 1670 (C=0) cm'1; 5h (270 MHz, 
CDC13) 7.78 (2H, t, J = 7.9 Hz, C-5-H and C-5'-H), 8.15 (2H, dt, / =  7.7 and ~2 Hz, 
C-4-H and C-4'-H or C-6 -H and C-6 '-H), 8.53 (2H, ddd, J=  8.2 and ~ 1-2 Hz, C-6 -H 
and C-6 '-H or C-4-H and C-4'-H) and 8.64 (2H, t, J  ~2 Hz, C-2-H and C-2'-H); MS 
m/z (FAB+) 273.0 [100, (M+H)+], 259.1 (90), 243.1 (50); MS m/z (FAB-) 425.2 [30, 
(M+NBA)'], 272.1 [100, (M)'], 257.2 (10); Acc. MS (FAB+) 273.0500 Ci3H9N20 5  
requires 273.0512. Found C, 57.1; H, 2.89; N, 10.30; C 13H8N2O5 requires C, 57.36; H, 
2.96; N, 10.29%.
3,3-Dihydroxybenzophenone (47)
A mixture of 46 (5.0 g, 18.37 mmol), tin chloride (25 g, 131.9 mmol) and 
concentrated hydrochloric acid (35 ml) was stirred at 70 °C for 6  hours. The dark 
yellow crystalline benzophenone-3,3'-diammonium chlorostannate was collected by 
filtration and suspended in concentrated hydrochloric acid (35 ml) and kept at 0 °C. 
This cold suspension was added dropwise to a cold solution (at 0°C) of sodium nitrite 
(2.56 g in 10 ml water). After the addition was completed, the suspension was stirred 
at 0 °C for an hour and then quickly filtered by means of a cold glass funnel. The 
resulting yellow precipitate (tetrazonium salt) was added (cold, 0-5°C) in small 
portions to boiling IN sulphuric acid (100 ml). The resulting red solution was treated 
with charcoal for decolourization and the suspension was filtered hot. On cooling the 
filtrate the yellow precipitate that formed was collected by filtration, washed with 
water and air-dried to give a yellow powder (1.92 g, 49%); which was recrystallized 
from acetone/hexane (1:2) to give 47 as yellow crystals (1.3 g, 33%); mp 161-163°C 
(lit. 163-164°C);207 TLC (chloroform/acetone, 8:1): R/0.63; vmax (KBr) 3500-3000 
(OH), 1630 (C=0) c m 1; 8 H (270 MHz, acetone-d6) 7.12 (2H, m, C-4-H and C-4'-H), 
7.23 (4H, m, C-6 -H, C-6 '-H, C-2-H and C-2'-H), 7.38 (2H, t, J = 8.1 Hz, C-5-H and 
C-5'-H) and 8.74 (2H, br s, exchanged with D20 , 2xOH); MS m/z (FAB+) 215.1 [100, 
(M+H)+], 199.1 (10), 185.1 (15); MS m/z (FAB-) 367.2 [40, (M+NBA)+], 213.1 [50, 
(M-H)'], 139.1 (5); Acc. MS (FAB+) 215.0715 C13H 11O3 requires 215.0708.
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Benzophenone-3,3'-0,0-bis-sulphamate (48) and 3 '-hydroxy benzophenone-3-O- 
sulphamate (49)
Upon sulphamoylation, 47 (1.0 g, 4.668 mmol) gave a dark yellow residue (1.42 g) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
brand ar Rf  0.21 (CH3Cl/acetone, 4:1) gave a yellow residue (567 mg) which was 
further purified by recrystallization from acetone/hexane (1:2) to give 48 as yellow 
crystals (310 g, 18%); mp 141-143°C; TLC (chloroform/acetone, 4:1): Rfs 0.42; vmax 
(KBr) 3360-3580 (NH2), 1650 (C=0), 1380 (S02); 8 H (270 MHz, acetone-de) 7.29 
(4H, br s, exchanged with D20 , 2xS02NH2) 7.65 (4H, m, C-5-H, C-5'-H and C-4-H, 
C-4'-H or C-6 -H, C-6 '-H) and 7.77 (4H, m, C-2-H, C-2'-H and C-6 -H, C-6 '-H or C-4- 
H, C-4'-H); MS m/z (FAB+) 373.0 [100, (M+H)+], 211.1 [20, (M-H-2xS02NH2)+]; 
MS m/z (FAB-) 371.1 [100, (M-H)]; Acc. MS (FAB+) 373.0165 Ci3Hi3N20 7S2 
requires 373.0164. Found C, 42.2; H, 3.23; N, 7.21; Ci3Hi2N2C>7S2 requires C, 41.93; 
H, 3.25; N, 7.52%.
The fraction at Rf  0.56 (CH3Cl/acetone, 2:1) gave a yellow residue (215 mg) which 
was further purified by recrystallization from ethyl acetate/hexane (1:2) to give 49 as 
yellow crystals (163 mg, 12%); mp 190-192°C; TLC (chloroform/acetone, 4:1): Rfs 
0.31; vmax (KBr) 3220-3000 (NH2 and OH), 1640 (C=0), 1400 (S02) c m 1; 8 h  (270 
MHz, acetone-d6) 6.64 (2H, br s, exchanged with D20 , C-3 -OSO9NUA 7.17 (1H, t, J  
= 7.5 Hz, C-5'-H), 7.47 (2H, m, C-2'-H and C-4'-H), 7.58 (2H, dd, 7 = 8.1 Hz, C-4-H 
and C-5-H), 7.79 (1H, d, J  = 1 3  Hz, C-6 '-H), 8.0 (1H, d, J  = 8 . 8  Hz, C-6 -H), 8.11 
(1H, s, C-2-H) and 8.87 (1H, br s, C-3-OH); MS m/z (FAB+) 447.1 [10, 
(M+H+NBA)*], 294.0 [100, (M+H)+], 214.1 [10, (M+H-S02NH2)+]; MS m/z (FAB-)
446.1 [20, (M+NBA)'], 292.0 [100, (M-H)'], 213.0 [30, (M-S02NH2)']; Acc. MS 
(FAB+) 294.0411 Ci3Hn N 05S requires 294.0436.
SulphonyIdipheny 1-4,4 '-O,O-bis-sulphamate (50)
Upon sulphamoylation, 4,4'-sulphonyldiphenol (1.0 g, 3.996 mmol) gave a brown 
residue (1.56 g). A 150 mg sample of this crude material was purified by fractionating 
on preparative TLC using chloroform/acetone gradient. The pale white residue that 
was obtained (117 mg) was further purified by recrystallization from acetone/hexane 
(1:2) to give 50 as white crystals (94 mg, 67%); mp 174-176°C; TLC
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(chloroform/acetone, 4:1 and 2:1): R/s 0.22 and 0.43 respectively; vmax (KBr) 3380- 
3240 (NH2), 1380 (SO2) cm'1; 8 h (270 MHz, acetone-d/s) 7.41 (4H, br s, exchanged 
with D20 , 2 x0 S0 2NH2) 7.57 (4H, d, J=  8 . 8  Hz, C-3-H, C-5-H, C-3'-H and C-5'-H) 
and 8.12 (4H, d, J=  8 . 8  Hz, C-2-H, C-6 -H, C-2'-H and C-6 '-H); MS m/z (FAB+)
562.1 [10, (M+H+NBA)4], 409.0 [60, (M+H)+], 330.1 [50, (M+H-S02NH)]; MS m/z 
(FAB-) 407.1 [100, (M-H)'], 328.1 [25, (M-S02NH2)'], 249.1 [25, (M+H-2xS02NH2)' 
]; Acc. MS m/z (FAB-) 406.9675 C12H 11N2O8S3 requires 406.9678. Found C, 35.4; H, 
3.0; N, 6.71; Ci2Hi2N20 8S3 requires C, 35.29; H, 2.96; N, 6 .8 6 %.
Thiodiphenyl-4,4'-OfO-bis-sulphamate (51) and 4'-hydroxy-diphenyl-4-0- 
sulphamate (52)
Upon sulphamoylation, 4,4'-thiodiphenol (760 mg, 3.482 mmol) gave a crude product 
(1.09 g) which was fractionated by flash chromatography (chloroform/acetone 
gradient). The fraction at R/0.42 (chloroform/acetone, 2:1) gave a beige residue that 
(889 mg) which was further purified by recrystallization from acetone/hexane (1:2) to 
give 51 as white crystals (665 mg, 50%); mp 142-144°C; TLC (chloroform/acetone, 
4:1): R/s 0.25; vmax (KBr) 3400-3220 (NH2), 1590, 1390 (S02) c m 1; 8 h (270 MHz, 
acetone-cU) 7.22 (4H, br s, exchanged with D20 , 2x0S 0 2NH2)i 7.34 (4H, d, J  = 8 . 8
Hz, C-3-H, C-5-H, C-3'-H and C-5'-H) 7.44 (4H, d, 7 = 6 . 6  Hz, C-2-H, C-6 -H, C-2'-H 
and C-6 '-H); MS m/z (FAB+) 530.1 [10, (M+H+NBA)] 376.0 [100, (M)+], 297.0 [40, 
(M+H-S02NH2)+]; 217.1 [20, (M+H-2xS02NH2)+]; MS m/z (FAB-) 529.2 [10, 
(M+NBA)-], 375.1 [100, (M-H)-], 296.1 [40, (M-S02NH2)]; 216.1 [10, (M- 
2S 0 2NH2)']; Acc. MS (FAB+) 376.9905 Ci2Hi3N2OsS3 requires 376.9936. Found C, 
38.8; H, 3.24; N, 7.37; Ci2Hl2N20 6S3 requires C, 38.29; H, 3.21; N, 7.44%.
The fraction at R/0.57 (chloroform/acetone, 2:1) gave a white residue (123 mg) which 
was further purified by recrystallization from ethyl acetone/hexane (1:4) to give 52 as 
white crystals (110 mg, 10%); mp 170-172 °C (dec); TLC (chloroform/acetone, 4:1): 
R/s 0.35 ; vmax (KBr) 3500-3000 (NH2 and OH), 1390 (S02) c m 1; 6 H (400 MHz, 
acetone-d6) 6.73 (2H, br s, exchanged with D2O, C-4-OSO?NH?) 6.95 (2H, d, J  = 8.5
Hz, C-3'-H and C-5'-H), 7.18 (2H, d, J = 8 . 8  Hz, C-2-H, C-6 -H or C-2'-H and C-6 '-H 
or C-3-H, C-5-H), 7.25 (2H, d, J  = 8 . 8  Hz, C-2-H, C-6 -H or C-2'-H and C-6 '-H), 7.42
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(2H, d, J  = 8.5 Hz, C-3-H, C-5-H or C-2-H, C-6 -H) and 8.97 (1H, br s, exchanged
with D20 , C-4'-OH); MS m/z (FAB+) 297.0 [100, (M)+], 217.1 [20, (M-S02NH2)+];
MS m/z (FAB-) 450.1 [20, (M+NBA)'], 296.1 [100, (M-H)']; 216.1 [20, (M-H- 
S 0 2NH2)']; A c c . MS (FAB+) 297.0129 Ci2H nN 0 4S2 requires 297.0129. Found C, 
48.2; H, 3.89; N, 4.57; Ci2H nN 0 4S2 requires C, 48.47; H, 3.73; N, 4.71%.
Anthraquinone-2,6-0,0-bis-sulphamate (53) 2-hydroxyanthraquinone-6-0-
sulphamate (54)
Upon sulphamoylation, 2,6-dihydroxyanthraquinone (1.0 g, 4.163 mmol) gave the 
crude products (1.41 g) of which a 1 0 0  mg sample was fractionated on preparative 
TLC (chloroform/acetone gradient). The fraction at R/0.39 (CHsCl/acetone, 2:1) gave 
a yellow residue (32 mg) which was further purified by recrystallization from 
acetone/hexane (1:2) to give 53 as yellow crystals (24 mg, 20%); mp > 220°C (dec); 
TLC (chloroform/acetone, 4:1): R/0.26; vmax (KBr) 3380-3260 (NH2), 1680 (C=0), 
1390 (S02) cm '1; 8h (270 MHz, acetone-d6) 7.57 (4H, br s, exchanged with D20 , 
2 x S 0 2NH2), 7.84 (2H, dd, 7c-i-h, c-3-h = 7c-5-h, c-7-h = 2.4 Hz and 7c-4-h, c-3-h = 7c-8-h, c-i- 
H = 8.4 Hz, C-3-H and C-7-H), 8.17 (2H, d, 7C-3-h. c-i-h = /c -7-h. c-s-h = 2.6 Hz, C-l-H 
and C-5-H) and 8.39 (2H, d, Jc-3-n, c-4-h = Jc-i-w, c-8-h = 8.4 Hz, C-4-H and C-8 -H); MS 
m/z (FAB+) 398.0 [40, (M)+], 240.1 [30, (M-2xS02NH)+]; MS m/z (FAB-) 551.1 [25, 
(M+NBA)'], 398.1 [100, (M)'], 239.1 [70, (M+H-2xS02NH2)']; Acc. MS m/z (FAB+) 
397.98868 C i4H i0N 2O 8S2 requires 397.98786.
The fraction at R/0.46 (CHaCl/acetone, 2:1) gave a white residue (46 mg) which was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 54 as white 
crystals (31 mg, 21%); mp > 285 °C (dec); TLC (chloroform/acetone, 4:1): Rf  0.3; 
vmax (KBr) 3500-3000 (OH, NH2), 1670 (0=0) and 1390 (S02) c m 1; 8h (270 MHz, 
acetone-d6) 7.34 (1H, dd, 7c-i-h, c-3-h = 2.57 Hz and 7c-4-h, c-3-h = 8.43 Hz, C-3-H), 7.53 
(2H, br s, exchanged with D20 , C-6 -SO?NH?), 7.65 (1H, d, 7c-3-h, c-i-h = 2.6 Hz, C-l- 
H), 7.77 (1H, dd, 7C-5-h, c-7-h= 2.4 Hz and / C-8-h, c-7-h =  8.43 Hz, C-7-H), 8.13 (1H, d, 
/c -7-h,c-5-h=  2.6 Hz, C-5-H), 8.2 (1H, d, 7C-3-h, c-4-h = 8.4 Hz, C-4-H), 8.33 (1H, d, J C-i- 
h, c-8-H  = 8.42 Hz, C-8 -H) and 9.98 (1H, s, exchanged with D20 , C-2-OH); MS m/z 
(FAB+) 320.0 [100, (M+H)+], 240.1 [30, (M+H-S02NH2)'], 225.1 (15); MS m/z 
(FAB-) 473.2 [20, (M+H+NBA)'], 318.1 [100, (M-H)'], 239.1 [90, (M-S02NH2)'];
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Acc. MS (FAB+) 320.02236 C i4H i0NO6S requires 320.02288. Found C, 52.5; H, 
2.84; N, 4.25; Ci4H9N 06S requires C, 52.67; H, 2.84; N, 4.39 %.
(l,3-Adamantanediyl)diphenyl-4,4 '-0,0-bis-sulphamate (55) (1,3-
adamantanediyl)diphenyl 4 '-hydroxy,4-O-sulphamate (56)
Upon sulphamoylation, 4,4'-(l,3-adamantanediyl)diphenol (210 mg, 655 pmol) gave a 
crude product (273 mg) which was fractionated by flash chromatography 
(chloroform/acetone gradient). The fraction at R / 0.25 (CHsCl/acetone, 4:1) gave a 
white residue (159 mg) which was further purified by recrystallization from 
acetone/hexane (1:2) to give 55 as white crystals (112 mg, 36%); mp 197-199°C; 
vmax (KBr) 3420-3240 (NH2), 1390 (S02) cm’1; 8h (270 MHz, acetone-d*) 1.8-2.25 
(14H, m), 7.12 (4H, br s, exchanged with D20 , 2xS02NH2), 7.24-7.32 (4H, AA' BB', 
Ar), 7.48-7.56 (4H, AA' BB', Ar); MS m/z (FAB+) 478.1 [80, (M)+], 399.2 [30, 
(M+H-S02NH2)+]; MS m/z (FAB-) 631.2 [30, (M+NBA)"], 477.2 [100, (M-H)"],
398.2 [20, (M-S02NH2)"]; A cc . MS (FAB+) 478.1227 C22H26N20 6S2 requires 
478.1232. Found C, 55.1; H, 5.63; N, 5.85; C22H26N2O6S2 requires C, 55.21; H, 5.48; 
N, 5.85%.
The fraction at R/0.39 (chloroform/acetone, 4:1) gave a white residue (38 mg) which 
was further purified by recrystallization from ethyl acetate/hexane (1:2) to give 56 as 
white crystals (20 mg, 8%); mp 140-142°C; vmax (KBr) 3500-3000 (NH2 and OH), 
1370 (S02) cm"1; 8 h  (270 MHz, acetone-d6) 1.8-2.29 (14H, m), 6.78 (2H, d, J  = 8 . 8  
Hz, C-3'-H and C-5'-H), 7.08 (2H, br s, exchanged with D20 , C-4-S02NH2), 7.26 
(4H, br d, J  = 8.79 Hz, Ar), 7.5 (2H, d, /  = 8 . 8  Hz, Ar) and 8.15 (1H, br s, exchanged 
with D 20 , C-4'-OH); MS m/z (FAB+) 399.1 [100, (M)+], 320.2 [15, (M+H-S02NH2)" 
], 306.1 (45), 288.1 (15); MS m/z (FAB-) 552.3 [30, (M+NBA)"], 398.2 [100, (M-H)"]; 
Acc. MS (FAB+) 400.1533 C22H26N 04S requires 400.1583.
4,4'-Di(tert-butyldimethylsilyloxy)benzophenone (57)
To a solution of 4,4'-dihydroxybenzophenone (5.0 g, 23.34 mmol) in anhydrous DMF 
(15 ml), tert-butyldimethylchlorosilane (4.22 g, 28 mmol) and imidazole (4.0 g, 58.75 
mmol) were added. The reaction mixture was stirred under N2 for 3 h, then diluted 
with 5% aqueous NaHCC>3 (100 ml), extracted with ethyl acetate (200 ml), washed
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with water, brine, dried (MgSCU), filtered and evaporated to give 57 as pale white oil, 
which was soldified on standing (10 g, 97%); TLC (chloroform): R/0.69; vmax (KBr) 
1620 (C=0) cm 1; SH (400 MHz, CDC13) 0.24 (12H, s, 2 x -SiCCH,^), 1.0 (18H, s, 2 x 
(CH3)3), 6.9 (4H, AA' BB', C-3-H, C-5-H, C-3'-H and C-5'-H) and 7.73 (4H, AA' 
BB', C-2-H, C-6 -H, C-2'-H and C-6 '-H); MS m/z (FAB+) 443.4 [60, (M+H)+], 385.3 
[10, (M-C(CH3)3)+], 235 (90), 73.0 (100); MS m/z (FAB-) 441.3 [10, (M-H)’], 401.2 
(10), 327.2 [100, (M-H-2xC(CH3)3)+], 255.1 (10). Found C, 67.6; H, 8.64; 
C25H3 8 0 3Si2 requires C, 67.82; H, 8.65%.
l-Cyclohexyl-l,l-di-[(4,4'-di-0,0-(tert-butyldimethylsilyl)phenyl]methanol (58)
To a solution of 57 (500 mg, 1.129 mmol) in dry ether (50 ml), cyclohexyl magnesium 
chloride (1.2 ml, 2.4 mmol) was added dropwise with stirring at 0 °C under N2 . The 
reaction mixture after being stirred overnight at room temperature was diluted with dil 
HC1 and extracted with ether. The combined ethered extracts were washed with water, 
brine, dried (MgS0 4 ), filered and evaporated to give crude 58 as pale white oil (550 
mg, 92%); the crude prduct could not purified and it was a single spot by TLC 
analysis, but NMR showed the presence of starting material (10-20%); TLC 
(chloroform): R/0.61; vmax (film) 3420 (OH), 1600 cm 1; 8 h (400 MHz, DMSO-d6) 
0.14 (12H, s, 2 x -Si(CH3)2), 0.92 (18H, s, 2 x (C H ^), 0.96-2.32 (11H, m), 4.95 (1H, 
s, exchanged with D20 , OH), 6.7 (4H, d, J  = 8.5 Hz, C-3-H, C-5-H, C-3'-H and C-5'- 
H) and 7.31 (4H, d, J  = 8 . 8  Hz, C-2-H, C-6 -H, C-2'-H and C-6 '-H); MS m/z (FAB+)
525.5 [30, (M-H)+], 443.4 [100, (M-cyclohexyl)+], 427.4 (50), 319 (20), 73.0 (60); MS 
m/z (FAB-) 679.0 [10, (M+NBA)'], 525.5 [40, (M-H)'], 441.3 [20, (M-H-cyclohexyl)* 
], 411.4 (100), 327.3 [50, (M-cyclohexane-Si(CH3)2C(CH3)3]\ 317.3 (40); Acc. MS 
(FAB+) 526.3214 C3 iH50O3Si2 requires 526.3298%.
l-Cyclohexyl-l,l-(4,4'-dihydroxyphenyl)methanol (59)
To a solution of 58 (500 mg, 950 jLimol) in dry THF (10 ml) terra-n-butylammonium 
fluoride (5.6 ml of 1M in THF, 5.68 mmol) was added dropwise. The resulting 
mixture was stirred for about 5-10 minutes and then diluted with ethyl acetate (100 
ml). The organic layer was washed with water (100 ml), dried (MgSO^, filtered and 
evaporated to give a white solid (280 mg) which was recrystallized from 
acetone/hexane (1:2) to give 59 as white crystals (260 mg, 92%); mp 115-117 °C; TLC
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(chloroform and chloroform/acetone, 8:1): R/s 0.21 and 0.52; vmax (KBr) 3500-3140 
(OH), 1600 c m 1; 8 h (400 MHz, DMSO-ck) 0.96-2.26 (11H, m), 4.74 ( 1 H, s, 
exchanged with D20 , OH), 6 . 6 6  (4H, d, J  = 8 . 8  Hz, C-3-H, C-5-H, C-3 '-H and C-5'- 
H), 7.21 (4H, d, J = 8 . 8  Hz, C-2-H, C-6 -H, C-2'-H and C-6 '-H) and 9.1 (2H, s, 
exchanged with D20 , 2 x OH); MS m/z (FAB+) 298.2 [10, (M)+], 215.1 [100, M- 
cyclohexyl]+, 205.2 (15); MS m/z (FAB-) 451.3 [40, (M+NBA) ], 297.3 [100, (M-H) ],
279.3 (30), 213.2 [30, (M-H-cyclohexane)]’; Acc. MS (FAB+) 298.1558 Ci9H220 3 
requires 298.1569.
l-Cyclohexyl-l,l-(4,4'-0,0-bis-sulphamoylphenyl)methanol (60)
To a solution of 59 (150 mg, 503 pmol) and 2,6-di-te?t-butyl-4-methylpyridine 
(DBMP) (930 mg, 4.529 mmol) in CH2CI2 (25 ml) was added sulphamoyl chloride in 
toluene (ca. 0.7 M, 3.0 mmol) dropwise with stirring. After 2 hours of stirring the 
solution was diluted with dichloromethane (100 ml). The organic layer was washed 
with water, brine, dried (MgSCU), filtered and evaporated to give a residue (450 mg) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
white solid that obtained (180 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 60 as pale white crystals (120 mg, 52%); mp 213-215 °C 
(dec); TLC (chloroform and chloroform/acetone, 8:1); R/s 0.12 and 0.31; vmax (KBr) 
3500-3000 (NH2), 1600, 1380 (S02) cm'1; 8 h (400 MHz, DMSO-ck) 1.31 (1H, br s), 
1.57 (6 H, br s), 2.15 (4H, br s), 7.25 (8 H, m, Ar-H), 8.0 (4H, br s, exchanged with 
D2O, OSO2NH2) and 9.68 (1H, br s, exchanged with D2O, OH); MS m/z (FAB+)
457.1 [10, (M+H)+], 206.2 (100); MS m/z (FAB-) 608.2 [40, (M-H+NBA)'], 455 [15, 
(M-H/], 249.0 (100); Acc. MS (FAB+) 457.1065 C19H25N2O7S2 requires 457.1103.
3-Hydroxybenzo[b]naphtho[2,3-d]-furan-6,ll-dione (61)
Resorcinol (6 . 6  g, 60 mmol) in ethanol (80 ml) was added dropwise to a stirred 
ethanolic sodium ethoxide solution (prepared by dissolving 3.8 g of Na in 120 ml of 
absolute ethanol) containing 2,3-dichloro-1,4-naphthoquinone (6.9 g, 30 mmol) at 0 
°C. After being stirred at room temperature overnight, the black reaction mixture was 
acidified with 5N HC1 at 0 °C. The yellow solid that precipitated was collected by 
filtration, washed successively with water, methanol, diethyl ether and air-dried to 
give crude 61 as a deep yellow solid (7.1 g, 8 8 %); mp >310 °C (lit. > 300 °C) ; 208 TLC
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(chloroform/acetone, 8:1): R/0.47; vmax (KBr) 3400 (OH), 1670 and 1620 (C=0) cm' 
8h (400 MHz, DMSO-d«) 7.05 (1H, d, 7c-5-h.c-4-h = 8.54 Hz, C-4-H), 7.16 (1H, s, C-
2-H), 7.:2-7.7 (2H, m, C-8-H and C-9-H), 7.95 (1H, d, 7C-4-h, c-5-h = 8.5 Hz, C-5-H), 
8.2-8.7 (2H, m, C-7-H and C-10-H) and 10.53 (1H, br s, exchanged with D2O, C-3- 
OH); MS m/z (FAB+) 265.1 [70, (M+H)+], 255.3 (75), 243.2 (30), 173.2 (100); MS 
m/z (FAB-) 263.1 [100, (M-H)'], 242.1 (20), 210.1 (25), 198.1 (45), 181.1 (35); Acc. 
MS (FAB+) 265.0502 C16H9O4 requires 265.0501.
Benzo[b]naphtho[2,3-d]-furan-6,ll-dione 3-O-sulphamate (62)
Upon sulphamoylation, 61 (500 mg, 1.892 mmol) gave a crude product (655 mg) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
yellow residue that was obtained (510 mg) was further purified by recrystallization 
from acetone/hexane (1:3) to give 62 as white crystals (450 mg, 69%); mp > 270 °C 
(dec); TLC (chloroform/acetone, 8:1): R/0.28; vmax (KBr) 3280, 3380 (NH2), 1680 
(C=0), 1380 (SO2) c m 1; 8h (270 MHz, DMSO-ds) 7.52 (1H, dd, 7C-5-h, c-4-h = 8.4 Hz 
a n d /C-2-H,c-4-H= 2.0 Hz, C-4-H), 7.85-8.0 (3H, m, Ar), 8.1-8.2 (2H, m, Ar), 8.25 (2H, 
br s, exchanged with D2O, SO9NH?) and 8.27 (1H, d, 7c-7-h. c-6-h = 8.4 Hz, C-7-H or 
C-10-H); MS m/z (FAB+) 344.1 [100, (M+H)+], 263.1 [30, (M-S02NH2)+]; MS m/z 
(FAB-) 242.2 [100, (M-H)']; 264.2 [20, (M-S02NH)']; Acc. MS (FAB+) 344.0218 
C 16H 10NO6S requires 344.0229. Found C, 55.83; H, 2.68; N, 3.96; C 16H9NO6S 
requires C, 55.98; H, 2.64; N, 4.08%.
(Z and E)-4-0-Sulphamoyltamoxifen (63a and 63b)
Upon sulphamolyation, 4-hydroxytamoxifen [70% (Z):30% (E) 75 mg, 193.5 pmol] 
gave a crude product (85 mg) which was fractionated by flash chromatography 
(chloroform/acetone gradient). The yellow residue that was obtained (40 mg) was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 63 as 
yellow crystals (25 mg, 28%); mp >123 °C; TLC (chloroform/acetone, 2:1, 1:1 and 
1:2): R/s 0.11, 0.17 and 0.21 respectively; vmax (KBr) 3500-3000 (NH2), 1390 (S 02) 
c m 1; 6h (400 MHz, DMSO-d«) 0.91 (3H, t, J  = 7.6 Hz, CH3CH2-), 2.25 (6 H, s, - 
N(CH3)2), 2.47 (2H, q, 7 = 7.3 Hz, -CH2CH3), 2.65 (2H, t, J  = 5.8 Hz, -N-CH2-), 4.15 
(2H, t, J  = 6.1 Hz, -OCH?-), 6.63-7.3 (13H, m, Ar-H) and 8.05 (2H, br s, exchanged 
with D20 , -S0 2NH2); MS m/z (FAB+) 467.1 [100, (M+H)+], 388.1 [50, (M+H-
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S 0 2NH2)+]; MS m/z (FAB-) 619.2 [10, (M+NBA)'], 466.1 [40, (M)'], 187.9 (100); 
Acc. MS (FAB+) 467.2009 requires C26H3 iN20 4S 467.2005.
4-n-Heptyloxyphenyl-O-sulphamate (64)
Upon sulphamoylation, 4-n-heptyloxyphenol (1.0 g, 4.80 mmol) gave a crude product 
(1.41 g) which was fractionated by flash chromatography (chloroform/acetone, 8:1). 
The white residue that was obtained (757 mg) was further purified by recrystallization 
from acetone/hexane (1:5) to give 64 as white crystals (557 mg, 40%); mp > 42°C 
(dec.); TLC (chloroform/acetone, 8:1 and 4:1): R/s 0.56 and 0.69 respectively; vmax 
(KBr) 3440, 3320 (NH2), 1370 (S02) cm'1; 6 H (270 MHz, acetone-c^) 0.89 (3H, t, 
CH3), 1.34 (8 H, m), 1.79 (2H, quintet, OCH^I^CHz), 4.0 (2H, t, J = 6.4 Hz, -OCH^ 
), 7.0 (4H, m, 2H exchanged with D20 , C-3-H, C-5-H and- OSOzNFh), 7.23 (2H, m, 
C-2 -H and C-6 -H); MS m/z (FAB+) 287.1 [100, (M)+], 208.2 [30, (M-S02NH)+]; MS 
m/z (FAB-) 286.0 [100, (M-H)']; Acc. MS (FAB+) 288.1246 Ci3H22N 04S requires 
288.1269. Found C, 54.2; H, 7.35; N, 4.7; Ci3H2 iN 04S requires C, 54.33; H, 7.37; N, 
4.87%.
(E)-N-[(4-0-Sulphamoyl-3-methoxybenzyl]-8-methyl-6-nonenamide (65)
Upon sulphamoylation, E-capsaicin (100 mg, 327.4 jimol) gave the crude product 
which was fractionated by flash chromatography with chloroform/acetone (2 :1 ) and 
the white residue that was obtained (85 mg) was further purified by recrystallization 
from acetone/hexane (1:2) to give 65 as white crystals (63 mg, 50%); mp 114-116 °C; 
TLC (chloroform/acetone, 2:1 and 4:1): R/s 0.4 and 0.15 respectively; vmax (KBr) 
3490, 3300 (-NH2), 1650 (C=0), 1380 (-S02N-) cm'1; 6h (270 MHz, CDC13) 0.94 (6 H, 
d, /  = 6 . 6  Hz, 2 x CH3), 1.4 (2H, quintet, J  « 7.2 Hz), 1.62 (2H, quintet, J  « 7.7 Hz), 
2.0 (2H, q, J  « 6.9 Hz, -CHjCfcCH-), 2.2 (3H, m, -CHzCONH- and -CH(CH3)2), 
3.87 (3H, s, -OCIL0, 4.39 (2H, d, J  = 5.9 Hz, ArCI^NHCO), 5.14 (2H, br s, 
exchanged with D20 , -OSC^NHj), 5.34 (2H, m, -CH=CH-), 5.87 (1H, br t, J  « 5.8 Hz, 
-NHCO-), 6.84 (1H, dd, Jc-2-n , c-6-h =1-9 Hz and 7c-5-h, c-6-h = 8.2 Hz C-6 -H), 6 . 8 6  
(1H, d, Jc-6-H, C-2-H = 1.8 Hz, C-2-H) and 7.26 (1H, d, Jc.6-h ,c -5-h  = 8.1 Hz, C-5-H); MS 
m/z (FAB+) (rel. intensity) 385.2 [100, (M+H)+], 304.2 [20, (M-S02NH2)+], 287.1 
[10, (M-OH)']; MS m/z (FAB-) 383.1 [100, (M-H)'], 303.2 [10, (M-H-S02NH2)']. 
Found C, 56.2; H, 7.38; N, 7.29; Ci8H28N20 5S requires C, 56.23; H, 7.34; N, 7.29%.
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(p-O-Tetradecanoyl)-N-tetradecanoyl tyramine (66)
Myristoyl chloride (2.7 g, 10.94 mmol) was added dropwise to a cold solution of 
tyramine (1.5 g, 10.94 mmol) and triethylamine (3 ml, 21.52 mmol) in THF (50 ml). 
After being stirred at room temperature for 48 h, the reaction mixture was poured into 
10% HC1 solution (100 ml), and the resulting mixture extracted with ethyl acetate 
(3x100 ml). The combined organic extracts were washed with brine until neutral, dried 
(MgSC>4), filtered and evaporated. The crude product that obtained was fractionated by 
flash chromatography with chloroform/acetone (8 :1 ) and the residue that was isolated 
(4.96 g) was further purified by recrystallization from hot toluene to give 6 6  as white 
crystals (3.85 g). Upon recrystallization from toluene of the residue recovered from the 
evaporation of mother liquor, a second crop of 6 6  was obtained (630 mg, 73% overall 
yield); mp 110-112 °C (lit. 111-112°C) ; 276 TLC (chloroform/acetone, 8:1): R /0.83; 
vmax (KBr) 3340 (NH), 1750 (C=0) cm'1; 8 h (400 MHz, DMSO-d6, 100 °C) 0.85 
(6 H, t, J = 6.9 Hz, 2 x CH3), 1.25 (40 H, m), 1.43 (2H, quintet, J  « 7.0 Hz, - 
NHCOCH2CH2-), 1.64 (2H, quintet, J  « 7 Hz, ArOCOCHzCHr), 2.03 (2H, t, /  = 7.3 
Hz, -NHCOCH2-), 2.51 (2H, t, J  = 7.2 Hz, -ArOCOCHz-), 2.72 (2H, t, J  = 7.3 Hz, 
ArCH2CH2NHCO-), 3.28 (2H, q, J = 7.3 Hz, -CHjNHCO-), 6.98 (2H, d, J  = 8.5 Hz, 
C-2-H and C-6 -H), 7.2 (2H, d, J  = 8.55 Hz, C-3-H and C-5-H) and 7.41 (1H, br s, J  «
5.5 Hz, -NHCO-); MS m/z (FAB+) 558.6 [100, (M+H)+]; MS m/z (FAB-) 710.9 [100, 
(M+H+NBA)'], 556.5 [70, (M-H)']. Found C, 77.60; H, 11.46; N, 2.51; C36H63NO3 
requires C, 77.50; H, 11.38; N, 2.51%.
N-Tetradecanoyl tyramine (67)
A mixture of 6 6  (2.0 g, 3.585 mmol), DMF (50 ml), 10% aqueous NaHC0 3  (15 ml)
and methanol (70 ml) was heated under reflux for 1 h and then stirred at room
temperature overnight. The reaction mixture was diluted with water and extracted with 
ethyl acetate. The combined organic extracts were washed with brine until neutral, 
dried (MgS0 4 ), filtered and evaporated to yield the crude product which was further 
purified by recrystallization from acetone/hexane (1:2) to give 67 as white crystals 
(1.15 g, 91%); mp 99-101 °C (lit. 98-99°C);276 TLC (chloroform/acetone, 8:1): R / 
0.50. vmax (KBr) 3320 (OH), 3300 (NH), 1640 (C=0) cm'1; 8 h (400 MHz, DMSO- 
d6) 0.85 (3H, t, /  = 6.7 Hz, CH3), 1.25 (20 H, m), 1.45 (2H, quintet, J  = 6.9 Hz,
NHCOCH2CH2-), 2.01 (2 H, t, J  = 7.5 Hz, -NHCOCH2), 2.56 (2H, t, /  = 7.6 Hz,
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ArCHs-), 3.17 (2H, q, 7 ~ 6 . 6  Hz, -CH2NHCO-), 6 . 6  (2H, d, 7 = 8.5 Hz, C-3-H and C-
5-H), 6.97 (2H, d, 7 = 8.3 Hz, C-2-H and C-6 -H), 7.79 (1H, br t, 7 = 5.4 Hz, -NHCO-) 
and 9.16 (1H, br s, exchange with D20 , OH); MS m/z (FAB+) 348.3 [100, (M+H)+]; 
MS m/z (FAB-) 500.2 [15, (M+NBA)'], 346.2 [100, (M-H)']; Acc. MS (FAB+) 
348.2903 C22H38NO2 requires 348.2903.
(p-O-Sulphamoyl)-N-tetradecanoyl tyramine (68)
Upon sulphamoylation, 67 (500 mg, 1.441 mmol) gave the crude product which was 
fractionated by flash chromatography (chloroform/acetone, 8 :1 ) and the white residue 
that was isolated (486 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 68 as white crystals (376 mg, 61%); mp 110-112°C; TLC 
(chloroform/ acetone, 8:1): R / 0.23; vmax (KBr) 3420, 3320 (-NH2), 1650 (C=0), 
1390 (-SO2-) cm’1; 8h  (400 MHz, DMSO-d«) 0.85 (3H, t, 7 =  6.7 Hz, CH3), 1.24 (20H, 
m), 1.45 (2H, quintet, 7 = 7.0 Hz, -NHCOCH2CH2-), 2.0 (2H, t, 7 = 7.3 Hz, - 
NHCOCH2-), 2.71 (2H, t, 7 = 7.3 Hz, ArCIfc-), 3.25 (2H, q, 7 = 7.0 Hz, -CH2NHCO-),
7.2 (2H, d, 7 = 8.24 Hz, Ar-H), 7.27 (2H, d, 7 = 8.55 Hz, Ar-H), 7.88 (1H, br t, 7 = 5.5 
Hz, -NHCO-) and 7.95 (2H, br s, exchanged with D20 , OSO2NH2); MS m/z (FAB+)
427.3 [100, (M+H)+], 348.3 [10, (M+H+S02NH)+]; MS m/z (FAB-) 425.3 [100, (M- 
H)']; Acc. MS (FAB+) 427.2637 C22H39N2O4S requires 427.2631. Found C, 62.1; H, 
9.02; N, 6 .6 6 ; C22H38N2O4S requires C, 61.94; H, 8.98; N, 6.57%.
p-0-(4-Hexyloxybenzoyl)-N-(4-hexyloxybenzoyl) tyramine (69)
4-Hexyloxybenzoyl chloride (2.63 g, 10.93 mmol) was added dropwise to a cold 
solution of tyramine (1.0 g, 7.29 mmol) and triethylamine (1.52 ml, 10.91 mmol) in 
THF (35 ml). After being stirred at room temperature for 48 h, the reaction mixture 
was poured into 10% HC1 solution (100 ml) and the resulting mixture extracted with 
ethyl acetate (3x100 ml). The combined organic extracts were washed with brine until 
neutral, dried (MgS0 4 ), filtered and evaporated. The crude product that was obtained 
was fractionated by flash chromatography with chloroform/acetone (8 :1 ) and the white 
residue that isolated (3.65 g) was further purified by recrystallization from methanol to 
give 69 as white crystals (3.2 g, 80%); mp 145-156 °C; TLC (chloroform/acetone, 
8:1): R / 0.7; vmax (KBr) 3320.(NH), 1740 (C=0) cm'1; 8h  (400 MHz, DMSO-d*,) 
0.86 (6 H, m, 2 x CH3), 1.31 ( 8  H, m), 1.42 (4H, quintet, J  « 6 . 8  Hz, 2 x
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OCH2CH2CH2), 1.72 (4H, quintet, J  « 7.3 Hz, 2  x ArOCH2CH2-, 2.86 (2H, t, J  = 13  
Hz, -ArCHr), 3.48 (2H, q, J  « 5.9 Hz, -CH2NHCO-), 4.0 (2H, t, J = 6.4 Hz, - 
ArOCHr), 4.08 (2H, t, J  = 6.3 Hz, A1-OCH2), 6.97 (2H, d, J  = 8.3 Hz, Ar-H), 7.1 (2H, 
d, J = 8.3 Hz, Ar-H), 7.16 (2H, d, J  = 7.82 Hz, Ar-H), 7.3 (2H, d, J  = 8.3 Hz, Ar-H),
7.8 (2H, d, /  = 8.3 Hz, Ar-H), 8.05 (2H, d, /  = 8.3 Hz, Ar-H) and 8.43 (1H, br t, J  =
5.5 Hz, -NHCO-); MS m/z (FAB+) 546.3 [100, (M+H)+], 342.2 [20, (M+H- 
OCOPhO(CH2)5CH3)+]; MS m/z (FAB-) 544.3 [40, (M-H)'], 340.2 [100, (M-H- 
OCOPhO(CH2)5CH3)']; Acc. MS (FAB+) 546.3233 C34H44N0 5 requires 546.3220.
N-(4~Hexyloxybenzoyl) tyramine (70)
A mixture of 69 (2.0 g, 3.665 mmol), DMF (50 ml), 10% aqueous NaHC03 (15 ml) 
and methanol (50 ml) was heated under reflux for 1 h and then stirred at room 
temperature overnight. The mixture was diluted with water and extracted with ethyl 
acetate. The combined organic extracts were washed with brine, dried (MgS04), 
filtered and evaporated. The crude product that was obtained was recrystallized from 
methanol to give 70 as white crystals (1.05 g, 87%); mp 160-162 °C; TLC 
(chloroform/acetone, 8:1): R/0.37; vmax (KBr) 3340 (NH), 3100 (OH), 1640 (C=0) 
cm '1; 8 h (400 MHz, DMSO-dg) 0.88 (3H, t, /  = 6.7 Hz, CHj), 1.31 (4H, m), 1.41 (2H, 
m), 1.71 (2H, quintet, J  « 7.0 Hz, -ArOCH2CH2-), 2.70 (2H, t, /  = 7.6 Hz, -ArCHrO, 
3.37 (2H, q, /  * 7.0 Hz, -CH2NHCO-), 4.0 (2H, t, /  = 6.4 Hz, -ArOCHs-), 6.67 (2H, d, 
J  = 7.3 Hz, Ar-H), 6.96 (2H, d, J  = 7.6 Hz, Ar-H), 7.01 (2H, d, J  = 7.6 Hz, Ar-H), 7.78 
(2H, d, J  = 7.3 Hz, Ar-H), 8.36 (1H, t, J  = 5.5 Hz, -NHCO-) and 9.17 (1H, br s, OH); 
MS m/z (FAB+) 342.2 [100, (M+H)+]; MS m/z (FAB-) 340.2 [100, (M-H)']; Acc. 
(FAB+) MS 342.2067 C2 iH28N 0 3 requires 342.2069. Found C, 73.73; H, 7.94; N, 
3.99; C2 iH27N 0 3 requires C, 73.87; H, 7.97; N, 4.10%.
(p-0-Sulphamoyl)-N-(4-hexyloxybenzoyl) tyramine (71)
Upon sulphamoylation, 70 (1.0 g, 2.928 mmol) gave the crude product which was 
fractionated by flash chromatography (chloroform/acetone, 8 :1 ) and the white residue 
that was isolated (860 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 71 as white crystals (650 mg, 53%); mp 159-160 °C; TLC 
(chloroform/acetone, 8:1): R/0.2; vmax (KBr) 3320, 3220 (-NH2), 1620 (C=0), 1390 
(-SO2-) cm'1; §h (400 MHz, DMSO-d6) 0.88 (3H, t, 7 = 7.0 Hz, CH3), 1.31 (4H, m),
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1.41 (2H, m), 1.71 (2H, quintet, J  « 7.0 Hz, OCH2 CH^), 2.85 (2H, t, J  = 7.3 Hz, 
ArCHz-), 3.48 (2H, q, /  = 6.3 Hz, -CH2NHCO-), 4.01 (2H, t, J  = 6.3 Hz, -ArOCHr), 
6.97 (2H, d, J = 8.9 Hz, Ar-H), 7.2 (2H, d, J  = 8 . 6  Hz, Ar-H), 7.32 (2H, d, J  = 8 . 6  Hz, 
Ar-H), 7.8 (2H, d, 7 =  8.5 Hz, Ar-H), 7.95 (2H, br s, exchanged with D20 , OSO9NH9) 
and 8.43 (1H, br t, J  = 5.5 Hz, -NHCO-); MS m/z (FAB+) 421.2 [100, (M+H)+]; MS 
m/z (FAB-) 573.4 [30, (M+NBA)’], 419.3 [100, (M-H)’], 340.3 [10, (M-H-S02NH)’]. 
Found C, 60.1; H, 6 .8 ; N, 6.63; C2 iH28N20 5S requires C, 59.98; H, 6.71; N, 6 .6 6 %.
N-(4-Octyloxybenzoyl) tyramine (72)
To a mixture of 4-octyloxybenzoic acid (2.63 g, 10.51 mmol) and triethylamine (1.52 
ml, 10.91 mmol) in THF (35 ml), at 0°C was added isobutylchloroformate (2.0 g, 
14.64 mmol), followed by tyramine (1.0 g, 7.290 mmol). After being stirred at 0 °C for 
48 h, the reaction mixture was poured into 10% HC1 solution (100 ml), and the 
resulting mixture was extracted with ethyl acetate (3x100 ml). The combined organic 
extracts were washed with brine until neutral, dried (MgSO/O, filtered and evaporated. 
The crude product that was obtained was fractionated by flash chromatography 
(chloroform/acetone, 8 :1 ) and the white residue that isolated (2 . 2  g) was further 
purified by recrystallization from methanol to give 72 as white crystals (1.93 g, 72%); 
mp 141-143 °C; TLC (chloroform/acetone, 8:1): Rf  0.36; vmax (KBr) 3280 (NH), 
1620 (C=0) cm’1; 6 H (400 MHz, DMSO-d6) 0.9 (3H, t, J  = 6 . 6  Hz, CHaCHz-), 1.31 
(8 H, m), 1.44 (2H, m), 1.74 (2H, quintet, J  « 7.3 Hz, OCH2CH2-), 2.74 (2H, t, J  = 7.5 
Hz, ArCHz-), 3.42 (2H, q, J  « 7.0 Hz, -CHzNHCO-), 4.04 (2H, t, J  = 6.4 Hz, - 
ArOCH2-), 6.72 (2H, d, J = 8.2 Hz, Ar-H), 7.0 (2H, d, J  = 8.5 Hz, Ar-H), 7.05 (2H, d, 
J  = 8.2 Hz, Ar-H), 7.82 (2H, d, J  = 8 . 6  Hz, Ar-H), 8.4 (1H, t, J  = 5.5 Hz, -NHCO-) 
and 9.21 (1H, br s, OH); MS m/z (FAB+) 370.2 [100, (M+H)+]; MS m/z (FAB-) 368.3 
[100, (M-H)’]; Acc. MS (FAB+) 370.2400 C23H32N 0 3 requires 370.2382. Found C, 
74.7; H, 8.54; N, 3.78; C23H3 iN 0 3 requires C, 74.76; H, 8.46; N, 3.79%.
(p-0-Sulphamoyl)-N-(4-octyloxybenzoyl) tyramine (73)
Upon sulphamoylation, 72 (1.0 g, 2.706 mmol) gave the crude product which was 
fractionated by flash chromatography (chloroform/acetone, 8 :1 ) and the white residue 
that was isolated (967 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 73 as white crystals (817 mg, 67%); mp > 120 °C (dec.);
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TLC (chloroform/acetone, 8:1): R/0.2; vmax (KBr) 3420, 3340 (-NH2), 1680 (C=0), 
1380 (-SO2-) cm'1; 5h (400 MHz, DMSO-de) 0.86 (3H, m), 1.25 (8 H, m), 1.40 (2H, 
quintet, J  « 7.0 Hz), 1.71 (2H, quintet, J  « 7.3 Hz, OCH2 CH2-), 2.7 (2H, t, /  = 7.3 Hz, 
ArCHs-), 3.45 (2H, q, J  » 6.3 Hz, -CH2NHCO-), 4.01 (2H, t, J  = 6.3 Hz, -ArOCHz-),
6.96 (2H, d , J =  9.2 Hz, Ar-H), 7.11 (2H, d, J = 8.3 Hz, Ar-H), 7.3 (2H, d, J  = 8.3 Hz, 
Ar-H), 7.80 (2H, d, J  = 8 . 8  Hz, Ar-H), 7.95 (2H, br s, exchanged with D20 , 
OSO2NH2) and 8.4 (1H, t, J = 5.9 Hz, -NHCO-); MS m/z (FAB+) (rel. intensity) 449.2 
[90, (M+H)+]; MS m/z (FAB-) 447.2 [100, (M-H)']; Acc. MS (FAB+) 449.2099 
C23H33N2O5S requires 449.2110.
7.2.3 Synthesis o f steroid sulphamates analogues (tricyclic sulphamates) 
2-(Hydroxymethylene)-6~methoxy-l~tetralone (74)
To a mixture of 6 -methoxy-l-tetralone (20 g, 113 mmol) and ethyl formate (18.6 ml, 
230 mmol) in toluene (250 ml) at -78 °C under N2 potassium terf-butoxide (25 g, 230 
mmol) was added in portions. The reaction mixture was slowly warmed to -5 °C over 
a period of 1 h, at which time TLC analysis (ethyl acetate/hexane, 1:2) indicated 
complete conversion to the less polar product. The reaction was quenched with 10% 
HC1 and the mixture was extracted with diethyl ether (3 x 300ml). The combined ether 
extracts were washed with water, brine, dried (MgS0 4 ), filtered and evaporated to give 
a brown oil (25.13 g), which was fractionated by flash chromatography 
(CHCls/acetone, 8:1). The yellow oil that was obtained (21.94, 95%), solidified on 
standing and was further purified by recrystallization from methanol to give 74 as pale 
yellow crystals (19.43 g, 84 %); mp 6 6 - 6 8  °C (lit. 68-69 °C) ; 214 TLC 
(chloroform/acetone, 8:1): R/0.85; vmax (KBr) 3340-2500 (OH), 1670 (C=0), 1600 
(CH=CH) cm'1; 8 h (400 MHz, CDC13) 2.54 (2H, t, J~ 6.5 Hz, C-3 -H2), 2.86 (2H, t,
6.9 Hz, C-4 -H2), 3.85 (3H, s, OCH3), 6.71 (1H, d, 7C-7-h. c-5-h = 2.4 Hz, C-5-H), 6.84 
(1H, dd, Jc-8-H, C-7-H = 8.5 Hz and 7C-5-h, c-7-h = 2.5 Hz, C-7-H), 7.88 (1H, s, C=CHOH), 
7.92 (1H, d, /c-7-h, c-8-H = 8.5 Hz, C-8 -H), 14.5 (1H, br s, exchanged with D20 , 
=CHOH); 5C (400 MHz, CDC13) 23.26 (t), 29.33 (t), 55.45 (q, OCH3), 108.16 (s), 
112.82 (d), 113.0 (d), 125.02 (s), 128.77 (d), 144.44 (s), 163.42 (s), 172.47 (d, C-8 ) 
and 184.53 (s, C=0); MS m/z (FAB+) 205.2 [100, (M+H)+], 175.1 (10); MS m/z 
(FAB-) 203.1 [100, (M-H)'], 188.0 (35), 171.1 (30); Acc. MS (FAB+) 205.0869
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C 12H 13O3 requires 205.0865. Found, C, 70.4; H; 5.98; C 12H12O3 requires C, 70.57; H, 
5.92%.
2-(3-Oxobutyl)-6-methoxy-l-tetralone (75)
To a cold (0-5 °C) suspension of 74 (15.0 g, 72.97 mmol) and methylvinyl ketone 
(7.87 g, 111.9 m m ol) in methanol (50 ml), a solution of triethylamine (1.5 ml, 10.76 
mmol) in methanol (2 ml) was added after being stirred at room temperature for 3 
days, the reaction mixture was diluted with ether (500 ml) washed with 10% aqueous 
K2CO3 (100 ml), brine (100 ml), dried (MgS0 4 ), filtered and evaporated to give a 
yellow brown oil (18.53 g) which was fractionated by flash chromatography 
(CHC^/acetone, 8:1). The yellow oil that was obtained (16.76 g, 93%) which 
solidified on standing, was further purified by recrystallization from methanol to give 
75 as pale yellow crystals (14.23 g, 79%); mp 68-70 °C (lit. 68-69 °C) ; 214 TLC 
(CHCl3/acetone, 8:1): R/0.79; vmax (KBr) 3030, 2970, 1720 (C=0), 1670 (C=0), 
1590 (CH=CH) cm'1; 5h (400 MHz, CDC13) 1.9 (2H, m, -CH2CH2CO-), 2.05-2.25 
(5H, m, C-3 -H2 and COCH3), 2.47 (1H, m, C-2-H), 2.63 (2H, t, J  = 7.6 Hz, -CH2-CO- 
CH3), 2.97 (2H, t, /  ~ 6.2 Hz, C-4 -H2), 3.85 (3H, s, OCH3), 6.67 (1H, d, J  =2.4 Hz, C-
5-H), 6.82 (1H, dd, / C-8-h , c-7-h  = 8 . 8  Hz and / C-5-h . c-7-h  = 2.44 Hz, C-7-H) and 7.98 
(1H, d, / C-7-h , c -8-h =  8 . 8  Hz, C-8 -H); 5c (400 MHz, CDC13) 24.1 (t), 28.8 (t), 29.06 (t),
29.94 (q, CH3CO-), 41.28 (t, CH2CO), 46.25 (d, C-2), 55.41 (q, OCH3), 112.4 (d), 
113.18 (d), 125.99 (s), 129.75 (d, C-8 ), 146.32 (s), 163.46 (s), 198.79 (s, C=0) and 
208.87 (s, -COCH3); MS m/z (FAB+) 247.2 [100, (M+H)+], 189.2 (10); Acc. MS 
(FAB+) 247.1325 Ci5Hi90 3 requires 247.1334. Found, C, 73.3; H; 7.52; Ci5Hi80 3 
requires C, 73.15; H, 7.37%.
1,9,10,1 Oa-Tetrahydro-7-methoxy-3(2H)-phenanthrenone (76)
A mixture of 75 (10 g, 43.86 mmol) and potassium hydroxide (8.0 g, 142.6 mmol) in 
methanol/water (200 ml, 1:1) was refluxed, under N2 for 8  h. The reaction mixture 
was cooled and the resulting precipitate was filtered, washed with water and air-dried 
to give a yellow residue (1 0 . 1 1  g), which was fractionated by flash chromatography 
(CHCl3/acetone, 8:1). The yellow residue that was obtained (7.87 g, 85%) was further 
purified by recrystallization from ethanol to give 76 as yellow crystals (6.79 g, 73%); 
mp 116-118 °C (lit. 115-115.5 °C) ; 214 TLC (chloroform/acetone, 8:1): R/0.58; vmax
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(KBr) 1670 (C=0) c m 1; 8h (400 MHz, CDC13, cosy) 1.58 (1H, ddd, JCio-He, cio-Ha~ IB 
Hz, J(C9-H2, cioa-H), ci0-Ha ~ 12 Hz and 5 Hz, C-10-Ha), 1.80 (1H, m, C-l-Ha), 2.06 (1H, 
m, C-10-Heq), 2.19 (1H, m, C-l-Heq), 2.50 (3H, m, C-2-H2 and ClOa-H), 2.94 (2H, 
m, C-9 -H2), 3.83 (3H, s, OCH3), 6.43 (1H, s, C-4-H), 6.62 (1H, d, / C-6-h , c-s-h  = 2.7 Hz, 
C-8-H), 6.81 (1H, dd, / C-8-h , c-6-h  = 2.4 Hz and / c -s-h , c -6-h  = 8.85 Hz, C-6-H) and 7.62 
(1H, d, / C-6-h , c-5-H = 8.8 Hz, C-5-H); 8C (400 MHz, CDC13, cosy) 30.34 (t), 30.41 (t), 
30.56 (t), 37.05 (d, C-lOa), 37.23 (t, C-2), 55.34 (q, -OCH3), 113.37 (d), 113.57 (d), 
118.65 (d, C-4), 124.07 (s), 127.1 (d, C-5), 141.92 (s), 158.43 (s), 161.43 (s) and 
200.16 (s, C=0); MS m/z (FAB+) 229.2 [100, (M+H)+], 200.1 (10); Acc. MS (FAB+) 
229.1223 C15H 17O2 requires 229.1228.
1,9,10,1 Oa-Tetrahydro- 7-hydroxy-3(2H)-phenanthrenone (77)
Method A
To a suspension of aluminium chloride (3.0 g, 21.90 mmol) in dry toluene (100ml) at 
room temperature was added 76 (2.0 g, 8.761 mmol) and the resulting brown green 
mixture refluxed, under N2 for 1 h. Upon cooling, water was added cautiously and the 
resulting mixture was further diluted with ethyl acetate. The organic layer that 
separated was washed with water (100 ml), dried (MgSO^, filtered and evaporated to 
give a brown residue (1.90 g) which was recrystallized from ethyl acetate to yield 77 
as fine yellow/ brown crystals (1.23 g, 5.739 mmol, 64%); mp 226-228 °C; TLC 
(chloroform/acetone, 8:1): R/0.36; vmax (KBr) 3500-3000 (OH), 1620 (C=0) cm'1; 
5h (400 MHz, DMSO-de, cosy) 1.44 (1H, ddd, /  ~ 18, 1 and 4.5 Hz, C-10-Ha), 1.66 
(1H, m, C-l-Ha), 1.95 (1H, m, C-10-Heq), 2.08 (1H, m, C-l-Heq), 2.37 (2H, m, C-2- 
H2), 2.62 (1H, m, C-lOa-H), 2.83 (2H, m, C-9 -H2), 6.42 (1H, s, C-4-H), 6.6 (1H, d, Jc.
6-H, C-8-H = 2.4 Hz, C-8-H), 6.66 (1H, dd, / c-8-h , c -6-h  = 2.4 Hz and / c -s-h , c -6-h  = 8.85 Hz, 
C-6-H), 7.75 (1H, d, / C-6-h , c-s-h  = 8.8 Hz, C-5-H) and 9.98 (1H, br s, exchanged with 
D20 , OH); MS m/z (FAB+) 215.1 [100, (M+H)+]; MS m/z (FAB-) 367.3 [M+NBA],
213.3 [100, (M-H)']; Acc. MS (FAB+) 215.1052 C14H 15O2 requires 215.1072.
Method B
Boron tribromide (11 ml of 1M solution in DCM, 11 mmol) was slowly added to a 
solution of 76 (500 mg, 2.19 mmol) in DCM (20 ml) at -78 °C. The reaction mixture
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was warmed up to 0 °C and stirred at this temperature for 30 minutes and then at room 
temperature for an additional of 30 minutes. Upon re-cooling of the reaction mixture 
to 0 °C water-ether was added cautiously and the resulting mixture was extracted with 
ether (3 x 100 ml). The combined ether extracts were washed with water (100 ml), 
brine (100 ml), dried (MgSC^), filtered and evaporated to give a residue (465 mg) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
yellow solid that isolated (432 mg) was further purified by recrystallization to give 77 
as white crystals (389 mg, 83%); mp 220-222 °C. The spectroscopic data of the 
crystals were found to be comparable to those described for 77 obtained by method A. 
Found, C, 78.9; H; 6.21; C14H14O2 requires C, 78.48; H, 6.59%.
l,9,10,10a-Tetrahydro-7-0-sulphamoyl-3(2H)-phenanthrenone (78)
Upon sulphamoylation, 77 (500 mg, 2.334 mmol) gave a crude product (670 mg) 
which was fractionated by flash chromatography (chloroform/acetone, 8:1). The 
yellow residue that was obtained (450 mg) was further purified by recrystallization 
from acetone/hexane (1:2) to give 78 as light yellow crystals (389 mg, 57%); mp 186- 
188°C; TLC (chloroform/acetone, 8:1): R/0.22; vmax (KBr) 3300, 3120 (NH2), 1620 
(C=0), 1390 (S02) cm'1; 8 H (400 MHz, DMSO-d6) 1.46 (1H, ddd, J  ~ 18, 12 and 5.8 
Hz, C-10-Ha), 1.69 (1H, m, C-l-Ha), 2.02 (1H, m, C-10-Heq), 2.14 (1H, m, C-l-Heq),
2.41 (2H, m, C-2 -H2), 2.69 (1H, m, C-lOa-H), 2.91 (2H, m, C-9 -H2), 6.62 (1H, s, C-4- 
H), 7.13 (2H, m, C-6-H and C-8-H), 8.03 (1H, d, 7C-6-h, c-5-h = 8.3 Hz, C-5-H) and 8.1 
(2H, br s, exchanged with D20 , OSO2NH2); MS m/z (FAB+) 294.1 [100, (M+H)+],
215.1 [15, (M+H-S02NH)+]; MS m/z (FAB-) 446.3 [M+NBA], 292.2 [100, (M-H)'],
213.2 [30, (M-SO2NH2)']. Found, C, 57.2; H; 5.23; N, 4.80 C 14H 15NO4S requires C, 
57.32; H, 5.15; N, 4.77%.
2-(Hydroxymethylene)-6,7-dimethoxy-l-tetralone (79)
This was prepared in a similar mannar to the preparation of 74 using 6,7-dimethoxy-l- 
tetralone (5.0 g, 24.244 mmol), ethyl formate (4.5 ml, 58.18 mmol) and potassium 
tert-butoxide (6.375 g, 58.65 mmol). The crude brown oil (6.23 g) that was obtained 
was fractionated by flash chromatography (CHC13/acetone, 8:1) and the yellow oil that 
isolated (5.68 g), which solidified on standing, was further purified by recrystallization 
from methanol to give 79 as pale yellow crystals (4.53 g); mp 151-153 °C.214 When
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the residue that resulted upon evaporation of the mother liquor was recrystallized from 
methanol a second crop of 79 was obtained (0.97 g, total yield, 97%); TLC 
(chloroform/acetone, 8:1): R/0.89; vmax (KBr) 3420-2500 (OH), 1630 (C=0), 1600 
(CH=CH) cm'1; 6h (400 MHz, CDC13), 2.55 (2H, t, J  ~ 7 Hz, C-3-H^, 2.84 (2H, t, J  ~
6.8 Hz, C-4 -H2), 3.93 (3H, s.OCHs), 3.94 (3H, s,OCH3), 6.71 (1H, s, C-5-H), 7.5 (1H, 
s, C-8-H), 7.78 (1H, s, C-2-C=CHOH), 14.55 (1H, br s, exchanged with D20 , 
=CHOH); 6C (400 MHz, CDC13) 23.48 (t), 28.69 (t), 56.09 (q), 56.36 (q), 108.32 (d),
110.2 (d), 124.92 (s), 136.99 (s), 148.15 (d), 153.24 (d), 169.71 (d, =CH), 186.14 (s) 
and 199.78 (s, C=0); MS m/z (FAB+) 235.1 [100, (M+H)+], 205.1 (10); MS m/z 
(FAB-) 233.1 [100, (M-H)'], 222.1 (20), 215.1 (25). Found, C, 66.4; H; 6.00; 
C 13H 14O4 requires C, 66.66; H, 6.02%.
2-(3-Oxobutyl)-6,7-dimethoxy-l-tetralone (80)
This was prepared in a similar manner to the preparation of 75 using 79 (3.0 g, 12.807 
mmol) and methylvinyl ketone (1.385 g, 19.704 mmol) in the presence of 
triethylamine (0.5 ml, 3.587 mmol). The yellow/ brown crude that was obtained (3.6 
g) was fractionated by flash chromatography (CHCl3/acetone, 8:1) and the yellow 
solid that isolated (3.36 g, 95% ) was further purified by recrystallization from ethanol 
to give 80 as yellow crystals (3.13 g, 88%); mp 82-84 °C (lit. 83-84 °C);214 TLC 
(CHCl3/acetone, 8:1): Rf 0.8; vmax (KBr) 1710, 1670 (C=0), 1590 (CH=CH) cm'1; 6r 
(400 MHz, CDCI3) 1.84 (2H, m, -CHzCHzCO-), 2.05-2.24 (5H, m, C-3 -H2 and - 
COCH3), 2.45 ( 1 H, m, C-2 -H), 2.64 (2H, t, J  = 7.5 Hz, -CH2-CO-CH3), 2.94 (2H, t, J  
~ 7.3 Hz, C-4 -H2), 3.91 (3H, s, OCH3), 3.93 (3H, s, OCH3), 6.67 (1H, s, C-5-H) and
7.49 (1H, s, C-8 -H); 6 c (400 MHz, CDC13) 24.14 (t), 28.13 (t), 29.33 (t), 29.96 (q), 
41.28 (t), 46.92 (d), 55.96 (q, OCH3), 108.5 (d), 110.08 (d), 125.47 (s), 138.68 (s), 
147.93 (d), 153.46 (d), 198.94 (s, C=0) and 208.89 (s, -COCH3); MS m/z (FAB+)
277.2 [100, (M+H)+], 219.2 (30). Found, C, 69.4; H; 7.36; C16H20O4 requires C, 
69.55; H, 7.30%.
1,9,10,10a- Tetrahydro-6,7-dimethoxy-3(2H)-phenanthrenone (81)
This was prepared in a similar mannar to the preparation of 76 from 80 (2.0 g, 7.238 
mmol) with potassium hydroxide (1.8 g, 32.08 mmol), but the refluxed time was for 
15 minutes. The yellow crude that was obtained (1.81 g) was fractionated by flash
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chromatography (CHCl3/acetone, 8:1) and the yellow solid that isolated (1.72 g, 92%) 
was further purified by recrystallization from ethanol to give 81 as yellow crystals 
(1.59 g, 85%); mp 210-212 °C (lit. 208-210 °C);214 TLC (CHCl3/acetone, 8:1): Rf  
0.74; vmax (KBr) 1650 (C=0) cm'1; 6H (400 MHz, CDC13, cosy) 1.60 (1H, ddd, J ~ 18 
Hz, 12 Hz and 5 Hz, C-10-Ha), 1.81 (1H, m, C-l-Ha), 2.05 (1H, m, C-10-Heq), 2.19 
(1H, m, C-l-Heq), 2.52 (3H, m, C-2-H2 and C-lOa-H), 2.9 (2H, m, C-9 -H2), 3.88 (3H, 
s, OCH3), 3.92 (3H, s, OCILO, 6.52 (1H, s, C-4-H), 6.63 (1H, s, C-8-H) and 7.2 (1H, s, 
C-5-H); 5C (400 MHz CDC13> cosy) 29.8 (t), 30.4 (t), 30.85 (t), 37.02 (d), 37.34 (t), 
55.91 (q, OCH3), 106.99 (d), 111.3 (d), 118.52 (d), 123.51 (s), 134.1 (s), 147.77 (s),
151.53 (s), 158.56 (s) and 200.25 (s, C=0); MS m/z (FAB+) 259.1 [100, (M+H)+],
230.1 (10); Acc. MS (FAB+) 259.1343 Ci6Hi90 3 requires 259.1334.
l,9,10,10a-Tetrahydro-6-hydroxy-7-methoxy-3(2H)-phenanthrenone (82) and 
l,9,10,10a-tetrahydro-7-hydroxy-6-methoxy-3(2H)-phenanthrenone (83)
To a suspension of aluminium chloride (460 mg, 3.36 mmol) in dry toluene (50ml) at 
room temperature was added 81 (600 mg, 2.323 mmol) and the brown/green mixture 
that formed was stirred at room temperature under N2 for 2.5 h. Upon cooling of the 
reaction mixture to 0°C water (10 ml) was added and the organic fraction that 
separated were extracted into ethyl acetate (200 ml). The organic layer was then 
separated washed with water (100 ml), dried (MgSO^, filtered and evaporated to give 
a yellow residue (550 mg) which was fractionated by flash chromatography 
(chloroform/acetone, 8:1). The first fraction that was collected gave a light yellow 
solid (380 mg) upon evaporation which was further purified by recrystallization from 
methanol to give 82 as white crystals (319 mg, 56%); mp 175-178 °C; TLC 
(chloroform/acetone, 8:1): R/0.64; vmax (KBr) 3300-3000 (OH), 1620 (C=0) cm '1; 
5h (400 MHz, CDC13, cosy) 1.61 (1H, ddd, J ~ 18 Hz, 12 Hz and 5 Hz, C-10-Ha), 1.82 
(1H, m, C-l-Ha), 2.1 (1H, m, C-10-Heq), 2.2 (1H, m, C-l-Heq), 2.55 (3H, m, C-2 -H2 
and C-lOa-H), 2.9 (2H, m, C-9-Hi), 3.89 (3H, s, C-7-OCH3), 6.2 (1H, br s, exchanged 
with D20 , C-6-OH), 6.6 (1H, s, C-4-H), 6.7 (1H, s, C-8-H), 7.22 (1H, s, C-5-H); 5c 
(400 MHz, CDC13, cosy) 29.22 (t), 30.19 (t), 30.38 (t), 36.91 (d, C-lOa), 37.27 (t),
55.96 (q, OCH3), 106.67 (d), 114.83 (d), 118.32 (d), 123.15 (s), 134.89 (s), 145.66 (s), 
148.63 (s), 159.2 (s) and 200.55 (s, C=0); MS m/z (FAB+) 245.1 [100, (M+H)+],
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216.1 (10); MS m/z (FAB-) 243.2 [100, (M-H)']. Found, C, 73.8; H; 6.61; Ci5Hi60 3 
requires C, 73.75; H, 6.60%.
The second fraction that appeared gave a pale white solid (161 mg) which was 
recrystallized from methanol to give 83 as pale white crystals (145 mg, 25%); mp 130- 
132 °C; TLC (chloroform/acetone, 8:1): R/0.54; vmax (KBr) 3320-3000 (OH), 1640 
(C=0) cm'1; 5h (400 MHz, CDC13) 1.81 (2H, m, C-l-Ha and C-10-Ha), 2.04 (1H, m, 
C-10-Heq), 2.16 (1H, m, C-l-Heq), 2.47 (1H, m, C-lOa-H), 2.72 (2H, m, C-2 -H2),
2.85 (2H, m, C-9-H^, 3.92 (3H, s, C-6 -OCH3), 5.82 (1H, br s, exchanged with D20 , 
C-7-OH), 6.48 (1H, s, C-4-H), 6.62 (1H, s, C-8 -H) and 7.31 (1H, s, C-5-H); MS m/z 
(FAB+) 245.1 [100, (M+H)+]; MS m/z (FAB-) 397.1 [10, (M+NBA)+], 243.0 [100, 
(M-H)']. Found, C, 73.7; H; 6.58; Ci5Hi60 3 requires C, 73.75; H, 6.60%.
1,9,10,10a-Tetrahydro-7-methoxy-6-0-sulphamoyl-3(2H)-phenanthrenone (84) 
Upon sulphamoylation, 82 (250 mg, 1.033 mmol) gave a crude product (325 mg) 
which was fractionated by flash chromatography (chloroform/acetone, 8 :1 ) and the 
yellow residue that obtained (252 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 84 as light yellow crystals (198 mg, 60%); mp > 116 °C 
(dec.); TLC (chloroform/ acetone, 8:1 and 4:1): R/S 0.46 and 0.6 respectively; vmax 
(KBr) 3320, 3180 (NH2), 1630 (C=0), 1390 (S02) cm 1; 8 h  (400 MHz, DMSO-d6) 
1.45 (1H, ddd, J -  18 Hz, 12 Hz and 5 Hz, C-10-Ha), 1.69 (1H, m, C-l-Ha), 2.02 (1H, 
m, C-10-Heq), 2.15 (1H, m, C-2-Heq), 2.45 (1H, m, C-lOa-H), 2.65 (2H, m, C-2-!£>),
2.9 (2H, m, C -9 -E 2 ) , 3.85 (3H, s, OCH3), 6.72 ( 1H, s, C-4-H), 7.18 (1H, s, C-8 -H),
7.53 (1H, s, C-5-H) and 8.01 (2H, br s, exchanged with D20 , OSONH?): MS m/z 
(FAB+) 324.1 [100, (M+H)+], 245.1 [35, (M+H-S02NH2)+]; MS m/z (FAB-) 476.2 
[90, (M+NBA)'], 323.2 [100, (M)'], 243.2 [65, (M-S02NH2)']. Found, C, 55.5; H; 
5.27; N, 4.34; C15H 17NO5S requires C, 55.72; H, 5.3; N, 4.23%.
l,9,10,10a-Tetrahydro-6-methoxy-7-0-sulphamoyl-3(2H)-phenanthrenone (85) 
Upon sulphamoylation, 83 (110 mg, 455 pmol) gave a crude product (150 mg) which 
was fractionated by flash chromatography (chloroform/acetone, 8 :1 ) and the yellow 
residue that obtained ( 1 2 2  mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 85 as light yellow crystals (96 mg, 6 6 %); mp > 120 °C
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(dec.); TLC (chloroform/ acetone, 8:1 and 4:1): R/S 0.46 and 0.6 respectively; vmax 
(KBr) 3340, 3200 (NH2), 1640 (C=0), 1380 (S02) cm'1; 6 H (270 MHz, acetone-d6) 
1.61-2.93 (9H, m), 3.94 (3H, s, OCH3), 6.4 (1H, s, C-4-H), 7.08 (1H, s, C-8 -H), 7.11 
(2H, br s, exchanged with D20 , C^-OSOzNH^ and 7.55 (1H, s, C-5-H); MS m/z 
(FAB+) 324.1 [100, (M+H)+], 244.1 [20, (M-S02NH2)+]; MS m/z (FAB-) 476.2 [95, 
(M+NBA)'], 323.2 [100, (M)'], 243.2 [65, (M-H-S02NH2)']; Acc. MS m/z (FAB+) 
324.0895 Ci5Hi8N 0 5S requires 324.0905. Found, C, 56.2; H; 5.16; N, 4.0 
C 15H 17NO5S requires C, 55.72; H, 5.3; N, 4.23%.
l,9,10,10a-Tetrahydro-6,7-dihydroxy~3(2H)-phenanthrenone (86)
To a suspension of aluminium chloride (266 mg, 1.995 mmol) in dry toluene (25 ml) 
at room temperature was added 81 (200 mg, 774.2 pmol). The brown/ green mixture 
that formed was refluxed, under N2 for 30 minutes. Upon cooling water was added 
cautiously and the resulting mixture was extracted into ethyl acetate (150 ml), and the 
organic layer was washed with water (50 ml), dried (MgSCXO, filtered and evaporated 
to give a brown residue which was decolourized by activated char coal gave 8 6  as 
yellow oil (160 mg, 8 8 %); TLC (chloroform/acetone, 8:1): R/0.26; vmax (KBr) 3500- 
2500 (OH), 1630 (C=0) cm'1; 8 h (DMSO-de, 400 MHz) 1.36-3.1 (9H, m), 6.5 (1H, s, 
C-4-H), 6.58 (1H, s, C-8 -H), 7.17 (1H, s, C-5-H), 9.1 (1H, s, exchanged with D20 , 
OH) and 9.67 (1H, s, exchanged with D20 , OH); MS m/z (FAB+) 383.2 [10, (M- 
NBA)+], 230.2 [100, (M)+], 173.2 (10); MS m/z (FAB-) 229.1 [100, (M-H)'], 171.0 
(55). Acc. MS 230.0936 C14H 14O3 requires 230.0943.
1,9,10', 10a-Tetrahydro-7-hydroxy-6-0-sulphamoyl-3(2H)-phenanthrenone (87a) or 
l,9,10,10a-tetrahydro-6-hydroxy-7-0-sulphamoyl-3(2H)-phenanthrenone (87b)
Upon sulphamoylation, 8 6  (110 mg, 478 pmol) gave a crude product (155 mg) which 
was fractionated by flash chromatography (chloroform/acetone gradient). The yellow 
residue obtained (116 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 87 as yellow crystals (90 mg, 60%); mp > 270 °C (dec.); 
TLC (chloroform/ acetone, 4:1): R/0.21; vmax (KBr) 3500 3000 (OH and NH2), 1670 
(C=0), 1390 (SO2) c m 1; 8h (270 MHz, DMSO-dfi) 1.43-3.1 (9H, m), 6.37 (1H, s, C-4- 
H), 6.77 (1H, s, C-8 -H), 7.73 (1H, s, C-5-H), 7.93 (2H, br s, exchanged with D20 , C-
7 -OSO2NH2) and 10.41 (1H, s, exchanged with D20 , OH); MS m/z (FAB+) 310.2
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[100, (M+H)+], 230.2 [20, (M-S02NH2)+]; MS m/z (FAB-) 308.1 [100, (M-H)'], 229.1 
[60, (M-H-S02NH2)']; Acc. MS m/z (FAB+) 310.0764 Ci4H 16N 05S requires 
310.0749.
1,4,4a, 9,10,1 Oa-Hexahydro- 7~methoxy-3(2H)-phenanthrenone(88) and
1,4,4a,9,10,10a-hexahydro-7-methoxy-3(2H)-phenanthrenol (89)
To a solution of 76 (2.0 g, 8.176 mmol) in ethyl acetate (30 ml), Pd-C (10%, 300 mg) 
was added and the mixture was subjected to hydrogenation at room temperature at 50 
psi overnight. The supported catalyst was removed by filtration and the solvent was 
evaporated under reduced pressure to give a yellow residue (2 . 1  g), which was 
fractionated by flash chromatography with chloroform/acetone 8:1. The less polar 
fraction gave 8 8  as light yellow oil (1.34 g, 67%), solidified on standing; mp 90-92 °C; 
TLC (chloroform/acetone, 8:1): R/0.65; vmax (KBr) 1710 (C=0), 1600 cm'1; 5 h  (400 
MHz, CDC13) 1.5-3.2 (12H, m) 3.84 (3H, s, OCH3), 6.5 (1H, d, / C-6 -h , c - 8 - h  = 2.83 Hz, 
C-8 -H), 6.73 (1H, dd, 7 C -8 -h , c - 6 - h  = 2.4 Hz and 7 C -5 -h , c - 6 - h  = 8.3 Hz C-6 -H) and 7.12 
(1H, d, «/ic-6-H, C -5 -H = 8.3 Hz, C-5-H); 8 C (400 MHz, CDC13) 23.23 (q), 30.34 (t), 30.41 
(t), 30.56 (t), 33.5 (t), 37.2 (t), 37.7 (d), 42.1 (d), 55.19 (q, OCH3), 111.94 (s), 113.87 
(s), 126.25 (d) 130.55 (s), 137.8 (s), 157.9 (s) and 211.56 (s, C=0); MS m/z (FAB+)
230.3 [30, (M)+]; Acc. MS (FAB+) 231.1375 Ci5Hi90 2 requires 231.1385. Found, C, 
77.7; H; 7.99; Ci5Hi80 2 requires C, 78.23; H, 7.88%.
The more polar fraction gave 89 as light yellow oil (310 mg, 31%), solidified on 
standing; mp 92-95 °C; TLC (chloroform/acetone, 8:1): R / 0.53; vmax (KBr) 3300 
(OH), 1600 cm'1; 5 h  (400 MHz, DMSO-de) 1.1-2.84 (12H, m), 3.54 (1H, pentet, C-3- 
H), 3.84 (3H, s, OCH3), 4.68 (1H, s, exchanged with D20 , C-3-OH), 6.44 (1H, d, JC-6- 
h ,  c-8-H = 2.1 Hz, C-8 -H), 6.53 (1H, dd, / c - 8 - h ,  c - 6 - h  = 2.4 Hz and Jc-5 -h ,  c - 6 - h  = 8.4 Hz C-
6 -H) and 7.1 (1H, d, 7 C-6 -h . c - 5- h  = 8.5 Hz, C-5-H); 8 C (400 MHz, CDC13) 28.11 (t),
30.1 (t), 35.33 (t), 37.9 (t), 38.99 (t), 38.78 (d), 41.23 (d), 64.35 (d), 69.3 (q), 112.84 
(d), 114.85 (d), 125.85 (d), 131.76 (s), 137.22 (s) and 156.9 (s); MS m/z (FAB+) 232.2 
[100, (M)+], 215.2 (45); Acc. MS (FAB+) 232.1448 Ci5H20O2 requires 232.1463. 
Found, C, 77.1; H; 8.62; Ci5H2q0 2 requires C, 77.55; H, 8 .6 8 %.
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1,4,4a,9,10,1 Oa-Hexahydro- 7-hydroxy-3(2H)-phenanthrenol (90)
Method A
To a solution of 89 (500 mg, 2.152 mmol) in DCM (30 ml) at -78°C, boron tribromide 
(1M solution in DCM, 11 ml) was added slowly and the mixture was warmed up to 0 
°C and stirred at this temperature for 30 minutes and then at room temperature for 30 
minutes. Upon cooling to at 0 °C water-ether was added cautiously and the resulting 
mixture was extracted with ether (3 x 100 ml). The combined ether extracts were 
washed with water (100 ml), brine (100 ml), dried (MgSCU), filtered and evaporated. 
The residue that was obtained (435 mg) was fractionated by flash chromatography 
(chloroform/acetone gradient) to give 90 as a colourless oil (189 mg, 40%) which 
solidified on standing to give a white solid; mp 94-96 °C; TLC (chloroform/acetone, 
8:1): Rf 0.44; vmax (KBr) 3500-3000 (OH), 1600 cm'1; 8 H (400 MHz, DMSO-d6 ) 
0.89-2.82 (12H, m), 3.53 (1H, pentet, C-3-H), 4.7 (1H, s, exchanged with D20 , C-3- 
OH), 6.46 (1H, d, 7 c -6-h, c-8-h = 2.1 Hz, C-8 -H), 6.51 (1H, dd, JC-8-h, c-6-h = 2.4 Hz and 
JC-5-H, C-6-H = 8.4 Hz C-6 -H), 7.0 (1H, d, 7C-6-h, c-5-h = 8.5 Hz, C-5-H) and 9.0 (1H, br s, 
exchanged with D20 , C-7-OH); 5C (400 MHz, CDC13) 28.51 (t), 30.3 (t), 35.63 (t),
37.94 (t), 38.93 (t), 38.8 (d), 40.35 (d), 69.2 (d, C-3), 112.64 (d), 114.65 (d), 125.85 
(d), 131.7 (s), 137.21 (d), 154.84 (s, C-7); MS m/z (FAB+) 218.0 [100, (M)+], 201.0 
(40); MS m/z (FAB-) 370.1 [100, (M-H+NBA)'], 217.1 [95, (M-H)']; Acc. MS 
(FAB+) 218.1305 Ci4H 180 2 requires 218.1307.
Method B
To a solution of 77 (1.0 g, 4.08 mmol) in ethyl acetate (30 ml), Pd-C (10%, 300 mg) 
was added and the mixture was subjected to hydrogenation at room temperature at 50 
psi overnight. The catalyst was removed by filtration and the solvent was evaporated 
under reduced pressure to give a yellow residue (986 mg), which was purified by flash 
chromatography with chloroform/acetone 8:1. The more polar fraction gave 90 as light 




This was prepared in the similar manner to the preparation of 90 (method A) using 8 8  
(500 mg, 2.171 mmol). The residue that was obtained (455 mg) was fractionated by 
flash chromatography (chloroform/acetone gradient) to give a yellow solid (410 mg) 
which was further purified by recrystallization to give 91 as creamy white crystals 
(119 mg, 40%); mp > 275 °C (dec.); TLC (chloroform/acetone, 8:1): Rf  56; vmax 
(KBr) 3500-3200 (OH), 1710 (C=0) 1600 cm 1; 8 H (400 MHz, DMSO-d6) 0.89-3.1 
(12H, m), 6.5 (1H, d, 7C-6-h. c-8-h = 2.1 Hz, C-8 -H), 6.55 (1H, dd, / C-8-h. c-6-h = 2.4 Hz 
and Jc-5-H, C-6-H = 8.5 Hz C-6 -H), 7.1 (1H, d, Jc.6-H, c-5-h = 8.5 Hz, C-5-H) and 8 .1 (1H, 
br s, exchanged with D20 , OH); 8 C (400 MHz, DMSO-de) 28.38 (t), 30.39 (t), 35.61 
(t), 37.91 (t), 38.3 (t), 37.32 (d), 41.35 (d), 112.84 (d), 115.15 (d), 126.31 (d), 130.57 
(s), 137.78 (s), 153.71 (s, C-7) and 211.2 (s, C=0); MS m/z (FAB+) 216.1 [100, 
(M)+]; MS m/z (FAB-) 215.1 [100, (M-H)']; Acc. MS (FAB+) 216.11281 Ci4Hi60 2 
requires 216.11502 . Found, C, 78.0; H; 7.03; Ci4Hi602 requires C, 77.75; H, 7.46.
Method B
This was also prepared by catalytic hydrogenation of 77 as described in method B of 
preparation of 90 as the less polar fraction gave 91 as light yellow oil (305 mg, 30%) 
which solidified on standing.
l,4,4a,9,10,10a-Hexahydro-7-O-sulphamoyl-3(2H)-phenanthrenol (92)
Upon sulphamoylation, 90 (300 mg, 1.375 mmol) gave a crude product (320 mg) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
yellow residue that was obtained (209 mg) was further purified by recrystallization 
from acetone/hexane (1:4) to give 92 as yellow crystals (160 mg, 40%); mp 131-132 
°C; TLC (chloroform/ acetone, 4:1): R/0.41; vmax (KBr) 3400-3200 (NH2 and OH), 
1600, 1390 (S02) cm'1; 8 h (400 MHz, CDC13) 0.85-3.05 (13H, m), 3.6 (1H, pentet, C-
3-H) 5.1 (2H, br s, exchanged with D20 , OSO7NH9). 7.04 (1H, d, 7 c -6-h. c-8-h = 2.4 Hz, 
C-8 -H), 7.15 (1H, dd, 7c -8-h, c-6-h = 2.4 Hz and 7c-5-h, c-6-h = 8.54 Hz C-6 -H), 7.3 (1H, 
d, Jc-6-h, C-5-H = 8.5 Hz, C-5-H); MS m/z (FAB+) 451.1 [10, (M+H+NBA)+], 298.1
203
[100, (M+H)+], 217.1 [40, (M-S02NH2)+]; MS m/z (FAB-) 450.1 [10, (M+NBA)'],
296.2 [95, (M-H)'], 216.2 [10, (M-H-S02NH2)']; Acc. MS (FAB+) 298.1153
C 1 4 H 2 0 N O 4 S  requires 298.1113.
l,4,4a,9,10,10a-Hexahydro-7-O-sulphamoyl-3(2H)-phenanthrenone(93)
Upon sulphamoylation, 91 (200 mg, 924.6 pmol) gave a crude product (260 mg) 
which was fractionated by flash chromatography (chloroform/acetone gradient). The 
yellow residue that was obtained (180 mg) was further purified by recrystallization 
from acetone/hexane (1:4) to give 93 as yellow crystals (150 mg, 55%); mp > 150 °C 
(dec.); TLC (chloroform/ acetone, 4:1): R/0.45; vmax (KBr) 3400-3300 (NH2),1670 
(C=0), 1390 (S02) cm'1; 8 h (400 MHz, CDC13) 0.85-3.05 (12H, m), 5.43 (2H, br s, 
exchanged with D20 , OSOzNHz), 7.1 ( 1H, d, 7 C-6-h, c-8-h = 2.4 Hz, C-8 -H), 7.18 ( 1H, 
dd, /c -8 -h , C-6-H = 2.4 Hz and ./c-s-h , c-6-h = 8.5 Hz C-6 -H) and 7.35 (1H, d, 7 c -6-h, c -s-h  =
8.55 Hz, C-5-H); MS m/z (FAB+) 295.1 [100, (M)+], 216.1 [30, (M+H-S02NH2)+]; 
MS m/z (FAB-) 294.0 [100, (M-H)*], 214.1 [20, (M-H-S02NH2) ]; Acc. MS (FAB+) 
295.0891 C14H 17NO4S requires 295.0878. Found, C, 56.55; H; 6.44; N, 4.71; 
Ci4H 17N 04S requires C, 56.93; H, 5.8; N, 4.71%.
1,9,10,10a-Tetrahydro-7-methoxy-phenanthrene (94)
To a solution of 76 (1.0 g, 4.380 mmol) in THF (35 ml) and IPA (35 ml), sodium 
borohydride (830 mg, 21.94 mmol) was added and the reaction mixture was stirred at 
room temperature for 16 h, at which time TLC analysis (chloroform/acetone, 8:1) 
indicated complete conversion of 76 to a more polar product. The reaction mixture 
was quenched with water (15 ml) and the resulting mixture evaporated under reduced 
pressure. The residue that resulted was diluted with ethyl acetate (150 ml) and at 0 °C 
was acidified by dropwise addition of 3M HC1. The organic layer that separated was 
washed with brine (100 ml), water (100 ml), dried (MgSCL), filtered and evaporated to 
give a yellow oil (930 mg) whose TLC analysis indicated the presence of more than 
one compound. In a second attempt of the reaction, the work-up procedure was altered 
by quenching with saturated aqueous N H 4 C I  and the resulting mixture evaporated at 
low temperature (> 30 °C) to give a yellow oil (850 mg). TLC (chloroform/acetone, 
8 :1 ) analysis of the oil immediately indicated the presence of one spot, but when the 
analysis was repeated after 30 minutes, further spots appeared whose intensity
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increased with time. After being left at room temperature in the air for 5 h the crude 
product was fractionated and was isolated as a brown oil (300 mg); TLC 
(chloroform/acetone, 8:1): R/ 0.37; vmax (KBr) 1600 cm'1; 5h (400 MHz, CDCI3) 
1.25-2.85 (7H, m), 3.91 (3H, s, OCH3), 5.93-7.58 (5H, m, C-2-H, C-3-H, C-4-H, C-6 - 
H and C-8 -H)) and 7.71 (1H, d, 7 C-6-h. c-5-h = 8.2 Hz, C-5-H); MS m/z (FAB+) 213.1 
[100, (M+H)+], 197.1 [30, (M-CH3)+]; MS m/z (FAB-) 211.1 [100, (M-H)']; Acc. MS 
(FAB+) 213.1215 C15H17O requires 213.1279.
7.2.4 Synthesis o f  steroid sulphamates
7.2.4.1 A-ring modifications
Direct iodination o f  oestrone
2,4-Di-iodooestrone (95)
Method A
A solution of iodine (470 mg, 1.85 mmol) in dichloromethane (DCM, 30 ml) was 
added to a mixture of oestrone (500 mg, 1.85 mmol) and copper (II) chloride dihydrate 
(757 mg, 4.444 mmol) in DCM (75 ml) and the resulting mixture was stirred at room 
temperature for 48 h. The precipitate formed was removed by filtration and the filtrate 
collected was evaporated under reduced pressure. The residue obtained in ether (100 
ml) was washed with water, 10% aqueous sodium thiosulphate (2x50 ml) followed by 
brine (3x50 ml), dried (MgSO^, filtered and evaporated. The yellow residue that was 
obtained (750 mg) was fractionated by flash chromatography (chloroform/acetone 
gradient) to give a pale yellow solid (150 mg) which was further purified by 
recrystallization from methanol to give 95 (2,4-diiodooestrone) as white crystals (100 
mg) mp 208-210 °C; TLC (chloroform/acetone, 8:1): R/0.85; vmax (KBr) 3400 (OH), 
1730 (C=0) cm'1; 5H(400 MHz, CDC13,) 0.89 (3H, s, CH,), 1.25-2.55 (13H, m), 2.87 
(2H, m, C-6 -CH2X 5.8 (1H, s, exchanged with D2O, OH) and 7.62 (1H, s, C-l-H); MS 
m/z (FAB+) 676.0 [10, (M+H+NBA)+], 521.9 [100, (M)+], 396.0 (15), 272.0 (10); MS 
m/z (FAB-) 673.9 [20, (M-H+NBA)'], 520.9 [100, (M-H)'], 395.0 (10); Acc. MS 
(FAB+) 521.9542 C 18H20I2O2 requires 521.9553. Found C, 41.7; H, 3.87; C18H20I2O2 
requires C, 41.4; H, 3.86%.
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The fraction with an R/value of 0.8 (CHCl3\acetone, 8:1) was found to be a mixture of 
2-iodo/4-iodo oestrone (230 mg), no attempt was made to separate these two isomers. 
Oestrone (245 mg) was recovered from the reaction.
Method B
Similar to method A except the reaction mixture was heated under reflux for 48 h. The 
yield of 95 was found to be 154 mg, a mixture of 2-iodo/4-iodo oestrone (315 mg) and 
that 150 mg of oestrone was recovered.
Method C
A mixture of oestrone (1.0 g, 3.7 mmol), iodine (1.41 g, 5.555 mmol) and copper (II) 
acetate monohydrate (1.11 g, 5.56 mmol) in acetic acid (50 ml) was stirred at 55 °C for 
22 h. Upon removal of the precipitate formed by filtration, the filtrate was diluted with 
water and extracted with ether (3 x 100 ml). The combined ethereal extracts were 
washed with NaHCC>3 (100 ml) then 10% aqueous sodium thiosulphate (100 ml) 
followed by brine (100 ml), dried (MgSCL), filtered and evaporated. The yellow 
residue obtained (890 mg) was fractionated by flash chromatography 
(chloroform/acetone gradient) to give a pale yellow solid ( 1 0 0  mg) which was further 
purified by recrystallization from methanol to give 95 (65 mg).
The more polar fraction gave a mixture of 2-iodo/4-iodo oestrone (670 mg) which they 
have approximately the same Rf  (0 .8 ) values and colud not separated even by 
preperative TLC.
Oestrone acetate (96)
A mixture of oestrone (10 g, 36.82 mmol), acetic anhydride (17.5 ml) and pyridine (75 
ml) was heated under reflux for 2 h. The cooled reaction mixture was concentrated in 
vacuo and then quenched with ice-water. The precipitate that formed was filtered off, 
washed with water, dried, and recrystallized from aqueous ethanol (95%) to give 96 as 
white crystals (11.2 g, 97%); mp 115-118 °C (lit. 124°C);277 TLC (chloroform/acetone, 
8:1): R/0.83; vmax (KBr) 1770, 1720 (C=0) cm'1; 8H(400 MHz, CDC13) 0.91 (3H, s, 
C -I8 -CH3), 1.42-2.19 (11H, m), 2.29 (3H, s, CH3CO), 2.38-2.54 (2H, m), 2.9 (2H, t, /  
= 4.4 Hz, C-6 -CH2), 6.81 (1H, d, 7C-2-h , c-4-h  = 2.1 Hz, C-4-H), 6 . 8 6  ( 1 H, dd, / C-4-h , c -2-
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h  = 2.4 Hz and Jfc-i-H. c -2-h  = 8.5 Hz, C-2-H) and 7.28 (1H, d, / C-2-h , c -i-h  = 8.2 Hz, C-l- 
H); MS m/z (FAB+) 466.2 [10, (M+H+NBA)*], 313.2 [65, (M+H)+], 270.2 [100, 
(M+H-CH3CO)+]; MS m/z (FAB-) 269.2 [100, (M-CH3CO)']. Found C, 76.9; H, 7.83 
C2oH2 4 0 3 requires C, 76.89; H, 7.74%.
2-Bromooestrone acetate (97)
To a solution of 96 (2.0 g, 6.402 mmol) in trifluoroacetic acid (TFA, 50 ml), thallic 
trifluoroacetate (6.958 g, 12.80 mmol) was added and the resulting mixture was stirred 
at 0 °C under nitrogen for 24 h. Upon removal of TFA under reduced pressure at < 40 
°C, the crystalline oestrone-thallium (IE) complex that obtained was washed twice 
with 1,2-dichloroethane. 1,4-Dioxane (30 ml) and copper bromide (8.58 g, 38.41 
mmol) were then added to this washed complex and the resulting mixture was heated 
under reflux for 3 h. After evaporation of the solvent, water (100 ml) were then added 
to this washed complex After evaporation of the solvent, water (100 ml) was added to 
the residue resulted and the crude product was extracted into dichloromethane (3 x 
150 ml). The combined organic extracts were washed with water, dried (MgS0 4 ), 
filtered and evaporated. The crude product obtained was fractionated by flash 
chromatography (ethyl acetate/hexane, 1:4) and the pale white solid obtained (2.05 g) 
was further purified by recrystallization from methanol to give 97 as colourless 
crystals (1.79 g, 72%); mp 229-231°C; TLC (chloroform/acetone, 8:1 and ethyl 
cetate/hexane, 4:1); R/S 0.89 and 0.62 respectively; vmax (KBr) 1770, 1730 (C=0) 
c m 1; §h (400 MHz, CDCI3) 0.91 (3H, s, C -I8 -CH3), 1.25-2.3 (12H, m), 2.34 (3H, s, 
CH3CO), 2.5 (1H, m), 2.86 (2H, t, J  = 4.58 Hz, C-6 -CH2 ), 6.85 (1H, s, C-4-H) and
7.49 (1H, s, C-l-H); MS m/z (FAB+) 545.2 [90, (M+H+NBA)+], 391.2 [100, (M)+],
348.1 [90, (M-CH3CO)+], 330.1 (10); Acc. MS (FAB+) 391.0856 C20H24BrO3 requires 
391.0909. Found C, 61.2; H, 5.89; C2oH2 3 Br0 3 requires C, 61.39; H, 5.92%.
2-Bromooestrone (98)
A mixture of 97 (1.5 g, 3.832 mmol), potassium carbonate (2.65 g, 19.17 mmol) in 
methanol (70 ml) was heated under reflux for 3 h. Upon evaporation of the solvent, 
water (50 ml) was added to the residue obtained and the crude product was extracted 
with dichloromethane (3 x 100 ml). The combined organic extracts were washed with 
water, dried (MgSCU), filtered and evaporated to give a yellow solid (1.3 g) which was
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purified by recrystallization from ethyl acetate/petroleum ether (60-80 °C) (3:2) to give 
98 as pale yellow crystals (1.23 g, 93%) mp 190-193°C (lit. 193-194°C);278 TLC 
(chloroform/acetone, 8:1 and 4:1): R/S 0.51 and 0.64 respectively; vmax (KBr) 1710 
(C=0) c m 1; 5h (400 MHz, CDC13) 0.87 (3H, s, CH3), 1.4-2.52 (13H, m), 2.84 (2H, m, 
C-6 -CH2), 5.32 (1H, br s, exchanged with D20 , OH), 6.73 (1H, s, C-4-H) and 7.52 
(1H, s, C-l-H); 8 c (400 MHz, CDC13) 13.81 (q, C-18), 21.56 (t), 25.89 (t), 26.26 (t),
29.9 (t), 31.54 (t), 31.91 (t), 38.04 (d), 43.6 (d), 47.93 (s, C13), 50.38 (d), 114.94 (d, 
C-4), 135.04 (d, C-l), 128.84 (s), 130.92 (s), 139.02 (s), 152.7 (s, C-3) and 220 (s, C- 
17-C=0); MS m/z (FAB+) 502.1 [20, (M+NBA)+], 349.1 [100, (M)+], 271.0 (20); MS 
m/z (FAB-) 502.2 [40, (M+NBA)'], 348.1 [100, (M-H)’]; Acc. MS (FAB+) 348.0753 
CigH2 iBr0 2  requires 348.0725.
2-Bromooestrone 3-O-sulphamate (99)
Upon sulphamoylation, 98 (500 mg, 1.431 mmol) gave a crude product (620 mg) 
which was fractionated by flash chromatography (chloroform/acetone, 8:1). The beige 
residue obtained (510 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 99 as beige crystals (405 mg, 6 6 %) mp > 155 °C (dec.); 
TLC (chloroform/acetone, 8:1 and 4:1): R/S 0.43 and 0.61 respectively; vmax (KBr) 
3500, 3300 (NH2), 1730 (C=0), 1390 (S0 2N) cm'1; 6 h (400 MHz, acetone-ds) 0.92 
(3H, s, CH3), 1.41-2.49 (13H, m), 2.86 (2H, m, C-6 -lfc), 7.27 (1H, s, C-4-H), 7.32 
(2H, br s, exchanged with D20 , OSCbNH?) and 7.55 (1H, s, C-l-H); MS m/z (FAB+)
428.1 [100, (M)+], 349.2 [40, (M+H-S02NH2)+]; MS m/z (FAB-) 580.2 [M-H+NBA],
428.1 [100, (M)’], 349.1 [30, (M+H-S02NH2)’]; Acc. MS (FAB+) 428.0430 
CigH23BrN0 4 S requires 428.0531.
2-Iodooestrone acetate (100)
This was prepared from 98 (5.0 g, 16.01 mmol) in the same manner as the preparation 
of 97 except that copper iodide (18.29 g, 96.03 mmol) was used. The crude product 
obtained was purified by flash chromatography with ethyl acetate/hexane (1:4), and 
the yellow solid obtained (6.25 g) was further purified by recrystallization from 
methanol to give 100 as pale yellow crystals (5.89 g, 84%); mp 170-172°C (crystals 
turned brown at > 145°C, lit. 176°C);233 TLC (chloroform/acetone, 8:1 and ethyl 
acetate, 4:1): R/S 0.8 and 0.67 respectively; vmax (KBr) 1770, 1730 (C=0), 8 h (400
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MHz, CDCI3) 0.92 (3H, s, C-I8 -CH3), 1.4-2.31 (12H, m), 2.34 (3H, s, CH3CO), 2.5 
(1H, m), 2.87 (2H, t, 7=  4.27 Hz, C-6 -CH2), 6.82 (1H, s, C-4-H) and 7.69 (1H, s, C-l- 
H); MS m/z (FAB+) 592.1 [20, (M+H+NBA)*], 439.1 [80, (M+H)+], 396.1 [100, 
(M+H-CH3CO)+], 270.2 (40); Acc. MS (FAB+) 439.0767 C20H24IO3 requires 
439.0770.
2-Iodooestrone (101)
This was prepared from 100 (4.0 g, 9.126 mmol) in the same manner as the 
preparation of its bromo analogue 98. The yellow crude product was obtained was 
recrystallized from mthanol to give 101 as pale yellow crystals (3.29 g, 91%); mp 207- 
209 °C (crystals turned brown at >169 °C, lit. 184°C);233 TLC (chloroform/acetone, 
8:1): R/0.75; vmax (KBr) 3400 (OH), 1730 (C=0) cm'1; 6 H (270 MHz, CDC13) 0.91 
(3H, s, C -I8 -CH3), 1.4-2.56 (13H, m), 2.83 (2H, m, C-6 -CH2), 5.24 (1H, s, exchanged 
with DzO, C-3-OH), 6.74 (1H, s, C-4-H) and 7.52 (1H, s, C-l-H); 6 C (400 MHz, 
CDCI3) 13.82 (q, C-18), 21.57 (t), 25.89 (t), 26.26 (t), 29.98 (t), 31.57 (t), 31.81 (t),
39.0 (d), 43.9 (d), 48.3 (s, C13), 50.38 (d), 116.54 (d, C-4), 138.14 (d, C-l), 129.64 
(s), 131.92 (s), 138.02 (s), 153.6 (s, C-3) and 220 (s, C-17, C=0); MS m/z (FAB+)
550.1 [20, (M+H+NBA)+], 396.1 [100, (M)+], 271.2 (40); MS m/z (FAB-) 549.2 [20, 
(M+NBA)'], 395.1 [100, (M-H)']; Acc. MS (FAB+) 397.0651 C18H22IO2 requires 
397.0665.
2-Iodooestrone 3-O-sulphamate (102)
Upon sulphamoylation, 101 (500 mg, 1.262 mmol) gave a crude product which was 
fractionated by flash chromatography (chloroform/acetone, 8:1). The beige residue 
that was obtained (450 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 102 as beige crystals (342 mg, 57%); mp > 145 °C (dec.); 
TLC (chloroform/acetone, 8:1 and 4:1): R/S 0.61 and 0.73 respectively; vmax (KBr) 
3500, 3200 (NH2), 1720 (C=0), 1390 (S02) cm'1; 6h(400 MHz, acetone-d6) 0.92 (3H, 
s, CH3), 1.4-2.53 (13H, m), 2.83 (2H, m, C-6 -H2), 7.25 (1H, s, C-4-H), 7.32 (2H, br s, 
exchanged with D20 , OSC^NH^ and 7.76 (1H, s, C-l-H); MS m/z (FAB+) 629.1 [40, 
(M+H+NBA)*], 476.1 [100, (M+H)+], 396.1 [40, (M+H-S02NH2)+]; MS m/z (FAB-)
628.1 [35, (M+NBA)'], 474.1 [100, (M-H)'], 395.1 [20, (M-SC>2NH2)']; Acc. MS
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(FAB+) 476.0387 C 18H23INO4 S requires 476.0393. Found, C, 45.8; H; 4.74; N, 2.85;
C 18H22INO4 S requires C, 45.48; H, 4.66; N, 2.95%.
2-Methoxyoestrone (103)
To a solution of sodium methoxide (6.541 g, 121.14 mmol) in anhydrous methanol 
(30 ml), at room temperature under N2 was added anhydrous pyridine (30 ml). After 
the resulting mixture was stirred for an additional 2 0  minutes at room temperature, 
anhydrous copper (II) chloride (12.22 g, 90.85 mmol) and 101 (3.0 g, 7.571 mmol) 
were added successively. The reaction mixture was then heated under reflux for 30 
minutes and upon cooling to room temperature concentrated at < 40 °C. Water (50 ml) 
was added to the residue resulted and the precipitate formed was extracted into ether 
(3 x 150 ml). The combined ethereal extracts were washed with brine, dried (MgSC>4), 
filtered and evaporated to give a yellow/brown residue (2.16 g), which was 
fractionated by flash chromatography (chloroform/acetone gradient). The yellow solid 
obtained (121 mg) was further purified by recrystallization from methanol to give 103 
as yellow crystals (85 mg, 4%); mp 180-185 °C (lit. 19l-192°C);279 TLC 
(chloroform/acetone, 8:1): tyO.81; vmax (KBr) 3390 (OH), 1730 (C=0), 1590 cm'1; 
5h (400 MHz, CDC13) 0.91 (3H, s, CH3), 1.25-2.54 (13H, m), 2.82 (2H, m, C-6 -H2),
3.86 (3H, s, O C H 3 ) ,  5.44 (1H, s, exchanged with D2O, O H ) ,  6 . 6 6  (1H, s, C-4-H) and
6.79 (1H, s, C-l-H); MS m/z (FAB+) 300.2 [100, (M)+], 91.0 (10); MS m/z (FAB-)
452.2 [30, (M-H+NBA)-], 299.1 [100, (M-H)'], 285.1 [20, (M-CH3)']; Acc. MS 
(FAB+) 300.1742 C19H24O3 requires 300.1725.
2-Methoxyoestrone 3-O-sulphamate (104)
Upon sulphamoylation, 103 (75 mg, 250.0 pmol) gave a crude product (103 mg) 
which was fractionated by flash chromatography (chloroform/acetone, 8 :1 ) and the 
pale white residue obtained (83 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 104 as white crystals (69 mg, 67%); mp 177-180 °C; TLC 
(chloroform/ acetone 4:1 and ethylacetate/hexane, 2:1): R/s 0.54 and 0.46 respectively; 
vmax (KBr) 3400, 3300 (NH2), 1610 (C=0), 1380 (S02) cm'1; 8 h (270 MHz, CDC13) 
0.92 (3H, s, CH3), 1.24-2.87 (15H, m), 3.88 (3H, s, OCH3), 5.0 (2H, br s, exchanged 
with D20,- SO2NH2), 6.93 (1H, s, C-4-H) and 7.06 (1H, s, C-l-H); MS m/z (FAB+)
379.1 [100, (M)+], 300.0 [25, (M+H-S02NH2)+]; MS m/z (FAB-) 378.0 [100, (M-H)'];
2 1 0
Acc. MS (FAB+) 380.1515 C 19H26NO5S requires 380.1532. Found C, 60.0; H, 6.7; N,
3.67; C19H25NO5S requires C, 60.14; H, 6.64; N, 3.69%.
2,4-Dibromooestrone (105)
A-Bromosuccinimide (3.95 g, 22 mmol) was added to a solution of oestrone (2.0 g, 
7.396 mmol) in ethanol (100 ml). After stirring the yellow reaction mixture at room 
temperature for 24 h, the solvent was evaporated to give a purple solid which was 
fractionated by flash chromatography (ethyl acetate/hexane, 4:1. The white solid 
isolated (3.1 g) was further purified by recrystallization from ethyl acetate/hexane 
(1:3) to give 105 as white crystals (2.89 g, 91%); mp 233-236 °C (lit. 235-236 °C) ; 232 
TLC (ethyl acetate/hexane, 4:1): R/ 0.57; vmax (KBr) 3400 (OH), 1730 (C=0) cm"1; 
SH (400 MHz, CDC13) 0.90 (3H, s, CH3), 1.12-2.55 (13H, m), 2.88 (2H, m, C-6 -CH2),
5.86 (1H, s, exchanged with D20 , OH) and 7.72 (1H, s, C-l-H); MS: m/z (FAB+)
582.0 [20, (M+H+NBA)+], 428.0 [100, (M)+], 287.0 (10); MS m/z (FAB-) 579.9 [20, 
(M-H+NBA)"], 426.9 [100, (M-H)"]; Acc. MS (FAB+) 426.98274 Ci8H2 iBr20 2  
requires 426.9908. Found C, 50.34; H, 4.67; Ci8H2oBr2 0 2  requires C, 50.49; H, 
4.71%.
Oestrone 3-benzyl ether (106)
Sodium hydride (1.11 g, 27.75 mmol) was added to a solution of oestrone (5.0 g, 18.5 
mmol) in DMF (40 ml), at 0 °C. After stirring the resulting mixture for an additional 
15 min, benzyl bromide (2.4 ml, 20.24 mmol) was added and the reaction mixture was 
heated under reflux for 30 min and then being left to stir overnight at room 
temperature. The excess of sodium hydride remaining was quenched by pouring the 
reaction mixture into ice/water. The organic fractions that separated were extracted 
into ethyl acetate ( 2 0 0  ml) and this organic layer was further washed exhaustively with 
brine, dried (MgSCU), filtered and evaporated. The pale yellow residue that obtained 
was triturated with hexane to give a white solid, which was recrystallized from ethyl 
acetate/hexane (1:3) to give 106 as white crystals (6.05 g, 91%); mp 130-132 °C (lit. 
134°C);277 TLC (chloroform/acetone, 8:1): R/0.88; vmax (KBr) 1730 (C=0), 1600 
c m 1; 8 h (400 MHz, CDC13) 0.90 (3H, s, CH3), 1.38-2.53 (13H, m), 2.88 (2H, m, C-6 - 
CH2), 5.04 (2 H, s, OCH2-), 6.73 (1 H, d, 7C-2-h, c-4-h = 2.75 HZ, C-4-H), 6.79 ( 1H, dd, 
7c-4-h, c-2-H = 2.75 Hz and /c - i - h ,  c-2-h = 8.5 Hz, C-2-H), 7.21 (1H, d, / c - i - h ,  c-2-h = 8.5
2 1 1
Hz, C-l-H) and 7.3-7.44 (5H, m, QHs-); MS m/z (FAB+) 360.2 [70, (M)+], 91 (100). 
Found C, 83.1; H, 7.8; C25H28O2 requires C, 83.29; H, 7.83%.
Oestradiol 3-benzyl ether (107)
Sodium borohydride (3.14 g, 82.98 mmol) was added portionwise to a solution of 106 
(3.0 g, 8.298 mmol) in THF (20 ml) and isopropyl alcohol (IPA, 40 ml). After being 
stirred at room temperature for 16 h, the reaction mixture was concentrated and then 
treated cautiously with 3N HC1. The organic fractions were extracted into ethyl acetate 
and after washing with brine, dried (MgSC>4), filtered and evaporated, the organic layer 
gave a white solid (3.2 g) which was recrystallized from acetone/hexane to give 107 as 
white crystals (3.0 g, 96%); mp 92-94 °C; TLC (chlorofom/acetone, 8:1): R / 0.75; 
vmax (KBr) 3300 (OH) cm'1; 8 h (400 MHz, CDCI3) 0.76 (3H, s, CH3), 1.15-2.33 
(14H, m), 2.81 (2H, m, C-6 -H2), 3.73 (1H, t, J=  8.2 Hz, C-17-H), 5.03 (2H, s, -CH2O- 
), 6.71 (1H, d, 7 C - 2 - h , c ^ h =  2.4 HZ, C-4-H), 6.77 (1H, dd, JCa-h , c - 2 - h  = 2.7 Hz and Jc.
i - h , c - 2 - h =  8.54 Hz, C-2-H), 7.19 (1H, d, / C-2.h, c-i-h = 8.55 Hz, C-l-H) and 7.36 (5H, 
m, CeH,-); 5c (400 MHz, CDCI3) 11.05 (q, C18), 23.12 (t), 26.21 (t), 27.23 (t), 29.79 
(t), 30.94 (t), 36.69 (t), 39.05 (d), 43.95 (d), 43.23 (s, C13), 50.0 (d), 69.92 (t, OCH2), 
81.88 (d, C-17), 112.23 (d, C-2), 114.79 (d, C-4), 126.33 (d, C-l), 127.45 (d), 127.83 
(d), 128.53 (d) 132.92 (s), 137.29 (s), 138.0 (s) and 156.69 (s, C-3); MS m/z (FAB+)




Pd-C (10%, 150 mg) was added to a solution of 107 (2.5 g, 6.587 mmol) in ethyl 
acetate (35 ml) and the resulting suspension was hydrogenated at 50 psi at room 
temperature overnight. After removal of the supported catalyst by filtration and 
evaporation of the filtrate, a white solid (2.05 g) was obtained, which was 
recrystallized from methanol to give 108 as white crystals (1.73 g, 91%); mp 177-179 
°C; TLC (chlorofom/acetone, 8:1) R/0.6; vmax (KBr) 3500-3100 (OH) c m 1; 8 h (400 
MHz, acetone-d6) 0.78 (3H, s, CH3), 1.13-2.51 (13H, m), 2.80 (2H, m, C-6 -H2), 3.69 
(2H, m, one H exchanged with D2O, C-17-H and C-17-OH), 6.51 (1H, d, 7 c-2-h, c -4 H =
2 1 2
2.4 HZ, C-4-H), 6.60 (1H, dd, Jc.4-h, c-2-h = 2.75 Hz and 7C-i-h , c-2-h = 8.5 Hz, C-2-H), 
7.10 (1H, d, 7c -2-h, c - i-h  = 8.5 Hz, C-l-H) and 7.97 (1H, s, exchanged with D2O, C-3- 
OH); 5C (400 MHz, acetone-de) 11.63 (q, C18), 23.77 (t), 27.23 (t), 28.13 (t), 30.41 
(t), 31.0 (t), 37.53 (t), 40.02 (d), 44.02 (s, C13), 44.90 (d), 50.9 (d), 81.82 (d, C-17), 
113.57 (d, C-2), 115.93 (d, C-4), 127.03 (d, C-l), 132.04 (s), 138.4 (s), 155.91 (s, C- 
3); MS m/z (FAB+) 426.3 [10, (M+H+NBA)*], 272.3 [100, (M)+] 255.3 [25, (M- 
OH)+]; MS m/z (FAB-) 424.3 [40, (M-H+NBA)'], 271.3 [100, (M-H)"]; Acc. MS 
(FAB+) 273.1845 C18H25O2 requires 273.1855. Found C, 79.8; H, 8.87 C18H24O2 
requires C, 79.37; H, 8 .8 8 %.
Method B
This was prepared from oestrone (5.0 g, 18.5 mmol) in the same manner as the 
preparation of 107 to give a white solid (4.9 g) which was recrystallized from 
methanol to give 108 as white crystals (4.7 g, 94%); mp 176-178 °C.
Oestradiol 3,17/3-diacetate (109)
A mixture of 108 (1.5 g, 5.507 mmol), acetic anhydride (5.25 ml) and pyridine (30 ml) 
was heated under reflux for 2 h. Upon cooling, the reaction mixture was concentrated 
and the resulted poured into ice-water. The precipitate that formed was filtered, 
washed with water, dried, and recrystallized from aqueous ethanol (90%) to give 109 
as white crystals (1.8 g, 97%); mp 126-128°C (lit. 124-126°C);233 TLC (chloroform 
and chloroform/acetone, 8:1) R/s 0.57 and 0.92 respectively; vmax (KBr) 1770, 1730 
(C=0) cm’1; 5h (400 MHz, CDC13) 0.82 (3H, s, C -I8 -CH3), 1.2-1.94 (10H, m), 2.05 
(3H, s, 17/3-CH3CO), 2.14-2.6 (3H, m), 2.29 (3H, s, C-3 -OCOCH3), 2.86 (2H, t, /  =
4.8 Hz, C-6 -CH2), 4.7 (1H, t, /  = 8.5 Hz, C-17-H), 6.79 (1H, d, / C-2-h, c-4-h = 2.1 Hz, 
C-4-H), 6.83 (1H, dd, 7C-4-h, c-2-h = 2.1 H z  and 7C-i-h , c-2-h = 8.5 Hz, C-2-H) and 7.28 
(1H, d, Jc-2-h, c - i-h  = 8.5 Hz, C-l-H); 5C (400 MHz, CDC13) 12.02 (q, C18), 21.12 (q),
21.2 (q), 23.24 (t), 26.23 (t), 26.99 (t), 27.54 (t), 29.48 (t), 36.83 (t), 38.17 (d), 42.85 
(s, C13), 43.96 (d), 49.78 (d), 82.64 (d, C-17), 118.58 (d, C-2), 121.49 (d, C-4), 
126.43 (d, C-l), 137.86 (s), 138.17 (s), 148.39 (s, C-3), 169.88 (s, C=0) and 171.23 (s, 
C=0); MS m/z (FAB+) 356.3 [40, (M)+], 314.3 [100, (M+H-CH3CO)+], 297.3 (50),
255.3 (30); MS m/z (FAB-) 355.0 (20, (M-H) ), 313.2 [100, (M-CH3CO)'], 297.1 (20). 
Found C, 74.2; H, 8.0; C22H28O4 requires C, 74.13; H, 7.92%.
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2-Iodooestradiol 3,17(3-diacetate (110)
This was prepared from 109 (1.5 g, 4.208 mmol) in the same manner as the 
preparation of 110. The crude product obtained was fractionated by flash 
chromatography (chloroform/acetone gradient) and the yellow solid that was isolated 
(1.83 g) was further purified by recrystallization from methanol to give 110 as creamy 
crystals (1.73 g, 85 %); mp 172-174°C; TLC (chloroform/acetone, 8:1 and ethyl 
acetate/hexane, 4:1): R/0.93 and 0.81 respectively; vmax (KBr) 1760, 1730 (C=0) 
c m 1; 6 h (400 MHz, CDC13) 0.82 (3H, s, C-I8 -CH3), 1.22-1.9 (10H, m), 2.06 (3H, s, 
I7 /J-CH3CO), 2.17-2.3 (3H, m), 2.34 (3H, s, C-3-OCOCH0, 2.82 (2H, m, C-6 -CH2), 
4.68 (1H, t, J  = 8.5 Hz, C-17-H), 7.0 (1H, s, C-4-H), and 7.68 (1H, s, C-l-H); MS m/z 
(FAB+) 636.2 [40, (M+H+NBA)+], 483.2 [40, (M+H)+], 440.2 [100, (M+H- 
CH3CO)+], 423.2 (40), 397.2 (10); MS m/z (FAB-) 440.2 [30, (M+H-CH3CO)'], 126.9 
(100). Found C, 54.5; H, 5.61; C 2 2 H 2 7 I O 4  requires C, 54.78; H, 5.64%.
2-Iodooestradiol (111)
This was prepared from 110 (1.5 g, 3.11 mmol) in the same manner as the hydrolysis 
of 101. The light yellow crude product that isolated (1.2 g) was purified by 
recrystallization from acetone to give 111 as white crystals (l.lg , 89%); mp 175- 
178°C (lit. 177-178°C);233 TLC (chloroform/acetone, 8:1 and ethyl acetate/hexane, 
4:1): Rys 0.5 and 0.34 respectively; vmax (KBr) 3500-3300 (OH) cm'1; 8 h (400 MHz, 
CDCI3) 0.78 (3H, s, C -I8 -CH3), 1.11-2.27 (14H, m, 1H exchanged with D20), 2.8 
(2 H, m, C-6 -CH2), 3.73 (1H, t, J  = 8 . 2  Hz, C-17-H), 5.24 (1H, br s, exchanged with 
D20 , C-3-OH), 6.72 (1H, s, C-4-H) and 7.52 (1H, s, C-l-H); MS m/z (FAB+) 552.2 
[10, (M+H+NBA)+], 398.1 [100, (M)+], 381.1 (30), 272.2 (10), 255.2 (10); MS m/z 
(FAB-) 550.0 [20, (M-H+NBA)*], 397.1 [100, (M-H)']; Acc. MS m/z (FAB+) 
399.07858 C18H24IO2 requires 399.08211.
2-Methoxyoestradiol (112)
This was prepared from 111 (3.0 g, 7.5323 mmol) in the same manner as the 
preparation of 103. The yellow/brown crude product that was isolated (2.2 g) was 
fractionated by flash chromatography (chloroform/acetone gradient) and the yellow 
solid that isolated (185 mg) was further purified by recrystallization from methanol to 
give 112 as yellow crystals (108 mg, 5%); mp 180-183°C; TLC (chloroform/acetone,
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8:1 and ethyl acetate/hexane, 4:1): R/s 0.58 and 0.31 respectively; vmax (KBr) 3500- 
3000 (OH), 1590 (CH=CH) c m 1; 8H(400 MHz, CDC13) 0.83 (3H, s, C -I8 -CH3), 1.14- 
2.29 (14H, m), 2.80 (2H, m, C-6 -H2), 3.7 (1H, t, /  = 8.2 Hz, C-17-H), 3.77 (3H, s, 
OCH3), 5.6 ( 1 H, br s, exchanged with D20 , C-3-OH), 6.58 ( 1H, s, C-4-H) and 6 . 8 6  
(1H, s, C-l-H); 8 c (400 MHz, CDC13) 11.1 (q, C-18), 23.2 (t), 26.3 (t), 27.45 (t), 29.26 
(t), 30.52 (t), 36.9 (t), 38.75 (d), 43.2 (s, C13), 44.1 (d), 50.06 (d), 55.90 (q, OCH3),
81.9 (d, C-17), 111.17 (d, C-4), 112.65 (d, C-l), 129.0 (s), 134.21 (s), 143.37 (s) and
144.9 (s); M S m/z (F A B +) 302.1 [100, (M )+], 285.1 (10); M S m/z (F A B -) 455.2 [30, 
(M + N B A )'], 301.2 [100, (M -H)']; A cc. M S (F A B +) 300.1742 C 1 9 H 2 6 O 3  requires 
300.1725. Found C, 75.3; H, 8.69; C i9 H 2 6 0 3  requires C, 75.46; H, 8.67%.
4-Nitrooestrone (113), 2-nitrooestrone (114), and 2,4-di-nitrooestrone (115)
A solution of concentrated nitric acid (0.7 ml) in glacial acetic acid (17.5 ml) was 
added to a solution of oestrone (3.0 g, 11.095 mmol) in glacial acetic acid (150 ml) at 
70-75 °C. Upon standing of the resulting deep purple/brown mixture at room 
temperature for 18 h. 113 seperated out as yellow precipitate which was collected by 
filtration, washed (toluene) and air dried to give a yellow powder (1.0 g). An analytical 
sample was recrystallized from methanol to give a yellow crystals; mp > 270-274 °C 
(dec.) [lit. 270-280°C (dec. ) ] ; 222 TLC (chloroform/acetone, 8:1): R/0.62; vmax (KBr) 
3460 (OH), 1720 (C=0), 1620 cm'1; 8 h (400 MHz, CDC13) 0.87 (3H, s, C -I 8 -C H 3 ), 
1.24-3.24 (15H, m), 7.0 (1H, d, 7C-i-h, c-2-h = 8 . 8  Hz, C-2-H), 7.5 (1H, d, 7c-2-h. c - i -h  =
8 . 8  Hz C-l-H) and 9.47 (1H, s, exchanged with D20 , OH); MS m/z (FAB+) 469.2 [40, 
(M+H+NBA)+], 316.2 [100, (M+H)+], 299.2 (35); MS m/z (FAB-) 467.1 [20, (M- 
H+NBA)'], 315.1 [100, (M)'], 298.1 (30); Acc. MS (FAB+) 316.1533 requires 
Ci8H22N 0 4 316.1548.
The filtrate from above was evaporated and to a solution of the residue that resulted in 
toluene (50 ml), was added aqueous 2% sodium bicarbonate (35 ml). After being 
stirred vigorously for 5-6 h, the two layers were separated. Upon acidification of the 
aqueous layer with 5M HC1, the precipitate that formed was collected by filtration, 
washed (water) and dried to give 115 as a light yellow powder (695 mg, 20%). An 
analytical sample was recrystallized from ethanol to give a light yellow crystals; mp 
180-183°C (lit. 179-180 °C) ; 222 TLC (chloroform/acetone, 8:1): R/0.68, vmax (KBr)
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3440 (OH), 1730 (C=0), 1620 cm 1; 5h (400 MHz, CDC13) 0.87 (3H, s, CH3), 1.24-
2.58 (13H, m), 2.9 (2H, m, C-6 -H2), 8.17 (1H, s, C-l-H), and 10.64 (1H, s, exchanged 
with D20 , OH). MS m/z (FAB+) 514.2 [60, (M+H+NBA)+], 361.2 [100, (M+H)+]; 
MS m/z (FAB-) 512.1 [80, (M-H+NBA)"], 360.1 [100, (M)"], 343.1 (40); Acc. MS 
(FAB+) 361.1390 Ci8H2 iN20 6 requires 361.1399.
The toluene layer was washed with water, dried (MgS0 4 ), filtered and concentrated, 
during which an additional portion of 113 was precipitated (650 mg, total yield 45% ). 
After the collection of 113 by filteration, the filtrate was evaporated and the residue 
that resulted was recrystallized from ethanol to give 114 as yellow crystals (1.1 g). The 
residue from the mother liquor gave a further crop of 114 upon recrystallization from 
ethanol (950 mg, overall yield 58%); mp 182-185°C (lit. 183.5-184°C);222 TLC 
(chloroform/acetone, 8:1): RfO.6; vmax (KBr) 3300 (OH), 1730 (C=0), 1620 cm"1; 8 h 
(400 MHz, CDCI3) 0.93 (3H, s, CH3), 1.24-3.01 (15H, m), 6.9 (1H, s, C-4-H), 8.0 
(1H, s, C-l-H) and 10.25 (1H, s, exchanged with D20 , OH); MS m/z (FAB+) 469.2 
[35, (M+H+NBA)+], 316.2 [100, (M+H)+], 299.2 (30);. MS m/z (FAB-) 467.1 [20, 
(M-H+NBA)"], 315.1 [100, (M)"], 298.1 (25); Acc. MS (FAB+) 316.15432 requires 
Ci8H2 iN 0 4 316.15488.
4-Nitooestrone 3-benzyl ether (116)
This was prepared from 4-nitrooestrone 113 (6.23 g, 19.75 mmol) in the same manner 
as the preparation of 106. The brown crude product that obtained (9.1 g) was dissolved 
in toluene and heated with activated charcoal. After filtration, the filtrate was 
evaporated and the yellow residue (8.17 g) resulted was recrystallized from IP A to 
give 116 creamy crystals (6.89, 8 6 %); mp > 140°C (dec.); TLC (chloroform/acetone, 
8:1): R/0.82; vmax (KBr) 1740 (C=0) cm 1; 8 h (400 MHz, CDCI3) 0.90 (3H, s, CH3), 
1.14-2.54 (13H, m), 2.82 (2H, m, C-6 -H2 ), 5.15 (2H, s, -CHjO-), 6 . 8 6  (1H, d, 7 C - i - h , c -  
2- h  = 8.55 Hz, C-2-H), 7.27 (1H, d, 7 C-2 H , c - i - h  = 8.85 Hz, C-l-H), and 7.36 (5H, m, 
C6 Hs-); MS m/z (FAB+) 405.49 [45, (M)+], 327.1 (20). Found C, 74.4 ; H, 6.81; N, 
3.48; C25H27NO4 requires C, 74.05; H, 6.71; N, 3.45%.
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4-Aminooestrone-3-benzyl ether (117)
A  solution of 116 (2.0 g, 6.341 mmol) in acetone (320 ml) and 0.5 M NaOH (65 ml) 
was added. The resulting mixture was heated to reflux and sodium hydrosulfite (6.37 
g, 36.586 mmol) was added. The mixture was heated under reflux with stirring for 35 
min, a further of sodium hydrosulfite (5.1 g, 29.292 mmol) and 0.5 M NaOH (65 ml) 
were added. After refluxing for a further 40 min, the reaction mixture was stirred at 
room temperature overnight, then water (50-100 ml) was added, and most of the 
acetone was removed under reduced pressure. The resulting suspension was coold in 
an ice-bath for 2  h and the resulting precipitated was collected by filteration, washed 
throughly with water and dried in vacuo to give a yellow solid (1.4 g) which was 
purified by flash chromatography with ethyl acetate/hexane (5:1). The pale yellow 
solid obtained (1.17 g) was further purified by recrystallization from methanol to give 
117 as pale yellow crystals (960 mg, 52%) mp > 170 °C (dec) (lit. 220-224 °C) ; 222 
TLC (chloroform/acetone, 8:1): R/0.54; vmax (KBr) 3480, 3440 (NH2), 1730 (C=0), 
1600 cm '; 5H (400 MHz, CDC13) 0.89 (3H, s, CH3), 1.39-2.85 (15H, m), 5.07 (2H, s, - 
CH2O), 6.7 (1H, d, 7C-i-h, c-2-h = 8.5 Hz, C-2-H), 6.74 (1H, d, Jc.2.H, c-i-h = 8 . 8  Hz, C-
1-H), and 7.34-7.45 (7H, m, 2H exchanged with D20 , C-4-NH?. and C-3-GTL-): MS 
m/z (FAB+) 375.2 [70, (M)+], 284.1 (10), 91.0 (100); Acc. MS (FAB+) 375.2192 
C25H29N 0 2 requires 375.2198.
4-Aminooestrone (118)
A  suspension of Pd-C (10%, 200 mg) in THF (60 ml) containing 113 (1.5 g, 4.76 
mmol) was stirred overnight at room temperature underatmosphere pressure of 
hydrogen. After removal of the supported catalyst by filtration, the filtrate was 
evaporated and the yellow solid (1.13 g) that resulted was recrystallized from toluene 
to give 118 as yellow crystals (985 mg, 73%), a further crop of 118 (120 mg) was 
obtained from the residue of the mother liquor upon recrystallization from toluene 
(overall yield 81%); mp > 200 °C (dec. and melted at 258-260 °C); TLC 
(chloroform/acetone, 8:1): Rf  0.35; vmax (KBr) 3480-3200 (NH2 and OH), 1720 
(C=0), 1600 cm'1; 5h (400 MHz, CDCI3) 0.81 (3H, s, CH3), 1.26-2.61 (15H, m), 4.11 
(2H, br s, exchanged with D20 , C-4-NH^, 6.4 (1H, d, / c-i-h, c-2-h = 8.2 Hz, C-2-H),
6.49 (1H, d, Jc-2-h, c-i-h = 8.2 Hz, C-l-H), and 8.83 (1H, br s, exchanged with D20 , 
OH); MS m/z (FAB+) 439.3 [10, (M+H+NBA)+], 285.3 [100, (M)+], 255.3 (10); MS
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m/z (FAB-) 284.2 [100, (M-H)'], 258.1 (70); Acc. MS (FAB+) 286.1804 C 18H24NO2 
requires 286.1807.
4-Sulphamido-oestrone 3-O-sulphamate (119)
Upon sulphamoylation of 118 (300 mg, 1.051 mmol) after treatment with 1 eq. of 
NaH, a yellow oil (410 mg) was obtained which was fractionated by flash 
chromatography (chloroform/acetone gradient) to give 119 as a yellow oil solidified 
on standing (220 mg, 57%); mp > 93°C (dec); TLC (chloroform/acetone, 8:1): R/0.23; 
vmax (KBr) 3380- 3200 (NH2), 1720 (C=0), 1380 (S02) cm'1; 5H (400 MHz, DMSO- 
d6) 0.85 (3H, s, CH3), 1.24-2.96 (15H, m), 6.74 (2H, br s, exchanged with D20 , 
SO2NH2), 7.22 (1H, d, / c-i-h, C-2-H = 8 . 8  Hz, C-2-H), 7.33 (1H, d, / C-2-h, c-i-h = 8 . 8  Hz, 
C-l-H),7.8 (1H, br s, -S0 2NH-) and 8.03 (2H, br s, exchanged with D20 , OSO2NH2); 
MS m/z (FAB+) 597.2 [10, (M+H+NBA)+], 444.2 [100, (M+H)+], 364.2 [95, (M+H- 
S 0 2NH2)+], 284.2 [80, (M+H-2xS02NH2)+], 272.2 (40); MS m/z (FAB-) 596.1 [10, 
(M+NBA)'], 442.1 [100, (M-H)'], 363.1 [40, (M-S02NH2)'], 272.1 (10); Acc. MS 
(FAB+) 444.1128 Cn H26N30 6S2 requires 444.1263.
Oestrone methyl ether (120)
To a stirred solution of oestrone (5.0 g, 18.5 mmol) in DMF (125 ml), anhydrous 
potassium carbonate (5.0 g, 36.18 mmol) and methyl iodide (6.75 ml, 108.4 mmol) 
were added. The resulting suspension was heated under reflux for 2 h, then stirred at 
room temperature for 24 h before pouring into cold HC1 (100 ml, 50% v/v). The white 
precipitate that formed was filtered, washed with water and air dried to give 1 2 0  as 
white solid (5.15 g, 98%), an analytical sample was recrystallized from acetone to give 
a white crystals; mp 169-171°C; TLC (chloroform/acetone, 8:1): R/0.71; vmax (KBr) 
1730 (C=0) c m 1; 5H (400 MHz, CDCI3) 0.91 (3H, s, CH3), 1.38-2.54 (13H, m), 2.92 
(2H, m, C-6 -H2), 3.78 (3H, s, OCH3), 6.54 (1H, d, Jc.2-h, c-i-h = 2.7 Hz, C-4-H), 6.71 
(1H, dd, 7C-4-h, c-2-h = 2.7 Hz and /c-i-h, c-2-h= 8.5 Hz, C-2-H) and 7.2 (1H, d, / C-i-H. c- 
2-h = 8.55 Hz, C-l-H); MS m/z (FAB+) 284.3 [100, (M)+], 255.3 (30); Acc. MS 
(FAB+) 285.1866 C 19H25O2 requires 285.1855. Found C, 79.7; H, 8.53; C19H24O2 
requires C, 80.24; H, 8.51%.
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2-Acetyloestrone 3-methyl ether (121)
To a suspension of anhydrous aluminium chloride (3.76 g, 28.20 mmol) and acetyl 
chloride (2.0 ml, 28.13 mmol) and anhydrous nitromethane (50 ml) at 0 °C, 120 (4.0 g, 
14.07 mmol) was added. After being stirred for 5 h at room temperature, The reaction 
mixture was poured into 10% HC1 (100 ml) and the resulting mixture was extracted 
with ethyl acetate (3x100 ml). The combined organic extracts were washed with, brine 
until neutral, dried (MgSCU), filtered and evaporated. The yellow/brown residue that 
was obtained was triturated with methanol and the resulting white precipitate was 
collected by filtration and air-dried to give a white solid (4.3 g) which was 
recrystallized from methanol to give 122 as white crystals (4.0 g, 87%); mp 181-184°C 
(lit. 189-190°C);224 TLC (chloroform/acetone, 8:1): R/0.82; vmax (KBr) 1730 (C-17, 
C=0), 1670 (acetyl, C=0) cm 1; 6 r  (400 MHz, CDC13) 0.9 (3H, s, C -I8 -CH3), 1.39-
2.54 (13H, m), 2.61 (3H, s, CH3CO), 2.94 (2H, t, J  = 4.4 Hz, C-6 -H2), 3.88 (3H, s, 
OCH3), 6.69 (1H, s, C-4-H), and 7.7 (1H, s, C-l-H); 5c (400 MHz, CDC13) 13.83 (q, 
C -l8 ), 21.56 (t), 25.82 (t), 26.3 (q, CH3CO), 29.9 (t), 31.44 (t), 31.93 (t), 35.84 (t), 
38.24 (d), 43.75 (d), 47.95 (s, C13), 50.33 (d), 55.5 (q, OCH3), 111.81 (d, C-4), 127.66 
(d, C-l), 125.67 (s), 132.08 (s), 143.21 (s), 157.15 (s, C-3), 199.39 (s, C=0) and 220 
(s, C-17-C=0). MS m/z (FAB+) 327.2 [100, (M+H)+], 311.2 (10), 173.2 (5). Found C, 
77.4; H, 8.04 C21H26O3 requires C, 77.27; H, 8.03%.
2-(l'-Hydroxyethyl)oestrone 3-methyl ether (122)
A  solution of 121 (1.0 g, 3.063 mmol) in THF (20 ml) was shaken with Pd-C (1.0 g, 
10%) under an atmosphere of hydrogen at room temperature for 5 h. After the 
supported catalyst was removed by filtration, the filtrate was evaporated to give a 
white solid (950 mg) which was recrystallized from methanol to give 122 as white 
crystals (900 mg, 90%); mp 184-186°C; TLC (chloroform/acetone, 8:1): Rf  0.53; 
vmax (KBr) 3500 (OH), 1730 (C=0) cm'1; 8 h (400 MHz, CDC13) 0.91 (3H, s, C-18- 
CH3), 1.5 [3H, d, / =  6.7 Hz, CH3CH(OH)], 1.5-2.69 (14H, m), 2.91 (2H, m, C-6 -H2), 
3.83 (3H, s, OCH3), 5.05 (1H, q, -CH(OH)CH3), 6.61 (1H, s, C-4-H), and 7.27 (1H, s, 
C-l-H); 6 c (400 MHz, CDC13) 13.86 (q, C-18), 23.21 (q, CH3-CHOH-), 21.56 (t),
25.79 (t), 26.66 (t), 29.62 (t), 31.57 (t), 35.86 (t), 38.41 (d), 44.07 (d), 48.04 (s, C13), 
50.35, 55.3 (q, OCH3), 66.7 (d, C-2-CHOH), 110.89 (d, C-4), 123.24 (d, C-l), 130.08 
(s), 131.31 (s), 136.41 (s), 154.55 (s, C-3) and 220 (s, C-17, C=0); MS m/z (FAB+)
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328.2 [50, (M)+], 311.2 [100, (M-OH)+], 255.2 (5). Found C, 76.5; H, 8.57 C21H28O3 
requires C, 76.79; H, 8.59%.
2-Acetyloestrone (123)
A mixture of 121 (700 mg, 2.144 mmol), acetic acid (5 ml) and hydrogen bromide (5 
ml, 48%) was heated on water-bath for 2 h and then stirred at room temperature 
overnight. The reaction mixture was poured into ice-water and the organic fractions 
were extracted into ether (3 x 100 ml). After washing the combined organic extracts 
with NaHCC>3 (5%, 50 ml) followed by, water (100 ml), it was dried (MgSC>4), filtered 
and evaporated to give a yellow solid (485 mg) which was recrystallized from 
methanol to give 123 as beige crystals (410 mg, 61%); mp 138-142°C; TLC 
(chloroform/acetone, 8:1): R/0.68; vmax (KBr) 3460 (OH), 1730, 1640 (C=0) cm'1; 
5h (400 MHz, CDCI3) 0.93 (3H, s, C -I8 -CH3), 1.42-2.57 (13H, m), 2.61 (3H, s, 
CH3CO), 2.92 (2H, m, C-6 -H2), 3.6 (1H, br s, exchanged with D20 , OH), 6.71 (1H, s, 
C-4-H), and 7.61 (1H, s, C-l-H); MS m/z (FAB+) 313.3 [30, (M+H)+], 295.2 (10),
281.1 (15); MS m/z (FAB-) 311.2 [100, (M-H)+], 298.1 (10), 283.0 (5), 271.1 (10); 
Acc. MS (FAB+) 313.1809 C20H25O3 requires 313.1804.
Reduction o f  2-acetyloestrone methyl ether
2-(l'-Hydroxyethyl) oestradiol 3-methyl ether (124)
To a solution of 121 (500 mg, 1.532 mmol) in THF/IPA (30 ml, 1:1), NaBH4 (290 mg, 
7.666 mmol) was added and the resulting mixture was stirred at room temperature for 
about 16 h, then 5N HC1 was added dropwise at 0 °C and the solvent was removed 
under reduced pressure. The aqueous layer was extracted with ethyl acetate (3 x 100 
ml). The combined extracts were washed with water, dried (MgSCU), filtered and 
evaporated to give a yellow residue, which was purified by flash chromatography with 
chloroform/acetone gradient. The more polar fraction obtained gave 124 as pale 
yellow oil (300 mg, 60%), solidfied on standing; mp 105-107°C; TLC 
(chloroform/acetone 8:1) R/0.49; vmax (KBr) 3500-3100 (OH), 1600 (CH=CH) cm '1; 
8 h (400 MHz, CDCI3) 0.77 (3H, s, C-I8 -CH3), 1.13-1.45 (7H, m), 1.5 (3H, d, 
CH3CHOH-), 1.65-2.63 (8 H, m, 2H exchanged with D20), 2.87 (2H, m, C-6 -H2), 3.7 
(1H, t, / =  8.5 Hz, C-17-H), 3.82 (3H, s, C-3 -OCH3), 5.0 (1H, pentet, CH3CHOH-),
6.59 (1H, s, C-4-H), 7.23 (1H, s, C-l-H); 8 C (400 MHz, CDC13) 11.43 (q), 22.64 (q),
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23.1 (t), 26.37 (t), 27.07 (t), 29.04 (t), 30.5 (t), 36.7 (t), 38.9 (d), 44.0 (s, C-13), 44.04 
(d), 50.0 (d), 55.58 (q, OCH3), 66.9 (d, CHOH), 81.84 (d, C-17), 110.9 (d, C-4),
123.55 (d, C-l), 130.63 (s), 132.41 (s), 136.69 (s) and 154.54 (s); MS m/z (FAB+)
330.1 [55, (M)+], 313 [100, (M-OH)+]; MS m/z (FAB-) 329.0 [100, (M-H) ], 312.1 
[45, (M-H-OH)']; Acc. MS (FAB+) 330.2207 C21H30O3 requires 330.2195.
The less polar fraction was collected and upon evaporation gave a pale yellow oil, 
solidfied on standing (160 mg, 32%), the structure of this fraction could not be 
assigned and it could be the other isomer of 124 and has the following data; mp 135- 
137 °C; TLC (chloroform/acetone, 8:1): R/0.58; vmax (KBr) 3500-3100 (OH), 1600 
(CH=CH) c m 1; SH (400 MHz, CDC13) 0.79 (3H, s, C-I8 -CH3), 1.15-1.36 (7H, m), 1.4 
(3H, t, CH3CH2-), 1.45-2.5 (6 H, m, 1H exchanged with D20), 2.87 (2H, m, C-6 -H2),
3.25 (2 H, d, CH3CH2), 3.73 ( 1 H, t, / =  8.5 Hz, C-17-H), 3.78 (3H, s, C-3 -OCH3), 6.58 
(1H, s, C-4-H) and 7.3 (1H, s, C-l-H); 8 c (400 MHz, CDC13) 11.1 (q), 22.7 (q), 23.12 
(t), 26.23 (t), 27.29 (t), 29.83 (t), 30.49 (t), 31.9 (t), 38.92 (d), 44.07 (s, C-13), 44.22 
(d), 50.02 (d), 55.36 (q), 56.56 (q), 73.52 (d), 81.84 (d), 110.7 (d, C-4), 122.9 (d, C-l),
128.8 (s), 132.44 (s), 136.39 (s) and 154.63 (s); MS m/z (FAB+) 313.1 [100, (M-H)+]; 
Acc. MS (FAB+) 313.2167 C21H29O2 requires 313.2168.
2-Ethyloestrone 3-methyl ether (125) and 2-(l'-hydroxyethyl)oestrone 3-methyl 
ether (1 2 2 )
A solution of 121 (1.0 g, 3.063 mmol) in THF/ethanol (1:2) (30 ml) was hydrogenated 
in the presence of Pd-C (1.0 g, 10%) 50 psi at room tempreature for 24 h. After the 
supported catalyst was removed by filtration the filtrate was evaporated to give a white 
solid (950 mg) which was fractionated by flash chromatography (chloroform/acetone 
gradient). The less polar fraction gave a white solid (805 mg) which was further 
purified by recrystallization from methanol to give 125 as white crystals (775 mg, 
78%); mp 112-115 °C; TLC (chloroform, and chloroform/acetone, 8:1): R/S 0.56 and 
0.78 respectively; vmax (KBr) 1730 (C=0), 1600 cm'1; 8 h ((400 MHz, CDCI3), 
CDCI3) 0.91 (3H, s, C -I8 -CH3), 1.17 (3H, t, J  = 7.7 Hz, CH3CH2), 1.39-2.48 (13H, 
m), 2.62 (2 H, q, C-2 -CH2CH3), 2.87 (2 H, m, C-6 -H2), 3.81 (3H, s, OCH3), 6.58 ( 1H, 
s, C-4-H), and 7.08 (1H, s, C-l-H); 8 C (400 MHz, CDC13) 13.86 (q), 14.54 (q), 21.58
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(t), 22.86 (t), 25.82 (t), 26.17 (t), 29.72 (t), 31.63 (t), 35.88 (t), 38.23 (d), 44.04 (d), 
48.23 (s, C13), 50.38, 55.32 (q, OCH3), 110.8 (d, C-4), 126.34 (d, C-l), 130.08 (s),
131.31 (s), 134.71 (d), 155.41 (s) and 220 (C-17, C=0); MS m/z (FAB+) 312.1 [100, 
(M)+]. Found C, 80.5; H, 9.03 C21H28O2 requires C, 80.73; H, 9.03%.
The more polar fraction gave a white solid (110 mg) which was recrystallized from 
methanol to give 122 as white crystals (90 mg, 10%).
2-Ethyloestrone (126)
Aluminum chloride (1.28 g, 9.615 mmol), sodium iodide (1.44 g, 9.615 mmol) and 
125 (300 mg, 961.5 pmol) were added in this order to a mixture of acetonitrile (25 ml) 
and dichloromethane (12.5 ml) at 0 °C under N2 . The resulting suspension was heated 
under reflux for 8 h, cooled to room temperature and then poured into water and 
followed by extraction with dichloromethane (3 x 100 ml). The combined DCM 
exctracts were washed with 10% sodium thiosulphate (100 ml), brine, dried (MgSCU), 
filtered and evaporated to give a yellow solid (290 mg), which was fractionated by 
flash chromatography (chloroform/acetone gradient). The yellow solid that isolated 
(254 mg) was further purified by recrystallization from acetone to give 126 as yellow 
crystals (240 mg, 83%); mp 201-204 °C; TLC (chloroform and chloroform/acetone, 
8:1): IV0.3 and 0.65 respectively; vmax (KBr) 3300 (OH), 1720 (C=0) c m 1; 8h (400 
MHz, CDCI3) 0.91 (3H, s, C -I8 -CH3), 1.22 (3H, t, CH3CH2-), 1.38-2.51 (13H, m), 
2.63 (2H, q, C-2-CH?CHO, 2.86 (2H, m, C-6 -H2), 4.68 (1H, br s, exchanged with 
D20 , OH), 6.52 (1H, s, C-4-H) and (1H, s, C-l-H); MS m/z (FAB+) 298.0 [100, 
(M)+], 271.9 (10), 255.1 (10); MS m/z (FAB-) 297.1 [100, (M-H) ], 276.0 (45), 258.0 
(40); Acc. mass (FAB+) 298.1928 requires C20H26O2 298.1933.
2-Ethyloestrone 3-O-sulphamate (127)
To a stirred solution of 126 (150 mg, 502.6 (imol) and 2,6-di-r-butyl-4-methylpyridine 
(DBMP) (310 mg, 1.51 mmol) in CH2CI2 (10 ml), sulphamoyl chloride in toluene 
(3.016 mmol) was added dropwise. After being stirred for 2 h the reaction mixture was 
diluted with dichloromethane ( 1 0 0  ml) and the resulting mixture washed with brine, 
dried (MgSC>4), filtered and evaporated. The residue that was obtained (170 mg) was 
fractionated by flash chromatography (chloroform/acetone gradient) and the white
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solid that isolated (155 mg) was further purified by recrystallization from ethyl 
acetate/hexane (1:2) to give 127 as white crystals (146 mg, 77%); mp 165-167 °C; 
TLC (chlorofom/acetone, 8:1): R/0.41; vmax (KBr) 3500-3300 (NH2), 1720 (C=0), 
1390 (S0 2N) cm'1; 8 H (400 MHz, CDC13) 0.91 (3H, s, C -I8 -CH3), 1.22 (3H, t, 
CH3CH2-), 1.41-2.55 (13H, m), 2.71 (2H, q, C-2 -CH2CH3), 2.89 (2H, m, C-6 -H2), 5.0 
(2H, br s, exchanged with D20 , OSO9NH9), 7.11 (1H, s, C-4-H) and 7.2 (1H, s, C-l- 
H); MS m/z (FAB+) 531.2 [10, (M+H+NBA)*], 377.1 [100, (M)+], 298.2 [20, (M+H- 
S 0 2NH2)+]; MS m/z (FAB-) 530.1 [30, (M+NBA)'], 376.1 [100, (M-H)'], 275.1 (10); 
Acc. MS (FAB+) 377.1683 requires C2oH27N 04S 377.1661. Found C, 63.4; H, 3.73; 
N, 7.4 requires C2oH27N 04S C, 63.63; H, 3.71; N, 7.21%.
Oestradiol 3,17{Ldibenzyl ether (128)
To a stirred solution of 107 (3.0 g, 6.628 mmol) in DMF (90 ml) at 0 °C, sodium 
hydride (795.4 mg, 19.885 mmol) was added and this was followed by benzyl bromide 
(2.8 ml, 23.54 mmol) after the evolution of H2 had ceased (ca. 15 min). The reaction 
mixture was heated under reflux for 25 min, stirred at room temperature overnight and 
then poured into ice-water containing 3N HC1 (10 ml). The resulting mixture was 
extracted with ethyl acetate (3 x 200 ml) and the combined extracts were washed with, 
brine (100 ml), dried (MgS04), filtered and evaporated. The viscous oil that obtained 
was triturated with hexane to give a white solid (4.25 g), which was collected by 
filtration and recrystallized from methanol to give 128 as white crystals (2.89 g). The 
residue that obtained from the evaporation of mother liquor was recrystallized from 
methanol to give other a second crop of 128 (0.89 g, total yield 76%); mp 76-78°C (lit. 
81-82 °C, from ethanol or acetone and 62 °C from aq. methanol) ; 239 mp 74-78 °C; 
TLC (hexane/ethyl acetate, 5:1): R/0.63; vmax (KBr) 1600 (CH=CH) cm'1; 8 h (400 
MHz, CDCI3) 0.87 (3H, s, CH3), 1.12-2.3 (13H, m), 2.84 (2H, m, C-6 -H2), 3.52 (1H, t, 
/ =  8.2 Hz, C-17-H), 4.56 (2H, s, C-17-OCH2-), 5.03 (2H, s, C-3-OCHr), 6.71 (1H, d, 
7c -2-h , C-4-H =2.1 Hz, C-4-H), 6.78 (1H, dd, 7c-4-h , c-2-h = 2.7 Hz and / c -i -h , c -2-h  = 8.5 
Hz, C-2-H), 7.2 (1H, d, Jc.2-h , c -i -h  = 8.5 Hz, C-l-H) and 7.35 (10H, m, 2 x Ar); MS 
m/z (FAB+) 452.3 [65, (M)+], 361.3 (5), 345.3 (15), 91.0 (100). Found C, 84.8; H, 
8.07; C32H3 6 0 2 requires C, 84.91; H, 8.02%.
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2-Bromooestradiol 3,17p-dibenzyl ether (129)
Bromine (0.44 ml, 7.248 mmol) was added to a stirred solution of 128 (3.416 g, 6.415 
mmol) in acetic acid-THF (3:2, 35 ml) at 0 °C. After being warmed to room 
temperature and stirred for an additional 1.5 h, the reaction mixture was poured into 
ice-water (150 ml) and extracted with dichloromethane (3 x 200ml). The combined 
organic layer extracts were washed successively with water ( 2 0 0  ml), saturated 
aqueous sodium bicarbonate ( 2 0 0  ml), 1 0 % aqueous sodium thiosulphate (150 ml) and 
brine (2 x 100 ml), dried (MgSO^, filtered and evaporated. The yellow syrup that 
resulted was triturated with hexane-ethyl acetate mixture and the creamy solid that 
collected (3.32 g) was further purified by recrystallization from methanol to give 129 
as white crystals (3.1 g, 78%); mp 153-155 °C (lit. 156-158 °C) ; 239 TLC (hexane/ethyl 
acetate, 5:1): R/0.55; vmax (KBr) 1600 (CH=CH) cm'1; 8 H (400 MHz, CDC13) 0.86 
(3H, s, CH3), 1.12-2.3 (13H, m), 2.77 (2H, m, C-6 -H2), 3.51 (1H, t, / =  8.2 Hz, C-17- 
H), 4.57 (2H, s, C-17-OCH2-), 5.1 (2H, s, C-3 -OCH2-), 6.65 (1H, s, C-4-H), and 7.19- 
7.48 (11H, m, C-l-H and 2 x Ar); MS m/z (FAB+) 530.2 [90, (M-H)+]; Acc. MS 
(FAB+) 531.1840 CsiHssBrCb requires 531.1899.
2-Iodooestradiol 3,17P-dibenzyl ether (130)
To a stirred solution of 110 (2.0 g, 5.016 mmol) in DMF (60 ml) at 0 °C, sodium 
hydride (600 mg, 15.0 mmol) was added and this was followed by benzyl bromide (1.8 
ml, 15.13 mmol) and then tetrabutylammonium iodide (500 mg, 1.354 mmol) after the 
evolution of H2 had ceased. The resulting mixture was stirred for 24 h at room 
temperature then poured into ice-water containing 3N HC1 (10 ml) and extracted with 
dichloromethane (3 x 200 ml). The combined organic extracts were washed with 
brine, dried (MgS0 4 ), filtered and evaporated. The viscous oil that obtained was 
triturated with hexane to give a white solid (2.85 g), which was collected by filtration, 
recrystallized from methanol to give 130 as white crystals (1.98 g). The residue that 
obtained upon evaporation of the mother liquor was recrystallized from methanol to 
give a seconed crop of 130 (500 mg, total yield 85%); mp 129-131°C; TLC 
(hexane/ethyl acetate 5:1) R/0.63; vmax (KBr) 1590 (CH=CH) cm'1; 8 h (400 MHz, 
CDCI3) 0.86 (3H, s, CH3), 1.12-2.25 (13H, m), 2.83 (2H, m, C-6 -H2), 3.51 (1H, t, J  =
8.2 Hz, C-17-H), 4.57 (2H, s, C-17-OCH2-), 5.09 (2H, s, C-3 -OCH2-), 6.58 (1H, s, C-
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4-H), and 7.21-7.48 (11H, m, C-l-H and 2 x Ar); MS m/z (FAB+) 578.1 [20, (M)+],
452.2 (20), 91.0 (100); Acc. MS (FAB+) 579.1728 C32H36IO2 requires 579.1760.
2-Formyl-3,17p-bis-(benzyloxy)oestra-l,3,5(10)triene (131)
A 1.6 M solution of «-BuLi in hexane(1.6 M, 14.9 ml, 23.84 mmol) was added 
dropwise by syringe under N2 at -78 °C to a solution of 129 (5.0 g, 9.524 mmol) in 
anhydrous THF (130 ml) and the resulting reaction mixture was stirred at -78 °C for 2 
h. Anhydrous DMF (5 ml) was added, and stirring was continued for 1 h at -78 °C. 
The mixture was warmed to 0 °C, stirred for 1 h and poured into an ice-cold solution 
of 3M HC1 (100 ml). The aqueous layer was extracted with ether (3 x 200 ml). The 
combined organic extracts were washed with 50% brine-water (100 ml), brine (150 
ml), dried (MgSCU), filtered and evaporated. The residue that obtained was 
fractionated by flash chromatography (hexane/ethyl acetate, 5:1) to give 131 as white 
solid (3.61 g, 80%) and an analytical sample of which was recrystallized from acetone 
to give 131 as colourless crystals; mp 144-146°C (lit. 145-147°C);239 TLC 
(hexane/ethyl acetate, 5:1, 4:1 and dichloromethane): Rf  0.37, 0.47 and 0.57 
respectively; vmax (KBr) 1680 (C=0), 1600 (CH=CH) cm'1; 5h (400 MHz, CDC13) 
0.86 (3H, s, CH3), 1.19-2.39 (13H, m), 2.93 (2H, m, C-6 -H2), 3.5 (1H, t, / =  8.2 Hz, 
C-17-H), 4.65 (2H, s, C-17-OCH2-), 5.2 (2H, s, C-3 -OCH2-), 6 . 8  (1H, s, C-4-H), 7.51 
(10H, m, 2 x Ar), 7.82 (1H, s, C-l-H) and 10.5 (1H, s, CHO-); 6 c (400 MHz, CDC13) 
11.78 (q, C18), 23.1 (t), 26.28 (t), 26.85 (t), 28.0 (t), 30.49 (t), 37.73 (t), 37.73 (d),
43.36 (s, C13), 43.67 (d), 50.16 (d), 70.37 (t), 71.71 (t), 88.20 (d, C-17), 113.04 (d, C- 
4), 122.98 (s), 125.4 (d, C-l), 127.25 (d), 127.3 (d), 128.05 (d), 128.16 (d), 128.27 (d), 
128.51 (d), 128.84 (d), 130.92 (s), 133.57 (s), 136.37 (s), 146.27 (s), 158.98 (s) and 
189.61 (d, CHO); MS m/z (FAB+) 481.2 [40, (M+H)+], 453.3 (10), 91.0 [100, (Ar- 
CH2)+]; MS m/z (FAB-) 633.2 [50, (M+NBA)'], 479.2 [30, (M-H)'], 389.2 [100, (M- 
ArCH2)]. Found C, 82.5; H, 7.48; C33H36O3 requires C, 82.46; H, 7.55%.
When the above procedure was repeated using 130 (2.0 g, 3.457 mmol) as the starting 
material, 131 was obtained with a slightly high yield (1.43 g, 89%).
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2-(Hydroxymethyl)oestradiol 17p-benzyl ether (132)
A solution of 131 (600 mg, 1.25 mmol) in anhydrous ethanol (20 ml) and anhydrous 
THF (10 ml) was hydrogenated at 50psi in the presence of 10% Pd-C (300 mg) at 
room temperature for 48 h. After the supported catalyst was removed by filtration, the 
filtrate was evaporated to give a white solid which was fractionated by flash 
chromatography (chloroform/acetone gradient). The white solid that isolated (470 mg) 
was further purified by recrystallization from ethanol to give 132 as white crystals 
(440 mg, 89%); mp 118-120°C; TLC (dichloromethane/hexane, 8:1 and 4:1): R/0.38 
and 0.46 respectively; vmax (KBr) 3500-3000 (OH), 1600 (CH=CH) cm'1; 5h (400 
MHz, CDCI3) 0.86 (3H, s, CH3), 1.14-2.26 (15H, m), 2.79 (2H, t, J = 4.4 Hz, C-6 -H2), 
3.5 (1H, t, 7=8.2 Hz, C-17-H), 4.57 (2H, s, OCHjPh), 4.81 (2H, s, CH2OH), 6.61 (1H, 
s, C-4-H), 6.95 (1H, s, C-l-H) and 7.26 (5H, m, C -I 7 -Q H 5 -) . Sc (400 MHz, CDC13)
11.81 (q, C -l8 ), 23.12 (t), 26.46 (t), 27.16 (t), 27.96 (t), 29.37 (t), 37.87 (t), 38.59 (d),
43.36 (s, C-13), 43.8 (d), 50.16 (d), 64.56 (t), 71.56 (t), 88.31 (d, C-17), 116.39 (d, C- 
4), 122.24 (s), 124.89 (d, C-l), 128.27 (d), 127.34 (d), 132.08 (s), 138.2 (s), 139.21 (s) 
and 153.6 (s). MS m/z (FAB+) 392.1 [45, (M)+], 375.1 [75, (M-OH)+], 283.0 (20);. 
MS m/z (FAB-) 545.2 [10, (M+NBA)*], 391.2 [100, (M-H)']; Acc. MS (FAB+) 
393.24162 requires C26H33O3 393.24297. Found C, 77.9; H, 8.25; C26H32O3 requires 
C, 79.56; H, 8.22%.
2-Hydroxy 3,17f$-bis-(benzyloxy)oestra-l,3,5 (10)triene (133)
3-Chloroperoxybenzoic acid (MCPBA) (350 mg, 2.028 mmol) was added to a solution 
of 131 (600 mg, 1.252 mmol) in anhydrous DCM (20 ml) after stirring the resulting 
mixture overnight at room temperature, an additional amount of MCPBA (120 mg,
695.4 jLimol) was added and stirring was continued for another 5 h. The reaction 
mixture was then diluted with DCM (200 ml), washed with 10% aqueous sodium 
sulphite ( 1 0 0  ml), water ( 1 0 0  ml), brine ( 1 0 0  ml), dried ( M g S O z O ,  filtered and 
evaporated. The light brown residue that obtained (480 mg) was suspended in 
methanol (25 ml), then treated with conc. H 2 S O 4  (1 ml) and the resulting mixture was 
heated under reflux for 1.5 h. Upon cooling to room temperature and evaporation 
under reduced pressure, the resulting residue in DCM (200 ml) was washed with water 
(100 ml), saturated NaHCC>3 (100 ml), water (100 ml), brine (100 ml), dried ( M g S O z O ,  
filtered and evaporated. The yellow gummy solid that was obtained (450 mg) was
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purified by flash chromatography (hexane/dichloromethane gradient) to give 133 as 
white solid (410 mg, 70%) and an analytical sample of which was recrystallized from 
acetone to give 133 as colourless crystals; mp 116-119 °C (lit. 117-118 °C) ; 239 TLC 
(hexane/ethyl acetate, 4:1, 8:1 and dichloromethane): Rf  0.6, 0.57 and 0.62 
respectively; vmax (KBr) 3520 (OH), 1590 (CH=CH) cm'1; 5h (400 MHz, CDC13) 
0.87 (3H, s, CH3), 1.11-2.27 (13H, m), 2.79 (2H, m, C-6 -H2), 3.5 (1H, t, J=  8.2 Hz, 
C-17-H), 4.57 (2H, s, C-17-OCH2-), 5.05 (2H, s, C-3 -OCH2-), 5.46 (1H, br s, 
exchanged with D20 , OH), 6.64 (1H, s, C-4-H), 6.9 (1H, s, C-l-H) and 7.41 (10H, m, 
2 x Ar); 6C(400 MHz, CDC13) 11.73 (q, C-18), 23.1 (t), 26.48 (t), 27.35 (t), 28.03 (t), 
29.7 (t), 37.98 (t), 38.5 (d), 43.39 (s, C13), 44.07 (d), 50.22 (d), 71.12 (t), 71.65 (t), 
88.29 (d, C-17), 111.7 (d, C-4), 112.51 (d, C-l), 127.3 (d), 128.03 (d), 128.25 (d),
128.31 (d), 128.7 (d), 128.84 (d), 130.92 (s), 133.65 (s), 136.59 (s), 139.28 (s), 143.51 
(s) and 143.69 (s); MS m/z (FAB+) 468.3 [30, (M)+], 91.0 (100), 72.9 (70); MS m/z 
(FAB-) 620.2 [30, (M-H+NBA)'], 467.2 [80, (M-H)'], 376.2 [70, (M-H-Bn)], 297.1 
(50), 223.1 (90); Acc. MS (FAB+) 469.2699 C32H37O3 requires 469.2743. Found C, 
81.9; H, 7.87; C32H36O3 requires C, 82.02; H, 7.74%.
2-Methoxyoestra-l,3,5(10)-triene 3,17p-Bis-benzyl ether or 2-methoxyoestradiol 
3,17/3-dibenzyl ether (134)
Methyl iodide (1.3 ml, 20.88 mmol) was added to a stirred suspension of anhydrous 
K2C 0 3 (885 mg, 6.402 mmol) in anhydrous DMF (40 ml) containing 133 (1.0 g, 2.134 
mmol). The yellow suspension, under N2 was refluxed for 2 h, then stirred at room 
temperature for 24 h and poured into a cold solution of 50% HC1 (100 ml). The light 
yellow precipitate that formed was collected by filtration, washed with water, dried 
over phosphorous pentoxide to give a yellow solid (1 . 0 1  g), which was recrystallized 
from methanol to give 134 as white crystals (940 mg, 91%); mp 96-98°C (lit. oil) ; 238 
TLC (chloroform/acetone, 8:1): R/0.85; vmax (KBr) 3040, 1590 (CH=CH) cm'1; 8 h 
(400 MHz, CDCI3) 0.87 (3H, s, C -I8 -CH3), 1.14-2.27 (13H, m), 2.75 (2H, m, C-6 - 
H2), 3.5 (1H, t, J = 8.2 HZ, C-17-H), 3.86 (3H, s, OCH3), 4.57 (2H, s, C-17-OCH2-),
5.1 (2H, s, C-3 -OCH2-), 6.62 (1H, s, C-4-H), 6.84 (1H, s, C-l-H) and 7.26-7.45 (10H, 
m, 2 x Ar); MS m/z (FAB+) 482.4 [70, (M)+], 91.1 (100), 73.1 (15); Acc. MS (FAB+) 
482.2819 C33H38O3 requires 482.2820.
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2-Ethoxyoestra-l,3,5(10)-triene 3,17p-bis-benzyl ether or 2-ethoxyoestradiol 3,17fi- 
dibenzylether (135)
This was prepared from 133 (300 mg, 0.6401 mmol) with ethyl iodide (0.45 ml, 6.4 
mmol) in a similar manner as in the preparation of 134. Water (100 ml) was added to 
the resulting suspension and the organic components were extracted into ether ( 2  x 
150 ml). The combined ether extracts were washed with brine (100 ml), dried 
(MgSCU), filtered and evaporated. The pale yellow oil that was obtained (315 mg) was 
fractionated by flash chromatography (ether/hexane, 1:5) to give 135 as pale yellow oil 
(210 mg, 6 6 %); TLC (hexane/DCM, 4:1): R f0.59; vmax (KBr) 3040, 1600, (CH=CH) 
c m 1; 5h (400 MHz, CDC13) 0.87 (3H, s, C-I8 -CH3), 1.24-1.4 (6 H, m), 1.42 (3H, t, J  =
7.32 Hz, CH3CH2O-), 1.42-2.07 (7H, m), 2.72 (2H, m, C-6 -H2), 3.49 (1H, t, J = 8.24 
HZ, C-17-H), 4.09 (2H, q, C-2 -OCH2CH3), 4.57 (2H, s, C-17-OCH2-), 5.09 (2H, s, C-
3 -OCH2-), 6.63 (1H, s, C-4-H), 6 . 8 6  (1H, s, C-l-H) and 7.28-7.45 (10H, m, 2x Ar); 
MS m/z (FAB+) 496.4 [60, (M)+], 405.3 (10), 91.1 (100); Acc. MS 497.3010 
C34H4 1O3 requires 497.3056.
2-Allyloxyoestra-l,3,5(10)-triene 3,17p-Bis-benzyl ether or 2-allyloxyoestradiol 
3,17-dibenzylether (136)
This was prepared by reacting 133 ( 3 0 0  mg, 0 . 6 0 4 1  mmol) with allyl bromide ( 0 . 2 8  
ml, 3 . 2  mmol) in a similar manner to that described for 135. The crude product that 
was obtained gave 136 as brownish oil ( 2 9 0  mg, 8 9 % ) ;  T L C  (ether/hexane, 1 : 4 ) :  R f 
0 . 3 9 ;  vmax (KBr) 3 0 4 0 ,  2 9 8 0 ,  1 5 9 0  cm'1; 8 h ( 4 0 0  MHz, C D C 1 3)  0 . 8 7  ( 3 H ,  s, C - 1 8 -  
C H 3) ,  1 . 1 3 - 2 . 2 3  ( 1 3 H ,  m), 2 . 7 2  ( 2 H ,  m, C - 6 - H 2 ) ,  3 . 5  ( 1 H ,  t, J= 7 . 9  Hz, C - 1 7 - H ) ,  4 . 5 6  
( 2 H ,  s, C - 1 7 - O C H 2 - ) ,  4 . 5 9  ( 2 H ,  d, / =  5 . 2  Hz, - O C H j C H ^ ,  5 . 0 8  ( 2 H ,  s, C - 3 - O Q k - ) ,
5 . 2 4  ( 1 H ,  dd, JH, H cis =  9 . 2  Hz, T H ^ ,  H cis =  1 . 4  Hz, O C H 2 C H = C H t r a n s  H cis) ,  5 . 4 1  
( 1 H ,  dd, J H ,  H tra n s  =  1 5 . 4  Hz, J H cis, H tra n s  =  1 .5  Hz, O C H 2 C H =  C H tr a n s  H c i s ) ,  6 . 0 6  ( 1 H ,  
m, = C H - C H 2 - 0 ) ,  6 . 6 3  ( 1 H ,  s, C - 4 - H ) ,  6 . 8 7  ( 1 H ,  s, C - l - H )  and 7 . 1 4 - 7 . 4 4  ( 1 0 H ,  m, 2x- 
C 6 H 5 - ) ;  8 c ( 4 0 0  MHz, C D C 1 3)  1 2 . 6 4  (q, C - 1 8 ) ,  2 3 . 0 8  (t), 2 6 . 5 2  (t), 2 6 . 6 6  (t), 2 7 . 0 7  (t), 
2 7 . 2 7  (t), 3 8 . 2 5  (t), 3 8 . 4 2  (d), 4 3 . 3 6  (s, C - 1 3 ) ,  4 3 . 9 6  (d), 4 9 . 9 6  (d), 7 0 . 9 2  (t), 7 1 . 2  (t),
7 1 . 6  (t), 8 8 . 2 4  (d, C - 1 7 ) ,  1 1 2 . 7 6  (d), 1 1 4 . 9 9  (d), 1 1 7 . 2 4  (t), 1 2 4 . 4 5  (d), 1 2 6 . 9  (d),
1 2 8 . 2 2  (d), 1 2 8 . 3 8  (d), 1 2 9 . 4 2  (d), 1 3 3 . 1 5  (d, = C H ) ,  1 2 9 . 6 1  (s), 1 3 2 . 2  (s), 1 4 2 . 8 8  (s),
1 4 3 . 5  (s), 1 4 6 . 9 1  (s) and 1 6 2 . 5 3  (s); MS m/z (FAB+) 5 0 8 . 4  [ 7 0 ,  (M)4], 4 1 7 . 3  ( 1 0 ) ,  
4 0 1 . 3  ( 1 0 ) ,  9 1  ( 1 0 0 ) ;  Acc. MS (FAB+) 5 0 8 . 2 9 7 4  C 3 5 H 4 0 O 3 requires 5 0 8 . 2 9 7 7 .
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Debenzylation o f p-oestradiol dibenzyl ether 
Method A
Aluminum chloride (1.5 g, 11.25 mmol), sodium iodide (1.7 g, 11.34 mmol), and fi- 
oestradiol dibenzyl ether 128 (500 mg, 1.105 mmol) were added in this order to a 
mixture of acetonitrile (50 ml) and dichloromethane (25 ml) at 0 °C under N2 . After 
being stirred for 6  h at 0 °C, the mixture was poured into water and extracted with 
dichloromethane (3 x 150 ml). The combined organic extracts were washed with 10 % 
aqueous sodium thiosulphate ( 1 0 0  ml), water ( 1 0 0  ml), brine ( 1 0 0  ml), dried 
(MgSC>4), filtered and evaporated to give a yellow solid (380 mg), which was 
fractionated by flash chromatography (chloroform/acetone gradient). The last polar 
fraction that isolated gave a light yellow solid (340 mg) which was further purified by 
recrystallization from methanol to give /3-oestradiol 3-benzyl ether 107 as white 
crystals (320 mg, 80%); mp 92-95°C.
The more polar fraction that isolated gave a creamy solid (40 mg) which was 
recrystallized from methanol to give oestradiol 108 as white crystals (29 mg, 10%) mp 
175-179 °C.
Method B
The reaction and work-up procedure was essentially the same as method A except that 
the reaction mixture was stirred at 0°C for 30 min and then at room temperature 
overnight. The yellow crude product that obtained (295 mg) was recrystallized from 
methanol to give oestradiol 108 as white crystals (275 mg, 91%); mp 175-178 °C.
Debenzylation o f 2-methoxyoestradiol 3,17fi-dibenzyl ether
Method B described above was used to debenzylate 134 (800 mg, 1.66 mmol). The 
yellow syrup that obtained (510 mg) upon work-up was fractionated by flash 
chromatography (chloroform/acetone gradient). The less polar fraction that was 
isolated was found to be 2 -methoxyoestradiol 1 1 2 , a yellow syrup ( 1 2 0  mg) which 
solidified on standing. Found C, 75.1; H, 8.70; C19H26O3 requires C, 75.46; H, 8.67%.
The more polar fraction that isolated was found to be 2-hydroxyoestradiol 137, a 
yellow syrup (300 mg) which solidified on standing; mp > 79°C (dec.); TLC 
(chlorofom/acetone, 8:1): R/0.37; vmax (KBr) 3500-2500 (OH), 1600 cm'1; 8 h (400
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MHz, C D C I 3 )  0.78 (3H, s, CH3), 1.13-2.23 (14H, m), 2.75 (2H, m, C-6 -H2), 3.73 (1H, 
t, J  = 8.2 Hz, C-17-H), 3.86 (1H, br s, exchanged with D2O, OH), 6.54 (1H, s, C-4-H) 
and 6.81 (1H, s, C-l-H); MS m/z (FAB+) 439.2 [20, (M-2H+NBA)+], 288.0 [100, 
(M)+], 271.0 [20, (M-OH)+]; MS m/z (FAB-) 441.1 [45, (M+NBA)+], 287.1 [100, (M- 
H)+] 255.1 (10); Acc. MS (FAB+) 288.1719 C18H24O3 requires 288.1725.
Oestra-l,3,5(10)triene-17p-ol 2,3-0,0-bis-sulphamate or catechol-like 2,3-0,0-bis- 
sulphamate (138) and oestra-l,3,5(10)triene 2,3,17p-0-0,0-tris-sulphamate or 
catechol-like 2,3,17f3-0-0,0-tris-sulphamate (139)
To a stirred solution of 137 (250 mg, 867 fimol) and 2,6-di-r-butyl-4-methylpyridine 
(DBMP) (535 mg, 2.605 mmol) in CH2CI2 (15 ml) at room temperature was added 
dropwise a solution of sulphamoyl chloride in toluene (5.202 mmol). After being 
stirred for 2  h the reaction mixture was diluted with dichloromethane ( 1 0 0  ml), 
washed with water (50 ml), brine (50 ml), dried (MgS0 4 ), filtered and evaporated. The 
residue that was obtained (450 mg) was fractionated by flash chromatography 
(chloroform/acetone gradient) and from the less polar fraction that isolated the yellow 
residue (180 mg) was further purified by recrystallization from ethyl acetate/hexane 
(1:2) to give 138 as white crystals (156 mg, 49%) mp > 131°C (dec.); TLC 
(chlorofom/acetone, 8:1): R/0.22; vmax (KBr) 3500-3000 (NH2 and OH), 1590, 1380 
(S02) cm '1; 6 h  (400 MHz, acetone-d6) 0.87 (3H, s, C -I8 -CH3), 1.27-2.84 (16H, m, 1H 
exchanged with D2O), 4.37 (1H, t, / =  8.2 Hz, C-17-H), 6 . 6  (2H, br s, exchanged with 
D20 , -OSO2NH2), 6.92 (1H, s, C-4-H), 7.16 (2H, br s, exchanged with D20 , - 
OSO2NH2) and 8.03 (1H, s, C-l-H); MS m/z (FAB+) 446.1 [100, (M)+], 288.2 [30, 
(M-2xS02NH2)+]; MS m/z (FAB-) 445.1 [100, (M-H)'], 365.1 [10, (M-H-S02NH2)]; 
Acc. MS (FAB+) 446.11800 C18H26N2O7S2 requires 446.11814.
The more polar fraction that isolated gave a yellow viscous oil (90 mg) which was 
further purified by recrystallization from ethyl acetate/hexane (1:2) to give 139 as pale 
white crystals (75 mg, 4%) mp > 113°C (dec.); TLC (chlorofom/acetone, 8:1): R /0.11; 
vmax (KBr) 3500-3200 (NH2), 1590, 1380 (S02) cm '; 6 h (400 MHz, acetone-d6) 0.89 
(3H, s, Cffc), 1.27-2.86 (15H, m), 4.44 (1H, t, J  = 8.2 Hz, C-17-H), 6 . 6  (2H, br s, 
exchanged with D2O, OSO9NH9), 6.93 (1H, s, C-4-H), 7.16 (4H, br s, exchanged with 
D20 , 2 x0 S0 2NH2) and 8.05 (1H, s, C-l-H); MS m/z (FAB+) 525.1 [50, (M)+], 446.1
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[100, (M-S02NH2)+], 288.1 [40, (M-3xS02NH2)+]; MS m/z (FAB-) 524.0 [100, (M- 
H) ], 445.1 [80, (M-S02NH2)‘], 365.1 [10, (M-2xS02NH2)']; Acc. MS (FAB+) 
525.0921 Ci8H27Ns0 9 S3 requires 525.0905.
2-Methoxy 3,17fi-[bis-(tert-butyldimethylsilyloxy)Joestradiol (140)
To a solution of 2-methoxyoestradiol 112 (100 mg, 332.9 jimol) and imidazole (278 
mg, 4.081 mmol) terf-butyldimethylsilyl chloride (280 mg, 1.858 mmol) in anhydrous 
DMF (5 ml), was added. The reaction mixture was stirred for at room temperature 24 
h under N2, then diluted with 5% NaHC0 3  (20 ml), and extracted with diethyl ether (3 
x 50 ml). The combined ether extracts were washed with water, dried (MgSC>4), 
filtered and evaporated to give a colourless oil which solidfied on standing to give 140 
as white solid (167 mg, 95%); mp > 62 °C (dec.); TLC (chloroform): R/0.93; vmax 
(KBr) 3040, 2990-2900, 1590 (CH=CH) c m 1; 8 h (400 MHz, CDC13) 0.15 (6 H, s, - 
Si(CH3)2-), 0.32 (6 H, s, -Si(CH3)2-), 0.83 (3H, s, C -I8 -CH3), 0.91 (9H, s, Si-C(CH3)3),
1.0 (9H, s, Si-C(CH3)3), 1.15-2.24 (14H, m), 2.84 (2H, m, C-6 -H^, 3.72 (1H, t, J = 8.2 
Hz, C-17-H), 3.78 (3H, s, OCH3), 6.57 ( 1 H, s, C-4-H), 6.83 (1H, s, C-l-H); MS m/z 
(FAB+) 530.1 [50, (M)+], 515.1 (10); Acc. MS (FAB+) 530.3620 C3 iH54 0 3Si2 
requires 530.3612.
2-Methoxy-17^-tert-butyldimethylsilyloxyoestradiol (141)
A mixture of 140 (150 mg, 283 jumol), tetra-n-butylammonium fluoride (0.29 ml, 1M 
in THF) and THF (10 ml) was stirred at room temperature for 10 minutes. The 
reaction mixture was then diluted with diethyl ether ( 1 0 0  ml) and the resulting mixture 
was washed with brine (50 ml), dried (MgS0 4 ), filtered and evaporated to give a crude 
oil which was fractionated by flash chromatography (chloroform/acetone gradient). 
The pale yellow oil that isolated, solidified on standing to give 141 as white solid (110 
mg, 94%); mp 140-142 °C; TLC (chloroform): R/0.50; vmax (KBr) 3500 (OH), 1600 
c m 1; 8 h (400 MHz, CDC13) 0.32 (6 H, s, Si(CH3)2), 0.81 (3H, s, CH3), 0.9 (9H, s, Si- 
C(CH3)3), 1.15-2.25 (13H, m), 2.85 (2H, m, C-6 -H2), 3.68 (1H, t, / =  8.2 Hz, C-17-H), 
3.85 (3H, s, OCH3), 5.5 (1H, br s, OH), 6.56 (1H, s, C-4-H) and 6.9 (1H, s, C-l-H); 
MS m/z (FAB+) 416.1 [100, (M)4]; MS m/z (FAB-) 568.1 [10, (M-H+NBA)'], 415.1 
[100, (M-H)*], 400.1 (10), 73.0 (80); Acc. MS (FAB+) 416.2732 C25H4o0 3Si requires 
416.2746.
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2-Methoxy-l 7j3-tert-butyldimethylsilyloxyoestradiol 3-O-sulphamate (142)
To a stirred solution of 141 (100 mg, 240.1 jimol) and DBMP (148 mg, 731.5 |xmol) 
in CH2CI2 (7 ml) at room temperature was added dropwise a solution of sulphamoyl 
chloride in toluene (721.5 pmol). After being stirred for 30 min of the reaction mixture 
was diluted with dichloromethane (100 ml), washed with water (50 ml), brine (50 ml), 
dried (MgS04), filtered and evaporated to give a crude product (116 mg) which was 
fractionated by flash chromatography (chloroform/acetone gradient). The beige solid 
that obtained (103 mg) was further purified by recrystallization from ethyl 
acetate/hexane (1:2) to give 142 as pale white crystals (92 mg, 77%); mp > 120°C 
(dec.); TLC (chlorofom/acetone, 8:1): R/0.73; vmax (KBr) 3500-3300 (NH2), 1600, 
1390 (S02) cm'1; 6 h (400 MHz, CDCI3) 0.61 (6 H, s, -Si(CH3)2), 0.83 (3H, s, CH3), 0.9 
(9H, s, Si-C(CH3)3C), 1.14-2.26 (13H, m), 2.84 (2H, m, C-6 -H2), 3.68 (1H, t, 7 =  8.2 
Hz, C-17-H), 3.83 (3H, s, OCH3), 5.1 (2H, br s, exchanged with D2O, OSO9NH7), 
6.71 (1H, s, C-4-H) and 7.13 (1H, s, C-l-H); MS m/z (FAB+) 495.1 [40, (M)+], 416.1 
[20, (M-S02NH2)+], 73.0 (100); MS m/z (FAB-) 648.2 [10, (M+NBA)'], 494.2 [100, 
(M-H)']; Acc. MS (FAB+) 495.2463 C25H4 iN0 5SSi requires 495.2475. Found C, 
60.4; H, 8.47; N, 2.65; C25H4iN 05SSi requires C, 60.57; H, 8.34; N, 2.83%.
2-Methoxyoestradiol 3-O-sulphamate (143)
To a solution of 142 (75 mg, 151.3 \imol) in acetic acid:water:THF (3:1:1) (10 ml) 
was stirred at room temperature for 5 days. The reaction mixture was then poured into 
water ( 1 0 0  ml) and the precipitate that formed was collected by filtration, washed with 
water and air-dried to give a white solid ( 8 8  mg) which was fractionated by flash 
chromatography (chloroform/acetone gradient). The white solid that isolated (65 mg) 
was further purified by recrystallization from ethyl acetate/hexane (1:2) to give 143 as 
white crystals (53 mg, 54%) mp > 146 °C (dec); TLC (chloroform/acetone, 8:1): Rf  
0.41; vmax (KBr) 3500-3000 (NH2, OH), 1590, 1390 (S02) cm 1; 5 h  (400 MHz, 
CDC13, 40 °C) 0.83 (3H, s, CH3), 1.16-2.29 (14H, m), 2.86 (2H, t, 7 = 4.1 Hz, C-6 -Ifc),
3.75 (1H, t, 7 = 8.2 Hz, C-17-H), 3.88 (3H, s, OCH3), 5.1 (2H, br s, exchanged with 
D20 , OSO2NH2 ), 6.73 (1H, s, C-4-H) and 7.12 (1H, s, C-l-H); MS m/z (FAB+) 381.1 
[100, (M)+], 301.1 [, (M-S02NH2)+], 287.0 (10), 272.0 (10); MS m/z (FAB-) 534.1 
[40, (M+NBA)'], 380.1 [100, (M-H)']; Acc. mass (FAB+) 381.1612 Ci9H27NOjS
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requires 381.1610. Found C, 59.67; H, 7.5; N, 3.47; C19H27NO5S requires C, 59.82; H,
7.13; N, 3.67%.
Oestradiol 3-methyl ether (144)
Sodium borohydride (665 mg, 17.579 mmol) was added to a solution of oestrone 
methyl ether 121 (1.0 g, 3.516 mmol) in THF/IPA (30ml, 1:1), after being stirred at 
room temperature for 16 h, the reaction mixture was concentrated and then treated 
cautiously with 5M HC1 (5 ml). The organic fractions were extracted into ethyl acetate 
(3 x 100) and after washing with brine, dried (MgSO/O, filtered and evaporated to give 
a white solid (986 mg) which was recrystallized from methanol to give 144 as white 
crystals (950 mg, 94%); mp 118-120°C (lit. 121-124°C);277 TLC (chloroform and 
chloroform/acetone, 8:1): R/s 0.22 and 0.69 respectively; vmax (KBr) 3500-3100 
(OH), 1600 (CH=CH) cm'1; 5h (400 MHz, CDC13) 0.87 (3H, s, CH3), 1.15-1.54 (7H, 
m), 1.6 (1H, br s, exchanged with D20 , OH), 1.65-2.4 (6 H, m), 2.87 (2H, m, C-6 -H2),
3.75 (1H, t, J = 8.2 Hz, C-17-H), 3.82 (3H, s, OCH3), 6.64 (1H, d, 7C-2-h. c-4-h = 2.1 
Hz, C-4-H), 6.71 (1H, dd, 7C-4-h, c-2-h = 2.7 Hz and 7 C-i-h , c-2-h = 8.5 Hz, C-2-H) and
7.22 (1H, d, / c -i -h , C-2-H = 8.5 Hz, C-l-H); MS m/z (FAB+) 286.3 [100, (M)+], 269.3 
[20, (M-OH)+]; Acc. MS (FAB+) 287.1987 C19H27O2 requires 287.2011. Found C, 
79.61; H, 8.19; C19H26O2 requires C, 79.68; H, 9.15%.
Oestradiol 3-methyl ether-17p-benzyl ether (145)
This was prepared by reacting a solution of 144 (1.5 g, 5.238 mmol) in DMF (50 ml) 
after treatment with sodium hydride (628.5 mg, 15.714 mmol) and benzyl bromide 
(1.0 ml, 8.41 mmol) in a similar manner to that described for 106. The crude syrup 
that obtained upon work-up was triturated with hexane and the white solid (1 . 6  g, 
81%) that formed was collected by filtration, air-dried and was recrystallized from 
methanol to give 145 as white crystals (1.29 g, 65%); mp 8 6 - 8 8  °C; TLC (chloroform 
and chloroform/acetone, 8:1): R/S 0.78 and 0.9 respectively; vmax (KBr) 1600 
(CH=CH) cm '; 5h(400 MHz, CDC13) 0.87 (3H, s, CH3), 1.2-2.3 (13H, m), 2.85 (2H, 
m, C-6 -H2), 3.5 (1H, t, 7 = 8.24 Hz, C-17-H), 3.77 (3H, s, OCH3), 4.58 (2H, s, 
OCHzPh), 6.62 (1H, d, 7C-2-h.c-4-h = 2.5 Hz, C-4-H), 6.72 (1H, dd, 7c^h,c-2-h= 2.5 Hz 
and J c -1-h , c-2-H = 8 . 8  Hz, C-2-H), 7.2 (1H, d, 7C-2-h, c-i-h = 8 . 8  Hz, C-l-H) and 7.34
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(5H, m, Ar); MS m/z (FAB+) 376.1 [90, (M)+], 285.1 [10, (M-Bn)+], 269.1 [15, (M-H- 
Bn-CH3)+], 91.0 (100). Found C, 83.0; H, 8.69; C26H32O2 requires C, 82.94; H, 8.57.
2-Acetyl-3-methoxyoestradiol 17p-acetate (146)
Method A
To a solution of anhydrous aluminium chloride (567 mg, 4.252 mmol) and acetyl 
chloride (0.35 ml, 4.922 mmol) in anhydrous nitromethane (30 ml) at 0 °C was added 
145 (800 mg, 2.125 mmol). After being stirred for 3 h at room temperature, the 
reaction mixture was poured into 10% HC1 (100 ml) and the result mixture was 
extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed 
with water (100 ml), brine (100 ml), dried (MgSCU), filtered and evaporated. The 
brown-yellow residue that was obtained was triturated with methanol and the white 
precipitate that formed was collected by filtration, air-dried to give a white solid (870 
mg) which was recrystallized from methanol to give 146 as white crystals (630 mg, 
71%); mp 183-186 °C (lit. 192-194°C);224 TLC (chloroform and chloroform/acetone, 
8:1): R/0.37 and 0.76 respectively; vmax (KBr) 1730 (C=0 of acetate), 1670 (C=0 of 
acetyl) cm'1; 8 H (400 MHz, CDC13) 0.82 (3H, s, CH3), 1.14-1.98 (10H, m), 2.06 (3H, 
s, OCOCH3), 2.14-2.51 (3H, m), 2.59 (3H, s, C-I7 -CH3CO), 2.89 (2H, m, C-6 -H2), 
3.87 (3H, s, OCH3), 4.68 (1H, t, J  = 7.9 Hz, C-17-H), 6 . 6 6  (1H, s, C-4-H), and 7.69 
(1H, s, C-l-H); 8 C (400 MHz, CDC13) 12.03 (q, C-18), 23.23 (q), 23.23 (t), 26.08 (t), 
26.98 (t), 27.56 (t), 30.01 (t), 31.91 (t), 31.91 (q), 38.44 (d), 42.85 (s, C13), 43.56 (d),
49.69 (d), 55.47 (q, OCH3), 82.63 (d, C-17), 111.76 (d, C-4), 127.63 (d, C-l), 125.6 
(s), 132.57 (s), 143.41 (s), 157.02 (s, C-3), 171.231 (s) and 199.54 (s); MS m/z 
(FAB+) 371.1 [100, (M+H)+], 311.1 (10). Found C, 74.6; H, 8.19; C23H30O4 requires 
C, 74.56; H, 8.16%.
Method B
This was essentially the same as method A except that 144 (3.6 g, 12.57 mmol) was 
used as the starting material. The crude product (4.5 g) that obtained upon work-up 
was recrystallized from methanol to give 146 as white crystals (2.5 g); mp 185-187 °C. 
The residue that resulted upon evaporation of the mother liquor was recrystallized 
from methanol to give a second crop of 146 as white crystals (1.45 g, overall yield, 
85%).
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2-Hydroxy-3-methoxyoestra-l,3,5(10)-triene-17P-ol or 2-hydroxyoestradiol 3-methyl 
ether (147)
A mixture of 146 (1.8 g, 4.8596 mmol), m-CPBA (2.0 g, 11.59 mmol) and anhydrous 
dichloromethane (DMC) (70 ml) was stirred at room temperature overnight under N 2 . 
Upon dilution with DCM (300 ml), the resulting mixture was washed with 10% 
aqueous sodium sulphite (100 ml), water (100 ml), brine (100 ml), dried (MgSC>4), 
filtered and evaporated. The light brown residue that was obtained (1.8 g) in methanol 
(50 ml) was refluxed for 1 h in the presence of con. H2SO4  (2 ml). Upon removal of 
the solvent the resulting residue in DCM (300 ml) was washed with water (100 ml), 
saturated aqueous NaHCC>3 (100 ml), water (100 ml), brine (100 ml), dried (MgSC>4), 
filtered and evaporated. The brown oil that obtained (1.5 g) was fractionated by flash 
chromatography (dichloromethane/ether gradient) and the white solid ( 1 .1  g) that 
isolated was further purified by recrystallization from acetone to give 147 as white 
crystals (889 mg, 60%); mp 178-180°C (lit. 179-181°C);223 TLC (ethyl acetate/DCM, 
1:4): R f 0.62; vmax (KBr) 3500-3000 (OH), 1590 (CH=CH) cm 1; 5h (400 MHz, 
CDCI3) 0.77 (3H, s, CH3), 1.13-2.27 (14H, m), 2.81 (2H, m, C-6 -H2), 3.72 (1H, t, J -
8.2 Hz, C-17-H), 3.72 (3H, s, OCH3), 5.5 (1H, br s, exchanged with D20 , OH), 6.56 
(1H, s, C-4-H), 6 . 8 8  (1H, s, C-l-H); 8 c (400 MHz, CDCI3) 11.06 (q, C-18), 23.1 (t), 
26.38 (t), 27.41 (t), 29.23 (t), 30.54 (t), 36.7 (t), 38.77 (d) 43.25 (s, C13), 44.06 (d),
50.0 (d), 55.93 (q, OCH3), 81.88 (d, C-17), 111.15 (d, C-4), 111.65 (d, C-l), 128.0 (s),
133.1 (s), 143.34 (s) and 144.5 (s); MS m/z (FAB+) 302.1 [100, (M)+], 285.1 [10, (M- 
OH)+], 189.0 (10); MS m/z (FAB-) 301.1 [100, (M-H)'], 292.0 (30), 276.1 (45); Acc. 
MS (FAB+) 302.1888 C 19H26O3 requires 302.1882. Found C, 75.1; H, 8.7; C 19H26O3 
requires C, 75.46; H, 8.67%.
2,17f3-[bis-(tert-butyldimethylsilyloxy)Joestradiol 3-methyl ether (148)
Compound 147 (360 mg, 1.19 mmol) in anhydrous DMF (7 ml) was treated with tert- 
butyldimethylsilyl chloride (1.0 g, 6.634 mmol) in the presence of imidazole (1.0 g,
14.69 mmol) in a similar method to that described for the synthesis of 140. Upon a 
similar aqueous work-up, a colourless oil was obtained which solidified on standing to 
give 148 as white solid (600 mg, 95%); mp >55°C (dec.); TLC (chloroform): R/0.91; 
vmax (KBr) 3040, 2990-2900, 1590 (CH=CH) c m 1; 6 H (400 MHz, CDC13) 0.3 (6 H, s, 
-Si-(CH3)2), 0.147 (6 H, s, -Si-(CH3)2), 0.74 (3H, s, C -I8 -CH3), 0.89 (9H, s, Si-
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C(CH3)3), 0.99 (9H, s, Si-C(CH3)3), 1.14-2.2 (14H, m), 2.81 (2 H, m, C-6 -H2), 3.7 ( 1 H, 
t, / =  8.2 Hz, C-17-H), 3.76 (3H, s, OCIfc), 6.54 (1H, s, C-4-H), 6.77 (1H, s, C-l-H); 
MS m/z (FAB+) 529.2 [40, (M-H)+], 515 (10), 473.1 [70, (M-C(CH3)3)+], 397.1 (10),
325.0 (10), 251.0 (10); Acc. MS (FAB+) 530.3570 C3 iH540 3Si2 requires 530.3612.
2-Hydroxy-17p-(tert-butyldimethylsilyloxy)oestradiol 3-methyl ether (149)
This was prepared from 148 (300 mg, 0.566mmol) upon treatment with tetra-n- 
butylammonium fluoride (0.566 ml, 1M in THF) in the same manner as the 
preparation of 141. The crude oil that was obtained from work-up was fractionated by 
flash chromatography (chloroform/acetone gradient) and the pale yellow oil that 
isolated solidified on standing to give gave 149 as beige solid (230 mg); mp 158-160 
°C; TLC (chloroform): R/0.56; vmax (KBr) 3520 (OH), 1600 cm*1; 6 h (400 MHz, 
CDC13) 0.3 (6 H, s, Si(CH3)2), 0.74 (3H, s, C-18-CH0, 0.9 (9H, s, S i-Q C H ^), 1.12-
2.25 (13H, m), 2.85 (2H, m, C-6 -H2), 3.63 (1H, t, J  = 8.2 Hz, C-17-H), 3.85 (3H, s, 
OCFb), 5.4 (1H, br s, exchanged with D20 , OH), 6.56 (1H, s, C-4-H) and 6 . 8 8  (1H, s, 
C-l-H); MS m/z (FAB+) 416.1 [100, (M)+], 359.1 (10), 283.0 (20); MS m/z (FAB-)
568.2 [10, (M-H+NBA)'], 415.2 [100, (M-H)-], 400.2 (10), 302.0 (10), 272.1 (10); 
Acc. MS (FAB+) 416.2717 C25H40O3Si requires 416.2746.
3-Methoxy-l 7/3-(tert-butyldimethylsilyloxy)oestradiol-2-0-sulphamate (150) 
Compound 149 (200 mg, 0.4803 mmol) was sulphamoylated in the presence of DBMP 
(296 mg, 1.463 mmol) in a similar manner to the preparation of 142. The crude 
product that obtained (215 mg) was fractionated by flash chromatography 
(chloroform/acetone gradient) to give 150 as beige solid (130 mg, 55%) mp > 179 °C 
(dec.); TLC (chlorofom/acetone, 8:1): R/0.76; vmax (KBr) 3500-3300 (NH2), 1390 
(S02) c m 1; 8 h  (400 MHz, CDCI3) 0.6 (6 H, s, -Si(CH3)2), 0.71 (3H, s, C -I8 -CH3), 0.86 
(9H, s, Si (CH3)3C), 1.1-2.2 (13H, m), 2.81 (2H, m, C-6 -H2), 3.63 (1H, t, J  = 8.2 Hz, 
C-17-H), 3.83 (3H, s, C-3 -OCH3), 4.93 (2 H, br s, exchanged with D20 , -OSC^NJh), 
6.67 (1H, s, C-4-H) and 7.19 (1H, s, C-l-H); MS m/z (FAB+) 495.1 [20, (M)+], 416.1 
[30, (M-S02NH)+], 362.0 (20), 73.0 (100); MS m/z (FAB-) 648.3 [10, (M+NBA) ],
494.2 [100, (M-H)'], 480.1 (10); Acc. MS (FAB+) 495.2463 C25H4 iN0 5SSi requires 




Compound 150 (100 mg, 202.0 pmol) was desilylated in a similar manner to the 
preparation of 143. The crude product that was obtained upon work-up was 
fractionated by flash chromatography (chloroform/acetone gradient) and the white 
solid that isolated (50 mg) was further purified by recrystallization from ethyl 
acetate/hexane (1:2) to give 151 as white crystals (35 mg, 45%); mp > 157 °C (dec); 
TLC (chloroform/acetone, 8:1): R/0.48; vmax (KBr) 3500-3000 (NH2, OH), 1590, 
1390 (S02) cm'1; 8 H (400 MHz, CDC13) 0.78 (3H, s, CH,), 1.14-2.28 (14H, m, 1H 
exchanged with D20), 2.84 (2H, t, /  = 4.1 Hz, C-6 -B2 ), 3.73 (1H, t, J  = 8.2 Hz, C-17- 
H), 3.86 (3H, s, OCH3), 4.92 (2H, br s, exchanged with D20 , -OSO?NH?). 6.7 (1H, s, 
C-4-H) and 7.23 (1H, s, C-l-H); MS m/z (FAB+) 534.2 [10, (M+NBA)+], 381.1 [100, 
(M)+], 301.1 [35, (M-S02NH2)+], 272.0 (10); MS m/z (FAB-) 534.1 [50, (M+NBA)'],
380.1 [100, (M-H) ]; Acc. MS (FAB+) 381.1616 Ci9H27N0 5S requires 381.1610.
2-Acetyloestradiol 17p-acetate (152)
Aluminum chloride (5.389 g, 40.42 mmol), sodium iodide (6.068 g, 40.48 mmol) and 
2-Acetyl-3-methoxyoestradiol 17/3-acetate 146 (1.5 g, 4.049 mmol) were added in this 
order to a mixture of acetonitrile (25 ml) and dichloromethane (12.5 ml) at 0 °C under 
N2. The resulting suspension was heated under reflux for 8  h, cooled to room 
temperature and then poured into water and followed by extraction with 
dichloromethane (3 x 100 ml). The combined DCM extracts were washed with 10% 
sodium thiosulphate (100 ml), brine, dried (MgSC^), filtered and evaporated to give a 
white solid (1.15 g), which was purified by recrystallization from methanol to give 
152 as white crystals (950 mg, 8 6 %); mp 198-200°C (lit. 202-204°C);M4 TLC 
(chloroform and ethyl acetate/hexane, 4:1): R/0.62 and 0.47 respectively; vmax (KBr) 
3600-3000 (OH), 1720 (C=0), 1630 (C=0) cm'1; 8 h (400 MHz, CDC13) 0.84 (3H, s, 
CH3), 1.14-2.0 (10H, m), 2.07 (3H, s, OCOCH3), 2.12-2.33 (3H, m), 2.6 (3H, s, Ar- 
COCH3), 2.86 (2H, m, C-6 -H^, 4.7 (1H, t, J = 8 . 6  Hz, C-17-H), 6.69 (1H, s, C-4-H),
7.6 (1H, s, C-l-H) and 12.04 (1H, s, 4/5 exchanged with D20 , C-3-H); 8 c (270 MHz, 
CDCI3) 12.07 (q, C-18), 21.2 (q), 23.22 (t), 26.52 (t), 26.79 (q), 27.55 (t), 29.89 (t), 
36.72 (t), 38.32 (t), 42.83 (d), 43.37 (s, C13), 43.56 (d), 49.82 (d), 82.58 (d, C-17), 
117.58 (d, C-4), 117.87 (s) 127.29 (d, C-l), 131.41 (s), 147.18 (s), 160.03 (s), 171.23 
(s) and 204.07 (s); MS m/z (FAB+) 357.2 [100, (M+H)+], 297.1 (15), 201.1 (10); MS
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m/z (FAB-) 508.2 [10, (M-H+NBA)'], 355.2 [100, (M-H)’]; Ac MS (FAB+) 357.2059 
C22H29O4 requires 357.2066. Found C, 74.0; H, 7.85; C22H28O4 requires C, 74.13; H, 
7.92%.
2-Acetyloestradiol-3-benzyl ether 17/3-acetate (153)
To a stirred solution of 152 (800 mg, 2.244 mmol) in DMF (15 ml), anhydrous 
potassium carbonate (2.0 g, 14.47 mmol) was added and this was followed by benzyl 
bromide (0.32 ml, 2.690 mmol) and then tetrabutylammonium iodide (100 mg, 270.7 
(Limol). The resulting mixture was stirred under N2 for 24 h at room temperature then 
poured into ice-water containing 3N HC1 (10 ml) and extracted with dichloromethane 
(3 x 100 ml). The combined organic extracts were washed with brine (100 ml), dried 
(MgSCU), filtered and evaporated. The viscous oil that obtained was triturated with 
hexane to give a white solid (910 mg), which was recrystallized from methanol to give 
153 as white crystals (850 mg, 85%); mp 162-164 °C (170-172°C);224 TLC 
(chloroform and ethyl acetate/hexane, 4:1): R/0.51 and 0.41 respectively; vmax (KBr) 
1730 (C=0), 1660 (C=0) cm'1; 8 H (400 MHz, CDC13) 0.82 (3H, s, CH3), 1.14-2.0 
(10H, m), 2.07 (3H, s, OCOCH3), 2.14-2.35 (3H, m), 2.6 (3H, s, Ar-COCITO, 2.88 
(2H, m, C-6 -H2), 4.67 (1H, t, J  = 7.9 Hz, C-17-H), 5.12 (2H, s, OCH2-), 6.73 (1H, s, 
C-4-H), 7.32-7.44 (5H, m, C-3-Bn) and 7.7 (1H, s, C-l-H); MS m/z (FAB+) 447.2 [20, 
(M+H)+], 242.3 (100); MS m/z (FAB-) 279.9 (100); Ac MS (FAB+) 447.25341 
C29H34O4 requires 447.25353. Found C, 77.7; H, 8.23; C29H34O4 requires C, 78.0; H, 
7.67%.
2-Hydroxyoestradiol 3-benzyl ether (154)
A mixture of 153 (600 mg, 1.344 mmol), ra-CPB A (700 mg, 4.057 mmol) and DMC 
(25 ml) was stirred at room temperature overnight under N2 . Upon dilution with DCM 
(300 ml), the resulting mixture was washed with 10% aqueous sodium sulphite (100 
ml), water (100 ml), brine (100 ml), dried (MgSCU), filtered and evaporated. The light 
brown residue that obtained (550 mg) in methanol (50 ml) was refluxed for 1 h in the 
presence of con. H 2 S O 4  (2 ml). Upon removal of the solvent the resulting residue in 
DCM (300 ml) was washed with water (100 ml), saturated aqueous NaHC03 (100 ml), 
water (100 ml), brine (100 ml), dried (MgSCU), filtered and evaporated. The brown 
residue that obtained (470 mg) was fractionated by flash chromatography
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(ether/hexane gradient) and the white solid (237 mg) that isolated was further purified 
by recrystallization from acetone to give 154 as white crystals (212 mg, 50%); > mp 
180 °C (dec, melted at 212-214 °C, lit. 227-228°C);224 TLC (hexane/ether, 1:2 and 1:1 
): R/5 0.30 and 0.52; vmax (KBr) 3500-3000 (OH), 1590 (CH=CH) cm 1; 8 h (400 
MHz, CDC13) 0.77 (3H, s, CH3), 1.14-2.27 (15H, m), 2.81 (2H, m, C-6 -H2), 3.73 (1H, 
t, J  = 8 . 8  Hz, C-17-H), 5.06 (2H, s, OCH2-), 6.65 (1H, s, C-4-H), 6.91 (1H, s, C-l-H) 
and 7.31-7.41 (5H, m, C-3-Bn); MS m/z (FAB+) 378.1 [50, (M)+], 355.0 (10), 73.0 
(100); MS m/z (FAB-) 377.2 [15, (M-H)'], 297.2 (100); Ac MS (FAB+) 378.2201 
C25H30O3 requires 378.2195.
2-Methoxyoestradiol 3-benzyl ether (155)
Methyl iodide ( 0.22 ml, 3.534 mmol) was added to a stirred suspension of anhydrous 
K2CO3 (240 mg, 1.736 mmol) in anhydrous DMF (40 ml) containing 154 (130 mg,
343.5 pmol). The yellow suspension, under N2 was stirred at room temperature for 48 
h and poured into a cold solution of 6 M HC1 (50 ml). The light yellow precipitate that 
formed was collected by filtration, washed with water, air-dried to give a yellow solid 
(131 mg), which was recrystallized from methanol to give 155 as white crystals (125 
mg, 93%); mp 145-147 °C (lit. 89-90°C);224 TLC (chloroform/acetone, 8:1): R/0.83; 
vmax (KBr) 3300 (OH), 1590 (CH=CH) cm’1; 8 h (400 MHz, CDC13) 0.81 (3H, s, 
CH3), 1.14-2.28 (14H, m), 2.81 (2H, m, C-6 -H2), 3.73 (1H, t, /  = 8 . 8  Hz, C-17-H),
3.81 (3H, s, OCH3), 5.05 (2 H, s, OCH2-), 6.63 (1H, s, C-4-H), 6.92 ( 1 H, s, C-l-H) and 
7.31-7.41 (5H, m, C-3-Bn); MS m/z (FAB+) 393.1 [100, (M+H)+], 378.1 (30); MS m/z 
(FAB-) 544.2 [10, (M-H+NBA)*], 391.2 [100, (M-H)’], 377.1 (20); Ac MS (FAB+) 
393.2428 C26H33O3 requires 393.2430. Found C, 79.3; H, 8.65; C26H32O3 requires C, 
79.56; H, 8.22 %.
Catalytic hydrogenation of 155 (100 mg) using 10% Pd-C in THF/ethanol (15 ml, 1:1) 
at balloon pressure at room temperature overnight, gave 2-methoxyoestradiol (70 mg, 
91%).
3-(Sulphooxy)oestrone, sodium salt (156)
Sulphur trioxide-pyridine complex (590 mg, 3.707 mmol) was added to a stirred 
solution of oestrone (500 mg, 1.849 mmol) in anhydrous pyridine (10 ml) under N2 ,
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and the reaction mixture was stirred overnight. After removal of pyridine under 
reduced pressure, methanol ( 1 0  ml) was added to the pale white solid obtained, and 
the resulting light yellow solution was basified (pH- 8 ) by dropwise addition of 1M 
sodium hydroxide in methanol. The white precipitate that formed was collected by 
filtration and washed with fresh methanol. The combined methanolic filtrates were 
concentrated to -10-15 ml, and diethyl ether was added in portions until complete 
precipitation had occurred. The white precipitate was collected by filtration and 
recrystallized from methanol/diethyl ether (1:2) to give 156 as white crystals (512 mg, 
79%); mp > 120 °C (dec. melt, 202-210°C, lit. 228-230°C);280 TLC (methanol/ether, 
1:3): R/0.57; vmax (KBr) 1720 (C=0) cm'1; 6h (400 MHz, CDC13) 0.83 (3H, s, CH3), 
1.13-2.44 (13H, m), 2.81 (2H, m, C-6 -H2), 6 . 8 8  (1H, d, 7 C-4- h ,c-2-h = 2.5 Hz a n d /C-i-H, 
C-2-H =  8 . 2  Hz, C-2-H), 6.9 (1H, d, 7 C-2-h, c-4-h = 2.4 Hz, C-4-H) and 7.16 (1H, d, 7 C-2-h, 
c-1-h  = 8.2 Hz, C-l-H); MS m/z (FAB-) 349.2 [90, (M-Na)'], 286.2 (10), 269.3 [30, 
(M-Na-SOs)']; Acc. MS (FAB-) 349.1126 Ci8H2 i0 5S requires 349.1110. HPLC 
[Spherisorb ODS5 column (25x 4.6); mobile phase, MeOH/H2 0  (70:30); flow rate 1 
ml/min; Xmax, 316 nm]; tR= 2.4 min (cf. oestrone = 7.9 min).
2-Methoxy-3-(sulphooxy)oestrone, sodium salt (157)
Using the procedure described for the preparation of 156, 2-methoxyoestrone 103 (100 
mg, 333 pmol) gave a beige precipitate which was recrystallized from 
methanol/diethyl ether (1:3) to give 157 as beige solid (85 mg, 63%); mp > 120°C 
(dec. melt, 180-185°C); TLC (methanol/ether, 1:3): R/0.51; vmax (KBr) 1730 (C=0), 
1350 (S0 20 ) cm'1; 8 h (400 MHz, DMSO-d*) 0.83 (3H, s, CH3), 1.13-2.51 (13H, m),
2.79 (2H, m, C-6 -H2), 3.69 (3H, s, OCH3), 6.78 ( 1 H, s, C-4-H), and 7.14 (1H, s, C-l- 
H); MS m/z (FAB+) 556.1 [20, (M+H+Na+NBA)+], 403.0 [30, (M+H)+] 330.0 (100); 
MS m/z (FAB-) 555.1 [20, (M+Na+NBA)'], 379.0 [100, (M-Na)‘], 329.0 (10); Acc. 
MS (FAB-) 379.1205 requires C19H23O6S 379.1215. HPLC [Spherisorb ODS5 column 
(25x 4.6); mobile phase, MeOH/H2 0  (60:40); flow rate 1 ml/min; X™*, 316 nm]; tR=
1.5 min (cf. 2-methoxy oestrone = 13.8 min).
Oestrone 3-methylphosphonate (158)
To a solution of oestrone (500 mg, 1.849 mmol) in anhydrous DMF (7 ml), sodium 
hydride (148 mg, 3.698, 2 eq) was added at 0 °C under N2 then the resulting mixture
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was stirred for 15 minutes at 0 °C and methylphosphonic dichloride (740 mg, 5.55 
mmol.) was added. The reaction mixture was allowed to warm to room tempreature 
and stirring was continued for further 24 h. Subsequently, the reaction mixture was 
poured into ice (20 ml) and was extracted with ethyl acetate (5 x 40 ml). The 
combined organic extracts were washed with water, dried (MgS0 4 ) and evaporated. 
The light yellow oil obtained (1.2 g) was fractionated by flash chromatography 
(chloroform/acetone gradient) gave a beige oil (750 mg) which was soldified on 
standing; mp >160°C (dec. melted 182-185 °C)243; TLC (chloroform/acetone, 8:1): R/
0.67; vmax (KBr) 1730 (C=0), 1670 cm’1; 5H (400 MHz, CDC13) 0.86 (3H, s, C-18- 
CH3), 1.13-1.75 (7H, m), 1.81 (3H, d, 7 =  17.4 Hz, CH3P-), 1.92-2.89 (8 H, m), 6.87 
(1H, d, 7C-2-h, C-4-H = 7.9 Hz, C-4-H), 6.97 (1H, d, 7 C-i-h , c-2-h = 8.5 Hz, C-2-H) and
7.32 (1H, d, 7 C-2-h, c - i - H  = 8.5 Hz, C-l-H); 8 p (decoupled) (400 MHz, CDC13) 25.34 (- 
PCH3); 6 c (400 MHz, CDC13) 11.85 (q, C-18), 13.35 (q, -PCH3), 21.01 (t), 25.22 (t), 
25.44 (t), 29.48 (t), 31.99 (t), 35.26 (t), 37.53 (d), 43.36 (d), 47.22 (s, C-13), 49.41 (d), 
117.54 (d), 120.19 (d), 126.88 (d), 136.3 (s), 136.99 (s), 147.69 (s, C-3), 219.58 (s, 
C=0); MS m/z (FAB+) 601.4 (80), 270.2 (20); MS m/z (FAB-) 599.3 (20), 347.2 [85, 
(M-H)'], 269.2 (100); Acc. MS (FAB+) 347.1414 C 19H24PO4 requires 347.1412.
7.2.4.2 D-ring modifications
3-Hydroxy-17(x-oxa-D-homo-oestra-l,3,5(10)-triene-17-one or Oestralactone (159) 
Hydrogen peroxide 6 % (127 ml) was added to a solution of oestrone (3.0 g. 11.10 
mmol) in 1M NaOH (600 ml). After being stirred at room temperature for 7 days, the 
reaction mixture was acidified with HC1 and the resulting precipitate was collected by 
filtration, washed with water and air-dried to give a white residue (3.2 g) which was 
fractionated by flash chromatography (chloroform/acetone, 8:1) to give 1 5 9  as white 
solid (2.67 g, 84%); mp 335-340 °C (lit. 335-340 °C) ; 245 vmax (KBr) 3220 (OH), 1680 
(C=0) c m 1; 8 h  (400 MHz, DMSO-d6) 1 .1 -2 . 8  (18H, m), 6.45 (1H, d, 7 C-2 h, c-t-n = 2.4 
Hz, C-4-H), 6.53 (1H, dd, 7 C-i-h , c-2-h = 8.2 Hz and 7 C-4-h, c-2-h = 2.1 Hz, C-2-H), 7.06 
(1H, d, ./(m-h. c-2-H = 8.5 Hz, C-l-H) and 9.68 (1H, br s, exchanged with D2O, OH); 8 c 
(400 MHz, DMSO-df,) 19.0 (t), 19.82 (q, C-18), 25.5 (t), 26.94 (t), 28.11 (t), 29.21 (t),
38.75 (t), 40.76 (d), 42.04 (d), 44.28 (d), 82.7 (s, C-13), 112.8 (d, C-2), 114.57 (d, C- 
4), 126.06 (d, C-l), 129.41 (s), 136.89 (s), 155.01 (s, C-3) and 170.57 (s, C=0); MS
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m/z (FAB+) 287.1 [90, (M+H)+], 274.1 (50), 255.2 (100); Acc. MS (FAB+) 287.1596 
C18H23O3 requires 287.1647.
Oestralactone 3-O-sulphamate (160)
Upon sulphamoylation, 159 (527 mg, 1.84 mmol) gave a beige residue (616 mg) 
which was fractionated by flash chromatography (chloroform/acetone, 8:1). The white 
solid that was obtained (436 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 160 as white crystals (360 mg, 54%); mp 217-219°C; 
vmax (KBr) 3320, 3220 (NH2), 1690 (C=0), 1390 (S02) cm 1; 8 h (400 MHz, DMSO- 
de) 1.1-2.9 (18H, m), 6.98 (1H, d, 7 C - 2 - h , c - 4 - h =  2.4 Hz, C-4-H), 7.03 (1H, dd, 7 C - i - h , c - 2 -  
h  = 8 . 8  Hz and /c -4 -h , c-2-h = 2.4 Hz, C-2-H), 7.37 (1H, d, Jc-2-n, c - i-h  = 8 . 8  Hz, C-l-H) 
and 7.91 (2H, br s, exchanged with D20 , SO2NH2); 6 c (400 MHz, DMSO-d6) 19.0 (t),
19.79 (q, C-18), 25.15 (t), 26.72 (t), 28.11 (t), 29.06 (t), 38.81 (t), 40.25 (d), 42.04 (d),
44.24 (d), 82.53 (s, C-13), 119.26 (d, C-2), 121.54 (d, C-4), 126.59 (d, C-l), 137.45 
(s), 137.78 (s), 148.01 (s, C-3) and 170.53 (s, C=0); MS m/z (FAB+) 366.1 [100, 
(M+H)+], 287.1 [25, (M+2H-S02NH2)+], 272.1 (20); MS m/z (FAB-) 518.3 [50, 
(M+H+NBA)'] 364.1 [100, (M-H)']; Acc. MS (FAB+) 366.1389 C 18H24NO5S requires 
366.1376. Found C, 59.0; H, 6.36; N, 3.74; C 18H23N0 5S requires C, 59.16; H, 6.34; N, 
3.83%.
(E)-3-Hydroxyimino-oestra-lf3,5(10)-triene-3-ol or (E)-3-hydroxyoestra-l,3,5(10)- 
triene-17-one oxime or (E)-oestrone oxime (161)
To a solution of oestrone (10 g, 36.98 mmol) in ethanol (300 ml), hydroxylamine 
hydrochloride (7.71 g, 111 mmol), sodium hydroxide (3.0 g, 75 mmol) and water (10 
ml) were added. The reaction mixture was refluxed for 2 h and then poured into 1M 
HC1 (100 ml) after cooling. The resulting precipitate was filtered, washed with cold 
water and air-dried to give 161 as white solid (10.132 g, 96%). An analytical sample 
was recrystallized from aqueous methanol (90%) to give 161 as colourless crystals; 
mp 249-251 °C (lit. mp 248-250 °C) ; 251 vmax (KBr) 3500-2500 (OH), 1690 (C=N) 
c m 1; §h (400 MHz, DMSO-d«) 0.85 (3H, s, C H 3 ) ,  1.26-2.8 (14H, m), 3.17 (1.5 H, d, J  
= 5.2 Hz, reduced to a singlet after D20  exchange, CH3OH), 4.13 (0.5H, q, J  = 5.2 Hz, 
exchanged with D20 , CH3OH), 6.44 (1H, d, 7 C-2-h, c-4-h = 2.13 Hz, C-4-H), 6.5 (1H, 
dd, 7 c -i-h , C-2-H = 8.2 Hz and 7 c-4-h, c-2-h = 2.4 Hz, C-2-H), 7.04 (1H, d, . /c - i-h , c-2-h  =
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8.55 Hz, C-l-H), 9.03 (1H, br s, exchanged with D20 , C-3-OH) and 10.1 (1H, br s, 
exchanged with D20 , C=N-OH); 5H (400 MHz, DMSO-d*;) 17.35 (q, C-18), 22.57 (t), 
24.94 (t), 25.99 (t), 26.90 (t), 29.13 (t), 34.33 (t), 37.91 (d), 43.62 (d), 43.61 (s, C-13), 
48.66 (q, CH3 from methanol), 52.52 (d), 112.79 (d, C-2), 114.99 (d, C-4), 126.0 (d, 
C-l), 130.19 (s), 137.103 (s), 155.025 (s, C-3) and 167.99 (s, C=N); MS m/z (FAB+)
439.3 [15, (M+H+NBA)+], 286.3 [100, (M+H)+], 268.3 [20, (M-H20 )+]; MS m/z 
(FAB-) 437.3 [65, (M-H+NBA)'], 284.2 [100, (M-H)']; Acc. MS (FAB+) 286.1805 
Ci8H24N 0 2 requires 286.1807. Found C, 73.5; H, 8.27; N, 4.48; 2Ci8H23N 0 2 .Me0H 
requires C, 73.72; H, 8.36; N, 4.65%.
(E)-17-Hydroxyimino-oestra-l,3,5(10)-triene 3-O-sulphamate or oestrone oxime 3- 
O-sulphamate (162)
Upon sulphamoylation, 161 (1.0 g, 3.504 mmol) gave a crude product (1.33 g) which 
was fractionated by flash chromatography (chloroform/acetone gradient). The white 
solid that was obtained (312 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 162 as white crystals (290 mg, 25%); mp 174-176°C; 
vmax (KBr) 3400-3280 (NH2 and oxime OH), 1710 (C=N), 1390 (S02) cm 1; 8 h (400 
MHz, DMSO-ds) 0.87 (3H, s, CH3), 1.29-2.85 (15H, m), 6.98 (1H, d, / C -2 - h ,  c - 4- h  = 2.1 
Hz, C-4-H), 7.02 ( 1H, dd, / c - i - h ,  c -2-h  = 8.5 Hz and / C-4-h , c-2-h  = 2.4 Hz, C-2-H), 7.35 
(1H, d, / c- i-h , c-2-H = 8.5 Hz, C-l-H), 7.9 (2H, s, exchanged with D20 , -OSC^NHz) and 
10.12 (1H, br s, exchanged with D20 , C=N-OH); 8 c (400 MHz, DMSO-d6)17.17 (q, 
C-18), 22.4 (t), 24.78 (t), 25.60 (t), 26.35 (t), 28.84 (t), 34.12 (t), 37.25 (d), 43.2 (s, C- 
13), 43.63 (d), 52.32 (d), 119.18 (d, C-2), 121.76 (d, C-4), 126.41 (d, C-l), 138.1 (s), 
137.86 (s), 147.86 (s, C-3) 167.71 (s, C=N); MS m/z (FAB+) 518.2 [90, 
(M+H+NBA)*], 365.2 [100, (M+H)+], 285.2 [10, (M+H-S02NH2)+]; MS m/z (FAB-)
517.2 [40, (M-H+NBA)], 363.2 [100, (M-H)']; Acc. MS (FAB+) 365.1545 
Ci8H25N20 4S requires 365.1535. Found C, 59.2; H, 6.84; N, 7.03; Ci8H24N 20 4S 
requires C, 59.32; H, 6.64; N, 7.69%.
3-Hydroxy-13cc-amino-13,17-seco-l,3,5(10)-estratrien-17-oic 13,17-lactam or 3- 
Hydroxy-17a-Aza-D-homoestrone-17-one or Oestralactam (163)
To a solution of 161 (1.0 g, 3.504 mmol) in anhydrous dioxane (35 ml), thionyl 
chloride (1 ml) was added dropwise at 40 °C. A white precipitate formed as the
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temperature rose to 49 °C, which became yellow and then light brown,. After stirring 
for another 1 0  min longer, the reaction mixture was quenched and made slightly 
alkaline by slow addition of aquoeus NaHCC>3 solution. The resulting precipitate was 
filtered, washed with water, dried to give a yellow solid which was then triturated with 
methanol. The precipitate was filtered and air-dried to give 163 as creamy powder 
(733 mg, 73%); mp >350 °C (lit. 373-377 °C, dec. ) ; 251 vmax (KBr) 3000-2500 (OH, 
NH), 1640 (C=0) cm'1; 8 h (400 MHz, DMSO-d6) 1.07 (3H, s, CHs), 1.12-2.71 (15H, 
m), 6.44 ( 1 H, d, Jc.2.H, c-4-h = 2.4 Hz, C-4-H), 6.51 (1H, dd, / c - i - h ,  c-2-h = 8.3 Hz and 
/c-4-H , c-2-H = 2.5 Hz, C-2-H), 7.05 (1H, d, / c - 2.h ,c - i - h  = 8.3 Hz, C-l-H), 7.56 (1H, br s, 
exchanged with D2O, NH) and 9.02 (1H, br s, exchanged with D2O, C-3-OH); MS m/z 




Upon sulphamoylation, 163 (272 mg, 954.4 jimol) gave a crude product (330 mg) 
which was fractionated by flash chromatography (chlorofom/acetone gradient). The 
beige residue that was isolated (286 mg) was further purified by recrystallization from 
acetone/hexane (1:2) to give 164 as creamy crystals (223 mg, 64%); mp > 265 °C 
(dec.); vmax (KBr) 3500 (NH, NH2), 1710 (C=0), 1420 (S02) cm'1; 8 h (400 MHz, 
DMSO-de) 1.1 (3H, s, Clfc), 1.21-2.9 (15H, m), 6.98 (1H, d, / c - 2-h, c-4- h = 2.1  Hz, C-4- 
H), 7.02 (1H, dd, / C-i-H, c-2-h = 8.5 Hz and / C-4-h, c-2-h = 2.1 Hz, C-2-H), 7.35 (1H, d, 
Jc-i-n, c-i-h = 8.5 Hz, C-l-H), 7.6 ( 1H, br s, peak height reduced by about 1/3 upon 
exchange with D2O, NHCO) and 7.94 (2H, s, exchanged completely with D2O, 
SO2NH2); MS m/z (FAB+) 365.2 [100, (M+H)+]; MS m/z (FAB-) 517.2 [50, 
(M+NBA)+], 363.1 [100, (M-H)']; Acc. MS (FAB+) 365.1550 C 18H25N2O4S requires 




Inhibition of steroid sulphatase is now an important target for the development 
of new drugs for the treatment of women with endocrine-dependent breast tumours. 
The first potent sulphatase inhibitor identified, oestrone 3-O-sulphamate (EMATE) 
proved, unexpectedly, to be oestrogenic. A number of strategies have therefore been 
adopted to design and synthesise non-oestrogenic inhibitors and to explore further 
structure- activity relationship for sulphamate-based steroid sulphatase inhibitors.
The attempts to overcome the oestrogenicity of EMATE were broadly 
successful. This not only led to the synthesis of potent El-STS inhibitors which were 
devoid of any oestrogenicity, but also some of these compounds were found to be 
more potent than EMATE (e.g. 2-bromo and 2-iodo EMATE analogues). These 
analogues were found to be about 100 and 4 times more potent respectively as 
sulphatase inhibitors than EMATE in placental microsomes. Other modifications 
have been made to the A and D rings of EMATE. 2-Ethyl EMATE, 2-methoxy 
EMATE and 2-methoxyoestradiol 3-O-sulphamate, while having similar in vitro and 
in vivo sulphatase inhibitory potencies to that of EMATE, were devoid of oestrogenic 
activity when tested at 2  mg/kg using an ovariectomised rat uterine weight gain assay. 
These analogues were found to be potent apoptosis inducers in MCF-7 breast cancer 
cells. A marked regression in tumour volume occurred when 2-methoxyEMATE was 
examined in intact rats with NMU-induced mammary tumours. 2-MethoxyEMATE 
was examined for its nature of inhibition and found to be similar to that of EMATE, 
acting as an irreversible inhibitor. Oestralactone 3-O-sulphamate was synthesised and 
found to be a potent steroid sulphatase inhibitor and was devoid of oestrogenic activity 
when tested in animals at 2 mg/kg. Oestrone oxime 3-O-sulphamate (OMATE) was 
also synthesised and found to be a potent El-STS inhibitor, but suprisingly, this 
compound was found to be about 1.5-fold more oestrogenic than EMATE. Therefore, 
OMATE may have some advantage over EMATE for use in hormone replacement or 
oral contraceptive therapies. The X-ray crystal structure of (F)-oximino-3-hydroxy- 
l,3,5(10)-estratriene (oestrone oxime) is included.
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The high cost of the starting material (2-methoxyoestrone) for 2- 
methoxyEMATE was a serious disadvantage. Therefore, we attempted to synthesise 
2 -methoxyoestrone in an efficient, cheap and simple fashion so that the preparation of 
2-methoxyEMATE synthesis could be carried on a large scale for further biological 
tests. This led to the synthesis of 2-methoxyoestradiol 3-O-sulphamate, the 
sulphamates of 2-hydroxyoestradiol and 3-methoxyoestradiol 2-O-sulphamate in novel 
and efficient manner. The ability of these derivatives to inhibit oestrone sulphatase 
activity was examined using MCF-7 cells and placental microsomes. 2- 
Methoxyoestradiol 3-O-sulphamate, as mentioned above, was found to be as potent as 
2-methoxyEMATE, while the regioisomer 3-methoxyoestradiol 2-O-sulphamate was 
found to be a weak sulphatase inhibitor.
Modifications to the A- and D- rings of the oestrone steroid nucleus, therefore, 
overcame problems with the oestrogenicity of EMATE, identified new potent 
compounds and offer additional routes for the development of potent sulphatase 
inhibitors.
Subsequent structure-activity studies have confirmed that the sulphamate 
group attached to an aryl ring is the active pharmacophore required for potent 
inhibition of steroid sulphatase activity. As an alternative approach to the use of 
steroid-based inhibitors a number of single ring, bicyclic non-fused ring, 2  fused/non­
fused ring and 3 ring sulphamate analogues were designed, synthesised and tested for 
their ability to inhibit steroid sulphatase activity.
In general, although the single ring and bicyclic non-fused ring sulphamate 
analogues could inhibit sulphatase activity, they were considerably less potent than 
EMATE. Benzophenone 4,4'-O, O-bis-sulphamate (BENZOMATE) a 2 non-fused 
ring sulphamate was a potent inhibitor, inhibiting in vivo steroid sulphatase activity by 
84% and 93% respectively at a single oral dose (1 mg/kg and 10 mg/kg) and is 
identified as a useful lead compound for further development.
We also focused upon designing and synthesising a number of molecules that 
might potentially possess both aromatase and steroid sulphatase inhibitory properties
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(flavonoid sulphamates). The isoflavane 4',7-0,0-bis-sulphamate (equol bis- 
sulphamate) and flavone 6,4'-O,0-bis-sulphamate were found to be the most potent 
inhibitors of all the flavonoid sulphamate analogues in vitro, inhibiting steroid 
sulphatase by about 99% at 0.1 jxM in MCF-7 cells. The isoflavone 4',7-0,0-bis- 
sulphamate, the mono- and bis-sulphamate derivatives of 5,7-dihydroxyisoflavone 
were relatively potent inhibitors, inhibiting in vivo steroid sulphatase activity by 90%, 
67% and 84% respectively at a single oral dose of 10 mg/kg. Some of these flavonoid 
sulphamates were also found to be active against both enzymes (e.g. 5-hydroxy-7- 
methoxyflavone 4'-(9-sulphamate 3, 5-hydroxyflavone 4',7-0,(9-bis-sulphamate 7 and 
5,7-dihydroxyflavanone 4'-0-sulphamate 23), thus demonstrating the novel concept of 
a dual inhibitor.
A pharmacophore for active-directed sulphatase inhibition is proposed. The 
potential mechanisms of steroid sulphatase inhibition by EMATE and related synthetic 
sulphamates are proposed. A computer modelling of isoflavone 4',7-0,<9-bis- 
sulphamate is reported. The stability studies for selective synthetic sulphamates are 
carried out using either HPLC or UV methods. The known general method of 
sulphamoylation was improved and a new method of sulphamoylation was also 
adapted using 2,6-terr-butyl-4-methylpyridine as a base. The sterically hindered 17/3- 
benzyl ether of steroid nucleus was cleaved applying new approach (aluminium 
chloride in acetonitrile-dichloromethane) and for the sulphamoylation of poly-hydoxyl 
steroid, the silyl technology was applied.
Several other inhibitors were found to be potent and the structure-activity 
relationships for different sulphamates were discussed. The identification of potent 
steroid- and non-steroid-based sulphatase inhibitors will enable the therapeutic value 
of this therapy to be examined in clinical trials in the near future not only in the 
potential exploitation of such inhibitors in endocrine therapy, but also in newly 
emerging indications related to autoimmune disease and memory enhancement 
(Alzheimer’s), where sulphatase inhibition may also be of therapeutic benefit.
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Appendix 1. Notes on nomenclature:The numbering of the main ring 





















Appendix 2. Supplementary X-Ray Crystallography data for oestrone 
oxime (161).
A crystal of approximate dimensions 0.25 x 0.25 x 0.15 mm was used for data 
collection.
Crystal data: C 3 7  H50 N2 O5, M = 301.40, Monoclinic , a = 7.0670(10), b 
= 13.533(2), c = 17.077(5) A, 0 = 96.10(3)°, U = 1624.0(6) A3, space group 
P2U Z = 2, Dc = 1.233 gem'3, fi(Mo-Ka) = 0.081 mm'1, F(000) = 652. 
Crystallographic measurements were mad
e at 293(2)° K on a CAD4 automatic four-circle diffractometer in the range 
2.39<0<23.93°. Data (2876 reflections) were corrected for Lorentz and 
polarization but not for absorption.
The asymmetric unit was seen to consist of 2 chirally similar molecules 
hydrogen bonded to each other via their oxime functionalities, and one 
molecule of methanol. The hydrogen attached to 02A is also involved in 
hydrogen bonding to the solvent oxygen. The geometric parameters for both 
molecules are similar within 2 estimated standard deviations.
Unfortunately, the absolute configuration could not be determined 
reliably for this structure, despite refining the Flack parameter both for the 
data presented and also in the inverted structure.
Examination of the supramolecular array revealed that the lattice is 
dominated by polymeric strands along b due to extended hydrogen bonding. 
In addition to the interactions within the asymmetric unit, H2 also interacts 
with 01 of the molecule generated via the x, 1+y, z  symmetry transformation. 
Also, the proximity of 05 as presented to 01A by the x, -1+y, z  operation 
seems indicative of a further interaction between the methanolic proton (not 
located) and this latter oxygen.
The solution of the structure (SHELX86)1 and refinement (SHELX93)2 
converged to a conventional [i.e. based on 1436 F2 data with Fo>4o(Fo)] R1 =
0.0619 and wR2 = 0.1101. Goodness of fit = 1.100. The max. and min. 
residual densities were 0.231 and -0.257 eA*3 respectively. The asymmetric 
unit (shown in Fig. 42), along with the labelling scheme used was produced 
using ORTEX.3 Final fractional atomic co-ordinates and isotropic thermal 
parameters, bond distances and angles are given in Tables 2,3,4 and 5 
respectively. Tables of anisotropic temperature factors are available as 
supplementary data.
1. Sheldrick G.M., Acta Cryst., A46, 467-73, 1990.
2. Sheldrick G.M., SHELXL, a computer program for crystal structure 
refinement, University of Gottingen, 1993.
3. McArdle P., J.Appl.Cryst., 27, 438, 1994
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Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2a(I)]
R indices (all data)
Absolute structure parameter 











a = 7.0670(10)A a  = 90° 
b = 13.533(2)A p = 96.10(3)° 




0.081 mm' 1 
652
0.25 x 0.25 x 0.15 mm 
2.39 to 23.93 °.
-8<=h<=0; 0<=k<=14; -19<=1<=19 
2876
2644 [R(int) = 0.0307]
Full-matrix least-squares on F2 
2 6 3 8 /1 /4 0 6  
1.100
R l=  0.0619 wR2 = 0.1101 
R l=  0.1618 wR2 = 0.1532 
-10(9)
0.231 and -0.257 eA' 3
ca lc  w = 1 /[o 2(F o2)+ (0 .0 6 5 8 P )2] w h ere
P=(Fo2+2Fc2)/3
0.0019(12)
Fc*=kFc[l +0.001 xFc27.3/sin(20) ] ‘ l/4
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic 
displacement parameters (A2 x 1 0 3) for 1 . U(eq) 
is defined as one third of the trace of the orthogonalized Uij tensor.
Atom X y z U(eq)
N (l) 6807(9) -2042(5) 6766(4) 47(2)
0 ( 1) 6576(8) -3073(5) 6614(4) 61(2)
0 (2 ) 3410(9) 5703(5) 5982(4) 69(2)
C (l) 6097(12) 3391(6) 6219(5) 47(2)
C(2) 5704(12) 4392(6) 6228(5) 45(2)
C(3) 3892(13) 4717(5) 5983(5) 47(2)
C(4) 2526(12) 4057(7) 5733(5) 51(2)
C(5) 2879(12) 3049(6) 5724(5) 44(2)
C(6 ) 1274(12) 2355(7) 5447(7) 72(3)
C(7) 1859(12) 1294(6) 5319(6) 58(2)
0 (8 ) 3337(10) 965(5) 5997(4) 38(2)
C(9) 5151(11) 1589(5) 5991(4) 39(2)
C (10 ) 4701(11) 2689(5) 5986(4) 39(2)
C ( ll) 6681(12) 1274(6) 6638(5) 53(2)
C (12 ) 7150(12) 169(6) 6623(6) 56(3)
C(13) 5303(10) -434(6) 6653(4) 37(2)
C(14) 3869(10) -116(5) 5950(4) 39(2)
C(15) 2382(11) -928(6) 5893(5) 53(2)
C(16) 3550(11) -1874(6) 6052(5) 49(2)
C(17) 5363(11) -1526(6) 6499(4) 39(2)
C(18) 4515(13) -327(6) 7444(4) 60(2)
N(1A) 10036(10) -3197(6) 7592(4) 53(2)
0(1 A) 10478(9) -2177(6) 7478(4) 6 8 (2 )
0(2A ) 13073(11) -10616(6) 9537(4) 83(2)
0(1 A) 10996(12) -8510(6) 8397(5) 58(2)
C(2A) 11137(13) -9423(7) 8739(5) 65(3)
C(3A) 12836(13) -9715(7) 9166(5) 58(2)
C(4A) 14340(12) -9057(7) 9233(5) 56(2)
C(5A) 14187(11) -8125(6) 8883(4) 43(2)
C(6 A) 15874(12) -7441(7) 9017(6) 60(3)
0 (7  A) 15659(11) -6481(6) 8566(5) 51(2)
C(8A) 13654(11) -6088(6) 8550(5) 45(2)
C(9A) 12280(10) -6813(6) 8096(5) 44(2)
C(10A) 12492(11) -7832(6) 8455(5) 45(2)
C(11A) 10188(11) -6450(6) 7993(6) 55(2)
C(12A) 9983(11) -5386(7) 7715(5) 54(2)
C(13A) 11266(11) -4698(6) 8217(5) 45(2)
C(14A) 13347(10) -5062(5) 8208(4) 37(2)
C(15A) 14562(11) -4190(7) 8533(5) 55(2)
C(16A) 13426(12) -3263(7) 8215(6) 64(3)
C(17A) 11436(11) -3652(6) 7965(5) 47(2)
C(18A) 10660(11) -4629(7) 9063(5) 56(2)
0 (5 ) 10007(13) -11778(8) 9116(6) 123(3)
0(19) 8232(22) -12031(12) 9358(9) 141(6)
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Table 3. Bond lengths [A] and angles [°]
N(l)-C(17) 1.280(9)













C (9)-C (ll) 1.522(11)
C(9)-C(10) 1.522(11)

































C (17)-N (l)-0(1) 113.4(7)




0(2)-C(3)-C(2) 1 2 2 .2 (8)
C(3)-C(4)-C(5) 1 2 2 .1(8)
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C(8 A)-C( 14 A)-C( 13 A) 112.6(6)
C( 15 A)-C(14A)-C( 13A) 104.3(6)
C( 14 A)-C( 15 A)-C( 16A) 104.2(6)
C(17A)-C(16A)-C(15A) 104.3(7)
N(1A)-C(17A)-C(13A) 121.4(8)
N( 1 A)-C( 17 A)-C( 16 A) 128.1(8)
C(13A)-C(17A)-C(16A) 110.5(8)
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Table 4. Anisotropic displacement parameters (A2 x 1 0 3). 
The anisotropic displacement factor exponent takes the form: 
-2 pi2 [ h2 a* 2 U11 + ... + 2 h k a* b* U12 ]
Atom U ll U22 U33 U23 U13 U12
N(l) 50(4) 26(4) 65(5) 0(3) 5(4) 0(4)
0 (1) 67(4) 29(3) 83(5) 1(3) -6(3) 9(3)
0 (2) 85(5) 36(4) 84(5) -5(3) -5(4) 12(3)
C(l) 46(5) 38(5) 56(5) -3(4) -1(4) 4(5)
C(2) 51(5) 39(5) 45(5) -1(4) -5(4) -5(4)
C(3) 63(6) 22(5) 56(5) 7(4) 2(5) 3(5)
C(4) 50(5) 37(5) 66(6) 4(5) 1(4) 4(5)
0(5) 46(5) 39(5) 48(5) 4(4) 8(4) -1(4)
C(6) 49(6) 42(5) 120(8) 16(6) -11(5) -5(5)
C(7) 53(6) 37(5) 78(6) 8(4) -15(5) 1(4)
0 (8) 34(4) 32(5) 47(5) -2(4) -2(4) -2(4)
0(9) 42(4) 35(5) 40(4) -3(4) 7(4) 2(4)
0 (10) 43(5) 37(5) 36(5) 2(4) 4(4) -1(4)
0 (11) 40(5) 39(5) 78(7) 3(4) -10(5) -2(4)
0 (12) 47(5) 34(5) 84(7) 9(5) -12(5) 4(5)
0(13) 34(4) 36(4) 39(4) -6(4) 1(3) 9(4)
0(14) 36(4) 40(5) 40(4) -10(4) 2(4) 4(4)
0(15) 41(5) 35(4) 79(6) 3(5) -8(4) 0(4)
0(16) 46(5) 34(5) 63(5) -2(4) -10(4) 2(4)
0(17) 44(5) 31(5) 42(4) 3(4) 1(4) 9(4)
0(18) 86(6) 48(5) 47(5) -2(4) 11(5) 16(5)
N(1A) 49(5) 47(4) 63(4) 7(4) 10(4) 4(4)
0(1 A) 56(4) 51(4) 94(5) 21(4) -2(4) -2(3)
0(2A) 101(5) 59(4) 86(5) 18(3) -3(4) 7(4)
0(1 A) 44(5) 55(6) 74(6) 4(5) -1(4) 5(5)
C(2A) 55(6) 61(6) 78(6) 7(5) 6(5) -4(5)
C(3A) 68(6) 52(5) 53(5) 12(4) 3(5) 4(5)
C(4A) 51(5) 65(6) 47(5) -3(5) -11(4) 10(5)
C(5A) 38(5) 54(5) 36(4) 0(4) 1(4) 15(4)
C(6A) 42(5) 65(7) 71(6) -1(5) -6(4) 15(5)
0(7 A) 32(5) 62(6) 59(5) 2(5) 0(4) 19(4)
C(8A) 41(5) 53(6) 42(5) 6(4) 9(4) 5(4)
C(9A) 23(4) 65(6) 44(5) -3(4) 3(3) 5(4)
C(10A) 48(5) 44(6) 43(5) -5(4) 6(4) 0(4)
C(11A) 38(5) 50(6) 74(6) 16(5) -1(4) 4(4)
C(12A) 31(5) 59(6) 72(6) 9(5) 0(4) 6(5)
C(13A) 31(4) 42(5) 60(5) 15(4) 7(4) -2(4)
C(14A) 29(4) 47(5) 33(4) 3(4) 2(3) 2(4)
C(15A) 39(5) 60(6) 67(6) 5(5) 1(4) -2(5)
C(16A) 44(5) 67(6) 80(6) 16(5) 3(5) 7(5)
C(17A) 35(5) 53(5) 51(5) 8(4) 0(4) 1(4)
C(18A) 44(4) 63(6) 64(6) 15(5) 20(4) 12(4)
0(5) 122(7) 97(6) 148(8) -11(6) 8(6) -24(6)
0(19) 163(14) 103(10) 176(14) -15(10) 104(12) -23(11)
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Table 5. Hydrogen coordinates ( x 104) and isotropic 
displacement parameters (A2 x 1 0 3).
Atom X y z U(eq)
H (l) 7363(92) -3383(7) 6904(41) 91
H(2) 4269(70) 6018(12) 6227(56) 104
H(1A) 7332(12) 3178(6) 6374(5) 56
H(2A) 6656(12) 4841(6) 6398(5) 54
H(4) 1312(12) 4286(7) 5561(5) 62
H(6A) 638(12) 2606(7) 4956(7) 86
H(6B) 357(12) 2361(7) 5831(7) 86
H(7A) 2399(12) 1239(6) 4822(6) 69
H(7B) 751(12) 868(6) 5297(6) 69
H(8) 2806(10) 1077(5) 6497(4) 45
H(9) 5658(11) 1448(5) 5490(4) 47
H(11A) 6262(12) 1438(6) 7145(5) 64
H(11B) 7831(12) 1649(6) 6584(5) 64
H(12A) 8053(12) 3(6) 7072(6) 68
H(12B) 7722(12) 10(6) 6147(6) 68
H(14) 4542(10) -182(5) 5479(4) 46
H(15A) 1678(11) -944(6) 5373(5) 63
H(15B) 1495(11) -838(6) 6283(5) 63
H(16A) 2894(11) -2337(6) 6363(5) 58
H(16B) 3793(11) -2190(6) 5563(5) 58
H(18A) 4225(72) 354(8) 7531(15) 90
H(18B) 5444(33) -553(38) 7855(5) 90
H(18C) 3377(45) -715(32) 7444(12) 90
H(1A1) 9616(74) -1919(21) 7188(53) 101
H(2A1) 12578(165) -11049(14) 9249(31) 124
H(1A2) 9851(12) -8331(6) 8113(5) 70
H(2A2) 10100(13) -9850(7) 8687(5) 78
H(4A) 15480(12) -9240(7) 9519(5) 67
H(6A1) 16095(12) -7292(7) 9575(6) 72
H(6A2) 16990(12) -7782(7) 8871(6) 72
H(7A1) 15959(11) -6587(6) 8032(5) 62
H(7A2) 16548(11) -5999(6) 8812(5) 62
H(8A) 13336(11) -6067(6) 9095(5) 54
H(9A) 12681(10) -6865(6) 7565(5) 53
H(11C) 9453(11) -6873(6) 7616(6) 66
H(11D) 9660(11) -6512(6) 8493(6) 66
H(12C) 10282(11) -5345(7) 7175(5) 65
H(12D) 8672(11) -5178(7) 7726(5) 65
H(14A) 13556(10) -5117(5) 7652(4) 44
H(15C) 15810(11) -4206(7) 8345(5) 66
H(15D) 14716(11) -4196(7) 9105(5) 66
H(16C) 13402(12) -2765(7) 8622(6) 77
H(16D) 13981(12) -2978(7) 7771(6) 77
H(18D) 10712(70) -5274(9) 9298(12) 84
H(18E) 9385(30) -4378(37) 9040(6) 84
H(18F) 11509(46) -4193(30) 9373(10) 84
H(19A) 7689(87) -12566(66) 9040(52) 211
H(19B) 7399(62) -11469(32) 9299(72) 211
H(19C) 8395(32) -12231(91) 9900(24) 211
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Part of the ‘H -’H COSY NIVIR spectrum of (±) 4',7-dihydroxyisoflavane (equol,
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Part of the ‘H-'H COSY NMR spectrum of (±) 4',7-dihydroxyisoflavane (equol,













130 125 115 110 105
Part of the lH-,3C COSY NMR spectrum of (±) 4',7-dihydroxyisoflavane (equol,
25), 400 MHz, acetone-d6.
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Part of the ‘H -i3C COSY NMR spectrum of (±) 4',7-dihydroxyisoflavane (equol,
25), 400 MHz, acetone-d6.
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SCANS 2 1 4
ACOTM 3.277 sec
PD 1 952 sec
PW] 5 . 9 us
IRNUC j h
CTCMP 21.6 c
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Part of the 'H -'H  COSY NMR spectrum of l,9,10,10a-tetrahydro-7-methoxy- 
3(2//)-phenanthrenonc (76), 400 MHz, CDC13, Ha= axial proton; H cq-
equatorial proton.
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Part of the 'H -i3C COSY NMR spectrum of the l,9,10,10a-tetrahydro-7- 
methoxy-3(2//)-phenanthrenone (76), 400 MHz, CDCI3.
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art of the 'H -i3C COSY NMR spectrum of the 1,9,10,10a-tetrahydro-7-















































































Part of the 'H - 'h COSY NMR spectrum of l,9,10,10a-tetrahydro-6,7-dimethoxy- 
3(2//)-phenanthrcnone (81), 400 MHz, CDC13, axial proton; Hcq= equatorial
proton.
291
Part of the ‘H -i3C COSY NMR spectrum of l,9,10,10a-tetrahydro-6,7-
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